CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2022



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2022

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

Cumulative Supplement 9
September 2022

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 APPLICANT NAME CHANGES vii
1.4 LEVOTHYROXINE SODIUM viii
1.5 AVAILABILITY OF THE EDITION ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST x
1.7 CUMULATIVE SUPPLEMENT LEGEND xi

DRUG PRODUCT LISTS
Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM
A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2022

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DAIICHI SANKYO INC (DAIICHI SANKYO)	COSETTE PHARMACEUTICALS INC (COSETTE)
DAIICHI SANKYO INC (DAIICHI SANKYO INC)	COSETTE PHARMACEUTICALS INC (COSETTE)
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)
LANNETT CO INC (LANNETT)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)

LANNETT CO INC (LANNETT CO INC)	CHARTWELL MOLECULAR HOLDINGS LLC (CHARTWELL MOLECULAR)
MERCK AND CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK AND CO INC (MERCK AND CO INC)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK RESEARCH LABORATORIES DIV MERCK CO INC (MERCK)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP (MERCK SHARP DOHME)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC (MSD MERCK CO)	ORGANON LLC A SUB OF ORGANON AND CO (ORGANON)
SANDOZ INC (SANDOZ)	EPIC PHARMA INC (EPIC PHARMA)
TELIGENT OU (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
TELIGENT PHARMA INC (TELIGENT)	PAI HOLDINGS LLC DBA PHARMACEUTICALS ASSOCIATES INC (PAI HOLDINGS PHARM)
WYTELLS PHARMA PRIVATE LTD (WYTELLS PHARMA)	EUGIA PHARMA SPECIALITIES LTD (EUGIA PHARMA SPECLTS)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active

[2] Please consult the Active Section of the Orange Book for information on other strengths.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline

count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2021	MAR 2022	JUN 2022	SEP 2022	DEC 2022
DRUG PRODUCTS	21133	21339	21640	21862	
LISTED SINGLE SOURCE	2701 (12.8%)	2716 (12.7%)	2748 (12.7%)	2709 (12.4%)	
MULTISOURCE	18432 (87.2%)	18623 (87.3%)	18892 (87.3%)	19153 (87.6%)	
THERAPEUTICALLY EQUIVALENT	18298 (86.6%)	18493 (86.7%)	18762 (86.7%)	19036 (87.1%)	
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)	130 (0.6%)	130 (0.6%)	117 (0.5%)	
EXCEPTIONS[4]	54 (0.3%)	53 (0.2%)	53 (0.2%)	53 (0.2%)	
NEW MOLECULAR ENTITIES APPROVED	13	11	23	16	
NUMBER OF APPLICANTS	1190	1204	1219	1210	

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET, FOR SUSPENSION;ORAL

TRIUMEQ PD

	+!	VIIV HLTHCARE	EQ 60MG BASE;EQ 5MG BASE;30MG	N215413	001	Mar 30, 2022	Mar NEWA

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

	@	AUROBINDO PHARMA	EQ 600MG BASE;300MG	A206151	001	Mar 28, 2017	Jun DISC
AB		LAURUS	EQ 600MG BASE;300MG	A216332	001	Jul 25, 2022	Jul NEWA

ABAMETAPIR

LOTION;TOPICAL

XEGLYZE

	+ @	HATCHTECH	0.74%	N206966	001	Jul 24, 2020	Jul CAHN

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		GLENMARK PHARMS	500MG	A209227	002	May 19, 2022	May NEWA
AB		NOVUGEN	250MG	A215947	001	Jan 05, 2022	Aug CAHN
AB			500MG	A215947	002	Jan 05, 2022	Aug CAHN
AB		TEVA PHARMS USA	125MG	A212206	001	Jun 24, 2022	Jun NFTG

YONSA

AB	+!	SUN PHARM	125MG	N210308	001	May 22, 2018	Jun CFTG
	+!		125MG	N210308	001	May 22, 2018	Feb CAHN

ABROCITINIB

TABLET;ORAL

CIBINQO

	+	PFIZER	50MG	N213871	001	Jan 14, 2022	Jan NEWA
	+		100MG	N213871	002	Jan 14, 2022	Jan NEWA
	+!		200MG	N213871	003	Jan 14, 2022	Jan NEWA

ACALABRUTINIB MALEATE

TABLET;ORAL

CALQUENCE

	+!	ASTRAZENECA	EQ 100MG BASE	N216387	001	Aug 03, 2022	Aug NEWA

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	!	AMNEAL PHARM	EQ 200MG BASE	A075047	001	Dec 30, 1999	Jul CTEC
	!		EQ 200MG BASE	A075047	001	Dec 30, 1999	Apr CTEC
AB	!		EQ 400MG BASE	A075047	002	Dec 30, 1999	Jul CTEC
	!		EQ 400MG BASE	A075047	002	Dec 30, 1999	Apr CTEC
AB		ANI PHARMS	EQ 200MG BASE	A074007	001	Oct 18, 1995	Jul CMFD
AB			EQ 400MG BASE	A074007	002	Oct 18, 1995	Jul CMFD
	@	MYLAN	EQ 200MG BASE	A074288	001	Apr 24, 1995	Apr DISC
AB			EQ 200MG BASE	A074288	001	Apr 24, 1995	Apr CAHN
	@		EQ 400MG BASE	A074288	002	Apr 24, 1995	Apr DISC
AB			EQ 400MG BASE	A074288	002	Apr 24, 1995	Apr CAHN

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP		ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Jul NEWA
AP		HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Aug CAHN
	+!		1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022	Jun CAHN
	+!	INNOPHARMA	1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022	Jun NEWA
AP	!	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Feb CHRS

OFIRMEV

	+ @	MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Feb DISC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

	AA	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015	Apr CTEC

BUTALBITAL AND ACETAMINOPHEN

	AA		AACE PHARMS	50MG;300MG	A214955	001	Aug 16, 2022	Aug NEWA
	AA		HAVIX	300MG;50MG	A214088	001	Apr 07, 2022	Apr NEWA
	AA			325MG;25MG	A214088	002	Apr 07, 2022	Apr NEWA
	AA			325MG;50MG	A214088	003	Apr 07, 2022	Apr NEWA
>A>	AA		RISE PHARMA	300MG;50MG	A214088	001	Apr 07, 2022	Sep CAHN
>A>	AA			325MG;25MG	A214088	002	Apr 07, 2022	Sep CAHN
>A>	AA			325MG;50MG	A214088	003	Apr 07, 2022	Sep CAHN
>D>	AA		SENORES PHARMS	300MG;50MG	A214088	001	Apr 07, 2022	Sep CAHN
	AA			300MG;50MG	A214088	001	Apr 07, 2022	Jun CAHN
>D>	AA			325MG;25MG	A214088	002	Apr 07, 2022	Sep CAHN
	AA			325MG;25MG	A214088	002	Apr 07, 2022	Jun CAHN
>D>	AA			325MG;50MG	A214088	003	Apr 07, 2022	Sep CAHN
	AA			325MG;50MG	A214088	003	Apr 07, 2022	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA		HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022	Sep DISC
>A>		@		300MG;50MG;40MG	A215135	001	Mar 25, 2022	Sep DISC
	AA			300MG;50MG;40MG	A215135	001	Mar 25, 2022	Mar NEWA
>D>	AA			325MG;50MG;40MG	A215135	002	Mar 25, 2022	Sep DISC
>A>		@		325MG;50MG;40MG	A215135	002	Mar 25, 2022	Sep DISC
	AA			325MG;50MG;40MG	A215135	002	Mar 25, 2022	Mar NEWA
	AA		NOVAST LABS	300MG;50MG;40MG	A215047	001	Nov 17, 2021	Aug CAHN

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	AA		GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Jul CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	AB		HIKMA	300MG;50MG;40MG;30MG	A215138	002	Jan 26, 2022	Jan NEWA
	AB			325MG;50MG;40MG;30MG	A215138	001	Jan 26, 2022	Jan NEWA
	AB		LGM PHARMA	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA		CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Apr CAHN
	AA		MIKART	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Mar CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@	CHARTWELL	300MG;15MG	A089997	001	Dec 28, 1994	Feb CAHN
		@		300MG;30MG	A089998	001	Dec 28, 1994	Feb CAHN
		@		300MG;60MG	A089999	001	Dec 28, 1994	Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	!	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Apr CAHN
>A>	AA		EYWA	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Sep CAHN
		!	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010	Apr CTEC
	AA	!		325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Mar CAHN
		@	TRIS PHARMA INC	300MG/15ML;10MG/15ML	A201295	002	Dec 30, 2021	Apr DISC
		@		325MG/15ML;7.5MG/15ML	A201295	001	Dec 30, 2021	Apr DISC
>D>	AA		WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Sep CAHN

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018	May CHRS
				325MG;2.5MG	A211487	001	Nov 07, 2018	May CTEC
	AA	!	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Apr CAHN
	AA	!		300MG;7.5MG	A040658	002	Mar 24, 2006	Apr CAHN
	AA	!		300MG;10MG	A040658	003	Jun 23, 2004	Apr CAHN
		@		325MG;7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
	AA			325MG;7.5MG	A040432	001	Jan 22, 2003	Apr CAHN
		@		325MG;10MG	A040248	002	Apr 28, 2000	Feb CAHN

```
      TABLET;ORAL
        HYDROCODONE BITARTRATE AND ACETAMINOPHEN
AA        MIKART                325MG;7.5MG                        A040432  001  Jan 22, 2003   Mar CAHN

    ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
      SOLUTION;ORAL
        OXYCODONE AND ACETAMINOPHEN
          MIKART                300MG/5ML;10MG/5ML                 A202142  001  Nov 27, 2018   Mar CAHN
      TABLET;ORAL
        OXYCODONE 5/APAP 500
        @ BRISTOL MYERS SQUIBB  500MG;5MG                          A085911  001                  Jun CRLD

    ACETAZOLAMIDE
      CAPSULE, EXTENDED RELEASE;ORAL
        ACETAZOLAMIDE
AB    !   CADILA                500MG                              A205301  001  Jan 16, 2019   May CHRS
        @ INDICUS PHARMA        500MG                              A090779  001  Jul 14, 2011   May DISC

    ACETIC ACID, GLACIAL
      SOLUTION/DROPS;OTIC
        ACETIC ACID
        @ WOCKHARDT BIO AG      2%                                 A040166  001  Jul 26, 1996   Jun DISC
        VOSOL
AT    !   AKORN                 2%                                 N012179  001                  Jun CHRS

    ACETYLCYSTEINE
      INJECTABLE;INTRAVENOUS
        ACETYLCYSTEINE
AP        ASPEN                 6GM/30ML (200MG/ML)                A213693  001  Feb 03, 2022   Jan NEWA
        @ EXELA PHARMA          6GM/30ML (200MG/ML)                A204797  001  Apr 15, 2021   Feb DISC
AP        INDOCO                6GM/30ML (200MG/ML)                A215620  001  Feb 23, 2022   Feb NEWA

    ACLIDINIUM BROMIDE
      POWDER, METERED;INHALATION
        TUDORZA PRESSAIR
      +!  COVIS                 0.4MG/INH                          N202450  001  Jul 23, 2012   Apr CAHN

    ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
      POWDER, METERED;INHALATION
        DUAKLIR PRESSAIR
      +!  COVIS                 0.4MG/INH;0.012MG/INH              N210595  001  Mar 29, 2019   Apr CAHN

    ACYCLOVIR
      OINTMENT;TOPICAL
        ACYCLOVIR
>A> AB    CHARTWELL RX          5%                                 A212495  001  Apr 07, 2020   Sep CAHN
        @ PRINSTON INC          5%                                 A212202  001  Nov 15, 2021   Mar DISC
>D> AB    SOLARIS PHARMA CORP   5%                                 A212495  001  Apr 07, 2020   Sep CAHN
      SUSPENSION;ORAL
        ACYCLOVIR
>D> AB    AUROBINDO PHARMA      200MG/5ML                          A216331  001  Mar 31, 2022   Sep DISC
>A>     @                       200MG/5ML                          A216331  001  Mar 31, 2022   Sep DISC
    AB                          200MG/5ML                          A216331  001  Mar 31, 2022   Mar NEWA
    AB    HETERO LABS LTD III   200MG/5ML                          A215669  001  Jul 01, 2022   Jun NEWA
    AB    RUBICON               200MG/5ML                          A215724  001  Aug 18, 2022   Aug NEWA

    ACYCLOVIR SODIUM
      INJECTABLE;INJECTION
        ACYCLOVIR SODIUM
>D> AP    AM INJECTABLES        EQ 50MG BASE/ML                    A207919  001  Jun 17, 2020   Sep CAHN
    AP                          EQ 50MG BASE/ML                    A207919  001  Jun 17, 2020   Apr CAHN
        @ CHARTWELL INJECTABLE  EQ 500MG BASE/VIAL                 A074596  002  Apr 22, 1997   Mar CAHN
        @                       EQ 1GM BASE/VIAL                   A074596  001  Apr 22, 1997   Mar CAHN
>A> AP    DR REDDYS             EQ 50MG BASE/ML                    A207919  001  Jun 17, 2020   Sep CAHN

    ADAPALENE; BENZOYL PEROXIDE
      GEL;TOPICAL
        ADAPALENE AND BENZOYL PEROXIDE
AB        ACTAVIS LABS UT INC   0.3%;2.5%                          A209641  001  Jun 22, 2022   Jun NEWA
AB        ALEOR DERMACEUTICALS  0.3%;2.5%                          A214185  001  Aug 04, 2022   Jul NEWA
AB        PADAGIS ISRAEL        0.3%;2.5%                          A212464  001  May 31, 2022   May NEWA
AB        ZYDUS PHARMS          0.3%;2.5%                          A214553  001  Jun 03, 2022   May NEWA
```

```
      GEL;TOPICAL
        ADAPALENE AND BENZOYL PEROXIDE
AT                            0.3%;2.5%                        A214553  001  Jun 03, 2022   May NEWA

    ALBENDAZOLE
      TABLET;ORAL
        ALBENDAZOLE
AB    !   DR REDDYS           200MG                            A211034  001  Jan 26, 2021   Jun CHRS
        ALBENZA
      + @ IMPAX LABS INC      200MG                            N020666  001  Jun 11, 1996   Jun DISC

    ALBUTEROL SULFATE
      SOLUTION;INHALATION
        ALBUTEROL SULFATE
        @ BAUSCH              EQ 0.083% BASE                   A075358  001  Mar 29, 2000   Jun CAHN
        @                     EQ 0.5% BASE                     A075050  001  Jun 18, 1998   Jun CAHN
      SYRUP;ORAL
        ALBUTEROL SULFATE
AA        CHARTWELL RX        EQ 2MG BASE/5ML                  A077788  001  Jun 26, 2007   May CMFD
      TABLET;ORAL
        ALBUTEROL SULFATE
>A> AB    AIZANT              EQ 2MG BASE                      A210948  001  Mar 15, 2019   Sep CAHN
>A> AB                        EQ 4MG BASE                      A210948  002  Mar 15, 2019   Sep CAHN
>D> AB    APPCO               EQ 2MG BASE                      A210948  001  Mar 15, 2019   Sep CAHN
>D> AB                        EQ 4MG BASE                      A210948  002  Mar 15, 2019   Sep CAHN
        @ CHARTWELL RX        EQ 4MG BASE                      A072151  002  Dec 05, 1989   Feb CMS1

    ALCOHOL
      SOLUTION;INTRA-ARTERIAL
        ABLYSINOL
      +   BPI LABS            99% (1ML)                        N207987  001  Jun 21, 2018   Jul CAHN
      +!                      99% (5ML)                        N207987  002  Jun 21, 2018   Jul CAHN

    ALFUZOSIN HYDROCHLORIDE
      TABLET, EXTENDED RELEASE;ORAL
        ALFUZOSIN HYDROCHLORIDE
        @ ATLANTIDE           10MG                             A090221  001  Aug 10, 2012   Apr CAHN

    ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE
      TABLET;ORAL
        TEKTURNA HCT
      + @ NODEN PHARMA        EQ 300MG BASE;12.5MG             N022107  003  Jan 18, 2008   May DISC
      + @                     EQ 300MG BASE;25MG               N022107  004  Jan 18, 2008   May DISC

    ALLOPURINOL
      INJECTABLE;INJECTION
        ALLOPURINOL
AP        GLAND PHARMA LTD    EQ 500MG BASE/VIAL               A212363  001  Jan 26, 2022   Jan NEWA
      TABLET;ORAL
        ALLOPURINOL
AB    !   ACCORD HLTHCARE     300MG                            A203154  002  May 06, 2013   Apr CHRS
AB        HARMAN FINOCHEM     100MG                            A214443  001  Mar 07, 2022   Feb NEWA
AB                            300MG                            A214443  002  Mar 07, 2022   Feb NEWA
        ZYLOPRIM
      +   CASPER PHARMA LLC   200MG                            N016084  003  Aug 04, 2022   Aug NEWA
AB    +                       300MG                            N016084  002                 Apr CHRS

    ALLOPURINOL SODIUM
      INJECTABLE;INJECTION
        ALOPRIM
AP    +!  MYLAN               EQ 500MG BASE/VIAL               N020298  001  May 17, 1996   Apr CAHN

    ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE
      TABLET;ORAL
        OSENI
      + @ TAKEDA PHARMS USA   EQ 12.5MG BASE;EQ 15MG BASE      N022426  004  Jan 25, 2013   Mar DISC
      + @                     EQ 12.5MG BASE;EQ 45MG BASE      N022426  006  Jan 25, 2013   Mar DISC
```

ALOSETRON HYDROCHLORIDE

		TABLET;ORAL					
		ALOSETRON HYDROCHLORIDE					
		@ PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Apr DISC
		@	EQ 1MG BASE	A206113	002	Feb 23, 2018	Apr DISC

ALPELISIB

		TABLET;ORAL					
		VIJOICE					
	+	NOVARTIS	50MG	N215039	001	Apr 05, 2022	Apr NEWA
	+		125MG	N215039	002	Apr 05, 2022	Apr NEWA
	+!		200MG	N215039	003	Apr 05, 2022	Apr NEWA

ALPROSTADIL

		SUPPOSITORY;URETHRAL					
		MUSE					
	+ @	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996	Jul DISC

AMANTADINE HYDROCHLORIDE

		CAPSULE;ORAL					
		AMANTADINE HYDROCHLORIDE					
	@	STRIDES PHARMA	100MG	A211354	001	Feb 18, 2022	Aug DISC
AB			100MG	A211354	001	Feb 18, 2022	Feb NEWA
		CAPSULE, EXTENDED RELEASE;ORAL					
		GOCOVRI					
	+	ADAMAS OPERATIONS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug CAHN
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug CAHN
		SYRUP;ORAL					
		AMANTADINE HYDROCHLORIDE					
>A>	@	ANDA REPOSITORY	50MG/5ML	A076352	001	Sep 10, 2004	Sep CAHN
AA	!	CHARTWELL RX	50MG/5ML	A074028	001	Jun 28, 1993	Mar CAHN
>D>	@	GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Sep CAHN
		TABLET;ORAL					
		AMANTADINE HYDROCHLORIDE					
AB		EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022	May NEWA
	@	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	May DISC
		TABLET, EXTENDED RELEASE;ORAL					
		OSMOLEX ER					
	+	ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug CAHN
	+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug CAHN
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug CAHN
	+ @		EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug CAHN

AMBRISENTAN

		TABLET;ORAL					
		AMBRISENTAN					
AB		APOTEX	5MG	A210701	001	May 19, 2022	May NEWA
AB			10MG	A210701	002	May 19, 2022	May NEWA
AB		AUROBINDO PHARMA	5MG	A216531	001	Jul 21, 2022	Jul NEWA
AB			10MG	A216531	002	Jul 21, 2022	Jul NEWA

AMCINONIDE

		CREAM;TOPICAL					
		AMCINONIDE					
AB	!	GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003	Aug CAHN
		LOTION;TOPICAL					
		AMCINONIDE					
>A>	!	ANDA REPOSITORY	0.1%	A076329	001	Nov 06, 2002	Sep CAHN
>D>	!	GENUS LIFESCIENCES	0.1%	A076329	001	Nov 06, 2002	Sep CAHN
	!		0.1%	A076329	001	Nov 06, 2002	Aug CAHN
		OINTMENT;TOPICAL					
		AMCINONIDE					
>A> AB	!	ANDA REPOSITORY	0.1%	A076096	001	Nov 19, 2002	Sep CAHN
>D> AB	!	GENUS LIFESCIENCES	0.1%	A076096	001	Nov 19, 2002	Sep CAHN
AB	!		0.1%	A076096	001	Nov 19, 2002	Aug CAHN

AMIFOSTINE

INJECTABLE;INJECTION

AMIFOSTINE

@	EUGIA PHARMA SPECLTS	500MG/VIAL	A204363	001	Jul 17, 2017	Mar CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

@	CHARTWELL RX	5MG	A204180	001	Aug 07, 2015	Aug CAHN
@	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	May DISC

AMINOCAPROIC ACID

SOLUTION;ORAL

AMINOCAPROIC ACID

AA	AGENIX	0.25GM/ML	A215510	001	Mar 23, 2022	Mar NEWA
>A> AA	AUROBINDO PHARMA	0.25GM/ML	A216804	001	Sep 26, 2022	Sep NEWA
AA	CARNEGIE	0.25GM/ML	A214140	001	Jan 26, 2021	Jun CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB	CARNEGIE	500MG	A213928	001	Feb 12, 2021	Jun CAHN
AB		1GM	A213928	002	Feb 12, 2021	Jun CAHN
>A> AB	OPTIMUS	500MG	A213944	001	Sep 14, 2022	Sep NEWA
>A> AB		1GM	A213944	002	Sep 14, 2022	Sep NEWA

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

@	EUGIA PHARMA	50MG/ML	A204550	001	Oct 25, 2017	Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D> AB	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	Sep CAHN
AB		10MG	A216243	001	Jun 06, 2022	May NEWA
>D> AB		25MG	A216243	002	Jun 06, 2022	Sep CAHN
AB		25MG	A216243	002	Jun 06, 2022	May NEWA
>D> AB		50MG	A216243	003	Jun 06, 2022	Sep CAHN
AB		50MG	A216243	003	Jun 06, 2022	May NEWA
>D> AB		75MG	A216243	004	Jun 06, 2022	Sep CAHN
AB		75MG	A216243	004	Jun 06, 2022	May NEWA
>D> AB		100MG	A216243	005	Jun 06, 2022	Sep CAHN
AB		100MG	A216243	005	Jun 06, 2022	May NEWA
>D> AB		150MG	A216243	006	Jun 06, 2022	Sep CAHN
AB		150MG	A216243	006	Jun 06, 2022	May NEWA
>A> AB	LEADING	10MG	A216243	001	Jun 06, 2022	Sep CAHN
>A> AB		25MG	A216243	002	Jun 06, 2022	Sep CAHN
>A> AB		50MG	A216243	003	Jun 06, 2022	Sep CAHN
>A> AB		75MG	A216243	004	Jun 06, 2022	Sep CAHN
>A> AB		100MG	A216243	005	Jun 06, 2022	Sep CAHN
>A> AB		150MG	A216243	006	Jun 06, 2022	Sep CAHN
@	UPSHER SMITH LABS	10MG	A212654	002	Sep 29, 2021	May DISC
@		25MG	A212654	001	Apr 07, 2020	May DISC
@		50MG	A212654	003	Sep 29, 2021	May DISC
@		75MG	A212654	004	Sep 29, 2021	May DISC
@		100MG	A212654	005	Sep 29, 2021	May DISC
@		150MG	A212654	006	Sep 29, 2021	May DISC
@	VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997	Jun DISC
@		25MG	A040218	002	Sep 11, 1997	Jun DISC
@		50MG	A040218	003	Sep 11, 1997	Jun DISC
@		75MG	A040218	004	Sep 11, 1997	Jun DISC
@		100MG	A040218	005	Sep 11, 1997	Jun DISC
@		150MG	A040218	006	Sep 11, 1997	Jun DISC

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Jan NEWA
AB		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Jan NEWA
AB	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Jan CTEC
AB !		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Jan CTEC
@	UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Apr CAHN
@		EQ 25MG BASE;10MG	A070766	001	Dec 10, 1986	Apr CAHN

AMLODIPINE BESYLATE

SOLUTION;ORAL

NORLIQVA

	+!	CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022	Feb NEWA

TABLET;ORAL

AMLODIPINE BESYLATE

	@	CHARTWELL RX	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
	@		EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
	@		EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN
AB		TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Mar CMFD
AB			EQ 5MG BASE	A076846	002	Jun 28, 2007	Mar CMFD
AB			EQ 10MG BASE	A076846	003	Jun 28, 2007	Mar CMFD

NORVASC

AB	+	VIATRIS	EQ 2.5MG BASE	N019787	001	Jul 31, 1992	Jan CAHN
AB	+		EQ 5MG BASE	N019787	002	Jul 31, 1992	Jan CAHN
AB	+!		EQ 10MG BASE	N019787	003	Jul 31, 1992	Jan CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015	Jun CMFD
AB			EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015	Jun CMFD
AB			EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015	Jun CMFD
AB			EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015	Jun CMFD
AB			EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015	Jun CMFD

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

	@	TORRENT	EQ 5MG BASE;20MG	A202933	001	Nov 25, 2016	Aug DISC
	@		EQ 5MG BASE;40MG	A202933	002	Nov 25, 2016	Aug DISC
	@		EQ 10MG BASE;20MG	A202933	003	Nov 25, 2016	Aug DISC
	@		EQ 10MG BASE;40MG	A202933	004	Nov 25, 2016	Aug DISC

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

	@	TORRENT	EQ 5MG BASE;40MG	A202517	001	Jan 08, 2014	Mar DISC
	@		EQ 5MG BASE;80MG	A202517	003	Jan 08, 2014	Mar DISC
	@		EQ 10MG BASE;40MG	A202517	002	Jan 08, 2014	Mar DISC
	@		EQ 10MG BASE;80MG	A202517	004	Jan 08, 2014	Mar DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		HETERO LABS	EQ 5MG BASE;160MG	A205137	001	Sep 16, 2016	Aug CAHN
AB			EQ 5MG BASE;320MG	A205137	003	Sep 16, 2016	Aug CAHN
AB			EQ 10MG BASE;160MG	A205137	002	Sep 16, 2016	Aug CAHN
AB			EQ 10MG BASE;320MG	A205137	004	Sep 16, 2016	Aug CAHN
AB		STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013	Jun CMFD
AB			EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013	Jun CMFD
AB			EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013	Jun CMFD
AB			EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013	Jun CMFD

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

	+ @	SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Aug CRLD

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB		MICRO LABS	250MG	A207471	001	Jun 24, 2022	Jun NEWA
AB			500MG	A207471	002	Jun 24, 2022	Jun NEWA

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PACK

	+!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May NEWA

VOQUEZNA TRIPLE PAK

	+!	PHATHOM	500MG;500MG;EQ 20MG BASE	N215152	001	May 03, 2022	May CMS1

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PACK

+!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May	NEWA

VOQUEZNA DUAL PAK

+!	PHATHOM	500MG;EQ 20MG BASE	N215153	001	May 03, 2022	May	CMS1

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403	001	Nov 26, 2021	May	DISC
	@		2.5MG;2.5MG;2.5MG;2.5MG	A214403	002	Nov 26, 2021	May	DISC
	@		3.75MG;3.75MG;3.75MG;3.75MG	A214403	003	Nov 26, 2021	May	DISC
	@		5MG;5MG;5MG;5MG	A214403	004	Nov 26, 2021	May	DISC
	@		6.25MG;6.25MG;6.25MG;6.25MG	A214403	005	Nov 26, 2021	May	DISC
	@		7.5MG;7.5MG;7.5MG;7.5MG	A214403	006	Nov 26, 2021	May	DISC

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@	ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jul	DISC
>D>	AB	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Sep	DISC
>A>	@		3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Sep	DISC
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	NEWA
>D>	AB		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Sep	DISC
>A>	@		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Sep	DISC
	AB		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	NEWA
>D>	AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Sep	DISC
>A>	@		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Sep	DISC
	AB		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	NEWA
>D>	AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Sep	DISC
>A>	@		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Sep	DISC
	AB		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	@	ACCORD HLTHCARE	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov 22, 2021	Jul	DISC
	@		1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov 22, 2021	Jul	DISC
	@		2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov 22, 2021	Jul	DISC
	@		3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov 22, 2021	Jul	DISC
	@		3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov 22, 2021	Jul	DISC
	@		5MG;5MG;5MG;5MG	A214347	006	Nov 22, 2021	Jul	DISC
	@		7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov 22, 2021	Jul	DISC
	AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jun	NEWA
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jun	NEWA
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jun	NEWA
	AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jun	NEWA
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jun	NEWA
>D>	AB	LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Sep	DISC
>A>	@		1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Sep	DISC
	AB		1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul 08, 2022	Jul	NEWA
>D>	AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Sep	DISC
>A>	@		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Sep	DISC
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul 08, 2022	Jul	NEWA
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Sep	DISC
>A>	@		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Sep	DISC
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul 08, 2022	Jul	NEWA
>D>	AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Sep	DISC
>A>	@		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Sep	DISC
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul 08, 2022	Jul	NEWA
>D>	AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Sep	DISC
>A>	@		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Sep	DISC
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul 08, 2022	Jul	NEWA
>D>	AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Sep	DISC
>A>	@		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Sep	DISC
	AB		5MG;5MG;5MG;5MG	A215565	006	Jul 08, 2022	Jul	NEWA
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Sep	DISC
>A>	@		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Sep	DISC
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul 08, 2022	Jul	NEWA
	AB	ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017	Mar	CAHN
	AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017	Mar	CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017	Mar	CAHN
	AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017	Mar	CAHN
	AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017	Mar	CAHN
	AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017	Mar	CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017	Mar	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>A>	AA	RISE PHARMA	5MG	A212901	001	May 22, 2020	Sep CAHN
>A>	AA		10MG	A212901	002	May 22, 2020	Sep CAHN
>D>	AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Sep CAHN
>D>	AA		10MG	A212901	002	May 22, 2020	Sep CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	@	AZURITY	2.5MG	N209905	005	Apr 16, 2021	Apr CAHN
+			5MG	N209905	001	Jan 30, 2019	Apr CAHN
+			10MG	N209905	002	Jan 30, 2019	Apr CAHN
+			15MG	N209905	003	Jan 30, 2019	Apr CAHN
+!			20MG	N209905	004	Jan 30, 2019	Apr CAHN

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

	@	MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Aug DISC
	@		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Aug DISC

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

AP	+!	MDD US	30MG/3ML (10MG/ML)	N021264	002	Apr 20, 2004	Feb CFTG

APOMORPHINE HYDROCHLORIDE

AP		SAGE CHEMS	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Feb NFTG

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

IOPIDINE

AT	+!	IMPRIMIS PHARMS USA	EQ 0.5% BASE	N020258	001	Jul 30, 1993	Jun CAHN
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987	Jun CAHN

APREMILAST

TABLET;ORAL

APREMILAST

	@	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jan DISC
	@		20MG	A211782	002	Jun 30, 2021	Jan DISC
	@		30MG	A211782	003	Jun 30, 2021	Jan DISC
AB		TEVA PHARMS USA INC	10MG	A211897	001	Aug 18, 2022	Aug NEWA
AB			20MG	A211897	002	Aug 18, 2022	Aug NEWA
AB			30MG	A211897	003	Aug 18, 2022	Aug NEWA

APREPITANT

EMULSION;INTRAVENOUS

>A>		APONVIE					
>A>	+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	N216457	001	Sep 16, 2022	Sep NEWA

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

AN		ALEMBIC PHARMS LTD	EQ 0.015MG BASE/2ML	A214779	001	May 10, 2022	Apr NEWA
AN		LUPIN	EQ 0.015MG BASE/2ML	A213068	001	Feb 07, 2022	Jan NEWA
>A>	@	RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Sep CAHN
>A>	AN	SLATE RUN PHARMA	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep CAHN
AN		SUN PHARM	EQ 0.015MG BASE/2ML	A215385	001	May 26, 2022	May NEWA
>D>	AN	TAP	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep CAHN
AN			EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Apr CAHN
>D>	@	VISTAPHARM	EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Sep CAHN
	@		EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Aug DISC
AN			EQ 0.015MG BASE/2ML	A214736	001	Mar 02, 2022	Feb NEWA

ARGATROBAN

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

+	@	CIPLA	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	Apr CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	!	FRESENIUS KABI USA	1MG/ML	A208231	001	Aug 31, 2018	Apr	CHRS
AP		GLAND PHARMA LTD	1MG/ML	A215059	002	Apr 22, 2022	Apr	NEWA

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE

	+!	AMIVAS	110MG/VIAL	N213036	001	May 26, 2020	Feb	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

	+ @	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001	Sep 21, 2000	Jan	DISC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT

	+ @	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001	Jan 30, 2004	Jan	DISC

M.V.I. ADULT (PHARMACY BULK PACKAGE)

	+ @	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001	Feb 18, 2004	Jan	DISC

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

	+!	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Mar	CHRS
	+		7.6MG/24HR	N212268	003	Oct 11, 2019	Mar	CHRS

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	@	LGM PHARMA	500MG;50MG;40MG	A205230	001	Oct 18, 2021	Apr	DISC
AA		NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007	Apr	CMFD

FIORINAL

	+ @	ALLERGAN	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jun	DISC
AA	+		325MG;50MG;40MG	N017534	005	Apr 16, 1986	Apr	CHRS

LANORINAL

AA	!	LANNETT	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Apr	CHRS

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	+ @	HIKMA INTL PHARMS	325MG;50MG;40MG	A086162	002	Feb 16, 1984	Mar	CRLD

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	@	MAYNE PHARMA INC	325MG;50MG;40MG;30MG	A203335	001	Oct 30, 2015	Jan	DISC
AB	!	STEVENS J	325MG;50MG;40MG;30MG	A074951	001	Aug 31, 1998	May	CHRS

FIORINAL W/CODEINE

	+ @	ALLERGAN	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	May	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC

		GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998	Mar	CMFD

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

	@ INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

	! LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021	Jul CMFD

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	HETERO LABS LTD III	EQ 150MG BASE	A212278	001	Feb 02, 2022	Jan NEWA
AB		EQ 200MG BASE	A212278	002	Feb 02, 2022	Jan NEWA
AB		EQ 300MG BASE	A212278	003	Feb 02, 2022	Jan NEWA

REYATAZ

	+ @ BRISTOL MYERS SQUIBB	EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr DISC

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

>A> AB	AGNITIO	EQ 10MG BASE	A214969	001	Sep 02, 2021	Sep CAHN
>A> AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Sep CAHN
>A> AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Sep CAHN
>A> AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Sep CAHN
>D> AB	AUGUST	EQ 10MG BASE	A214969	001	Sep 02, 2021	Sep CAHN
>D> AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Sep CAHN
>D> AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Sep CAHN
>D> AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Sep CAHN
AB	DR REDDYS	EQ 10MG BASE	A214659	001	Jul 14, 2021	Aug CMFD
AB		EQ 20MG BASE	A214659	002	Jul 14, 2021	Aug CMFD
AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Aug CMFD
AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Aug CMFD

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

>D>	@ SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep CTNA
>D>	@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep CTNA
>D>	@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep CTNA
>D>	@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Sep CTNA

LYPQOZET

>A>	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Sep CTNA
>A>		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Sep CTNA
>A>		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Sep CTNA
>A>	!	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Sep CTNA

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

	+! MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	May CAHN
	+!	EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	May CAHN
	+!	EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	May CAHN
	+!	EQ 2MG SULFATE/0.7ML	N017106	001		May CAHN

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	+! ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	May CFTG
AP	+!	1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	May CFTG
AP	AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	May NFTG
AP		1MG/ML (1MG/ML)	A216120	002	May 26, 2022	May NFTG
AP	AMNEAL	0.5MG/5ML (0.1MG/ML)	A215342	001	Jan 26, 2022	Jan NEWA
AP	+! HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jan CMFD

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AT	AMNEAL	1%	A214752	001	Jul 14, 2022	Jul NEWA
	+! BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022	Jul CAHN
	+! PARAGON BIOTECK	1%	N213581	001	Mar 15, 2022	Jul NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	CHARTWELL RX	0.025MG;2.5MG	A207128	001	Oct 21, 2020	Jun CAHN
	@ MAYNE PHARMA INC	0.025MG;2.5MG	A210789	001	Jun 03, 2020	Jan DISC

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

DUODOTE

+!	MMT	2.1MG/0.7ML;600MG/2ML	N021983	001	Sep 28, 2006	Jan CAHN

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Jan NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

	@ AKORN	0.05%	A203660	001	Nov 08, 2016	Aug DISC

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

	@ APOTEX INC	0.2055MG/SPRAY	A201846	001	Aug 31, 2012	May DISC
	@ AUROBINDO PHARMA LTD	0.2055MG/SPRAY	A212775	001	Nov 12, 2020	May DISC
	@ HIKMA	0.2055MG/SPRAY	A207243	001	Sep 22, 2017	May DISC

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

	@ LUPIN LTD	EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Aug DISC
AB		EQ 40MG MEDOXOMIL	A214489	001	Jul 20, 2022	Jul NFTG
	@	EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Aug DISC
AB		EQ 80MG MEDOXOMIL	A214489	002	Jul 20, 2022	Jul NFTG

EDARBI

+	AZURITY	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Aug CTEC
AB +		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jul CFTG
+		EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Mar CAHN
+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Aug CTEC
AB +!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jul CFTG
+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Mar CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Mar CAHN
+!		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Mar CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

>D> AB	TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Sep DISC
>A>	@	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Sep DISC

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+!	THEA PHARMA	1%	N050810	001	Apr 27, 2007	Apr CAHN

TABLET;ORAL

AZITHROMYCIN

AB	ACI	EQ 250MG BASE	A215772	001	Jul 15, 2022	Jul NEWA
AB		EQ 500MG BASE	A215773	001	Jul 12, 2022	Jul NEWA
AB	ATLANTIDE	EQ 250MG BASE	A065404	001	Feb 11, 2008	Apr CAHN
AB		EQ 500MG BASE	A065405	001	Feb 11, 2008	Apr CAHN
AB		EQ 600MG BASE	A065302	003	Feb 11, 2008	Apr CAHN
AB	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Jul NEWA

BACLOFEN

GRANULES;ORAL

LYVISPAH

+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Feb CAHN
+		10MG/PACKET	N215422	002	Nov 22, 2021	Feb CAHN
+!		20MG/PACKET	N215422	003	Nov 22, 2021	Feb CAHN

		INJECTABLE;INTRATHECAL					
		BACLOFEN					
AP		AMNEAL	0.05MG/ML	A091193	001	May 03, 2016	Jun CAHN
AP			0.5MG/ML	A091193	002	May 03, 2016	Jun CAHN
AP			2MG/ML	A091193	003	May 03, 2016	Jun CAHN
		LIORESAL					
AP	+!	AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
AP	+!		0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
AP	+!		2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN
		SUSPENSION;ORAL					
		FLEQSUVY					
	+!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb NEWA
		TABLET;ORAL					
		BACLOFEN					
AB		MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan NEWA
AB			10MG	A215885	002	Jan 25, 2022	Jan NEWA
AB			20MG	A215885	003	Jan 25, 2022	Jan NEWA
		BARICITINIB					
		TABLET;ORAL					
		OLUMIANT					
	+	ELI LILLY AND CO	4MG	N207924	003	May 10, 2022	May NEWA
		BENAZEPRIL HYDROCHLORIDE					
		TABLET;ORAL					
		LOTENSIN					
	+ @	VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Jun DISC
		BENZONATATE					
		CAPSULE;ORAL					
		BENZONATATE					
AA		ACELLA	100MG	A091310	001	Jan 16, 2015	Jan CAHN
AA			200MG	A091310	002	Jan 16, 2015	Jan CAHN
AA	!	THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Jan CMS1
AA	!		150MG	A040627	003	Sep 24, 2014	Jan CMS1
AA	!		200MG	A040627	002	Jul 25, 2007	Mar CMS1
		BENZOYL PEROXIDE					
		CREAM;TOPICAL					
		EPSOLAY					
	+!	GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022	Jun CAHN
	+!	SOL GEL TECHNOLOGIES	5%	N214510	001	Apr 22, 2022	Apr NEWA
		BENZOYL PEROXIDE; ERYTHROMYCIN					
		GEL;TOPICAL					
		ERYTHROMYCIN AND BENZOYL PEROXIDE					
		@ ENCUBE	5%;3%	A065112	001	Mar 29, 2004	Jul CAHN
		BENZOYL PEROXIDE; TRETINOIN					
		CREAM;TOPICAL					
		TWYNEO					
	+!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Mar CMFD
	+ @		3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
	+ @	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC
		BENZPHETAMINE HYDROCHLORIDE					
		TABLET;ORAL					
		BENZPHETAMINE HYDROCHLORIDE					
		CHARTWELL	25MG	A090473	001	Sep 15, 2010	Apr CAHN
AA			50MG	A090473	002	Sep 15, 2010	Apr CAHN
		MIKART	25MG	A090473	001	Sep 15, 2010	Mar CAHN
AA			50MG	A090473	002	Sep 15, 2010	Mar CAHN
		BENZTROPINE MESYLATE					
		INJECTABLE;INJECTION					
		BENZTROPINE MESYLATE					
AP	!	HIKMA FARMACEUTICA	1MG/ML	A090287	001	Aug 31, 2009	Mar CHRS
		COGENTIN					
	+ @	AKORN	1MG/ML	N012015	001		Mar DISC

BETAINE

FOR SOLUTION;ORAL

BETAINE

>A>	AB	ETON	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Sep CAHN
>D>	AB	LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Sep CAHN
	AB		1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

>D>	AB	AKORN	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Sep DISC
>A>		@	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Sep DISC

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Aug CAHN

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	PADAGIS ISRAEL	EQ 0.05% BASE	A215847	001	Apr 12, 2022	Apr NEWA
	AB	TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb NEWA

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Aug CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

		@ NOVAST LABS	0.12%	A207144	001	May 24, 2017	Aug CAHN

BEXAROTENE

GEL;TOPICAL

BEXAROTENE

	AB	AMNEAL	1%	A215398	001	Apr 27, 2022	Apr NFTG

TARGRETIN

	AB	+! BAUSCH	1%	N021056	001	Jun 28, 2000	Apr CFTG

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

>A>	AT	EUGIA PHARMA	0.03%	A205537	001	Oct 06, 2022	Sep NEWA

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	AB	CADILA	5MG	A215680	001	Jul 25, 2022	Jul NEWA
	AB		10MG	A215680	002	Jul 25, 2022	Jul NEWA
	AB	UNITED RES LABS	5MG	A075474	001	Oct 25, 2002	Apr CAHN
	AB		10MG	A075474	002	Oct 25, 2002	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	AB	GLENMARK PHARMS LTD	2.5MG;6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
	AB		5MG;6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
	AB		10MG;6.25MG	A215995	003	Jan 26, 2022	Jan NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

	AP	MEITHEAL	250MG/VIAL	A091602	001	Jul 16, 2018	Apr CAHN

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	AP	ACCORD HLTHCARE	3.5MG/VIAL	A204405	001	Jul 26, 2022	Jul NEWA
	AP	APOTEX	3.5MG/VIAL	A205533	001	May 02, 2022	Apr NFTG
	AP	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	Apr NFTG
	AP	DR REDDYS	3.5MG/VIAL	A202963	001	Jul 26, 2022	Jul NEWA
	AP	EUGIA PHARMA	3.5MG/VIAL	A212825	001	May 02, 2022	Apr NFTG
	AP	FRESENIUS KABI USA	3.5MG/VIAL	A209659	001	May 02, 2022	Apr NFTG
	AP	HOSPIRA	3.5MG/VIAL	A208460	001	Jul 26, 2022	Jul NEWA
	AP	JIANGSU HANSOH PHARM	3.5MG/VIAL	A215011	001	Jul 26, 2022	Jul NEWA

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

>D>	AP		KINDOS	3.5MG/VIAL	A212958	001	Jul 26, 2022	Sep CAHN
	AP			3.5MG/VIAL	A212958	001	Jul 26, 2022	Jul NEWA
>A>	AP		MEITHEAL	3.5MG/VIAL	A212958	001	Jul 26, 2022	Sep CAHN
	AP		MSN	3.5MG/VIAL	A209622	001	Jul 26, 2022	Jul NEWA
	AP		PHARMASCIENCE INC	3.5MG/VIAL	A208392	001	May 02, 2022	Apr NFTG
	AP		QILU PHARM HAINAN	3.5MG/VIAL	A210824	001	May 02, 2022	Apr NFTG
	AP		SANDOZ INC	3.5MG/VIAL	A203654	001	Jul 26, 2022	Jul NEWA
>A>	AP		WAVERLEY PHARMA INC	3.5MG/VIAL	A211898	001	Oct 11, 2022	Sep NEWA
	AP		ZYDUS PHARMS	3.5MG/VIAL	A210204	001	May 02, 2022	Apr NFTG

VELCADE

	AP	+!	TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003	Apr CFTG

POWDER;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

		+!	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022	May NEWA
		+!		2.5MG/VIAL	N209191	002	May 02, 2022	May NEWA

SOLUTION;INTRAVENOUS

BORTEZOMIB

		+!	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022	Jul NEWA
		+!		3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022	Jul NEWA
		+!	MAIA PHARMS INC	3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022	Jul NEWA

BOSENTAN

TABLET;ORAL

BOSENTAN

		@	CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020	Mar CAHN
		@		125MG	A210342	002	Jan 03, 2020	Mar CAHN

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

>A>	AB		SANDOZ INC	0.25MG	A213570	001	Sep 26, 2022	Sep NEWA
>A>	AB			0.5MG	A213570	002	Sep 26, 2022	Sep NEWA
>A>	AB			1MG	A213570	003	Sep 26, 2022	Sep NEWA
>A>	AB			2MG	A213570	004	Sep 26, 2022	Sep NEWA
>A>	AB			3MG	A213570	005	Sep 26, 2022	Sep NEWA
>A>	AB			4MG	A213570	006	Sep 26, 2022	Sep NEWA
	AB		TEVA PHARMS USA INC	0.25MG	A213692	001	Aug 11, 2022	Aug NFTG
	AB			0.5MG	A213692	002	Aug 11, 2022	Aug NFTG
	AB			1MG	A213692	003	Aug 11, 2022	Aug NFTG
	AB			2MG	A213692	004	Aug 11, 2022	Aug NFTG
	AB			3MG	A213692	005	Aug 11, 2022	Aug NFTG
	AB			4MG	A213692	006	Aug 11, 2022	Aug NFTG

REXULTI

	AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Aug CFTG
	AB	+		0.5MG	N205422	002	Jul 10, 2015	Aug CFTG
	AB	+		1MG	N205422	003	Jul 10, 2015	Aug CFTG
	AB	+!		2MG	N205422	004	Jul 10, 2015	Aug CFTG
	AB	+		3MG	N205422	005	Jul 10, 2015	Aug CFTG
	AB	+		4MG	N205422	006	Jul 10, 2015	Aug CFTG

BRIMONIDINE TARTRATE

GEL;TOPICAL

BRIMONIDINE TARTRATE

		@	PADAGIS ISRAEL	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Apr DISC

MIRVASO

		+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Apr CTEC

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

	AT		APOTEX	0.15%	A078479	001	Jan 31, 2022	Jan NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	AB		APOTEX INC	0.2%;EQ 0.5% BASE	A091442	001	Apr 20, 2022	Apr NEWA
	AB		SANDOZ INC	0.2%;EQ 0.5% BASE	A091087	001	Apr 04, 2022	Mar NFTG
>A>	AB		WATSON LABS TEVA	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep NEWA

COMBIGAN

	AB	+!	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007	Mar CFTG

BRINCIDOFOVIR

SUSPENSION;ORAL

TEMBEXA

>D>	+!	CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021	Sep	CAHN
>A>	+!	EMERGENT BIODEFENSE	10MG/ML	N214460	001	Jun 04, 2021	Sep	CAHN

TABLET;ORAL

TEMBEXA

>D>	+!	CHIMERIX	100MG	N214461	001	Jun 04, 2021	Sep	CAHN
>A>	+!	EMERGENT BIODEFENSE	100MG	N214461	001	Jun 04, 2021	Sep	CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

AB		BAUSCH AND LOMB	1%	A204884	001	Aug 18, 2021	Mar	CAHN

BRIVARACETAM

TABLET;ORAL

BRIVARACETAM

	@	SUNSHINE	10MG	A214748	001	Jun 09, 2022	Aug	DISC
AB			10MG	A214748	001	Jun 09, 2022	Jun	NFTG
	@		25MG	A214748	002	Jun 09, 2022	Aug	DISC
AB			25MG	A214748	002	Jun 09, 2022	Jun	NFTG
	@		50MG	A214748	003	Jun 09, 2022	Aug	DISC
AB			50MG	A214748	003	Jun 09, 2022	Jun	NFTG
	@		75MG	A214748	004	Jun 09, 2022	Aug	DISC
AB			75MG	A214748	004	Jun 09, 2022	Jun	NFTG
	@		100MG	A214748	005	Jun 09, 2022	Aug	DISC
AB			100MG	A214748	005	Jun 09, 2022	Jun	NFTG
>A> AB		ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022	Sep	NEWA
>A> AB			25MG	A214501	002	Oct 03, 2022	Sep	NEWA
>A> AB			50MG	A214501	003	Oct 03, 2022	Sep	NEWA
>A> AB			75MG	A214501	004	Oct 03, 2022	Sep	NEWA
>A> AB			100MG	A214501	005	Oct 03, 2022	Sep	NEWA

BRIVIACT

>D>	+	UCB INC	10MG	N205836	001	May 12, 2016	Sep	CTEC
>A> AB	+		10MG	N205836	001	May 12, 2016	Sep	CTEC
	+		10MG	N205836	001	May 12, 2016	Aug	CTEC
AB	+		10MG	N205836	001	May 12, 2016	Jun	CFTG
>D>	+		25MG	N205836	002	May 12, 2016	Sep	CTEC
>A> AB	+		25MG	N205836	002	May 12, 2016	Sep	CTEC
	+		25MG	N205836	002	May 12, 2016	Aug	CTEC
AB	+		25MG	N205836	002	May 12, 2016	Jun	CFTG
>D>	+		50MG	N205836	003	May 12, 2016	Sep	CTEC
>A> AB	+		50MG	N205836	003	May 12, 2016	Sep	CTEC
	+		50MG	N205836	003	May 12, 2016	Aug	CTEC
AB	+		50MG	N205836	003	May 12, 2016	Jun	CFTG
>D>	+		75MG	N205836	004	May 12, 2016	Sep	CTEC
>A> AB	+		75MG	N205836	004	May 12, 2016	Sep	CTEC
	+		75MG	N205836	004	May 12, 2016	Aug	CTEC
AB	+		75MG	N205836	004	May 12, 2016	Jun	CFTG
>D>	+!		100MG	N205836	005	May 12, 2016	Sep	CTEC
>A> AB	+!		100MG	N205836	005	May 12, 2016	Sep	CTEC
	+!		100MG	N205836	005	May 12, 2016	Aug	CTEC
AB	+!		100MG	N205836	005	May 12, 2016	Jun	CFTG

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

	@	CHARTWELL RX	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Apr	CAHN
AT2		EUGIA PHARMA	EQ 0.09% ACID	A204813	001	Mar 18, 2022	Mar	NEWA
	@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

	@	RHODES PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202955	001	Nov 05, 2020	Jun	DISC

BUDESONIDE

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

	@ NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
	@ SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Jul DISC

ORTIKOS

+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019	Jul CDFR
+!		9MG	N211929	002	Jun 13, 2019	Jul CDFR

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

BREYNA

AB		MYLAN	0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Jul CTNA
AB			0.08MG/INH;0.0045MG/INH	A211699	001	Mar 15, 2022	Mar NFTG
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Jul CTNA
AB			0.16MG/INH;0.0045MG/INH	A211699	002	Mar 15, 2022	Mar NFTG

SYMBICORT

AB	+!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Mar CFTG
AB	+!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Mar CFTG

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
AP		GLAND PHARMA LTD	0.25MG/ML	A216434	001	May 26, 2022	May NEWA
AP		MSN	0.25MG/ML	A215364	001	Aug 04, 2022	Jul NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

	+!	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CMFD
	+!	INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

	@	CIVICA	0.5%	A211096	001	Feb 19, 2019	Apr CAHN
	@	NOVOCOL PHARM	0.5%	A211096	001	Feb 19, 2019	Mar CAHN
	@	STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
	@		0.5%	A091503	002	Oct 18, 2011	Feb CAHN

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

	@	STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
	@		0.5%	A091487	001	Oct 18, 2011	Feb CAHN
	@		0.75%	A091487	003	Oct 18, 2011	Feb CAHN

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

ZYNRELEF KIT

+	@	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML	N211988	001	May 12, 2021	Apr DISC
+	@		300MG/10.5ML (29.25MG/ML);9MG/10.5ML	N211988	003	May 12, 2021	Apr DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB		ALVOGEN	5MCG/HR	A207490	001	May 17, 2022	May CAHN
AB			10MCG/HR	A207490	002	May 17, 2022	May CAHN
AB			15MCG/HR	A207490	003	May 17, 2022	May CAHN
AB			20MCG/HR	A207490	004	May 17, 2022	May CAHN
AB		ALVOGEN PINE BROOK	5MCG/HR	A207490	001	May 17, 2022	May NEWA
AB			10MCG/HR	A207490	002	May 17, 2022	May NEWA
AB			15MCG/HR	A207490	003	May 17, 2022	May NEWA
AB			20MCG/HR	A207490	004	May 17, 2022	May NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC

FILM;BUCCAL
BELBUCA

	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CTEC
	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CTEC
	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CTEC

BUPRENORPHINE HYDROCHLORIDE

	@	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan DISC
	@		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan DISC
	@		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan DISC
	@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
	@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
	@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC
	@		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		AVEVA	EQ 8MG BASE;EQ 2MG BASE	A212756	001	Jun 02, 2022	May NEWA
AB			EQ 12MG BASE;EQ 3MG BASE	A212756	002	Jun 02, 2022	May NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

>D> AB3		ADAPTIS	150MG	A211020	001	Jan 28, 2019	Sep CAHN
>D> AB3			300MG	A211020	002	Jan 28, 2019	Sep CAHN
	@	GRANULES	150MG	A215568	001	Feb 02, 2022	Jul DISC
AB3			150MG	A215568	001	Feb 02, 2022	Jan NEWA
	@		300MG	A215568	002	Feb 02, 2022	Jul DISC
AB3			300MG	A215568	002	Feb 02, 2022	Jan NEWA
>A> AB3		GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Sep CAHN
>A> AB3			300MG	A211020	002	Jan 28, 2019	Sep CAHN
AB3		WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb NEWA

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
AUVELITY

	+!	AXSOME	105MG;45MG	N215430	001	Aug 18, 2022	Aug NEWA

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL
BUSPAR

>D>	@	BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000	Sep CRLD
>A>	+ @		5MG	N021190	001	Dec 20, 2000	Sep CRLD
>D>	@		7.5MG	N021190	002	Dec 20, 2000	Sep CRLD
>A>	+ @		7.5MG	N021190	002	Dec 20, 2000	Sep CRLD
>D>	@		10MG	N021190	003	Dec 20, 2000	Sep CRLD
>A>	+ @		10MG	N021190	003	Dec 20, 2000	Sep CRLD
>D>	@		15MG	N021190	004	Dec 20, 2000	Sep CRLD
>A>	+ @		15MG	N021190	004	Dec 20, 2000	Sep CRLD

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB	!	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb CHRS
	@	MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
AB		TEVA	15MG	A075022	003	Feb 28, 2002	Feb CHRS

BUSULFAN

TABLET;ORAL
MYLERAN

	+!	WOODWARD SPECL	2MG	N009386	001		Apr CAHN

CABAZITAXEL

SOLUTION;INTRAVENOUS
CABAZITAXEL

	+ @	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021	Jul DISC
	@	BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022	Jul DISC
AP			60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022	Jun NFTG

JEVTANA KIT

	+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jul CTEC
AP	+!		60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010	Jun CFTG

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB		STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005	Mar CMFD

CAFFEINE CITRATE

SOLUTION;ORAL

CAFCIT

	+ @	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan DISC

CAFFEINE CITRATE

AA	!	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan CHRS

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

	+!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983	Jul CRLD

CALCIPOTRIENE

OINTMENT;TOPICAL

CALCIPOTRIENE

>D>	!	GLENMARK GENERICS	0.005%	A090633	001	Mar 24, 2010	Sep CTEC
>A> AB	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010	Sep CTEC

DOVONEX

>D>	+ @	LEO PHARMA AS	0.005%	N020273	001	Dec 29, 1993	Sep CMFD
>A> AB	+		0.005%	N020273	001	Dec 29, 1993	Sep CMFD

CALCITONIN SALMON

SPRAY, METERED;NASAL

CALCITONIN-SALMON

	!	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul CTEC
	@	PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S

>D> AP		FRESENIUS KABI USA	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Sep DISC
>A>	@		20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Sep DISC
AP			20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A210332	001	Mar 28, 2022	Mar NEWA

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	@	FRESENIUS KABI USA	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	A211428	001	Nov 09, 2021	Apr DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

	@	AKORN	0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML	A075503	001	Sep 27, 2006	Aug DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

	@	FRESENIUS KABI USA	17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML	A214623	001	Feb 18, 2022	Aug DISC
AT			17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML	A214623	001	Feb 18, 2022	Feb NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

>D> AB		AMNEAL PHARMS	150MG	A204741	001	Feb 28, 2017	Sep DISC
>A>	@		150MG	A204741	001	Feb 28, 2017	Sep DISC
>D> AB			500MG	A204741	002	Feb 28, 2017	Sep DISC
>A>	@		500MG	A204741	002	Feb 28, 2017	Sep DISC

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB	ATLANTIDE	12.5MG	A074532	001	Mar 28, 1997	Mar	CAHN
AB		25MG	A074532	002	Mar 28, 1997	Mar	CAHN
AB		50MG	A074532	003	Mar 28, 1997	Mar	CAHN
AB		100MG	A074532	004	Mar 28, 1997	Mar	CAHN

CARBAMAZEPINE

SUSPENSION;ORAL

CARBAMAZEPINE

>A> AB	NOVITIUM PHARMA	100MG/5ML	A214277	001	Oct 06, 2022	Sep	NEWA

TABLET;ORAL

CARBAMAZEPINE

AB	UNICHEM	200MG	A213284	001	Aug 22, 2022	Aug	NEWA
@	VGYAAN	200MG	A214328	001	Aug 16, 2021	Feb	DISC

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB	TARO PHARM INDS	100MG	A075687	001	Oct 24, 2000	Aug	CHRS

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	UMEDICA LABS PVT LTD	100MG	A216594	001	Aug 18, 2022	Aug	NEWA
AB		200MG	A216594	002	Aug 18, 2022	Aug	NEWA
AB		400MG	A216594	003	Aug 18, 2022	Aug	NEWA
AB	ZHEJIANG JIUZHOU	100MG	A215591	001	Mar 31, 2022	Mar	NEWA
AB		200MG	A215591	002	Mar 31, 2022	Mar	NEWA
AB		400MG	A215591	003	Mar 31, 2022	Mar	NEWA

CARBIDOPA

TABLET;ORAL

CARBIDOPA

@	ANI PHARMS	25MG	A203261	001	Mar 10, 2014	Jun	DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	RISING	12.5MG;200MG;50MG	A213212	001	Jan 25, 2022	Jan	NEWA
AB		18.75MG;200MG;75MG	A213212	002	Jan 25, 2022	Jan	NEWA
AB		25MG;200MG;100MG	A213212	003	Jan 25, 2022	Jan	NEWA
AB		31.25MG;200MG;125MG	A213212	004	Jan 25, 2022	Jan	NEWA
AB		37.5MG;200MG;150MG	A213212	005	Jan 25, 2022	Jan	NEWA
AB		50MG;200MG;200MG	A213212	006	Jan 25, 2022	Jan	NEWA

STALEVO 125

AB +	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Jan	CTEC

STALEVO 200

AB +!	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Jan	CTEC

STALEVO 50

AB +!	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Jan	CTEC

STALEVO 75

AB +	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Jan	CTEC

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

>A> AB	RUBICON	10MG;100MG	A216505	001	Sep 21, 2022	Sep	NEWA
>A> AB		25MG;100MG	A216505	002	Sep 21, 2022	Sep	NEWA
>A> AB		25MG;250MG	A216505	003	Sep 21, 2022	Sep	NEWA

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP	TEYRO LABS	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	Apr	CAHN
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	Apr	CAHN
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	Apr	CAHN
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	Apr	CAHN

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

		AP	AMNEAL	EQ 0.25MG BASE/ML	A215337	001	Jan 27, 2022	Jan NEWA
		AP	LONG GROVE PHARMS	EQ 0.25MG BASE/ML	A214499	001	Aug 09, 2022	Jul NEWA

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARGLUMIC ACID

		AB	NAVINTA LLC	200MG	A213395	001	Jun 22, 2022	Jun NEWA

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

>A>	AB		SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022	Sep NEWA
>A>	AB			EQ 3MG BASE	A213932	002	Sep 30, 2022	Sep NEWA
>A>	AB			EQ 4.5MG BASE	A213932	003	Sep 30, 2022	Sep NEWA
>A>	AB			EQ 6MG BASE	A213932	004	Sep 30, 2022	Sep NEWA
>A>	AB		ZYDUS PHARMS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022	Sep NFTG
>A>	AB			EQ 3MG BASE	A213984	002	Sep 09, 2022	Sep NFTG
>A>	AB			EQ 4.5MG BASE	A213984	003	Sep 09, 2022	Sep NFTG
>A>	AB			EQ 6MG BASE	A213984	004	Sep 09, 2022	Sep NFTG

VRAYLAR

>D>		+	ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep CFTG
>A>	AB	+		EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep CFTG
>D>		+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep CFTG
>A>	AB	+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep CFTG
>D>		+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep CFTG
>A>	AB	+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep CFTG
>D>		+!		EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep CFTG
>A>	AB	+!		EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep CFTG

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>A>	AA		CHARTWELL RX	350MG	A040245	001	Sep 08, 1997	Sep CAHN
>D>	AA		MLV	350MG	A040245	001	Sep 08, 1997	Sep CAHN
	AA		WANBANG BIOPHARMS	350MG	A081025	001	Apr 13, 1989	Jun CAHN

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

		+!	AZURITY	7.7MG	N020637	001	Sep 23, 1996	Jun CAHN

INJECTABLE;INJECTION

CARMUSTINE

		AP	INGENUS PHARMS LLC	100MG/VIAL	A211011	001	Jun 21, 2022	Jun NEWA

POWDER;INTRAVENOUS

CARMUSTINE

		+!	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May NEWA
		+!		300MG/VIAL	N215000	002	May 16, 2022	May NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

TABLET;ORAL

CEFADROXIL

		AB	! TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987	Mar CTEC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

			QILU	EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Mar NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

		AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jan CMFD
		AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jan CMFD

CEFIXIME

CAPSULE;ORAL

CEFIXIME

AB		ALKEM LABS LTD	400MG	A210574	001	Oct 09, 2018	Aug CTEC
			400MG	A210574	001	Oct 09, 2018	Aug CHRS

SUPRAX

AB	+!	LUPIN LTD	400MG	N203195	001	Jun 01, 2012	Aug CMFD

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN IN PLASTIC CONTAINER

	@	PAI HOLDINGS PHARM	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Apr CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Apr CAHN

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+	@	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jul DISC
+	@		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jul DISC

CEFPODOXIME PROXETIL

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		ALKEM LABS LTD	EQ 100MG BASE	A210568	001	May 18, 2022	May NEWA
AB			EQ 200MG BASE	A210568	002	May 18, 2022	May NEWA

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

	@	CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005	Mar CAHN
	@		250MG/5ML	A065236	002	Dec 08, 2005	Mar CAHN

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

	@	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Mar DISC
	@		600MG/VIAL	A208075	002	Sep 21, 2021	Mar DISC

TEFLARO

	+!	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Mar CTEC
	+!		600MG/VIAL	N200327	002	Oct 29, 2010	Mar CTEC

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME IN DEXTROSE CONTAINER

+	@	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jul DISC
+	@		EQ 2GM BASE	N050823	002	Jun 13, 2011	Jul DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		ATLANTIDE	EQ 1GM BASE/VIAL	A065180	001	May 12, 2006	Apr CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		ATLANTIDE	EQ 250MG BASE/VIAL	A065391	001	Apr 12, 2007	Apr CAHN
AP			EQ 500MG BASE/VIAL	A065391	002	Apr 12, 2007	Apr CAHN
AP			EQ 2GM BASE/VIAL	A065391	003	Apr 12, 2007	Apr CAHN

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ATLANTIDE	EQ 125MG BASE	A065166	001	Jul 29, 2005	Mar CAHN
AB			EQ 250MG BASE	A065166	002	Jul 29, 2005	Mar CAHN
AB			EQ 500MG BASE	A065166	003	Jul 29, 2005	Mar CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

ZINACEF

AP	+!	PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP	+!		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+!	PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

	@	UNICHEM	50MG	A213301	001	Jan 12, 2021	Feb DISC
	@		100MG	A213301	002	Jan 12, 2021	Feb DISC
	@		200MG	A213301	003	Jan 12, 2021	Feb DISC
	@		400MG	A213301	004	Jan 12, 2021	Feb DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

	@	ATLANTIDE	5MG/5ML	A078757	001	Aug 28, 2009	Apr CAHN
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Jun CAHN
	@	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jun DISC
AA			5MG/5ML	A078870	001	Apr 27, 2009	May CMFD

CETRORELIX

POWDER;SUBCUTANEOUS

CETROTIDE

AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CFTG

CETRORELIX ACETATE

INJECTABLE;INJECTION

CETROTIDE

	@	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CAIN

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP		AKORN	EQ 0.25MG BASE/VIAL	A215737	001	Aug 12, 2022	Aug NFTG

CETROTIDE

AP	+!	EMD SERONO INC	EQ 0.25MG BASE/VIAL	N021197	001	Aug 11, 2000	Aug CAIN
	+ @		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CRLD
	@		EQ 3MG BASE/VIAL	N021197	002	Aug 11, 2000	Aug CPOT
	@		EQ 3MG BASE/ML	N021197	002	Aug 11, 2000	Aug CDFR

CHLORAMBUCIL

TABLET;ORAL

LEUKERAN

	+!	WOODWARD SPECL	2MG	N010669	002		Apr CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	!	BARR	25MG	A084769	001		Aug CHRS
AB		CHARTWELL RX	5MG	A084678	001		Jul CMFD
AB			10MG	A084041	001		Jul CMFD
AB			25MG	A084679	002		Jul CMFD

LIBRIUM

AB	+	BAUSCH	25MG	A085475	001		Aug CHRS
AB	+!		25MG	A085475	001		Jul CAHN
AB	+	VALEANT PHARM INTL	5MG	A085461	001		Jan CRLD
AB	+		10MG	A085472	001		Jan CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

	AB	CHARTWELL RX	5MG;2.5MG	A213530	001	Oct 20, 2020	Jun CAHN
>D>	AB	COREPHARMA	5MG;2.5MG	A215453	001	Jul 29, 2022	Sep CAHN
	AB		5MG;2.5MG	A215453	001	Jul 29, 2022	Jul NEWA
	AB	MICRO LABS	5MG;2.5MG	A215835	001	Jul 19, 2022	Jul NEWA
	@	TEVA PHARMS USA	5MG;2.5MG	A211476	001	Nov 02, 2021	Jun DISC
>A>	AB	WESTMINSTER PHARMS	5MG;2.5MG	A215453	001	Jul 29, 2022	Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

	@	AKORN	0.12%	A074356	001	May 07, 1996	Jul DISC
>D>		PAROEX					
>D>	AT	SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005	Sep DISC
>A>	@		0.12%	A076434	001	Nov 29, 2005	Sep DISC

		SOLUTION;DENTAL						
		PERIOGARD						
		@ COLGATE PALMOLIVE CO	0.12%		A073695	001	Jan 14, 1994	Apr DISC
		TABLET;DENTAL						
		PERIOCHIP						
		+ @ DEXCEL PHARMA	2.5MG		N020774	001	May 15, 1998	Aug DISC
		CHLOROPROCAINE HYDROCHLORIDE						
>A>		GEL;OPHTHALMIC						
>A>		IHEEZO						
>A>		+! SINTETICA SA	3%		N216227	001	Sep 27, 2022	Sep NEWA
		CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX						
		SUSPENSION, EXTENDED RELEASE;ORAL						
		TUZISTRA XR						
		+! TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML		N207768	001	Apr 30, 2015	Jun CAHN
		CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX						
		CAPSULE, EXTENDED RELEASE;ORAL						
		TUSSICAPS						
		@ ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE		A077273	002	Sep 24, 2007	Feb DISC
		@	EQ 8MG MALEATE;EQ 10MG BITARTRATE		A077273	001	Sep 24, 2007	Feb DISC
		CHLORPROMAZINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		CHLORPROMAZINE HYDROCHLORIDE						
>D>	AP	! WEST-WARD PHARMS INT	25MG/ML		A083329	001		Sep CRLD
>A>	AP	+!	25MG/ML		A083329	001		Sep CRLD
		TABLET;ORAL						
		CHLORPROMAZINE HYDROCHLORIDE						
		@ APPCO	10MG		A213590	001	Aug 31, 2020	Mar CAHN
		@	25MG		A213590	002	Aug 31, 2020	Mar CAHN
		@	50MG		A213590	003	Aug 31, 2020	Mar CAHN
		@	100MG		A213590	004	Aug 31, 2020	Mar CAHN
		@	200MG		A213590	005	Aug 31, 2020	Mar CAHN
	AB	MSN	25MG		A214827	001	Jan 27, 2022	Jan NEWA
	AB		50MG		A214827	002	Jan 27, 2022	Jan NEWA
	AB		100MG		A214827	003	Jan 27, 2022	Jan NEWA
	AB		200MG		A214827	004	Jan 27, 2022	Jan NEWA
		CHLORTHALIDONE						
		TABLET;ORAL						
		CHLORTHALIDONE						
	AB	ALEMBIC PHARMS LTD	25MG		A216262	001	Aug 26, 2022	Aug NEWA
	AB		50MG		A216262	002	Aug 26, 2022	Aug NEWA
	AB	CHARTWELL RX	25MG		A211063	001	Feb 26, 2019	Jan CAHN
	AB		50MG		A211063	002	Feb 26, 2019	Jan CAHN
	AB	INVENTIA	25MG		A211320	001	Feb 09, 2022	Jan NEWA
	AB		50MG		A211320	002	Feb 09, 2022	Jan NEWA
	AB	MANKIND PHARMA	25MG		A215587	001	Aug 04, 2022	Jul NEWA
	AB		50MG		A215587	002	Aug 04, 2022	Jul NEWA
		@ SUNNY	25MG		A209068	001	Jan 25, 2022	May DISC
	AB		25MG		A209068	001	Jan 25, 2022	Jan NEWA
		@	50MG		A209068	002	Jan 25, 2022	May DISC
	AB		50MG		A209068	002	Jan 25, 2022	Jan NEWA
	AB	TAGI	25MG		A212878	001	Feb 24, 2022	Feb NEWA
	AB		50MG		A212875	001	Feb 24, 2022	Feb NEWA
	AB	UMEDICA LABS PVT LTD	25MG		A207222	001	May 24, 2018	Aug CTEC
	AB		50MG		A207222	002	May 24, 2018	Aug CTEC
		CHLORZOXAZONE						
		TABLET;ORAL						
		CHLORZOXAZONE						
	AB	RISING	375MG		A213126	001	Apr 05, 2022	Mar NEWA
	AB		500MG		A213126	002	Apr 05, 2022	Mar NEWA
	AB		750MG		A213126	003	Apr 05, 2022	Mar NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

		@ UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Mar DISC
	AB		EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan NEWA
		@	EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Mar DISC
	AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

>D>	AB	ADAPTIS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Sep CAHN
>D>	AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Sep CAHN
>A>	AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Sep CAHN
>A>	AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Sep CAHN

CICLOPIROX

GEL;TOPICAL

CICLOPIROX

	+ @	ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Aug DISC
AB	!	GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Aug CHRS

SHAMPOO;TOPICAL

CICLOPIROX

AT		PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018	Mar CAHN

SOLUTION;TOPICAL

CICLOPIROX

AT		CHARTWELL RX	8%	A078046	001	Sep 18, 2007	Mar CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	@	CHARTWELL RX	200MG	A074100	001	Jan 31, 1995	Jan CAHN
	@		300MG	A074100	002	Jan 31, 1995	Jan CAHN
	@		400MG	A074100	003	Jan 31, 1995	Jan CAHN
	@		800MG	A074100	004	Jan 31, 1995	Jan CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

	@	AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb DISC
	@		60MG	A204364	002	Dec 02, 2021	Feb DISC
	@		90MG	A204364	003	Dec 02, 2021	Feb DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

	@	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
	@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
	@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN AND DEXAMETHASONE

AB		SUN PHARM	0.3%;0.1%	A210470	001	Aug 30, 2022	Aug NEWA

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	AP	HIKMA	EQ 10MG BASE/ML	A203078	001	Jun 28, 2022	Jun NEWA
	AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	001	May 24, 2022	May NEWA
	AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	May NEWA
>D>	AP	PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Sep DISC
>A>		@	EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Sep DISC
	AP		EQ 2MG BASE/ML	A212432	001	Mar 11, 2022	Mar NEWA
>D>	AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Sep DISC
>A>		@	EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Sep DISC
	AP		EQ 10MG BASE/ML	A212432	002	Mar 11, 2022	Mar NEWA
	AP	SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020	Mar CMFD

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

+!	ALMATICA	EQ 30MG BASE	N215428	001	Jan 31, 2022	Jan NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

!	HETERO LABS LTD V	12GM/PACKET;3.5GM/PACKET;10MG/PACKET	A212789	001	Jul 18, 2022	Jul NFTG

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB	ALEMBIC PHARMS LTD	250MG	A210459	001	Jan 31, 2022	Jan NEWA
AB		500MG	A210459	002	Jan 31, 2022	Jan NEWA

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB2	AMNEAL	EQ 1% BASE	A214668	001	Aug 05, 2022	Jul NEWA

LOTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB	ENCUBE	EQ 1% BASE	A215607	001	Jan 18, 2022	Jan NEWA

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT	PAI HOLDINGS PHARM	EQ 1% BASE	A206945	001	Dec 30, 2016	Mar CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB1	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
AB2	SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb NFTG

VELTIN

AB2 +!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CFTG

ZIANA

AB1 +!	BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb CTEC

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB	ACCORD HLTHCARE	2.5MG/ML	A216008	001	Sep 06, 2022	Aug NEWA
AB	AUROBINDO PHARMA LTD	2.5MG/ML	A214404	001	Mar 24, 2022	Mar NEWA
>D> AB	HIKMA	2.5MG/ML	A209715	001	Oct 22, 2018	Sep DISC
>A> @		2.5MG/ML	A209715	001	Oct 22, 2018	Sep DISC

TABLET;ORAL

CLOBAZAM

>D> AB	HIKMA	10MG	A208785	001	Oct 22, 2018	Sep DISC
>A> @		10MG	A208785	001	Oct 22, 2018	Sep DISC
>D> AB		20MG	A208785	002	Oct 22, 2018	Sep DISC
>A> @		20MG	A208785	002	Oct 22, 2018	Sep DISC
AB	MSN	10MG	A213404	001	May 11, 2021	Feb CMFD
AB		20MG	A213404	002	May 11, 2021	Feb CMFD

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1	ALEOR DERMACEUTICALS	0.05%	A215838	001	Apr 21, 2022	Apr NEWA

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Aug CAHN
>D>	EMBELINE E					
>D> AB2	AKORN	0.05%	A075325	001	Dec 24, 1998	Sep DISC
>A> @		0.05%	A075325	001	Dec 24, 1998	Sep DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	PAI HOLDINGS PHARM	0.05%	A208881	001	Mar 06, 2017	Mar CAHN

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB	PAI HOLDINGS PHARM	0.05%	A208667	001	Nov 29, 2016	Mar CAHN

```
          OINTMENT;TOPICAL
            CLOBETASOL PROPIONATE
    AB        PAI HOLDINGS PHARM     0.05%                          A208589  001  Jan 23, 2019   Mar CAHN
          SOLUTION;TOPICAL
            CLOBETASOL PROPIONATE
            @ ENCUBE                 0.05%                          A076977  001  Aug 05, 2005   Jul CAHN
            @ PRINSTON INC           0.05%                          A213139  001  Feb 08, 2021   Aug DISC
    AT        SOLARIS PHARMA CORP    0.05%                          A211240  001  Feb 17, 2022   Feb NEWA
            @ TOLMAR                 0.05%                          A076977  001  Aug 05, 2005   Feb DISC
            @ WOCKHARDT BIO AG       0.05%                          A075205  001  Nov 13, 1998   Jun DISC

        CLOFARABINE
          SOLUTION;INTRAVENOUS
            CLOFARABINE
>A> AP      EUGIA PHARMA             20MG/20ML (1MG/ML)             A212457  001  Oct 03, 2022   Sep NEWA

        CLOMIPHENE CITRATE
          TABLET;ORAL
            CLOMIPHENE CITRATE
          !   COSETTE                50MG                           A075528  001  Aug 30, 1999   Jun CAHN

        CLONAZEPAM
          TABLET;ORAL
            CLONAZEPAM
>D>         @ RUBICON                0.5MG                          A075468  001  Oct 06, 2000   Sep CMFD
>A> AB                               0.5MG                          A075468  001  Oct 06, 2000   Sep CMFD
>D>         @                        1MG                            A075468  002  Oct 06, 2000   Sep CMFD
>A> AB                               1MG                            A075468  002  Oct 06, 2000   Sep CMFD
>D>         @                        2MG                            A075468  003  Oct 06, 2000   Sep CMFD
>A> AB                               2MG                            A075468  003  Oct 06, 2000   Sep CMFD

        CLONIDINE
          TABLET, EXTENDED RELEASE;ORAL
            NEXICLON XR
              ATHENA                 EQ 0.17MG BASE                 N022500  001  Dec 03, 2009   Feb CMFD
            @                        EQ 0.17MG BASE                 N022500  001  Dec 03, 2009   Jan CAHN
            @                        EQ 0.26MG BASE                 N022500  002  Dec 03, 2009   Jan CAHN

        CLONIDINE HYDROCHLORIDE
          TABLET;ORAL
            CLONIDINE HYDROCHLORIDE
    AB        AUROBINDO PHARMA LTD   0.1MG                          A070886  002  Aug 31, 1988   May CMFD
    AB                               0.2MG                          A070886  001  Aug 31, 1988   May CMFD
    AB                               0.3MG                          A070886  003  Aug 31, 1988   May CMFD
    AB        CHARTWELL MOLECULES    0.1MG                          A071785  002  Apr 05, 1988   Aug CMFD
    AB                               0.2MG                          A071785  003  Apr 05, 1988   Aug CMFD
    AB                               0.3MG                          A071785  001  Apr 05, 1988   Aug CMFD
    AB        URL LABS               0.1MG                          A070923  003  Sep 04, 1987   Apr CAHN
    AB                               0.2MG                          A070923  002  Sep 04, 1987   Apr CAHN
    AB                               0.3MG                          A070923  001  Sep 04, 1987   Apr CAHN
          TABLET, EXTENDED RELEASE;ORAL
            CLONIDINE HYDROCHLORIDE
            @ MAYNE PHARMA INC       0.1MG                          A210680  001  Apr 30, 2018   Feb DISC

        CLOPIDOGREL BISULFATE
          TABLET;ORAL
            CLOPIDOGREL BISULFATE
    AB        DR REDDYS              EQ 75MG BASE                   A076273  001  Jan 14, 2008   Apr CAHN

        CLORAZEPATE DIPOTASSIUM
          CAPSULE;ORAL
            TRANXENE
          + @ KEY THERAP             3.75MG                         N017105  001                  Aug CAHN
          + @                        7.5MG                          N017105  002                  Aug CAHN
          + @                        15MG                           N017105  003                  Aug CAHN
          TABLET;ORAL
            CLORAZEPATE DIPOTASSIUM
>A> AB      AUROBINDO PHARMA         3.75MG                         A071858  002  Jul 17, 1987   Sep CAHN
>A> AB                               7.5MG                          A071858  003  Jul 17, 1987   Sep CAHN
>A> AB    !                          15MG                           A071858  001  Jul 17, 1987   Sep CAHN
>D> AB      AUROLIFE PHARMA LLC      3.75MG                         A071858  002  Jul 17, 1987   Sep CAHN
>D> AB                               7.5MG                          A071858  003  Jul 17, 1987   Sep CAHN
```

```
          TABLET;ORAL
            CLORAZEPATE DIPOTASSIUM
>D> AB    !                          15MG                              A071858  001  Jul 17, 1987   Sep CAHN
    AB        COREPHARMA             3.75MG                            A215566  001  Jun 14, 2022   Jun NEWA
    AB                               7.5MG                             A215566  002  Jun 14, 2022   Jun NEWA
    AB                               15MG                              A215566  003  Jun 14, 2022   Jun NEWA
    AB        NOVITIUM PHARMA        3.75MG                            A213730  001  Jun 16, 2022   Jun NEWA
    AB                               7.5MG                             A213730  002  Jun 16, 2022   Jun NEWA
            TRANXENE
          + @ KEY THERAP             3.75MG                            N017105  006                  Aug CAHN
    AB    +                          7.5MG                             N017105  007                  Aug CAHN
          + @                        15MG                              N017105  008                  Aug CAHN
            TRANXENE SD
          + @ KEY THERAP             11.25MG                           N017105  005                  Aug CAHN
          + @                        22.5MG                            N017105  004                  Aug CAHN

        COLCHICINE
          SOLUTION;ORAL
            GLOPERBA
          +!  SCILEX PHARMS          0.6MG/5ML                         N210942  001  Jan 30, 2019   Jun CAHN
          TABLET;ORAL
            COLCHICINE
            @ PAR PHARM INC          0.6MG                             A203976  001  Aug 12, 2021   Feb DISC
    AB        STRIDES PHARMA         0.6MG                             A209173  001  Mar 10, 2022   Mar NEWA

        COLESEVELAM HYDROCHLORIDE
          TABLET;ORAL
            COLESEVELAM HYDROCHLORIDE
            @ LUPIN LTD              625MG                             A201354  001  Dec 17, 2020   May DISC
    AB        SPH                    625MG                             A213456  001  Jan 21, 2022   Jan NEWA

        COLESTIPOL HYDROCHLORIDE
          TABLET;ORAL
            COLESTID
    AB    +   PFIZER                 1GM                               N020222  001  Jul 19, 1994   Apr CHRS
            COLESTIPOL HYDROCHLORIDE
    AB    !   IMPAX LABS             1GM                               A077510  001  Oct 24, 2006   Apr CHRS
    AB        ZYDUS PHARMS           1GM                               A215223  001  Mar 10, 2022   Feb NEWA

>A>     COPPER CU-64 DOTATATE
>A>       SOLUTION;INTRAVENOUS
>A>         DETECTNET
>A>       +!  RADIOMEDIX             4mL (1mCi/ML)                     N213227  001  Sep 03, 2020   Sep CAIN

>D>     COPPER DOTATATE CU-64
>D>       SOLUTION;INTRAVENOUS
>D>         DETECTNET
>D>       +!  RADIOMEDIX             4mL (1mCi/ML)                     N213227  001  Sep 03, 2020   Sep CAIN

        CROMOLYN SODIUM
          SOLUTION;INHALATION
            CROMOLYN SODIUM
            @ BAUSCH                 10MG/ML                           A075585  001  Dec 21, 2000   Jun CAHN
    AN        FERA PHARMS LLC        10MG/ML                           A075437  001  Apr 21, 2000   Mar CMFD
    AN        MICRO LABS             10MG/ML                           A213658  001  Apr 29, 2022   Apr NEWA

        CUPRIC SULFATE
          INJECTABLE;INJECTION
            CUPRIC SULFATE
          + @ ABRAXIS PHARM          EQ 0.4MG COPPER/ML                N019350  001  May 05, 1987   Apr DISC

        CYANOCOBALAMIN
          INJECTABLE;INJECTION
            CYANOCOBALAMIN
>A> AP        SOLA PHARMS            1MG/ML                            A215417  001  Apr 15, 2022   Sep CAHN
>D> AP        WELDING                1MG/ML                            A215417  001  Apr 15, 2022   Sep CAHN
    AP                               1MG/ML                            A215417  001  Apr 15, 2022   Apr NEWA
    AP        ZYDUS PHARMS           1MG/ML                            A214655  001  Apr 15, 2022   Apr NEWA
            DODEX
    AP        ACCORD HLTHCARE        1MG/ML                            A083022  001                  May CTEC
                                     1MG/ML                            A083022  001                  Apr CMFD
```

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

		@ ANI PHARMS	25MG	A207014	001	Mar 19, 2018	May DISC
		@	50MG	A207014	002	Mar 19, 2018	Apr DISC
>A>	AB	ANIMA	25MG	A209872	001	May 07, 2018	Sep CAHN
>A>	AB		50MG	A209872	002	May 07, 2018	Sep CAHN
>D>	AB	STI PHARMA LLC	25MG	A209872	001	May 07, 2018	Sep CAHN
>D>	AB		50MG	A209872	002	May 07, 2018	Sep CAHN

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

	AB1	STRIDES PHARMA	25MG	A216046	001	Aug 02, 2022	Jul NEWA
	AB1		50MG	A216046	002	Aug 02, 2022	Jul NEWA
	AB1		100MG	A216046	003	Aug 02, 2022	Jul NEWA

EMULSION;OPHTHALMIC

CYCLOSPORINE

	AB	MYLAN	0.05%	A205894	001	Feb 02, 2022	Jan NFTG

RESTASIS

	AB	+! ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan CFTG

SOLUTION;ORAL

CYCLOSPORINE

		@ MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	AA	CHARTWELL MOLECULAR	2MG/5ML	A203191	001	Jul 13, 2017	Jun CAHN
		@ TRIS PHARMA INC	2MG/5ML	A205431	001	Dec 21, 2021	Apr DISC

CYSTEAMINE BITARTRATE

GRANULE, DELAYED RELEASE;ORAL

PROCYSBI

		+ HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020	May CAHN
		+!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020	May CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

CYSTEINE HYDROCHLORIDE

>D>							
>D>	AP	DR REDDYS LABS SA	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Sep DISC
>A>		@	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Sep DISC
	AP		500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Jun CAHN
	AP	ETON	500MG/10ML (50MG/ML)	A214082	001	Apr 08, 2022	Apr NFTG

ELCYS

>D>	AP	+! EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Sep CTEC
>A>		+!	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Sep CTEC
	AP	+!	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr CFTG

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

	AP	HONG KONG	20MG/ML	A208485	001	Feb 28, 2022	Feb NEWA
		@ MEITHEAL	20MG/ML	A206189	001	Jun 26, 2020	Jun CAHN

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

	AB	ALKEM LABS LTD	EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug CMFD
		@	EQ 150MG BASE	A208040	002	Mar 11, 2020	Aug DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

DALFAMPRIDINE

		@ HIKMA	10MG	A206646	001	Oct 24, 2018	May DISC

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

	+	PFIZER	10,000IU/4ML (2,500IU/ML)	N020287	012	Mar 15, 2022	Mar	NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION

DANTROLENE SODIUM

	@	EUGIA PHARMA SPECLTS	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	CAHN

DAPAGLIFLOZIN

TABLET;ORAL

DAPAGLIFLOZIN

	@	ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Jul	DISC
AB			5MG	A211582	001	Feb 22, 2022	Feb	NFTG
	@		10MG	A211582	002	Feb 22, 2022	Jul	DISC
AB			10MG	A211582	002	Feb 22, 2022	Feb	NFTG

FARXIGA

	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Jul	CTEC
AB	+		5MG	N202293	001	Jan 08, 2014	Feb	CFTG
	+!		10MG	N202293	002	Jan 08, 2014	Jul	CTEC
AB	+!		10MG	N202293	002	Jan 08, 2014	Feb	CFTG

DAPSONE

GEL;TOPICAL

DAPSONE

>A>	AB	COSETTE	5%	A210178	001	Mar 31, 2022	Sep	CAHN
	AB	MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan	NEWA
>D>	AB	SEEGPHARM SA	5%	A210178	001	Mar 31, 2022	Sep	CAHN
	AB		5%	A210178	001	Mar 31, 2022	Mar	NEWA
	AB	TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb	NEWA

TABLET;ORAL

DAPSONE

>A>		@ ANDA REPOSITORY	25MG	A204074	001	May 10, 2016	Sep	CAHN
>A>		@	100MG	A204074	002	May 10, 2016	Sep	CAHN
>D>		@ VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Sep	CAHN
		@	25MG	A204074	001	May 10, 2016	Jan	DISC
>D>		@	100MG	A204074	002	May 10, 2016	Sep	CAHN
		@	100MG	A204074	002	May 10, 2016	Jan	DISC

DAPTOMYCIN

INJECTABLE;INJECTION

DAPTOMYCIN

>A>	AP	ASPIRO	500MG/VIAL	A216413	001	Sep 23, 2022	Sep	NEWA

POWDER;INTRAVENOUS

>D>		CUBICIN RF						
>D>	+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016	Sep	DISC
>A>	+ @		500MG/VIAL	N021572	003	Jul 06, 2016	Sep	DISC

DAPTOMYCIN

	AP	HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022	Aug	NEWA

DAPZURA RT

	+!	BAXTER HLTHCARE CORP	500MG/VIAL	N213645	001	Jan 25, 2022	Jan	NEWA

DARIDOREXANT HYDROCHLORIDE

TABLET;ORAL

QUVIVIQ

	+	IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022	Apr	NEWA
	+!		EQ 50MG BASE	N214985	002	Apr 07, 2022	Apr	NEWA

DARUNAVIR

TABLET;ORAL

DARUNAVIR

>A>	AB	LUPIN LTD	600MG	A202073	001	Sep 29, 2022	Sep	NEWA
>A>	AB		800MG	A202073	002	Sep 29, 2022	Sep	NFTG

PREZISTA

>D>	+!	JANSSEN PRODS	800MG	N021976	006	Nov 09, 2012	Sep	CFTG
>A> AB	+!		800MG	N021976	006	Nov 09, 2012	Sep	CFTG

DASATINIB

TABLET;ORAL

DASATINIB

		@	APOTEX	80MG	A203180	001	Nov 23, 2021	May DISC
		@		140MG	A203180	002	Nov 23, 2021	May DISC

SPRYCEL

		+	BRISTOL MYERS SQUIBB	80MG	N021986	005	Oct 28, 2010	May CTEC
		+		140MG	N021986	006	Oct 28, 2010	May CTEC

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

>D>	AP	+!	OTSUKA	50MG/VIAL	N021790	001	May 02, 2006	Sep DISC
>A>		+ @		50MG/VIAL	N021790	001	May 02, 2006	Sep DISC

DECITABINE

>D>	AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Sep CHRS
>A>	AP	!		50MG/VIAL	A203475	001	Feb 27, 2017	Sep CHRS
	AP		JIANGSU HANSOH PHARM	50MG/VIAL	A213472	001	Apr 15, 2022	Apr NEWA
	AP		NOVAST LABS	50MG/VIAL	A210984	001	Sep 16, 2019	Aug CAHN

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

		@	AMNEAL	90MG	A214194	003	Aug 02, 2021	Mar DISC
		@		180MG	A214194	001	Feb 09, 2021	Jul DISC
		@		360MG	A214194	002	Feb 09, 2021	Jul DISC
>A>	AB		ANNORA PHARMA	180MG	A216229	001	Sep 22, 2022	Sep NEWA
>A>	AB			360MG	A216229	002	Sep 22, 2022	Sep NEWA
	AB		CIPLA	90MG	A215026	001	Feb 23, 2022	Feb NEWA
	AB			180MG	A215026	002	Feb 23, 2022	Feb NEWA
	AB			360MG	A215026	003	Feb 23, 2022	Feb NEWA
	AB		MSN	90MG	A214650	003	Apr 20, 2022	Apr NEWA
	AB		TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Aug CMFD
		@		90MG	A214180	001	Nov 19, 2021	Jun DISC
	AB			180MG	A214180	002	Nov 19, 2021	Aug CMFD
		@		180MG	A214180	002	Nov 19, 2021	Jun DISC
	AB			360MG	A214180	003	Nov 19, 2021	Aug CMFD
		@		360MG	A214180	003	Nov 19, 2021	Jun DISC

TABLET;ORAL

DEFERASIROX

		@	AMNEAL	180MG	A210727	003	Jun 15, 2020	Apr DISC

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

>A>	AB		TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Sep NEWA
>A>	AB			250MG	A207124	002	Sep 23, 2022	Sep NEWA
>A>	AB			500MG	A207124	003	Sep 23, 2022	Sep NEWA

DEFERIPRONE

TABLET;ORAL

DEFERIPRONE

	AB		HIKMA	1GM	A213239	002	Feb 08, 2022	Jan NFTG

FERRIPROX

	AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	Jan CFTG

DESLORATADINE

TABLET;ORAL

DESLORATADINE

>D>	AB		PERRIGO	5MG	A078361	001	Dec 22, 2011	Sep DISC
>A>		@		5MG	A078361	001	Dec 22, 2011	Sep DISC
>D>	AB		SANDOZ	5MG	A078364	001	Dec 03, 2010	Sep DISC
>A>		@		5MG	A078364	001	Dec 03, 2010	Sep DISC

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DESMOPRESSIN ACETATE

	AP		DR REDDYS	0.004MG/ML	A215961	001	Aug 19, 2022	Aug NEWA

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE

	AB	!	BAUSCH	0.01MG/SPRAY	A074830	001	Jan 25, 1999	Jun CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

@	MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Jan DISC
@		0.1MG,0.125MG,0.15MG;0.025MG,0.025 MG,0.025MG	A077182	001	Jan 24, 2006	Jan DISC

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB	PAI HOLDINGS PHARM	0.25%	A208101	001	Feb 25, 2016	Mar CAHN

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

+ @	SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CAHN
+ @		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB	LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022	Apr NEWA

>A> DEUCRAVACITINIB

>A> TABLET;ORAL

>A> SOTYKTU

>A> +!	BRISTOL	6MG	N214958	001	Sep 09, 2022	Sep NEWA

DEXAMETHASONE

SOLUTION;ORAL

DEXAMETHASONE

+!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983	Mar CRLD

TABLET;ORAL

DEXAMETHASONE

>A>	AB		AMNEAL	2MG	A216295	001	Sep 08, 2022	Sep NEWA
	BP	+	HIKMA	0.5MG	A084611	001		Jan CRLD
>D>	BP	+!		2MG	A087916	001	Aug 26, 1982	Sep CTEC
>A>	AB	+!		2MG	A087916	001	Aug 26, 1982	Sep CTEC
	AB		NOVITIUM PHARMA	1.5MG	A215604	001	Aug 08, 2022	Jul NEWA
	AB			4MG	A215604	002	Aug 08, 2022	Jul NEWA
	AB			6MG	A215604	003	Aug 08, 2022	Jul NEWA
	AB		PRASCO	4MG	A080399	002	Apr 20, 2022	Apr NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	+!	IMPRIMIS PHARMS USA	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Jun CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRAMYCIN AND DEXAMETHASONE

AB	PADAGIS US	0.1%;0.3%	A212715	001	Feb 11, 2022	Feb NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	+!	PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Apr CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun CFTG

DEXLANSOPRAZOLE

AB		PAR PHARM INC	30MG	A202294	002	Jun 16, 2022	Jun NFTG
>A> AB		TWI PHARMS	30MG	A202666	001	Sep 16, 2022	Sep NEWA

```
          CAPSULE, DELAYED RELEASE;ORAL
            DEXLANSOPRAZOLE
>A> AB                            60MG                              A202666  002  Sep 16, 2022   Sep NEWA

        DEXMEDETOMIDINE HYDROCHLORIDE
          FILM;BUCCAL, SUBLINGUAL
            IGALMI
          +!  BIOXCEL               EQ 0.12MG BASE                   N215390  001  Apr 05, 2022   Apr NEWA
          +!                        EQ 0.18MG BASE                   N215390  002  Apr 05, 2022   Apr NEWA
          INJECTABLE;INJECTION
            DEXMEDETOMIDINE HYDROCHLORIDE
    AP        MEITHEAL              EQ 200MCG BASE/2ML (EQ 100MCG    A204843  001  Jan 18, 2019   Apr CAHN
                                    BASE/ML)
            @ PIRAMAL CRITICAL      EQ 200MCG BASE/2ML (EQ 100MCG    A214794  001  Sep 03, 2021   Feb DISC
                                    BASE/ML)

        DEXTROAMPHETAMINE
>D>       SYSTEM;TRANSDERMAL
>D>         XELSTRYM
>D>       +   NOVEN PHARMS INC      4.5MG/9HR                        N215401  001  Mar 22, 2022   Sep DISC
>A>       + @                       4.5MG/9HR                        N215401  001  Mar 22, 2022   Sep DISC
          +                         4.5MG/9HR                        N215401  001  Mar 22, 2022   Mar NEWA
>D>       +                         9MG/9HR                          N215401  002  Mar 22, 2022   Sep DISC
>A>       + @                       9MG/9HR                          N215401  002  Mar 22, 2022   Sep DISC
          +                         9MG/9HR                          N215401  002  Mar 22, 2022   Mar NEWA
>D>       +                         13.5MG/9HR                       N215401  003  Mar 22, 2022   Sep DISC
>A>       + @                       13.5MG/9HR                       N215401  003  Mar 22, 2022   Sep DISC
          +                         13.5MG/9HR                       N215401  003  Mar 22, 2022   Mar NEWA
>D>       +!                        18MG/9HR                         N215401  004  Mar 22, 2022   Sep DISC
>A>       + @                       18MG/9HR                         N215401  004  Mar 22, 2022   Sep DISC
          +!                        18MG/9HR                         N215401  004  Mar 22, 2022   Mar NEWA

        DEXTROAMPHETAMINE SULFATE
          CAPSULE, EXTENDED RELEASE;ORAL
            DEXTROAMPHETAMINE SULFATE
            @ MAYNE PHARMA          5MG                              A076137  001  Jan 18, 2002   Feb DISC
            @                       10MG                             A076137  002  Jan 18, 2002   Feb DISC
            @                       15MG                             A076137  003  Jan 18, 2002   Feb DISC
          TABLET;ORAL
            DEXTROAMPHETAMINE SULFATE
              ARBOR PHARMS LLC      2.5MG                            A090533  001  Oct 25, 2011   Jan CTEC
                                    7.5MG                            A090533  003  Oct 25, 2011   Jan CTEC
                                    15MG                             A090533  005  Oct 25, 2011   Jan CTEC
                                    20MG                             A090533  006  Oct 25, 2011   Jan CTEC
                                    30MG                             A090533  007  Oct 25, 2011   Jan CTEC
    AA        TRIS PHARMA INC       5MG                              A206095  001  Aug 18, 2022   Aug NEWA
    AA                              10MG                             A206095  002  Aug 18, 2022   Aug NEWA
            @ WINDER LABS LLC       2.5MG                            A212160  001  Jun 07, 2021   Jan DISC
            @                       5MG                              A212160  002  Jun 07, 2021   Jan DISC
            @                       7.5MG                            A212160  003  Jun 07, 2021   Jan DISC
            @                       10MG                             A212160  004  Jun 07, 2021   Jan DISC
            @                       15MG                             A212160  005  Jun 07, 2021   Jan DISC
            @                       20MG                             A212160  006  Jun 07, 2021   Jan DISC
            @                       30MG                             A212160  007  Jun 07, 2021   Jan DISC

        DEXTROSE; POTASSIUM CHLORIDE
          INJECTABLE;INJECTION
            DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%
>D>         @ FRESENIUS KABI USA    5GM/100ML;75MG/100ML             A212346  001  Sep 10, 2020   Sep CMFD
>A> AP                              5GM/100ML;75MG/100ML             A212346  001  Sep 10, 2020   Sep CMFD
            DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%
>D>         @ FRESENIUS KABI USA    5GM/100ML;150MG/100ML            A212346  002  Sep 10, 2020   Sep CMFD
>A> AP                              5GM/100ML;150MG/100ML            A212346  002  Sep 10, 2020   Sep CMFD

        DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
          INJECTABLE;INJECTION
            POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%
>A> AP        FRESENIUS KABI USA    5GM/100ML;149MG/100ML;450MG/100ML A213523  005  Oct 11, 2022   Sep NEWA
```

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

		SOLUTION;ORAL, RECTAL					
		DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM					
AA		GUARDIAN DRUG	66%;10%	A214201	001	Jun 27, 2022	Jun NEWA

DIAZEPAM

		CONCENTRATE;ORAL					
		DIAZEPAM					
AA		CHARTWELL MOLECULAR	5MG/ML	A204433	001	Apr 14, 2014	Aug CMFD
	@		5MG/ML	A204433	001	Apr 14, 2014	Jun CAHN
		DIAZEPAM INTENSOL					
AA	!	HIKMA	5MG/ML	A071415	001	Apr 03, 1987	Aug CTEC
		GEL;RECTAL					
		DIASTAT					
	+!	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	May CHRS
		DIASTAT ACUDIAL					
	+!	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	May CHRS
		SOLUTION;ORAL					
		DIAZEPAM					
AA		CHARTWELL MOLECULAR	5MG/5ML	A206477	001	Jun 24, 2016	Jun CAHN
		TABLET;ORAL					
		VALIUM					
AB	+	WAYLIS THERAP	2MG	N013263	002		Mar CAHN
AB	+		5MG	N013263	004		Mar CAHN
AB	+!		10MG	N013263	006		Mar CAHN

DICLOFENAC

		CAPSULE;ORAL					
		ZORVOLEX					
	+ @	ZYLA	35MG	N204592	002	Oct 18, 2013	Jul DISC

DICLOFENAC POTASSIUM

		CAPSULE;ORAL					
		DICLOFENAC POTASSIUM					
AB		STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019	Apr CMFD
		FOR SOLUTION;ORAL					
		DICLOFENAC POTASSIUM					
AB		ALKEM LABS LTD	50MG	A216635	001	Jul 20, 2022	Jul NEWA
AB		ANNORA PHARMA	50MG	A215375	001	Mar 04, 2022	Feb NEWA
		TABLET;ORAL					
		DICLOFENAC POTASSIUM					
AB		NOVAST LABS	50MG	A215585	001	Oct 08, 2021	Aug CAHN
AB		UMEDICA LABS PVT LTD	50MG	A215750	001	May 11, 2022	Apr NEWA

DICLOFENAC SODIUM

		GEL;TOPICAL					
		DICLOFENAC SODIUM					
AB		ALEOR DERMACEUTICALS	3%	A212351	001	Jul 27, 2022	Jul NEWA
		CIPLA	1%	A209903	001	Aug 03, 2018	Mar CTEC
		SOLUTION;TOPICAL					
		DICLOFENAC SODIUM					
AB		AMNEAL	2%	A208198	001	Aug 18, 2022	Aug NEWA
AB		APOTEX	2%	A207714	001	May 06, 2022	Apr NFTG
>A> AB		LUPIN PHARMS	2%	A208021	001	Sep 20, 2022	Sep NEWA
>A> AB		TARO	2%	A208098	001	Sep 29, 2022	Sep NEWA
		PENNSAID					
AB	+!	HORIZON	2%	N204623	001	Jan 16, 2014	Apr CFTG
		SOLUTION/DROPS;OPHTHALMIC					
		DICLOFENAC SODIUM					
	@	AKORN	0.1%	A077845	001	Apr 17, 2008	Aug DISC
		TABLET, EXTENDED RELEASE;ORAL					
		DICLOFENAC SODIUM					
>A> AB		RICONPHARMA LLC	100MG	A216275	001	Sep 23, 2022	Sep NEWA

DICLOXACILLIN SODIUM

		CAPSULE;ORAL					
		DICLOXACILLIN SODIUM					
>A> AB		AUROBINDO PHARMA	EQ 250MG BASE	A216845	001	Sep 23, 2022	Sep NEWA
>A> AB			EQ 500MG BASE	A216845	002	Sep 23, 2022	Sep NEWA
>D>	!	TEVA	EQ 500MG BASE	A062286	002	Jun 03, 1982	Sep CTEC

CAPSULE;ORAL
DICLOXACILLIN SODIUM

>A>	AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Sep CTEC

DIGOXIN

ELIXIR;ORAL
DIGOXIN

	AA	AMICI	0.05MG/ML	A215209	001	Mar 11, 2022	Mar NEWA

TABLET;ORAL
DIGOXIN

	AB	AUROBINDO PHARMA LTD	0.0625MG	A214982	001	Feb 08, 2022	Jan NFTG
	AB		0.125MG	A214982	002	Feb 08, 2022	Jan NEWA
	AB		0.25MG	A214982	003	Feb 08, 2022	Jan NEWA
	AB	NOVITIUM PHARMA	0.0625MG	A215307	003	Aug 25, 2022	Aug NEWA

LANOXIN

	AB	+ CONCORDIA	0.0625MG	N020405	001	Sep 30, 1997	Jan CFTG

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION
D.H.E. 45

		+ @ BAUSCH	1MG/ML	N005929	001		Jul DISC

DIHYDROERGOTAMINE MESYLATE

	AP	! HIKMA PHARMS	1MG/ML	A206621	001	Sep 15, 2017	Jul CHRS

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

		@ AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022	Jul DISC
	AB	HIKMA	0.5MG/SPRAY	A211393	001	Feb 28, 2020	Aug CAHN

TRUDHESA

		+! IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

	AB2	AMTA	120MG	A216304	001	Aug 08, 2022	Jul NEWA
	AB2		180MG	A216304	002	Aug 08, 2022	Jul NEWA
	AB2		240MG	A216304	003	Aug 08, 2022	Jul NEWA
	AB1	MAYNE PHARMA INTL	60MG	A215775	001	May 05, 2022	Apr NEWA
	AB1		90MG	A215775	002	May 05, 2022	Apr NEWA
	AB1		120MG	A215775	003	May 05, 2022	Apr NEWA

SOLUTION;INTRAVENOUS
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

		+ @ EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021	Feb DISC
		+ @	250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021	Feb DISC

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

>A>	AB	SCIEGEN PHARMS INC	30MG	A216521	001	Sep 23, 2022	Sep NEWA
>A>	AB		60MG	A216521	002	Sep 23, 2022	Sep NEWA
>A>	AB		90MG	A216521	003	Sep 23, 2022	Sep NEWA
>A>	AB		120MG	A216521	004	Sep 23, 2022	Sep NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

		@ PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Apr DISC
		@	240MG	A210436	002	Mar 26, 2021	Apr DISC
		@ SAWAI USA	120MG	A210285	001	Dec 21, 2021	Jun DISC
		@	240MG	A210285	002	Dec 21, 2021	Jun DISC
		@ SOLA PHARMS	120MG	A210436	001	Mar 26, 2021	Jul CAHN
		@	240MG	A210436	002	Mar 26, 2021	Jul CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

	AP	! CHARTWELL INJECTABLE	5MG/ML	A074939	001	Apr 13, 1998	Mar CAHN
		@ EUGIA PHARMA SPECLTS	5MG/ML	A075769	001	Nov 27, 2002	Mar CAHN

TABLET;ORAL
DIPYRIDAMOLE

>A>		@ ANDA REPOSITORY	25MG	A040898	001	Apr 23, 2008	Sep CAHN
>A>		@	50MG	A040898	002	Apr 23, 2008	Sep CAHN
>A>		@	75MG	A040898	003	Apr 23, 2008	Sep CAHN
>D>		@ GENUS	25MG	A040898	001	Apr 23, 2008	Sep CAHN
>D>		@	50MG	A040898	002	Apr 23, 2008	Sep CAHN

```
          TABLET;ORAL
            DIPYRIDAMOLE
>D>         @                        75MG                              A040898  003  Apr 23, 2008   Sep CAHN

        DISOPYRAMIDE PHOSPHATE
          CAPSULE;ORAL
            DISOPYRAMIDE PHOSPHATE
    AB        MAYNE PHARMA           EQ 100MG BASE                     A070173  001  May 31, 1985   Feb CMFD
    AB                               EQ 150MG BASE                     A070173  002  May 31, 1985   Feb CMFD

        DIVALPROEX SODIUM
          CAPSULE, DELAYED REL PELLETS;ORAL
            DIVALPROEX SODIUM
            @ RISING                 EQ 125MG VALPROIC ACID            A090407  001  Mar 28, 2011   Aug CAHN
          TABLET, EXTENDED RELEASE;ORAL
            DIVALPROEX SODIUM
    AB        UNICHEM                EQ 250MG VALPROIC ACID            A214643  001  Feb 25, 2022   Feb NEWA
    AB                               EQ 500MG VALPROIC ACID            A214643  002  Feb 25, 2022   Feb NEWA

        DOCETAXEL
          INJECTABLE;INJECTION
            DOCETAXEL
    AP        MEITHEAL               20MG/2ML (10MG/ML)                A209634  001  Aug 24, 2018   Apr CAHN
    AP                               80MG/8ML (10MG/ML)                A209634  002  Aug 24, 2018   Apr CAHN
    AP                               160MG/16ML (10MG/ML)              A209634  003  Aug 24, 2018   Apr CAHN

        DOFETILIDE
          CAPSULE;ORAL
            DOFETILIDE
    AB        TEVA PHARMS USA        0.125MG                           A210018  001  Apr 15, 2022   Apr NEWA
    AB                               0.25MG                            A210018  002  Apr 15, 2022   Apr NEWA
    AB                               0.5MG                             A210018  003  Apr 15, 2022   Apr NEWA
          TABLET;ORAL
            DOFETILIDE
    AB        NUVO PHARM             0.125MG                           A215323  001  Apr 14, 2022   Aug CAHN
    AB                               0.25MG                            A215323  002  Apr 14, 2022   Aug CAHN
    AB                               0.5MG                             A215323  003  Apr 14, 2022   Aug CAHN
    AB        VGYAAN                 0.125MG                           A215323  001  Apr 14, 2022   Apr NEWA
    AB                               0.25MG                            A215323  002  Apr 14, 2022   Apr NEWA
    AB                               0.5MG                             A215323  003  Apr 14, 2022   Apr NEWA

        DONEPEZIL HYDROCHLORIDE
          SYSTEM;TRANSDERMAL
            ADLARITY
          +   CORIUM                 5MG/DAY                           N212304  001  Mar 11, 2022   Mar NEWA
          +!                         10MG/DAY                          N212304  002  Mar 11, 2022   Mar NEWA
          TABLET;ORAL
            DONEPEZIL HYDROCHLORIDE
    AB        CHARTWELL RX           5MG                               A090425  001  May 31, 2011   Mar CAHN
    AB                               10MG                              A090425  002  May 31, 2011   Mar CAHN
>D> AB        GRAVITI PHARMS         5MG                               A202114  001  Jul 05, 2013   Sep CAHN
>D> AB                               10MG                              A202114  002  Jul 05, 2013   Sep CAHN
>D> AB        INDICUS PHARMA         23MG                              A203419  001  Apr 12, 2016   Sep DISC
>A>         @                        23MG                              A203419  001  Apr 12, 2016   Sep DISC
>A> AB        RISING                 5MG                               A202114  001  Jul 05, 2013   Sep CAHN
>A> AB                               10MG                              A202114  002  Jul 05, 2013   Sep CAHN

        DORZOLAMIDE HYDROCHLORIDE
          SOLUTION/DROPS;OPHTHALMIC
            DORZOLAMIDE HYDROCHLORIDE
    AT        GLAND PHARMA LTD       EQ 2% BASE                        A215660  001  Jan 27, 2022   Jan NEWA
    AT    !   MICRO LABS             EQ 2% BASE                        A204778  001  Nov 08, 2019   May CHRS
            TRUSOPT
          + @ MERCK                  EQ 2% BASE                        N020408  001  Dec 09, 1994   May DISC
          + @ MSD SUB MERCK          EQ 2% BASE                        N020408  001  Dec 09, 1994   Jun CAHN
```

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

	AT	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N020869	001	Apr 07, 1998	Apr CAHN

COSOPT PF

	AT	+!	THEA PHARMA	EQ 2% BASE;EQ 0.5% BASE	N202667	001	Feb 01, 2012	Apr CAHN

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT		GLAND PHARMA LTD	EQ 2% BASE;EQ 0.5% BASE	A215520	001	Sep 19, 2022	Sep NEWA
	AT		MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	Jan NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

	AP		CHARTWELL INJECTABLE	20MG/ML	A076266	001	Jan 10, 2003	Mar CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA

	AB	+!	VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan CAHN
	AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan CAHN
	AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan CAHN
	AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan CAHN

DOXAZOSIN MESYLATE

		@	CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
		@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
		@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
		@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN
>D>	AB		METHOD	EQ 1MG BASE	A212727	001	Mar 15, 2022	Sep CAHN
	AB			EQ 1MG BASE	A212727	001	Mar 15, 2022	Mar NEWA
>D>	AB			EQ 2MG BASE	A212727	002	Mar 15, 2022	Sep CAHN
	AB			EQ 2MG BASE	A212727	002	Mar 15, 2022	Mar NEWA
>D>	AB			EQ 4MG BASE	A212727	003	Mar 15, 2022	Sep CAHN
	AB			EQ 4MG BASE	A212727	003	Mar 15, 2022	Mar NEWA
>D>	AB			EQ 8MG BASE	A212727	004	Mar 15, 2022	Sep CAHN
	AB			EQ 8MG BASE	A212727	004	Mar 15, 2022	Mar NEWA
>A>	AB		PHARMGEN	EQ 1MG BASE	A212727	001	Mar 15, 2022	Sep CAHN
>A>	AB			EQ 2MG BASE	A212727	002	Mar 15, 2022	Sep CAHN
>A>	AB			EQ 4MG BASE	A212727	003	Mar 15, 2022	Sep CAHN
>A>	AB			EQ 8MG BASE	A212727	004	Mar 15, 2022	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

		+	VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan CAHN
		+!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

	AB		EDENBRIDGE PHARMS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Apr NEWA
	AB		EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb NEWA
	AB			EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb NEWA
	AB		JUBILANT CADISTA	EQ 10MG BASE	A215483	001	Mar 14, 2022	Mar NEWA
	AB			EQ 25MG BASE	A215483	002	Mar 14, 2022	Mar NEWA
	AB			EQ 50MG BASE	A215483	003	Mar 14, 2022	Mar NEWA
	AB			EQ 75MG BASE	A215483	004	Mar 14, 2022	Mar NEWA
	AB			EQ 100MG BASE	A215483	005	Mar 14, 2022	Mar NEWA
	AB		MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA
	AB			EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA
	AB			EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA
	AB			EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA
	AB			EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA
	AB		MSN	EQ 10MG BASE	A215113	001	Jun 24, 2022	Jun NEWA
	AB			EQ 25MG BASE	A215113	002	Jun 24, 2022	Jun NEWA
	AB			EQ 50MG BASE	A215113	003	Jun 24, 2022	Jun NEWA
	AB			EQ 75MG BASE	A215113	004	Jun 24, 2022	Jun NEWA
	AB			EQ 100MG BASE	A215113	005	Jun 24, 2022	Jun NEWA
	AB	!	PAR PHARM	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

	AB		STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jun CMFD
		@		EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
	AB			EQ 6MG BASE	A202510	002	Jul 24, 2020	Jun CMFD
		@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@	AKORN	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Aug DISC
	@		4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Aug DISC
AP		EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP			4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	@	IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Mar DISC
	@	STRIDES PHARMA	EQ 150MG BASE	A202778	001	Jun 08, 2012	Aug CAHN

MONODOX

AB	+	CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

AB		STRIDES PHARMA	EQ 50MG BASE	A065070	001	Dec 15, 2000	Jul CMFD
AB			EQ 75MG BASE	A065070	003	Dec 30, 2002	Jul CMFD
AB			EQ 100MG BASE	A065070	002	Dec 15, 2000	Jul CMFD
AB			EQ 150MG BASE	A065070	004	Jul 14, 2005	Jul CMFD

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		CADILA	EQ 50MG BASE	A207774	001	May 31, 2018	May CAHN
AB			EQ 100MG BASE	A207774	002	May 31, 2018	May CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	!	CHARTWELL MOLECULAR	EQ 20MG BASE	A065277	001	Nov 10, 2005	Jun CAHN
	@	EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan DISC
	@	PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022	Aug DISC
AB			EQ 100MG BASE	A212487	001	Mar 30, 2022	Mar NEWA

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

>D> AB	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Sep CTEC
>A>	+!		20MG;20MG	N209661	001	Nov 07, 2016	Sep CTEC
AB	+!		20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

>D> AB		ACTAVIS LABS FL INC	20MG;20MG	A212472	001	Mar 01, 2022	Sep DISC
>A>	@		20MG;20MG	A212472	001	Mar 01, 2022	Sep DISC
AB			20MG;20MG	A212472	001	Mar 01, 2022	Feb NFTG

DROSPIRENONE

TABLET, CHEWABLE;ORAL

DROSPIRENONE

	+!	EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022	Jun NEWA

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		CELLTRION	100MG	A214217	001	May 05, 2022	Apr NEWA
AB			200MG	A214217	002	May 05, 2022	Apr NEWA
AB			300MG	A214217	003	May 05, 2022	Apr NEWA
	@	SLATE RUN PHARMA	100MG	A215265	001	Nov 01, 2021	May DISC
	@		200MG	A215265	002	Nov 01, 2021	May DISC
	@		300MG	A215265	003	Nov 01, 2021	May DISC
AB		UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Aug CAHN
AB			200MG	A213661	002	Feb 18, 2021	Aug CAHN
AB			300MG	A213661	003	Feb 18, 2021	Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

	+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Feb CAHN
	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Feb CAHN
	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Feb CAHN
	+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Feb CAHN

DUVELISIB

CAPSULE;ORAL

COPIKTRA

+	SECURA	15MG	N211155	001	Sep 24, 2018	May	CMFD
+ @		15MG	N211155	001	Sep 24, 2018	Apr	DISC
+		25MG	N211155	002	Sep 24, 2018	May	CMFD
+ @		25MG	N211155	002	Sep 24, 2018	Apr	DISC

ECONAZOLE NITRATE

CREAM;TOPICAL

SPECTAZOLE

+ @	ALVOGEN	1%	N018751	001	Dec 23, 1982	Aug	DISC

EDARAVONE

SUSPENSION;ORAL

RADICAVA ORS

+!	MITSUBISHI TANABE	105MG/5ML	N215446	001	May 12, 2022	May	NEWA

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

@	AUROBINDO PHARMA	600MG	A205322	001	Aug 30, 2018	Apr	DISC
>D> AB	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Sep	CHRS
>A> AB !		600MG	A078886	001	Apr 27, 2018	Sep	CHRS

SUSTIVA

>D> AB +!	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Sep	DISC
>A> + @		600MG	N021360	002	Feb 01, 2002	Sep	DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD V	600MG;200MG;300MG	A203053	001	Jan 24, 2022	Jan	NEWA

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

@	LUPIN LTD	10%	A212169	001	Mar 02, 2022	May	DISC
AB		10%	A212169	001	Mar 02, 2022	Feb	NEWA
AB	NIVAGEN PHARMS INC	10%	A211969	001	Jun 21, 2021	Aug	CAHN
AB	ZYDUS	10%	A212178	001	Jul 15, 2022	Jul	NEWA

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

+ @	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000	Feb	DISC

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

+!	MSD SUB MERCK	50MG;100MG	N208261	001	Jan 28, 2016	Jun	CAHN

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB	BEXIMCO PHARMS USA	EQ 20MG BASE	A215467	001	Jul 13, 2022	Jul	NEWA
AB		EQ 40MG BASE	A215467	002	Jul 13, 2022	Jul	NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

AB	AIZANT	EQ 84MG BASE	A212463	001	Sep 08, 2021	Feb	CAHN
AB	DR REDDYS	EQ 84MG BASE	A212449	001	Aug 17, 2022	Aug	NEWA
@	TEVA PHARMS USA INC	EQ 84MG BASE	A212474	001	Dec 27, 2021	Jun	DISC

EMPAGLIFLOZIN

TABLET;ORAL

EMPAGLIFLOZIN

AB	ZYDUS PHARMS	10MG	A212138	001	Aug 03, 2022	Jul	NFTG
AB		25MG	A212138	002	Aug 03, 2022	Jul	NFTG

TABLET;ORAL
JARDIANCE

AB	+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Jul CFTG
AB	+!		25MG	N204629	002	Aug 01, 2014	Jul CFTG

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL
EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

AB		ZYDUS PHARMS	5MG;500MG	A212198	001	Jul 07, 2022	Jul NFTG
AB			5MG;1GM	A212198	002	Jul 07, 2022	Jul NFTG
AB			12.5MG;500MG	A212198	003	Jul 07, 2022	Jul NFTG
AB			12.5MG;1GM	A212198	004	Jul 07, 2022	Jul NFTG

SYNJARDY

AB	+	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015	Jul CFTG
AB	+		5MG;1GM	N206111	002	Aug 26, 2015	Jul CFTG
AB	+		12.5MG;500MG	N206111	003	Aug 26, 2015	Jul CFTG
AB	+!		12.5MG;1GM	N206111	004	Aug 26, 2015	Jul CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
DESCOVY

	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	Jan NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL
ENALAPRIL MALEATE

AB		ALKEM LABS LTD	1MG/ML	A213714	001	Mar 30, 2022	Mar NEWA
AB		AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Jun NEWA
AB		ANNORA PHARMA	1MG/ML	A214467	001	Feb 24, 2022	Feb NEWA

TABLET;ORAL
ENALAPRIL MALEATE

	@	AIPING PHARM INC	2.5MG	A075178	002	Mar 23, 2001	Jun CAHN
	@		5MG	A075178	001	Mar 23, 2001	Jun CAHN
	@		10MG	A075178	003	Mar 23, 2001	Jun CAHN
	@		20MG	A075178	004	Mar 23, 2001	Jun CAHN
AB		PRINSTON INC	2.5MG	A213273	001	Jul 07, 2022	Jul NEWA
AB			5MG	A213273	002	Jul 07, 2022	Jul NEWA
AB			10MG	A213273	003	Jul 07, 2022	Jul NEWA
AB			20MG	A213273	004	Jul 07, 2022	Jul NEWA

ENALAPRILAT

INJECTABLE;INJECTION
ENALAPRILAT

AP		ATHENEX INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jan CHRS
AP		CHARTWELL INJECTABLE	1.25MG/ML	A075634	001	Aug 22, 2000	Mar CAHN
AP	!	HIKMA FARMACEUTICA	1.25MG/ML	A078687	001	Dec 23, 2008	Jan CHRS
AP		HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Jan CHRS

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

AB		NANJING KING-FRIEND	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Jun NEWA

ENTECAVIR

TABLET;ORAL
ENTECAVIR

	@	ACCORD HLTHCARE	0.5MG	A205824	001	Aug 25, 2017	Apr DISC
	@		1MG	A205824	002	Aug 25, 2017	Apr DISC
	@	YUNG SHIN PHARM	0.5MG	A208195	001	Nov 10, 2021	May DISC
	@		1MG	A208195	002	Nov 10, 2021	May DISC

ENZALUTAMIDE

CAPSULE;ORAL
ENZALUTAMIDE

	@	ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	Feb DISC
AB		APOTEX	40MG	A209645	001	Apr 22, 2022	Apr NEWA

XTANDI

AB	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Apr CTEC
	+!		40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

	+!	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun CAHN
	+ @		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun CAHN
	+ @		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun CAHN

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

>D>	AP	AGGREGA	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Sep CAHN
	AP		50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Apr NEWA
	+!	ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	May NEWA
	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CMFD
	AP	GLAND PHARMA LTD	50MG/ML (50MG/ML)	A216146	001	Feb 25, 2022	Feb NEWA
>A>	AP	XIROMED	50MG/ML (50MG/ML)	A215825	001	Apr 21, 2022	Sep CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ELESTAT

	+ @	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Aug DISC

EPINASTINE HYDROCHLORIDE

	@	AKORN	0.05%	A204055	001	May 05, 2017	Aug DISC
AT	!	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Aug CHRS

EPINEPHRINE

SOLUTION;INTRAVENOUS

EPINEPHRINE

	+!	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022	Aug NEWA

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

	+!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD

LIGNOSPAN STANDARD

	+!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan CRLD

EPLERENONE

TABLET;ORAL

EPLERENONE

	AB	KARTHA	25MG	A214663	001	Mar 23, 2022	Mar NEWA
	AB		50MG	A214663	002	Mar 23, 2022	Mar NEWA
>D>		@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Sep CMFD
>A>	AB		25MG	A212765	001	Aug 10, 2020	Sep CMFD
>D>		@	50MG	A212765	002	Aug 10, 2020	Sep CMFD
>A>	AB		50MG	A212765	002	Aug 10, 2020	Sep CMFD

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

	@	AKORN	2MG/ML	A204589	001	Apr 18, 2017	Aug DISC
	@		75MG/100ML	A204589	002	Apr 18, 2017	Aug DISC
>D>	AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Sep DISC
>A>	@		2MG/ML	A208554	001	Nov 23, 2018	Sep DISC
	AP	SHUANGCHENG	75MG/100ML	A213081	002	Apr 20, 2022	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

	AB	EUGIA PHARMA	EQ 25MG BASE	A216342	001	Jun 22, 2022	Jun NEWA
	AB		EQ 100MG BASE	A216342	002	Jun 22, 2022	Jun NEWA
	AB		EQ 150MG BASE	A216342	003	Jun 22, 2022	Jun NEWA

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

INVANZ

AP	+!	MSD SUB MERCK	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Jun CAHN

ERTUGLIFLOZIN

		TABLET;ORAL					
		STEGLATRO					
	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Jun CAHN
	+!		15MG	N209803	002	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

		TABLET;ORAL					
		SEGLUROMET					
	+	MSD SUB MERCK	2.5MG;500MG	N209806	001	Dec 19, 2017	Jun CAHN
	+		2.5MG;1GM	N209806	002	Dec 19, 2017	Jun CAHN
	+		7.5MG;500MG	N209806	003	Dec 19, 2017	Jun CAHN
	+!		7.5MG;1GM	N209806	004	Dec 19, 2017	Jun CAHN

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

		TABLET;ORAL					
		STEGLUJAN					
	+	MSD SUB MERCK	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017	Jun CAHN
	+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017	Jun CAHN

ERYTHROMYCIN

		SOLUTION;TOPICAL					
		ERYTHRA-DERM					
AT		MICRO LABS	2%	A062687	001	Feb 05, 1988	Aug CAHN
		ERYTHROMYCIN					
		@ BAUSCH	2%	A064039	001	Jan 27, 1994	Jul CAHN
		TABLET;ORAL					
		ERYTHROMYCIN					
AB		ALKEM LABS LTD	250MG	A216066	001	Jul 13, 2022	Jul NEWA
AB			500MG	A216066	002	Jul 13, 2022	Jul NEWA
		TABLET, COATED PARTICLES;ORAL					
		PCE					
	+ @	AZURITY	333MG	N050611	001	Sep 09, 1986	May CAHN
	+ @		500MG	N050611	002	Aug 22, 1990	May CAHN

ERYTHROMYCIN ETHYLSUCCINATE

		GRANULE;ORAL					
		E.E.S.					
AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	001		May CAHN
		ERYPED					
AB	+	AZURITY	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	May CAHN
AB	+!		EQ 400MG BASE/5ML	N050207	002		May CAHN
		TABLET, CHEWABLE;ORAL					
		E.E.S.					
		@ AZURITY	EQ 200MG BASE	N050297	002		May CAHN
		ERYPED					
		@ AZURITY	EQ 200MG BASE	N050297	003	Jul 05, 1988	May CAHN

ERYTHROMYCIN LACTOBIONATE

		INJECTABLE;INJECTION					
		ERYTHROMYCIN LACTOBIONATE					
AP		NEXUS PHARMS	EQ 500MG BASE/VIAL	A215290	001	Feb 14, 2022	Feb NEWA

ESMOLOL HYDROCHLORIDE

		INJECTABLE;INJECTION					
		ESMOLOL HYDROCHLORIDE					
AP		EUGIA PHARMA	10MG/ML	A216244	001	Mar 21, 2022	Mar NEWA
AP			20MG/ML	A216244	002	Mar 21, 2022	Mar NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

		TABLET, DELAYED RELEASE;ORAL					
		NAPROXEN AND ESOMEPRAZOLE MAGNESIUM					
AB		ACTAVIS LABS FL INC	EQ 20MG BASE;375MG	A204470	001	Aug 24, 2022	Aug NEWA
AB			EQ 20MG BASE;500MG	A204470	002	Aug 24, 2022	Aug NEWA
>A> AB		AJANTA PHARMA LTD	EQ 20MG BASE;375MG	A213699	001	Oct 06, 2022	Sep NEWA
>A> AB			EQ 20MG BASE;500MG	A213699	002	Oct 06, 2022	Sep NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

	AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Feb NEWA
		@ MYLAN	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Apr CAHN
		@	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr CAHN
		@ MYLAN LABS LTD	EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Apr DISC
		@ SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb CAHN
	AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb CAHN

ESTRADIOL

GEL;TRANSDERMAL

DIVIGEL

	AB	+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jul CFTG

ESTRADIOL

	AB	CHEMO RESEARCH SL	0.1%	A211783	001	Aug 10, 2022	Jul NFTG

SYSTEM;TRANSDERMAL

ESTRADIOL

>D>	AB	AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019	Sep CTEC
>A>	AB1		0.025MG/24HR	A211293	001	Feb 04, 2019	Sep CTEC
	AB		0.025MG/24HR	A211293	001	Feb 04, 2019	Aug CTEC
>D>	AB		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep CTEC
>A>	AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep CTEC
	AB		0.0375MG/24HR	A211293	002	Feb 04, 2019	Aug CTEC
>D>	AB		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep CTEC
>A>	AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep CTEC
	AB		0.05MG/24HR	A211293	003	Feb 04, 2019	Aug CTEC
>D>	AB		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep CTEC
>A>	AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep CTEC
	AB		0.075MG/24HR	A211293	004	Feb 04, 2019	Aug CTEC
>D>	AB		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep CTEC
>A>	AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep CTEC
	AB		0.1MG/24HR	A211293	005	Feb 04, 2019	Aug CTEC

TABLET;ORAL

ESTRADIOL

		@ LANNETT CO INC	0.5MG	A040138	001	Jan 30, 1998	May CAHN
		@	1MG	A040138	002	Jan 30, 1998	May CAHN
		@	2MG	A040138	003	Jan 30, 1998	May CAHN
		@ MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
		@	1MG	A040114	001	Mar 14, 1996	Feb DISC
		@	2MG	A040114	002	Mar 14, 1996	Feb DISC

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

		+ @ THERAPEUTICSMD INC	0.5MG;100MG	N210132	002	Dec 28, 2021	Apr DISC
		+!	1MG;100MG	N210132	001	Oct 28, 2018	May CTEC
	AB	+!	1MG;100MG	N210132	001	Oct 28, 2018	May CFTG

ESTRADIOL AND PROGESTERONE

		@ AMNEAL PHARMS	1MG;100MG	A214293	001	May 16, 2022	May DISC
	AB		1MG;100MG	A214293	001	May 16, 2022	May NFTG

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

		@ CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan CAHN
		@	2MG	A091165	002	Jul 14, 2011	Jan CAHN
		@	3MG	A091165	003	Jul 14, 2011	Jan CAHN

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

		@ ALVOGEN	25MG	A205709	001	Jul 24, 2018	Aug DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ZOVIA 1/35E-28

		@ MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan DISC

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

HALOETTE

AB		MAYNE PHARMA	0.015MG/24HR;0.12MG/24HR	A211328	001	Aug 05, 2022	Jul NEWA

NUVARING

AB	+!	ORGANON USA ORGANON	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Jul CAHN

VERARING

	@	DR REDDYS LABS SA	0.015MG/24HR;0.12MG/24HR	A207577	001	Dec 09, 2021	Jun DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

	@	MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Aug DISC

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1		NAARI PTE LTD	0.02MG;0.1MG	A207065	001	Aug 17, 2020	Apr CTEC

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB		AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Jul CTEC

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

FEMCON FE

	+ @	APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	May CDFR

NEXESTA FE

AB		AUROBINDO PHARMA	0.035MG;0.4MG	A207535	001	Feb 02, 2017	May CDFR

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	0.035MG;0.4MG	A078892	001	Sep 26, 2011	May CDFR
AB		BARR	0.035MG;0.4MG	A078965	001	Aug 05, 2010	May CDFR
AB		LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	May CDFR
AB	!	MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	May CDFR
AB		NAARI PTE LTD	0.035MG;0.4MG	A207066	001	Mar 29, 2017	May CDFR

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

	@	MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Jan DISC

RHUZDAH

>A>							
>A> AB		AUROBINDO PHARMA	0.035MG;0.4MG	A207585	001	Oct 11, 2022	Sep NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		GLENMARK PHARMS LTD	0.02MG;1MG	A213418	001	Jul 27, 2022	Jul NEWA
>D> AB		MAYNE PHARMA	0.02MG;1MG	A213901	001	Apr 28, 2022	Sep DISC
>A>	@		0.02MG;1MG	A213901	001	Apr 28, 2022	Sep DISC
AB			0.02MG;1MG	A213901	001	Apr 28, 2022	Apr NEWA

TABLET;ORAL

FINZALA

AB		TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	May CDFR

MIBELAS 24 FE

AB		LUPIN	0.02MG;1MG	A206287	001	May 24, 2016	May CDFR

MINASTRIN 24 FE

AB	+!	APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CDFR

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	@	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jun DISC
	@		0.02MG;1MG	A207514	001	Sep 11, 2017	May CDFR
AB	!	GLENMARK PHARMS LTD	0.02MG;1MG	A204847	001	Nov 17, 2017	Jun CHRS
AB			0.02MG;1MG	A210369	001	Dec 26, 2017	May CDFR
	@	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017	May CDFR
AB		XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	May CDFR

TABLET;ORAL-21

LOESTRIN 21 1.5/30

	+ @	TEVA BRANDED PHARM	0.03MG;1.5MG	N017875	001		Jun DISC

LOESTRIN 21 1/20

	+ @	TEVA BRANDED PHARM	0.02MG;1MG	N017876	001		Jul DISC

LOESTRIN FE 1.5/30

	+ @	TEVA BRANDED PHARM	0.03MG;1.5MG	N017355	001		Jun DISC

MICROGESTIN 1.5/30

	@	MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan DISC

```
        TABLET;ORAL-21
          MICROGESTIN 1/20
          @ MAYNE PHARMA          0.02MG;1MG                        A075647  002  Jul 30, 2003   Jan DISC
        TABLET;ORAL-28
          JUNEL FE 1.5/30
    AB  !   BARR                  0.03MG;1.5MG                      A076064  001  Sep 18, 2003   Jun CHRS
          LOESTRIN FE 1/20
        + @ TEVA BRANDED PHARM    0.02MG;1MG                        N017354  001                  Jun DISC
          MICROGESTIN FE 1.5/30
          @ MAYNE PHARMA          0.03MG;1.5MG                      A075548  001  Feb 05, 2001   Jan DISC
          MICROGESTIN FE 1/20
          @ MAYNE PHARMA          0.02MG;1MG                        A075647  001  Feb 05, 2001   Jan DISC
          NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
          @ MAYNE PHARMA          0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A076629  001  Mar 18, 2010   Jan DISC
    AB      MYLAN                 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A205069  001  Jun 22, 2018   Feb CMFD
    AB                            0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A205069  001  Jun 22, 2018   Feb CAHN
        TABLET, CHEWABLE;ORAL
          FINZALA
    AB      TEVA PHARMS USA INC   0.02MG;1MG                        A210087  001  Apr 07, 2020   Jan CMFD
          NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
          @ AMNEAL PHARMS         0.02MG;1MG                        A207514  001  Sep 11, 2017   Jan DISC

      ETHINYL ESTRADIOL; NORGESTIMATE
        TABLET;ORAL-28
          TRI-LO-LINYAH
    AB      NOVAST LABS           0.025MG,0.025MG,0.025MG;0.18MG,0.2 A090541  001  Sep 02, 2022   Aug NEWA
                                  15MG,0.25MG

      ETHINYL ESTRADIOL; NORGESTREL
        TABLET;ORAL-21
          LO/OVRAL
        + @ CADENCE HEALTH        0.03MG;0.3MG                      N017612  001                  Apr CRLD
        TABLET;ORAL-28
          CRYSELLE
    AB  !   DURAMED PHARMS BARR   0.03MG;0.3MG                      A075840  002  Nov 30, 2001   Apr CHRS
          LO/OVRAL-28
        + @ WYETH PHARMS          0.03MG;0.3MG                      N017802  001                  Apr CRLD

      ETONOGESTREL
        IMPLANT;IMPLANTATION
          IMPLANON
          @ ORGANON               68MG/IMPLANT                      N021529  001  Jul 17, 2006   Jan CAHN
          NEXPLANON
        +!  ORGANON               68MG/IMPLANT                      N021529  002  May 31, 2011   Jan CAHN

      ETRAVIRINE
        TABLET;ORAL
          ETRAVIRINE
    AB      CARNEGIE              100MG                             A215402  001  Apr 13, 2022   Apr NEWA
    AB                            200MG                             A215402  002  Apr 13, 2022   Apr NEWA

      EXEMESTANE
        TABLET;ORAL
          EXEMESTANE
    AB      EUGIA PHARMA          25MG                              A216454  001  May 20, 2022   May NEWA

      EZETIMIBE
        TABLET;ORAL
          EZETIMIBE
          @ APOTEX                10MG                              A208332  001  Jun 12, 2017   Apr DISC
    AB      HETERO LABS LTD III   10MG                              A210859  001  Jul 26, 2022   Jul NEWA
>A> AB      ORIENT PHARMA         10MG                              A215693  001  Sep 13, 2022   Sep NEWA

>D>   EZETIMIBE; ROSUVASTATIN CALCIUM
>D>     TABLET;ORAL
>D>       ROSZET
>D>     +   ALTHERA PHARMS        10MG;EQ 5MG BASE                  N213072  001  Mar 23, 2021   Sep DISC
>A>     + @                       10MG;EQ 5MG BASE                  N213072  001  Mar 23, 2021   Sep DISC
>D>     +                         10MG;EQ 10MG BASE                 N213072  002  Mar 23, 2021   Sep DISC
>A>     + @                       10MG;EQ 10MG BASE                 N213072  002  Mar 23, 2021   Sep DISC
>D>     +                         10MG;EQ 20MG BASE                 N213072  003  Mar 23, 2021   Sep DISC
```

```
          TABLET;ORAL
            ROSZET
>A>       + @                       10MG;EQ 20MG BASE                N213072  003  Mar 23, 2021   Sep DISC
>D>       +!                        10MG;EQ 40MG BASE                N213072  004  Mar 23, 2021   Sep DISC
>A>       + @                       10MG;EQ 40MG BASE                N213072  004  Mar 23, 2021   Sep DISC

        FAMCICLOVIR
          TABLET;ORAL
            FAMCICLOVIR
            @ CIPLA                 125MG                            A078278  001  Mar 21, 2011   Mar DISC
            @                       250MG                            A078278  002  Mar 21, 2011   Mar DISC
            @                       500MG                            A078278  003  Mar 21, 2011   Mar DISC

        FAMOTIDINE
          FOR SUSPENSION;ORAL
            FAMOTIDINE
    AB        AMNEALS PHARMS        40MG/5ML                         A216427  001  Aug 04, 2022   Jul NEWA
          INJECTABLE;INJECTION
            FAMOTIDINE PRESERVATIVE FREE
            @ AKORN                 10MG/ML                          A076324  001  Nov 27, 2002   Feb CAHN
            FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)
            @ AKORN                 10MG/ML                          A076322  001  Nov 27, 2002   Feb CAHN
          TABLET;ORAL
            FAMOTIDINE
>D> AB        PERRIGO R AND D       20MG                             A077352  002  Jul 27, 2005   Sep DISC
>A>         @                       20MG                             A077352  002  Jul 27, 2005   Sep DISC
>D> AB                              40MG                             A077352  001  Jul 27, 2005   Sep DISC
>A>         @                       40MG                             A077352  001  Jul 27, 2005   Sep DISC
    AB        ZYDUS PHARMS          20MG                             A216441  001  Jun 03, 2022   May NEWA
    AB                              40MG                             A216441  002  Jun 03, 2022   May NEWA

        FEBUXOSTAT
          TABLET;ORAL
            FEBUXOSTAT
    AB        PRINSTON INC          40MG                             A206266  001  Mar 28, 2022   Mar NEWA
    AB                              80MG                             A206266  002  Mar 28, 2022   Mar NEWA

        FELODIPINE
          TABLET, EXTENDED RELEASE;ORAL
            FELODIPINE
            @ ATLANTIDE             2.5MG                            A091484  001  Aug 15, 2012   Apr CAHN
            @                       5MG                              A091484  002  Aug 15, 2012   Apr CAHN
            @                       10MG                             A091484  003  Aug 15, 2012   Apr CAHN

        FENOFIBRATE
          CAPSULE;ORAL
            ANTARA (MICRONIZED)
          + @ LUPIN                 30MG                             N021695  004  Oct 18, 2013   Jul DISC
          TABLET;ORAL
            FENOFIBRATE
>D> AB        ADAPTIS               54MG                             A210606  001  Aug 17, 2018   Sep CAHN
>D> AB                              160MG                            A210606  002  Aug 17, 2018   Sep CAHN
>A> AB        AUROBINDO PHARMA      54MG                             A216798  001  Sep 27, 2022   Sep NEWA
>A> AB                              160MG                            A216798  002  Sep 27, 2022   Sep NEWA
>A> AB        GRAVITI PHARMS        54MG                             A210606  001  Aug 17, 2018   Sep CAHN
>A> AB                              160MG                            A210606  002  Aug 17, 2018   Sep CAHN

        FENOPROFEN CALCIUM
          CAPSULE;ORAL
            FENOPROFEN CALCIUM
    AB        RISING                EQ 400MG BASE                    A214475  001  Jul 18, 2022   Jul NFTG
            NALFON
    AB    +!  XSPIRE PHARMA         EQ 400MG BASE                    N017604  004  Jul 21, 2009   Jul CFTG
          TABLET;ORAL
            FENOPROFEN CALCIUM
            @ STRIDES PHARMA        EQ 600MG BASE                    A072429  001  Aug 17, 1988   Jul CAHN
```

FENTANYL

SPRAY;SUBLINGUAL

SUBSYS

	+ @	BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Aug DISC
	+ @		0.2MG	N202788	002	Jan 04, 2012	Aug DISC
	+ @		0.4MG	N202788	003	Jan 04, 2012	Aug DISC
	+ @		0.6MG	N202788	004	Jan 04, 2012	Aug DISC
	+ @		0.8MG	N202788	005	Jan 04, 2012	Aug DISC
	+ @		1.2MG	N202788	006	Aug 30, 2012	Aug DISC
	+ @		1.6MG	N202788	007	Aug 30, 2012	Aug DISC

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

	@	ADALVO	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Aug CAHN
	@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Aug CAHN
	@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Aug CAHN
	@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Aug CAHN
	@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Aug CAHN

SPRAY, METERED;NASAL

LAZANDA

	+ @	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Aug DISC
	+ @		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Aug DISC

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

AB		MAYNE PHARMA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022	Aug NEWA
AB			EQ 0.2MG BASE	A206329	002	Aug 22, 2022	Aug NEWA
			EQ 0.3MG BASE	A206329	003	Aug 22, 2022	Aug NEWA
AB			EQ 0.4MG BASE	A206329	004	Aug 22, 2022	Aug NEWA
AB			EQ 0.6MG BASE	A206329	005	Aug 22, 2022	Aug NEWA
AB			EQ 0.8MG BASE	A206329	006	Aug 22, 2022	Aug NEWA

FENTORA

AB	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006	Aug CTEC
AB	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006	Aug CTEC
AB	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006	Aug CTEC
AB	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006	Aug CTEC
AB	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006	Aug CTEC

FERRIC CARBOXYMALTOSE

SOLUTION;INTRAVENOUS

INJECTAFER

	+!	AM REGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB		ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	May CMFD
AB			8MG	A204827	002	Dec 10, 2015	May CMFD
AB		DR REDDYS	4MG	A204975	001	Aug 13, 2019	Jun CMFD
AB			8MG	A204975	002	Aug 13, 2019	Jun CMFD

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

	@	CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan CAHN
	@		60MG	N020625	001	Jul 25, 1996	Jan CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

>D>	@	ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Sep CMFD
>A> AB			EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Sep CMFD
AB		DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Aug CMFD
>D>	@	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Sep CMFD
>A> AB			EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Sep CMFD
AB		HETERO LABS LTD V	EQ 0.5MG BASE	A207933	001	May 18, 2020	Jul CMFD
AB		MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Aug CMFD
	@		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb DISC
AB			EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb CAHN
AB		PRINSTON INC	EQ 0.5MG BASE	A208003	001	Sep 07, 2022	Aug NEWA
AB		SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug CMFD

```
          CAPSULE;ORAL
            FINGOLIMOD HYDROCHLORIDE
            @ TEVA PHARMS USA       EQ 0.25MG BASE                    A212152  001  Nov 12, 2021   Jun DISC
            GILENYA
          +   NOVARTIS              EQ 0.25MG BASE                    N022527  002  May 11, 2018   Jun CTEC

>D>     FINGOLIMOD LAURYL SULFATE
>D>       TABLET, ORALLY DISINTEGRATING;ORAL
>D>         TASCENSO ODT
>D>       +!  HANDA                 EQ 0.25MG BASE                    N214962  001  Dec 23, 2021   Sep DISC
>A>       + @                       EQ 0.25MG BASE                    N214962  001  Dec 23, 2021   Sep DISC

        FLECAINIDE ACETATE
          TABLET;ORAL
            FLECAINIDE ACETATE
            @ CHARTWELL             50MG                              A079164  001  Jul 09, 2009   Feb CAHN
            @                       100MG                             A079164  002  Jul 09, 2009   Feb CAHN
            @                       150MG                             A079164  003  Jul 09, 2009   Feb CAHN
    AB        YICHANG HUMANWELL     50MG                              A215599  001  Sep 08, 2022   Aug NEWA
    AB                              100MG                             A215599  002  Sep 08, 2022   Aug NEWA
    AB                              150MG                             A215599  003  Sep 08, 2022   Aug NEWA

        FLORTAUCIPIR F-18
          SOLUTION;INTRAVENOUS
            TAUVID
>A>       +!  AVID RADIOPHARMS INC  50ML (8.1-100mCi/ML)              N212123  003  Jul 01, 2022   Sep NEWA
>A>       +!                        100ML (8.1-100mCi/ML)             N212123  004  Jul 01, 2022   Sep NEWA

        FLUCONAZOLE
          TABLET;ORAL
            FLUCONAZOLE
    AB        THINQ PHARM-CRO PVT   50MG                              A076957  001  Sep 28, 2005   Jun CAHN
    AB                              100MG                             A076957  002  Sep 28, 2005   Jun CAHN
    AB                              150MG                             A076957  004  Feb 27, 2017   Jun CAHN
    AB                              200MG                             A076957  003  Sep 28, 2005   Jun CAHN

        FLUCYTOSINE
          CAPSULE;ORAL
            FLUCYTOSINE
    AB        STRIDES PHARMA        250MG                             A212632  001  Apr 17, 2020   Feb CMFD
    AB                              500MG                             A212632  002  Apr 17, 2020   Feb CMFD

        FLUDARABINE PHOSPHATE
          INJECTABLE;INJECTION
            FLUDARABINE PHOSPHATE
    AP        HIKMA                 50MG/VIAL                         A076349  001  Aug 28, 2003   Aug CAHN

        FLUDROCORTISONE ACETATE
          TABLET;ORAL
            FLUDROCORTISONE ACETATE
    AB        NOVITIUM PHARMA       0.1MG                             A215279  001  May 31, 2022   May NEWA

        FLUNISOLIDE
          SPRAY, METERED;NASAL
            FLUNISOLIDE
            @ APOTEX                0.029MG/SPRAY                     A077436  001  Aug 09, 2007   May DISC
    AB    !   BAUSCH                0.025MG/SPRAY                     A074805  001  Feb 20, 2002   Jun CAHN
    AB        RICONPHARMA LLC       0.025MG/SPRAY                     A207802  001  Jun 16, 2022   Jun NEWA

        FLUOCINOLONE ACETONIDE
          CREAM;TOPICAL
            FLUOCINOLONE ACETONIDE
>D>         @ ALLIED                0.025%                            A088045  001  Dec 16, 1982   Sep CAHN
>A>         @ MLV                   0.025%                            A088045  001  Dec 16, 1982   Sep CAHN
          OIL;TOPICAL
            FLUOCINOLONE ACETONIDE
            @ AMNEAL                0.01%                             A201759  001  Oct 17, 2011   Jul DISC
            @                       0.01%                             A201764  001  Oct 17, 2011   Jul DISC
          OIL/DROPS;OTIC
            FLUOCINOLONE ACETONIDE
            @ AMNEAL                0.01%                             A091306  001  Oct 17, 2011   Jul DISC
```

```
          SOLUTION;TOPICAL
            FLUOCINOLONE ACETONIDE
            @ PAI HOLDINGS PHARM     0.01%                          A088312  001  Jan 27, 1984   Apr CAHN

        FLUOCINONIDE
          CREAM;TOPICAL
            FLUOCINONIDE
            @ ENCUBE                 0.05%                          A211410  001  Oct 16, 2018   Jul CAHN
            LIDEX-E
          + @ ALVOGEN                0.05%                          N016908  003                  Aug DISC

        FLUOROMETHOLONE
          OINTMENT;OPHTHALMIC
            FML
          + @ ALLERGAN               0.1%                           N017760  001  Sep 04, 1985   Aug DISC

        FLUOROURACIL
          CREAM;TOPICAL
            FLUOROPLEX
          + @ CHARTWELL RX           1%                             N016988  001                  Jul CAHN
          INJECTABLE;INJECTION
            FLUOROURACIL
            @ EUGIA PHARMA SPECLTS   500MG/10ML (50MG/ML)           A202668  001  Jul 17, 2012   Mar CAHN
            @                        1GM/20ML (50MG/ML)             A202668  002  Jul 17, 2012   Mar CAHN
            @                        2.5GM/50ML (50MG/ML)           A202669  001  Jul 17, 2012   Mar CAHN
            @                        5GM/100ML (50MG/ML)            A202669  002  Jul 17, 2012   Mar CAHN

        FLUOXETINE HYDROCHLORIDE
          CAPSULE;ORAL
            FLUOXETINE HYDROCHLORIDE
    AB1       MICRO LABS             EQ 10MG BASE                   A216232  001  Mar 29, 2022   Mar NEWA
    AB1                              EQ 20MG BASE                   A216232  002  Mar 29, 2022   Mar NEWA
    AB                               EQ 40MG BASE                   A216232  003  Mar 29, 2022   Mar NEWA
          TABLET;ORAL
            FLUOXETINE HYDROCHLORIDE
>A> AB        PIRAMAL HLTHCARE UK    EQ 10MG BASE                   A211444  001  Sep 13, 2022   Sep NEWA
>A> AB                               EQ 20MG BASE                   A211444  002  Sep 13, 2022   Sep NEWA

        FLUPHENAZINE HYDROCHLORIDE
          TABLET;ORAL
            FLUPHENAZINE HYDROCHLORIDE
    AB        APOTEX                 1MG                            A216649  001  Jul 15, 2022   Jul NEWA
    AB                               2.5MG                          A216649  002  Jul 15, 2022   Jul NEWA
    AB                               5MG                            A216649  003  Jul 15, 2022   Jul NEWA
    AB                               10MG                           A216649  004  Jul 15, 2022   Jul NEWA
    AB        PRASCO                 1MG                            A089804  002  Aug 12, 1988   Jun CMFD
            @                        1MG                            A089804  002  Aug 12, 1988   Mar CAHN
    AB                               2.5MG                          A089804  003  Aug 12, 1988   Jun CMFD
            @                        2.5MG                          A089804  003  Aug 12, 1988   Mar CAHN
    AB                               5MG                            A089804  004  Aug 12, 1988   Jun CMFD
            @                        5MG                            A089804  004  Aug 12, 1988   Mar CAHN
    AB                               10MG                           A089804  001  Aug 12, 1988   Jun CMFD
            @                        10MG                           A089804  001  Aug 12, 1988   Mar CAHN
    AB        TARO PHARM INDS LTD    1MG                            A215674  001  Apr 14, 2022   Apr NEWA
    AB                               2.5MG                          A215674  002  Apr 14, 2022   Apr NEWA
    AB                               5MG                            A215674  003  Apr 14, 2022   Apr NEWA
    AB                               10MG                           A215674  004  Apr 14, 2022   Apr NEWA
    AB        TWI PHARMS             2.5MG                          A215848  001  Apr 01, 2022   Mar NEWA
    AB                               5MG                            A215848  002  Apr 01, 2022   Mar NEWA
    AB                               10MG                           A215848  003  Apr 01, 2022   Mar NEWA

        FLURANDRENOLIDE
>D>       CREAM;TOPICAL
>D>         CORDRAN SP
>D>       +!  ALMIRALL               0.05%                          N012806  002                  Sep DISC
>A>       + @                        0.05%                          N012806  002                  Sep DISC
          +!                         0.05%                          N012806  002                  Feb CTEC
            FLURANDRENOLIDE
            @ CINTEX SVCS            0.05%                          A205342  001  Apr 13, 2016   Feb DISC
```

```
      LOTION;TOPICAL
        FLURANDRENOLIDE
        @ CINTEX SVCS           0.05%                           A205343  001  Dec 22, 2016   Feb DISC

    FLURAZEPAM HYDROCHLORIDE
      CAPSULE;ORAL
        FLURAZEPAM HYDROCHLORIDE
          RISING                15MG                            A070345  002  Nov 27, 1985   Apr CAHN
      !                         30MG                            A070345  001  Nov 27, 1985   Apr CAHN

    FLUTAMIDE
      CAPSULE;ORAL
        FLUTAMIDE
        @ CHARTWELL RX          125MG                           A075818  001  Sep 18, 2001   Jan CAHN

    FLUTICASONE PROPIONATE
      LOTION;TOPICAL
        CUTIVATE
      + @ FOUGERA PHARMS        0.05%                           N021152  001  Mar 31, 2005   Mar DISC
AB    +                         0.05%                           N021152  001  Mar 31, 2005   Mar CHRS
        FLUTICASONE PROPIONATE
AB    !   GLENMARK GENERICS     0.05%                           A090759  001  May 02, 2011   Mar CHRS
      POWDER;INHALATION
        ARMONAIR DIGIHALER
      + @ TEVA PHARM            0.03MG/INH                      N208798  008  Apr 08, 2022   Apr NEWA

    FLUVOXAMINE MALEATE
      CAPSULE, EXTENDED RELEASE;ORAL
        FLUVOXAMINE MALEATE
AB        BIONPHARMA INC        100MG                           A212182  002  Sep 16, 2020   Feb CMFD
      TABLET;ORAL
        FLUVOXAMINE MALEATE
        @ CHARTWELL RX          25MG                            A075900  001  Feb 23, 2006   Aug CAHN
        @                       50MG                            A075900  002  Feb 23, 2006   Aug CAHN
        @                       100MG                           A075900  003  Feb 23, 2006   Aug CAHN

    FORMOTEROL FUMARATE
      SOLUTION;INHALATION
        FORMOTEROL FUMARATE
AN        LUPIN                 0.02MG/2ML                      A215053  001  Aug 22, 2022   Aug NEWA

    FOSAPREPITANT DIMEGLUMINE
      POWDER;INTRAVENOUS
        FOSAPREPITANT DIMEGLUMINE
        @ ARTHUR GRP            EQ 150MG BASE/VIAL              A211624  001  Sep 05, 2019   Mar CAHN
        @                       EQ 150MG BASE/VIAL              A213199  001  Oct 04, 2021   Mar CAHN
        @ PRAXGEN               EQ 150MG BASE/VIAL              A211624  001  Sep 05, 2019   Feb DISC
        @                       EQ 150MG BASE/VIAL              A213199  001  Oct 04, 2021   Feb DISC

    FOSDENOPTERIN HYDROBROMIDE
      POWDER;INTRAVENOUS
        NULIBRY
      +!  SENTYNL THERAPS INC   EQ 9.5MG BASE/VIAL              N214018  001  Feb 26, 2021   Mar CAHN

    FOSFOMYCIN TROMETHAMINE
      FOR SOLUTION;ORAL
        FOSFOMYCIN TROMETHAMINE
AA        CIPLA                 EQ 3GM BASE/PACKET              A211881  001  Jan 26, 2022   Jan NEWA

    FOSPHENYTOIN SODIUM
      INJECTABLE;INJECTION
        FOSPHENYTOIN SODIUM
AP        ATLANTIDE             EQ 50MG PHENYTOIN NA/ML         A078137  001  Aug 06, 2007   Apr CAHN

    FROVATRIPTAN SUCCINATE
      TABLET;ORAL
        FROVATRIPTAN SUCCINATE
AB        RENATA                EQ 2.5MG BASE                   A213891  001  Apr 06, 2022   May CAHN
AB        ZENARA                EQ 2.5MG BASE                   A213891  001  Apr 06, 2022   Mar NEWA
```

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FULVESTRANT

	@	APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
AO		JIANGSU HANSOH PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
AO		ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
AP		MEITHEAL	10MG/ML	A212803	001	Jan 27, 2022	Mar CAHN

SOLUTION;ORAL

FUROSEMIDE

	!	HIKMA	10MG/ML	A070434	001	Apr 22, 1987	May CTEC
	@	WOCKHARDT BIO AG	10MG/ML	A070655	001	Oct 02, 1987	May DISC

TABLET;ORAL

FUROSEMIDE

	@	EPIC PHARMA LLC	40MG	N018750	002	Jul 30, 1984	Mar CAHN

>A> FUTIBATINIB

>A> TABLET;ORAL

>A> LYTGOBI

>A>	+!	TAIHO ONCOLOGY	4MG	N214801	001	Sep 30, 2022	Sep NEWA

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

	@	CHARTWELL RX	100MG	A091008	001	Oct 26, 2017	Jun CAHN
	@		300MG	A091008	002	Oct 26, 2017	Jun CAHN
	@		400MG	A091008	003	Oct 26, 2017	Jun CAHN

NEURONTIN

AB	+	VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb CAHN
AB	+		300MG	N020235	002	Dec 30, 1993	Feb CAHN
AB	+!		400MG	N020235	003	Dec 30, 1993	Feb CAHN

SOLUTION;ORAL

GABAPENTIN

AA		BELCHER	250MG/5ML	A091286	001	Mar 14, 2016	Jun CAHN
	@	PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN
	@	VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN

NEURONTIN

AA	+!	VIATRIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb CAHN

TABLET;ORAL

NEURONTIN

AB	+	VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb CAHN
AB	+!		800MG	N020882	002	Oct 09, 1998	Feb CAHN

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

	+	AZURITY	300MG	N022399	002	Dec 13, 2011	Mar CAHN
	+!		600MG	N022399	001	Apr 06, 2011	Mar CAHN

>A> GADOPICLENOL

>A> SOLUTION;INTRAVENOUS

>A> ELUCIREM

>A>	+!	GUERBET	1.4553GM/3ML (485.1MG/ML)	N216986	001	Sep 21, 2022	Sep NEWA
>A>	+!		3.63825GM/7.5ML (485.1MG/ML)	N216986	002	Sep 21, 2022	Sep NEWA
>A>	+!		4.851GM/10ML (485.1MG/ML)	N216986	003	Sep 21, 2022	Sep NEWA
>A>	+!		7.2765GM/15ML (485.1MG/ML)	N216986	004	Sep 21, 2022	Sep NEWA
>A>	+!		14.553GM/30ML (485.1MG/ML)	N216986	005	Sep 21, 2022	Sep NEWA
>A>	+!		24.255GM/50ML (485.1MG/ML)	N216986	006	Sep 21, 2022	Sep NEWA
>A>	+!		48.51GM/100ML (485.1MG/ML)	N216986	007	Sep 21, 2022	Sep NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

GADOTERATE MEGLUMINE

AP		HENGRUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Jun CAHN
AP			3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Jun CAHN
AP			5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Jun CAHN
AP			7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Jun CAHN

```
          SOLUTION;INTRAVENOUS
            GADOTERATE MEGLUMINE
    AP                              37.69GM/100ML (376.9MG/ML)        A215982  001  Apr 15, 2022   Jun CAHN
    AP        JIANGSU HENGRUI MED   1.8845GM/5ML (376.9MG/ML)         A215304  001  Apr 11, 2022   Apr NEWA
    AP                              3.769GM/10ML (376.9MG/ML)         A215304  002  Apr 11, 2022   Apr NEWA
    AP                              5.6535GM/15ML (376.9MG/ML)        A215304  003  Apr 11, 2022   Apr NEWA
    AP                              7.538GM/20ML (376.9MG/ML)         A215304  004  Apr 11, 2022   Apr NEWA
    AP                              37.69GM/100ML (376.9MG/ML)        A215982  001  Apr 15, 2022   Apr NEWA

>D>     GALLIUM DOTATOC GA-68
>D>       SOLUTION;INTRAVENOUS
>D>         GALLIUM DOTATOC GA 68
>D>       +!  UIHC PET IMAGING      0.5-4mCi/ML                       N210828  001  Aug 21, 2019   Sep CAIN

>A>     GALLIUM GA-68 DOTATOC
>A>       SOLUTION;INTRAVENOUS
>A>         GALLIUM GA 68 DOTATOC
>A>       +!  UIHC PET IMAGING      0.5-4mCi/ML                       N210828  001  Aug 21, 2019   Sep CAIN

        GALLIUM GA-68 GOZETOTIDE
          POWDER;INTRAVENOUS
            ILLUCCIX
          +!  TELIX                 N/A                               N214032  001  Dec 17, 2021   Mar CPOT
            LOCAMETZ
          +!  AAA USA NOVARTIS      N/A                               N215841  001  Mar 23, 2022   Mar NEWA
          SOLUTION;INTRAVENOUS
            GALLIUM GA 68 GOZETOTIDE
          +!  UNIV CA LOS ANGELES   0.5-5mCi/mL                       N212642  001  Dec 01, 2020   Jul CPOT
          +!                        30ML (0.5-5mCi/mL)                N212642  001  Dec 01, 2020   Jun CTNA
          +!                        30ML (0.5-5mCi/mL)                N212642  001  Dec 01, 2020   Jun CAIN
          +!  UNIV OF CA SAN FRAN   0.5-5mCi/mL                       N212643  001  Dec 01, 2020   Jul CPOT
          +!                        20ML (0.5-5mCi/mL)                N212643  001  Dec 01, 2020   Jun CTNA
          +!                        20ML (0.5-5mCi/mL)                N212643  001  Dec 01, 2020   Jun CAIN

        GANAXOLONE
          SUSPENSION;ORAL
            ZTALMY
          +!  MARINUS               50MG/ML                           N215904  001  Jun 01, 2022   Jun NEWA

        GANCICLOVIR SODIUM
          INJECTABLE;INJECTION
            GANCICLOVIR SODIUM
            @ STERISCIENCE          EQ 500MG BASE/VIAL                A204560  001  Nov 17, 2017   Feb CAHN

        GANIRELIX ACETATE
          INJECTABLE;INJECTION
            FYREMADEL
    AP        SUN PHARM             250MCG/0.5ML                      A204246  001  Nov 30, 2018   May CTNA
            GANIRELIX ACETATE
    AP        AMPHASTAR PHARMS INC  250MCG/0.5ML                      A212613  001  Apr 07, 2022   Apr NEWA
    AP        HONG KONG             250MCG/0.5ML                      A214996  001  Jun 06, 2022   May NEWA

        GATIFLOXACIN
          SOLUTION/DROPS;OPHTHALMIC
            GATIFLOXACIN
            @ RISING                0.5%                              A206446  001  Jun 08, 2018   Jun CAHN

        GEFITINIB
          TABLET;ORAL
>A>         GEFITINIB
>A> AB        APOTEX                250MG                             A209532  001  Sep 23, 2022   Sep NFTG
            IRESSA
>D>       +!  ASTRAZENECA           250MG                             N206995  001  Jul 13, 2015   Sep CFTG
>A> AB    +!                        250MG                             N206995  001  Jul 13, 2015   Sep CFTG

        GEMCITABINE HYDROCHLORIDE
          INJECTABLE;INJECTION
            GEMCITABINE HYDROCHLORIDE
    AP        TEYRO LABS            EQ 200MG BASE/VIAL                A078759  001  Jul 25, 2011   Apr CAHN
    AP                              EQ 1GM BASE/VIAL                  A078759  002  Jul 25, 2011   Apr CAHN
```

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

	@	CHARTWELL RX	600MG	A074615	001	Sep 29, 1995	Feb CAHN

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

	+ @	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan DISC

GEMIFLOXACIN MESYLATE

	@	ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan DISC

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

	@	AKORN	EQ 0.3% BASE	A062635	001	Jan 08, 1987	Aug DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB	!	APOTEX	10MG	A075795	002	Jun 13, 2001	May CHRS
AB		AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb CAHN
AB			10MG	A074226	002	May 10, 1994	Feb CAHN
>D>	@	BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Sep CAHN
>D>	@		10MG	A074542	002	Jun 20, 1995	Sep CAHN
>A>	@	CHARTWELL RX	5MG	A074542	001	Jun 20, 1995	Sep CAHN
>A>	@		10MG	A074542	002	Jun 20, 1995	Sep CAHN

GLUCOTROL

	+ @	PFIZER	5MG	N017783	001	May 08, 1984	May DISC
	+ @		10MG	N017783	002	May 08, 1984	May DISC

GLYBURIDE

TABLET;ORAL

GLYBURIDE

	@	CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016	Jul CAHN
	@		2.5MG	A203581	002	Apr 14, 2016	Jul CAHN
	@		5MG	A203581	003	Apr 14, 2016	Jul CAHN
	@	SUNNY	1.25MG	A203581	001	Apr 14, 2016	Mar DISC
	@		2.5MG	A203581	002	Apr 14, 2016	Mar DISC
	@		5MG	A203581	003	Apr 14, 2016	Mar DISC

GLYBURIDE (MICRONIZED)

	@	CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb CAHN
	@		3MG	A075174	002	Jun 22, 1998	Feb CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

	@	EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018	Jul DISC
	@	ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021	May DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

	+!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022	Apr NEWA

SOLUTION;ORAL

GLYCOPYRROLATE

AA		ANNORA PHARMA	1MG/5ML	A213698	001	Jul 05, 2022	Jun NEWA
AA		SUVEN PHARMS	1MG/5ML	A212467	001	Jul 05, 2022	Jun NEWA

TABLET;ORAL

GLYCOPYRROLATE

	@	CHARTWELL RX	1MG	A040568	001	Dec 22, 2004	Jul CAHN
	@		2MG	A040568	002	Dec 22, 2004	Jul CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

	@	AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009	Jul DISC
AP		AMNEAL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	May CAHN
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	May CAHN
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	May CAHN
	@	EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jul DISC

```
      INJECTABLE;INJECTION
        GRANISETRON HYDROCHLORIDE
        @                       EQ 4MG BASE/4ML (EQ 1MG BASE/ML)   A204238  002  Jul 06, 2016   Jul DISC

    GUANFACINE HYDROCHLORIDE
      TABLET;ORAL
        GUANFACINE HYDROCHLORIDE
AB        TWI PHARMS            EQ 1MG BASE                        A216399  001  Jun 08, 2022   May NEWA
AB                              EQ 2MG BASE                        A216399  002  Jun 08, 2022   May NEWA
      TABLET, EXTENDED RELEASE;ORAL
        GUANFACINE HYDROCHLORIDE
AB        YICHANG HUMANWELL     EQ 1MG BASE                        A213428  001  Nov 25, 2020   May CMFD
AB                              EQ 2MG BASE                        A213428  002  Nov 25, 2020   May CMFD
AB                              EQ 3MG BASE                        A213428  003  Nov 25, 2020   May CMFD
AB                              EQ 4MG BASE                        A213428  004  Nov 25, 2020   May CMFD

    HALOPERIDOL
      TABLET;ORAL
        HALOPERIDOL
AB        ACTAVIS GROUP         0.5MG                              A200854  001  Jul 01, 2022   Jun NEWA
AB                              1MG                                A200854  002  Jul 01, 2022   Jun NEWA
AB                              2MG                                A200854  003  Jul 01, 2022   Jun NEWA
AB                              5MG                                A200854  004  Jul 01, 2022   Jun NEWA
AB                              10MG                               A200854  005  Jul 01, 2022   Jun NEWA
AB                              20MG                               A200854  006  Jul 01, 2022   Jun NEWA
AB        SANDOZ                0.5MG                              A071209  002  Nov 17, 1986   Mar CMS1
AB                              1MG                                A071209  003  Nov 17, 1986   Mar CMS1
        @                       2MG                                A071209  004  Nov 17, 1986   Mar CMS1

    HALOPERIDOL LACTATE
      INJECTABLE;INJECTION
        HALOPERIDOL
        @ AKORN                 EQ 5MG BASE/ML                     A204849  001  Sep 06, 2017   Aug DISC

    HEPARIN SODIUM
      INJECTABLE;INJECTION
        HEPARIN SODIUM
      + @ HIKMA                 1,000 UNITS/ML                     N017007  001                  Jul CAHN
      + @                       2,500 UNITS/ML                     N017007  007                  Jul CAHN
      + @                       5,000 UNITS/ML                     N017007  002                  Jul CAHN
      + @                       5,000 UNITS/0.5ML                  N017007  010                  Jul CAHN
      + @                       7,500 UNITS/ML                     N017007  003                  Jul CAHN
      + @                       10,000 UNITS/ML                    N017007  004                  Jul CAHN
      + @                       15,000 UNITS/ML                    N017007  005                  Jul CAHN
      + @                       20,000 UNITS/ML                    N017007  006                  Jul CAHN
        HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
      +!  B BRAUN               4,000 UNITS/100ML                  N019952  001  Jul 20, 1992   Mar CTEC
        HEPARIN SODIUM PRESERVATIVE FREE
AP        SHENZHEN TECHDOW      1,000 UNITS/ML                     A202732  001  Jun 12, 2014   Jul CMFD

    HYDRALAZINE HYDROCHLORIDE
      INJECTABLE;INJECTION
        HYDRALAZINE HYDROCHLORIDE
>A> AP    BEOWULF ASSET         20MG/ML                            A203110  001  Jun 29, 2015   Sep CAHN
>D> AP    I3 PHARMS             20MG/ML                            A203110  001  Jun 29, 2015   Sep CAHN

    HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE
      TABLET;ORAL
        BIDIL
AB    +!  AZURITY               37.5MG;20MG                        N020727  001  Jun 23, 2005   Mar CFTG
      +!                        37.5MG;20MG                        N020727  001  Jun 23, 2005   Mar CAHN
        ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
AB        RICONPHARMA LLC       37.5MG;20MG                        A215586  001  Apr 06, 2022   Mar NFTG

    HYDROCHLOROTHIAZIDE
      TABLET;ORAL
        HYDROCHLOROTHIAZIDE
        @ CHARTWELL RX          25MG                               A087565  001  Mar 09, 1982   Feb CAHN
        @                       50MG                               A084912  001                  Feb CAHN
```

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987	Feb CAHN
	@	25MG;80MG	A071061	001	Aug 26, 1987	Jan CAHN
	@ RISING	25MG;40MG	A070947	002	Mar 04, 1987	Jul CAHN
	@	25MG;80MG	A070947	001	Apr 01, 1987	Jul CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Jun CTNA
	@	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May DISC
AB		12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	May CTNA
	@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Jun CTNA
	@	12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May DISC
AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	May CTNA
	@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Jun CTNA
	@	25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May DISC
AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	May CTNA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@ MYLAN	25MG;37.5MG	A074701	001	Jun 07, 1996	Jun DISC

TABLET;ORAL

MAXZIDE

AB	+! AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984	Feb CAHN

MAXZIDE-25

AB	+ AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988	Feb CAHN

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	RUBICON	25MG;37.5MG	A216211	001	Feb 23, 2022	Feb NEWA
AB		50MG;75MG	A216211	002	Feb 23, 2022	Feb NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB	ALVOGEN	20MG	A208269	001	Mar 01, 2021	May CAHN
AB		30MG	A208269	002	Mar 01, 2021	May CAHN
AB		40MG	A208269	003	Mar 01, 2021	May CAHN
AB		60MG	A208269	004	Mar 01, 2021	May CAHN
AB		80MG	A208269	005	Mar 01, 2021	May CAHN
AB		100MG	A208269	006	Mar 01, 2021	May CAHN
AB		120MG	A208269	007	Mar 01, 2021	May CAHN

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

	@ ENCUBE	2.5%	A203810	001	Jul 23, 2018	Jul CAHN
	@ LANNETT CO INC	2.5%	A040503	001	Mar 12, 2004	Jun DISC

LOTION;TOPICAL

ALA-SCALP

	DERM RX	2%	A083231	001		Jun CAHN

HYDROCORTISONE

	@ LANNETT CO INC	2.5%	A040417	001	Jul 30, 2003	Jun DISC

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROMORPHONE HYDROCHLORIDE

	HOSPIRA INC	0.5MG/0.5ML	N200403	004	Jun 13, 2022	Jun NEWA

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	@ ANDA REPOSITORY	5MG/5ML	A207108	001	Apr 22, 2020	Sep CAHN
>D>	@ GENUS	5MG/5ML	A207108	001	Apr 22, 2020	Sep CAHN

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

>A>	@ ANDA REPOSITORY	2MG	A077471	002	Dec 09, 2009	Sep CAHN
>A>	@	4MG	A077471	003	Dec 09, 2009	Sep CAHN
>A>	@	8MG	A077471	001	Dec 09, 2009	Sep CAHN
>D>	@ GENUS	2MG	A077471	002	Dec 09, 2009	Sep CAHN
>D>	@	4MG	A077471	003	Dec 09, 2009	Sep CAHN

TABLET;ORAL
HYDROMORPHONE HYDROCHLORIDE

>D>		@	8MG	A077471	001	Dec 09, 2009	Sep CAHN
		@ HIKMA	4MG	A074597	003	May 29, 2009	Aug DISC
		@	8MG	A074597	001	Jul 29, 1998	Aug DISC

HYDROXOCOBALAMIN

INJECTABLE;INJECTION
CYANOKIT

		@ BTG INTL	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Mar CAHN
	+!		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Mar CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL
HYDROXYCHLOROQUINE SULFATE

>D>		ACCORD HLTHCARE	100MG	A213342	002	Aug 18, 2021	Sep CTEC
>A>	AB		100MG	A213342	002	Aug 18, 2021	Sep CTEC
>D>			300MG	A213342	003	Aug 18, 2021	Sep CTEC
>A>	AB		300MG	A213342	003	Aug 18, 2021	Sep CTEC
>D>	!		400MG	A213342	004	Aug 18, 2021	Sep CTEC
>A>	AB !		400MG	A213342	004	Aug 18, 2021	Sep CTEC
	!		400MG	A213342	004	Aug 18, 2021	Jan CHRS
	!		400MG	A213342	004	Aug 18, 2021	Jan CHRS
>A>	AB	APPCO	100MG	A210441	002	Sep 19, 2022	Sep NEWA
>A>	AB		300MG	A210441	003	Sep 19, 2022	Sep NEWA
>A>	AB		400MG	A210441	004	Sep 19, 2022	Sep NEWA
	AB	AUROBINDO PHARMA USA	200MG	A040274	001	May 29, 1998	May CAHN
	+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan NEWA
	+!		300MG	N214581	002	Jan 14, 2022	Jan NEWA
>A>	AB	RISE PHARMA	200MG	A212902	001	May 14, 2020	Sep CAHN
>D>	AB	SENORES PHARMS	200MG	A212902	001	May 14, 2020	Sep CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL
HYDROXYZINE HYDROCHLORIDE

		@ AKORN	10MG/5ML	A040010	001	Oct 28, 1994	Aug DISC
		@ PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Jan CAHN

TABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

	AB	AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982	May CMFD
	AB		25MG	A087871	003	Dec 20, 1982	May CMFD
	AB		50MG	A087871	001	Dec 20, 1982	May CMFD

IBRUTINIB

SUSPENSION;ORAL
IMBRUVICA

	+!	PHARMACYCLICS INC	70MG/ML	N217003	001	Aug 24, 2022	Aug NEWA

IBUPROFEN

SUSPENSION;ORAL
IBUPROFEN

>D>	AB	AKORN	100MG/5ML	A205647	001	Nov 03, 2016	Sep DISC
>A>		@	100MG/5ML	A205647	001	Nov 03, 2016	Sep DISC
	AB	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	May CTEC
	AB	STRIDES PHARMA	100MG/5ML	A215311	001	May 27, 2022	May NEWA

TABLET;ORAL
IBUPROFEN

>D>	AB	L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Sep DISC
>A>		@	400MG	A077114	001	Jul 18, 2005	Sep DISC
>D>	AB		600MG	A077114	002	Jul 18, 2005	Sep DISC
>A>		@	600MG	A077114	002	Jul 18, 2005	Sep DISC
>D>	AB		800MG	A077114	003	Jul 18, 2005	Sep DISC
>A>		@	800MG	A077114	003	Jul 18, 2005	Sep DISC
		@ SUNSHINE	400MG	A204062	001	Sep 10, 2018	Mar CAHN
		@	600MG	A204062	002	Sep 10, 2018	Mar CAHN
		@	800MG	A204062	003	Sep 10, 2018	Mar CAHN
	AB	YICHANG HUMANWELL	400MG	A215318	001	Mar 30, 2022	Mar NEWA
	AB		600MG	A215318	002	Mar 30, 2022	Mar NEWA
	AB		800MG	A215318	003	Mar 30, 2022	Mar NEWA

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	+!	TAKEDA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB		TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Jul CMFD

ILOPERIDONE

TABLET;ORAL

FANAPT

	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jul CTEC
AB	+!		1MG	N022192	001	May 06, 2009	Apr CTEC
	+		2MG	N022192	002	May 06, 2009	Jul CTEC
AB	+		2MG	N022192	002	May 06, 2009	Apr CTEC
	+		4MG	N022192	003	May 06, 2009	Jul CTEC
AB	+		4MG	N022192	003	May 06, 2009	Apr CTEC
	+		6MG	N022192	004	May 06, 2009	Jul CTEC
AB	+		6MG	N022192	004	May 06, 2009	Apr CTEC
	+		8MG	N022192	005	May 06, 2009	Jul CTEC
AB	+		8MG	N022192	005	May 06, 2009	Apr CTEC
	+		10MG	N022192	006	May 06, 2009	Jul CTEC
AB	+		10MG	N022192	006	May 06, 2009	Apr CTEC
	+		12MG	N022192	007	May 06, 2009	Jul CTEC
AB	+		12MG	N022192	007	May 06, 2009	Apr CTEC

ILOPERIDONE

	@	LUPIN LTD	1MG	A206890	001	May 05, 2022	Jul DISC
AB			1MG	A206890	001	May 05, 2022	Apr NEWA
	@		2MG	A206890	002	May 05, 2022	Jul DISC
AB			2MG	A206890	002	May 05, 2022	Apr NEWA
	@		4MG	A206890	003	May 05, 2022	Jul DISC
AB			4MG	A206890	003	May 05, 2022	Apr NEWA
	@		6MG	A206890	004	May 05, 2022	Jul DISC
AB			6MG	A206890	004	May 05, 2022	Apr NEWA
	@		8MG	A206890	005	May 05, 2022	Jul DISC
AB			8MG	A206890	005	May 05, 2022	Apr NEWA
	@		10MG	A206890	006	May 05, 2022	Jul DISC
AB			10MG	A206890	006	May 05, 2022	Apr NEWA
	@		12MG	A206890	007	May 05, 2022	Jul DISC
AB			12MG	A206890	007	May 05, 2022	Apr NEWA

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB		QILU PHARM HAINAN	EQ 100MG BASE	A212135	001	Jun 21, 2022	Jun NEWA
AB			EQ 400MG BASE	A212135	002	Jun 21, 2022	Jun NEWA

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

	@	CHARTWELL RX	1.25MG	A074594	001	May 23, 1996	Feb CAHN
	@		2.5MG	A074594	002	May 23, 1996	Feb CAHN

INDIGOTINDISULFONATE SODIUM

SOLUTION;INTRAVENOUS

BLUDIGO

	+!	PROVEPHARM SAS	40MG/5ML (8MG/ML)	N216264	001	Jul 08, 2022	Jul NEWA

IODIXANOL

INJECTABLE;INJECTION

IODIXANOL

AP		HENGRUI PHARMA	55%	A214271	001	May 19, 2022	May NFTG
AP			65.2%	A214271	002	May 19, 2022	May NFTG

VISIPAQUE 270

AP	+!	GE HEALTHCARE	55%	N020351	001	Mar 22, 1996	May CFTG

VISIPAQUE 320

AP	+!	GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996	May CFTG

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

DATSCAN

AP	+!	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011	Mar CFTG

IOFLUPANE I-123

AP		CURIUM	5mCi/2.5ML (2mCi/ML)	A213792	001	Mar 30, 2022	Mar NFTG

IPRATROPIUM BROMIDE

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

	@	BAUSCH	0.02%	A075835	001	Oct 15, 2001	Jun CAHN

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB		AMNEAL	0.021MG/SPRAY	A215104	001	Aug 16, 2022	Aug NEWA
AB			0.042MG/SPRAY	A215105	001	Aug 16, 2022	Aug NEWA
AB		BAUSCH	0.021MG/SPRAY	A076025	001	Mar 31, 2003	Jun CAHN
AB			0.042MG/SPRAY	A076103	001	Mar 31, 2003	Jun CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP		EUGIA PHARMA	500MG/25ML (20MG/ML)	A213278	004	Apr 11, 2022	Apr NEWA

ISONIAZID

SYRUP;ORAL

ISONIAZID

	@	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Mar CAHN

TABLET;ORAL

ISONIAZID

+	@	EPIC PHARMA LLC	100MG	N008678	002		Jul CAHN
+	@		300MG	N008678	003		Jul CAHN
AA		MIKART	100MG	A040090	001	Jun 26, 1997	Mar CAHN
AA			300MG	A040090	002	Jun 26, 1997	Mar CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		MYLAN LABS LTD	0.2MG/ML	A212573	001	Sep 06, 2022	Aug NEWA
>A> AP		STI PHARMA LLC	0.2MG/ML	A215542	001	Sep 20, 2022	Sep NEWA

ISOSORBIDE DINITRATE

TABLET;ORAL

ISOSORBIDE DINITRATE

AB		RUBICON	5MG	A215723	001	Jul 08, 2022	Jul NEWA
AB			10MG	A215723	002	Jul 08, 2022	Jul NEWA
AB			20MG	A215723	003	Jul 08, 2022	Jul NEWA
AB			30MG	A215723	004	Jul 08, 2022	Jul NEWA
AB			40MG	A215723	005	Jul 08, 2022	Jul NEWA

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		SHANDONG	120MG	A214115	001	Apr 29, 2022	Apr NEWA
AB		ZYDUS PHARMS	30MG	A075395	001	Mar 16, 2000	Mar CAHN
AB			60MG	A075395	002	Mar 16, 2000	Mar CAHN
AB			120MG	A075395	003	Mar 16, 2000	Mar CAHN

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

	@	EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	Jul DISC
>A> AP		FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	Sep NEWA
>A> AP		MSN	1%	A216090	001	Sep 16, 2022	Sep NEWA

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

	@	JUBILANT GENERICS	100MG	A203445	001	Feb 23, 2017	May DISC

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

>D>		+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Sep CTEC
>A>	AB	+		EQ 5MG BASE	N206143	001	Apr 15, 2015	Sep CTEC
		+		EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan CTEC
>D>		+!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Sep CTEC
>A>	AB	+!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Sep CTEC
		+!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan CTEC

IVABRADINE HYDROCHLORIDE

>A>	AB		ANNORA PHARMA	EQ 5MG BASE	A213366	001	Oct 05, 2022	Sep NEWA
>A>	AB			EQ 7.5MG BASE	A213366	002	Oct 05, 2022	Sep NEWA
>D>		@	CENTAUR PHARMS PVT	EQ 5MG BASE	A214051	001	Dec 30, 2021	Sep CAHN
		@		EQ 5MG BASE	A214051	001	Dec 30, 2021	Jan DISC
>D>		@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Sep CAHN
		@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan DISC
>A>		@	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	Sep CAHN
>A>		@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Sep CAHN

IVACAFTOR; LUMACAFTOR

GRANULE;ORAL

ORKAMBI

>A>		+	VERTEX PHARMS INC	94MG/PACKET;75MG/PACKET	N211358	003	Sep 02, 2022	Sep NEWA

IVERMECTIN

CREAM;TOPICAL

IVERMECTIN

	AB		ZYDUS	1%	A215210	001	Aug 02, 2022	Jul NEWA

>D> KETOCONAZOLE

>D> GEL;TOPICAL

>D> XOLEGEL

>D>		+!	ALMIRALL	2%	N021946	001	Jul 28, 2006	Sep DISC
>A>		+ @		2%	N021946	001	Jul 28, 2006	Sep DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

		@	STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007	Feb CAHN
		@		15MG/ML	A201155	001	Aug 04, 2014	Feb CAHN
		@		30MG/ML	A078299	002	Jul 16, 2007	Feb CAHN
		@		30MG/ML	A201155	002	Aug 04, 2014	Feb CAHN
>D>		@	SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Sep CMFD
>A>	AP			15MG/ML	A078737	001	Oct 06, 2008	Sep CMFD
>D>		@		30MG/ML	A078737	002	Oct 06, 2008	Sep CMFD
>A>	AP			30MG/ML	A078737	002	Oct 06, 2008	Sep CMFD

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

		@	AKORN	0.4%	A078399	001	Nov 05, 2009	Jun DISC

TABLET;ORAL

KETOROLAC TROMETHAMINE

	AB		HAVIX	10MG	A215788	001	Mar 23, 2022	Mar NEWA
	AB		HETERO LABS LTD III	10MG	A216651	001	Aug 25, 2022	Aug NEWA
	AB		SENORES PHARMS	10MG	A215788	001	Mar 23, 2022	Mar CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

	AT	+!	RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb CAHN

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

		+!	JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

		@	STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb CAHN

		SOLUTION;INTRAVENOUS						
		LABETALOL HYDROCHLORIDE						
		+! HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Aug	NEWA
		TABLET;ORAL						
		LABETALOL HYDROCHLORIDE						
	AB	UNICHEM	100MG	A212719	001	Aug 08, 2022	Jul	NEWA
	AB		200MG	A212719	002	Aug 08, 2022	Jul	NEWA
	AB		300MG	A212719	003	Aug 08, 2022	Jul	NEWA
		LACOSAMIDE						
		SOLUTION;INTRAVENOUS						
		LACOSAMIDE						
>A>	AP	ASPIRO	200MG/20ML (10MG/ML)	A216335	001	Sep 14, 2022	Sep	NEWA
	AP	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A214677	001	May 03, 2022	Apr	NEWA
>A>	AP	GLAND PHARMA LTD	200MG/20ML (10MG/ML)	A215628	001	Sep 19, 2022	Sep	NEWA
	AP	INDOCO	200MG/20ML (10MG/ML)	A214301	001	Apr 07, 2022	Apr	NFTG
	AP	ZYDUS PHARMS	200MG/20ML (10MG/ML)	A209465	001	Jun 29, 2022	Jun	NEWA
		VIMPAT						
	AP	+! UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008	Apr	CFTG
		SOLUTION;ORAL						
		LACOSAMIDE						
	AA	ALKEM LABS LTD	10MG/ML	A214672	001	May 19, 2022	May	NFTG
>A>	AA	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Sep	NEWA
	AA	HETERO LABS LTD III	10MG/ML	A209301	001	May 31, 2022	May	NEWA
	AA	NOVITIUM PHARMA	10MG/ML	A216151	001	Aug 26, 2022	Aug	NEWA
		VIMPAT						
	AA	+! UCB INC	10MG/ML	N022255	001	Apr 20, 2010	May	CFTG
		TABLET;ORAL						
		LACOSAMIDE						
	AB	ACCORD HLTHCARE	50MG	A205011	001	Jul 12, 2022	Jul	NEWA
	AB		100MG	A205011	002	Jul 12, 2022	Jul	NEWA
	AB		150MG	A205011	003	Jul 12, 2022	Jul	NEWA
	AB		200MG	A205011	004	Jul 12, 2022	Jul	NEWA
	AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A204974	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A204974	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A204974	004	Mar 17, 2022	Mar	NFTG
	AB	ALKEM LABS LTD	50MG	A214695	001	Mar 31, 2022	Mar	NEWA
	AB		100MG	A214695	002	Mar 31, 2022	Mar	NEWA
	AB		150MG	A214695	003	Mar 31, 2022	Mar	NEWA
	AB		200MG	A214695	004	Mar 31, 2022	Mar	NEWA
	AB	AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A204857	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A204857	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A204857	004	Mar 17, 2022	Mar	NFTG
>A>	AB	APOTEX	50MG	A214567	001	Sep 23, 2022	Sep	NEWA
>A>	AB		100MG	A214567	002	Sep 23, 2022	Sep	NEWA
>A>	AB		150MG	A214567	003	Sep 23, 2022	Sep	NEWA
>A>	AB		200MG	A214567	004	Sep 23, 2022	Sep	NEWA
	AB	GLENMARK PHARMS LTD	50MG	A205006	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A205006	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A205006	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A205006	004	Mar 17, 2022	Mar	NFTG
	AB	HETERO LABS LTD V	50MG	A204787	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A204787	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A204787	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A204787	004	Mar 17, 2022	Mar	NFTG
	AB	INDOCO	50MG	A208308	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A208308	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A208308	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A208308	004	Mar 17, 2022	Mar	NFTG
	AB	MSN LABS PVT LTD	50MG	A204921	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A204921	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A204921	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A204921	004	Mar 17, 2022	Mar	NFTG
	AB	SCIEGEN PHARMS INC	50MG	A205237	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A205237	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A205237	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A205237	004	Mar 17, 2022	Mar	NFTG
	AB	SUN PHARM	50MG	A205031	001	Mar 17, 2022	Mar	NFTG
	AB		100MG	A205031	002	Mar 17, 2022	Mar	NFTG
	AB		150MG	A205031	003	Mar 17, 2022	Mar	NFTG
	AB		200MG	A205031	004	Mar 17, 2022	Mar	NFTG

```
        TABLET;ORAL
          VIMPAT
    AB   +   UCB INC              50MG                          N022253  001  Oct 28, 2008   Mar CFTG
    AB   +                        100MG                         N022253  002  Oct 28, 2008   Mar CFTG
    AB   +                        150MG                         N022253  003  Oct 28, 2008   Mar CFTG
    AB   +!                       200MG                         N022253  004  Oct 28, 2008   Mar CFTG

      LACTULOSE
        SOLUTION;ORAL
          LACTULOSE
          @ TORRENT               10GM/15ML                     A207786  001  Jun 11, 2018   Jun DISC
        SOLUTION;ORAL, RECTAL
          LACTULOSE
          @ TORRENT               10GM/15ML                     A203762  001  Mar 27, 2015   Jun DISC

      LAMIVUDINE
        TABLET;ORAL
          LAMIVUDINE
>D> AB      APPCO                 150MG                         A206974  001  Nov 21, 2016   Sep CAHN
>D> AB                            300MG                         A206974  002  Nov 21, 2016   Sep CAHN
>A> AB      UPSHER SMITH LABS     150MG                         A206974  001  Nov 21, 2016   Sep CAHN
>A> AB                            300MG                         A206974  002  Nov 21, 2016   Sep CAHN

      LAMIVUDINE; ZIDOVUDINE
        TABLET;ORAL
          LAMIVUDINE AND ZIDOVUDINE
          @ CHARTWELL RX          150MG;300MG                   A079081  001  May 25, 2011   Mar CAHN

      LAMOTRIGINE
        TABLET, EXTENDED RELEASE;ORAL
          LAMOTRIGINE
          @ TORRENT               200MG                         A203370  004  Dec 23, 2013   Aug DISC
        TABLET, FOR SUSPENSION;ORAL
          LAMICTAL CD
    AB   +   GLAXOSMITHKLINE LLC  2MG                           N020764  004  Sep 08, 2000   Jan CDFR
    AB   +                        5MG                           N020764  001  Aug 24, 1998   Jan CDFR
    AB   +!                       25MG                          N020764  002  Aug 24, 1998   Jan CDFR
          @                       100MG                         N020764  003  Aug 24, 1998   Jan CDFR
          LAMOTRIGINE
    AB      ALEMBIC PHARMS LTD    5MG                           A201168  001  Jun 12, 2014   Jan CDFR
    AB                            25MG                          A201168  002  Jun 12, 2014   Jan CDFR
    AB      AUROBINDO PHARMA      5MG                           A090401  002  Nov 04, 2009   Jan CDFR
    AB                            25MG                          A090401  003  Nov 04, 2009   Jan CDFR
    AB      DR REDDYS LABS LTD    5MG                           A076701  001  Jan 22, 2009   Jan CDFR
    AB                            25MG                          A076701  002  Jan 22, 2009   Jan CDFR
    AB      GLENMARK PHARMS LTD   5MG                           A079099  001  Feb 19, 2009   Jan CDFR
    AB                            25MG                          A079099  002  Feb 19, 2009   Jan CDFR
          @ JUBILANT GENERICS     5MG                           A200220  001  Feb 28, 2011   Jan CDFR
          @                       25MG                          A200220  002  Feb 28, 2011   Jan CDFR
          @ MYLAN                 5MG                           A076630  001  Jan 22, 2009   Jan CDFR
          @                       25MG                          A076630  002  Jan 22, 2009   Jan CDFR
          @ SANDOZ                5MG                           A078409  002  Jan 22, 2009   Jan CDFR
          @                       25MG                          A078409  003  Jan 22, 2009   Jan CDFR
    AB      TARO                  5MG                           A079204  001  Feb 04, 2009   Jan CDFR
    AB                            25MG                          A079204  002  Feb 04, 2009   Jan CDFR
          @ TEVA                  5MG                           A076420  001  Jun 21, 2006   Jan CDFR
          @                       25MG                          A076420  002  Jun 21, 2006   Jan CDFR
    AB      WATSON LABS           2MG                           A076928  001  Jan 22, 2009   Jan CDFR
    AB                            5MG                           A076928  002  Jan 22, 2009   Jan CDFR
    AB                            25MG                          A076928  003  Jan 22, 2009   Jan CDFR
    AB      ZYDUS PHARMS USA INC  5MG                           A078009  002  Jan 22, 2009   Jan CDFR
    AB                            25MG                          A078009  003  Jan 22, 2009   Jan CDFR
        TABLET, ORALLY DISINTEGRATING;ORAL
          LAMOTRIGINE
    AB      AMRING PHARMS         25MG                          A214124  001  Feb 03, 2022   Jan NEWA
    AB                            50MG                          A214124  002  Feb 03, 2022   Jan NEWA
    AB                            100MG                         A214124  003  Feb 03, 2022   Jan NEWA
    AB                            200MG                         A214124  004  Feb 03, 2022   Jan NEWA
          @ IMPAX LABS INC        25MG                          A200828  001  Jul 15, 2013   Jun DISC
          @                       50MG                          A200828  002  Jul 15, 2013   Jun DISC
          @                       100MG                         A200828  003  Jul 15, 2013   Jun DISC
          @                       200MG                         A200828  004  Jul 15, 2013   Jun DISC
```

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB	ATLANTIDE	15MG	A202176	001	Sep 14, 2012	Apr CAHN
AB		30MG	A202176	002	Sep 14, 2012	Apr CAHN

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD
AB	WANBANG BIOPHARMS	10MG	A077087	001	Sep 13, 2005	Jun CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jun CAHN

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB	APOTEX	5MG	A211022	001	Aug 30, 2022	Aug NEWA
AB		10MG	A211022	002	Aug 30, 2022	Aug NEWA
AB		15MG	A211022	003	Aug 30, 2022	Aug NEWA
AB		25MG	A211022	004	Aug 30, 2022	Aug NEWA
AB	CIPLA	5MG	A210435	001	Sep 06, 2022	Aug NEWA
AB		10MG	A210435	002	Sep 06, 2022	Aug NEWA
AB		15MG	A210435	003	Sep 06, 2022	Aug NEWA
AB		25MG	A210435	004	Sep 06, 2022	Aug NEWA
AB	DR REDDYS	5MG	A209348	003	Aug 30, 2022	Aug NEWA
AB		10MG	A209348	004	Aug 30, 2022	Aug NEWA
AB		15MG	A209348	005	Aug 30, 2022	Aug NEWA
AB		25MG	A209348	006	Aug 30, 2022	Aug NEWA
AB	LOTUS PHARM CO LTD	5MG	A210480	001	Aug 31, 2022	Aug NEWA
AB		10MG	A210480	002	Aug 31, 2022	Aug NEWA
AB		15MG	A210480	003	Aug 31, 2022	Aug NEWA
AB		25MG	A210480	004	Aug 31, 2022	Aug NEWA
AB	MYLAN	5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		5MG	A213912	001	Aug 30, 2022	Aug CAHN
AB		5MG	A213912	001	Aug 30, 2022	Aug NEWA
AB		10MG	A213912	002	Aug 30, 2022	Aug NEWA
AB		15MG	A213912	003	Aug 30, 2022	Aug NEWA
AB		25MG	A213912	004	Aug 30, 2022	Aug NEWA
>A> AB	ZYDUS PHARMS	5MG	A210154	001	Sep 12, 2022	Sep NEWA
>A> AB		10MG	A210154	002	Sep 12, 2022	Sep NEWA
>A> AB		15MG	A210154	003	Sep 12, 2022	Sep NEWA
>A> AB		25MG	A210154	004	Sep 12, 2022	Sep NEWA

LETROZOLE

TABLET;ORAL

LETROZOLE

>D> AB	INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	Sep DISC
>A>	@	2.5MG	A201804	001	Jun 03, 2011	Sep DISC

LEUPROLIDE ACETATE

FOR SUSPENSION;INTRAMUSCULAR

LUTRATE DEPOT KIT

+!	GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	May CMFD
+!	INVAGEN PHARMS	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun CAHN

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	May NEWA

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

	+!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021	Jan CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

>A>	AP	BEOWULF ASSET	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN
	AP	PRINSTON INC	500MG/5ML (100MG/ML)	A209474	001	Mar 28, 2022	Mar NEWA
>D>	AP	XGEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Sep CAHN

SOLUTION;ORAL

LEVETIRACETAM

	AA	AIPING PHARM INC	100MG/ML	A090079	001	Apr 11, 2012	Jun CAHN
	AA	BELCHER	100MG/ML	A090461	001	Sep 30, 2010	Jun CAHN
	AA	MSN	100MG/ML	A214757	001	Jul 15, 2022	Jul NEWA
	@	WOCKHARDT BIO AG	100MG/ML	A090028	001	Mar 03, 2010	Apr DISC

TABLET;ORAL

LEVETIRACETAM

	AB	ALKEM LABS LTD	250MG	A216375	001	May 27, 2022	May NEWA
	AB		500MG	A216375	002	May 27, 2022	May NEWA
	AB		750MG	A216375	003	May 27, 2022	May NEWA
	AB		1GM	A216375	004	May 27, 2022	May NEWA
>A>	AB	MSN	250MG	A214815	001	Oct 07, 2022	Sep NEWA
>A>	AB		500MG	A214815	002	Oct 07, 2022	Sep NEWA
>A>	AB		750MG	A214815	003	Oct 07, 2022	Sep NEWA
>A>	AB		1GM	A214815	004	Oct 07, 2022	Sep NEWA
	AB	SCIEGEN PHARMS INC	250MG	A215069	003	May 27, 2022	May NEWA
	AB		500MG	A215069	004	May 27, 2022	May NEWA
	AB		750MG	A215069	001	Jun 11, 2021	Jun CMFD
	@		750MG	A215069	001	Jun 11, 2021	Apr DISC
	AB		1GM	A215069	002	Jun 11, 2021	Jun CMFD
	@		1GM	A215069	002	Jun 11, 2021	Apr DISC
	@	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Jan DISC
	@		1GM	A205102	003	Dec 16, 2015	Jan DISC
	AB	STALLION LABS	250MG	A079042	001	Jan 15, 2009	Mar CAHN
	AB		500MG	A079042	002	Jan 15, 2009	Mar CAHN
	AB		750MG	A079042	003	Jan 15, 2009	Mar CAHN
	AB		1GM	A079042	004	Jan 15, 2009	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	AB	AIPING PHARM INC	500MG	A204754	001	Aug 26, 2016	Aug CAHN
	AB		750MG	A204754	002	Aug 26, 2016	Aug CAHN
>A>	@	ANDA REPOSITORY	500MG	A091291	001	Sep 12, 2011	Sep CAHN
>A>	@		750MG	A091291	002	Sep 12, 2011	Sep CAHN
>D>	@	VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011	Sep CAHN
>D>	@		750MG	A091291	002	Sep 12, 2011	Sep CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AA	CHARTWELL MOLECULAR	2.5MG/5ML	A204599	001	May 15, 2017	Jun CAHN

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

	AP !	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Jul CHRS
	AP !		EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Jul CHRS
	@	EUGIA PHARMA	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Jul DISC
	@		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Jul DISC

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jul DISC
	@		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jul DISC
	@		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jul DISC

TABLET;ORAL

LEVOFLOXACIN

	AB	CHARTWELL MOLECULAR	250MG	A076890	001	Mar 30, 2012	Mar CAHN
	AB		500MG	A076890	002	Mar 30, 2012	Mar CAHN
	AB		750MG	A076890	003	Mar 30, 2012	Mar CAHN

LEVOLEUCOVORIN

POWDER;INTRAVENOUS

KHAPZORY

+!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018	Jul CAHN
+!		300MG/VIAL	N211226	002	Oct 19, 2018	Jul CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@	HIKMA	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul DISC

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@	PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb DISC

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

@	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May DISC

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

@	TEVA PHARMS USA INC	0.112MG	A211369	003	Apr 16, 2021	Jan DISC

TIROSINT

+	INSTITUT BIOCHIMIQUE	0.0375MG	N021924	014	Jun 22, 2022	Jun NEWA
+		0.044MG	N021924	015	Jun 22, 2022	Jun NEWA
+		0.0625MG	N021924	016	Jun 22, 2022	Jun NEWA
+		0.112MG	N021924	008	Oct 02, 2009	Jan CTEC

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

+!	HIKMA	100MCG/ML	N214253	001	May 17, 2021	Aug CAHN

SOLUTION;ORAL

ERMEZA

+!	MYLAN	150MCG/5ML	N215809	001	Apr 29, 2022	Apr NEWA

THYQUIDITY

+!	AZURITY	100MCG/5ML	N214047	001	Nov 30, 2020	Jul CAHN

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

AB1, AB2, AB3, AB4	GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Aug CTEC
AB1, AB3, AB4		0.025MG	N021137	001	Jun 06, 2003	Jan CMFD
AB1, AB2, AB3, AB4		0.05MG	N021137	002	Jun 06, 2003	Aug CTEC
AB1, AB3, AB4		0.05MG	N021137	002	Jun 06, 2003	Jan CMFD
AB1, AB2, AB3, AB4		0.075MG	N021137	003	Jun 06, 2003	Aug CTEC
AB1, AB3, AB4		0.075MG	N021137	003	Jun 06, 2003	Jan CMFD
AB1, AB2, AB3, AB4		0.088MG	N021137	004	Jun 06, 2003	Aug CTEC
AB1, AB3, AB4		0.088MG	N021137	004	Jun 06, 2003	Jan CMFD
AB1, AB2, AB3, AB4		0.1MG	N021137	005	Jun 06, 2003	Aug CTEC
AB1,		0.1MG	N021137	005	Jun 06, 2003	Jan CMFD

TABLET;ORAL
LEVOLET

	AB3, AB4						
	AB1, AB2, AB3, AB4	0.112MG	N021137	006	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.112MG	N021137	006	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.125MG	N021137	007	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.125MG	N021137	007	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.137MG	N021137	008	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.137MG	N021137	008	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Jan	CMFD
	AB1, AB2, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Aug	CTEC
	AB1, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Jan	CMFD
	LEVOTHYROXINE SODIUM						
>D>	AB2 ACCORD HLTHCARE	0.025MG	A212399	001	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.025MG	A212399	001	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.05MG	A212399	002	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.05MG	A212399	002	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.075MG	A212399	003	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.075MG	A212399	003	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.088MG	A212399	004	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.088MG	A212399	004	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.1MG	A212399	005	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.1MG	A212399	005	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.112MG	A212399	006	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3, AB4	0.112MG	A212399	006	Oct 19, 2020	Sep	CTEC
>D>	AB2	0.125MG	A212399	007	Oct 19, 2020	Sep	CTEC
>A>	AB2, AB3,	0.125MG	A212399	007	Oct 19, 2020	Sep	CTEC

TABLET;ORAL
LEVOTHYROXINE SODIUM

	AB4						
>D>	AB2		0.137MG	A212399	008	Oct 19, 2020	Sep CTEC
>A>	AB2, AB3, AB4		0.137MG	A212399	008	Oct 19, 2020	Sep CTEC
>D>	AB2		0.15MG	A212399	009	Oct 19, 2020	Sep CTEC
>A>	AB2, AB3, AB4		0.15MG	A212399	009	Oct 19, 2020	Sep CTEC
>D>	AB2		0.175MG	A212399	010	Oct 19, 2020	Sep CTEC
>A>	AB2, AB3, AB4		0.175MG	A212399	010	Oct 19, 2020	Sep CTEC
>D>	AB2		0.2MG	A212399	011	Oct 19, 2020	Sep CTEC
>A>	AB2, AB3, AB4		0.2MG	A212399	011	Oct 19, 2020	Sep CTEC
>D>	AB2		0.3MG	A212399	012	Oct 19, 2020	Sep CTEC
>A>	AB2, AB3, AB4		0.3MG	A212399	012	Oct 19, 2020	Sep CTEC
>D>	AB1, AB2	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Sep CTEC
>A>	AB2		0.025MG	A207588	001	May 10, 2022	Sep CTEC
	AB1, AB2		0.025MG	A207588	001	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.05MG	A207588	002	May 10, 2022	Sep CTEC
>A>	AB2		0.05MG	A207588	002	May 10, 2022	Sep CTEC
	AB1, AB2		0.05MG	A207588	002	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.075MG	A207588	003	May 10, 2022	Sep CTEC
>A>	AB2		0.075MG	A207588	003	May 10, 2022	Sep CTEC
	AB1, AB2		0.075MG	A207588	003	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.088MG	A207588	004	May 10, 2022	Sep CTEC
>A>	AB2		0.088MG	A207588	004	May 10, 2022	Sep CTEC
	AB1, AB2		0.088MG	A207588	004	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.1MG	A207588	005	May 10, 2022	Sep CTEC
>A>	AB2		0.1MG	A207588	005	May 10, 2022	Sep CTEC
	AB1, AB2		0.1MG	A207588	005	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.112MG	A207588	006	May 10, 2022	Sep CTEC
>A>	AB2		0.112MG	A207588	006	May 10, 2022	Sep CTEC
	AB1, AB2		0.112MG	A207588	006	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.125MG	A207588	007	May 10, 2022	Sep CTEC
>A>	AB2		0.125MG	A207588	007	May 10, 2022	Sep CTEC
	AB1, AB2		0.125MG	A207588	007	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.137MG	A207588	008	May 10, 2022	Sep CTEC
>A>	AB2		0.137MG	A207588	008	May 10, 2022	Sep CTEC
	AB1, AB2		0.137MG	A207588	008	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.15MG	A207588	009	May 10, 2022	Sep CTEC
>A>	AB2		0.15MG	A207588	009	May 10, 2022	Sep CTEC
	AB1, AB2		0.15MG	A207588	009	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.175MG	A207588	010	May 10, 2022	Sep CTEC
>A>	AB2		0.175MG	A207588	010	May 10, 2022	Sep CTEC
	AB1, AB2		0.175MG	A207588	010	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.2MG	A207588	011	May 10, 2022	Sep CTEC
>A>	AB2		0.2MG	A207588	011	May 10, 2022	Sep CTEC
	AB1, AB2		0.2MG	A207588	011	May 10, 2022	Apr NEWA
>D>	AB1, AB2		0.3MG	A207588	012	May 10, 2022	Sep CTEC

```
          TABLET;ORAL
            LEVOTHYROXINE SODIUM
>A> AB2                           0.3MG                          A207588  012  May 10, 2022   Sep CTEC
    AB1,                          0.3MG                          A207588  012  May 10, 2022   Apr NEWA
    AB2
            THYRO-TABS
    AB1,  +   ALVOGEN             0.025MG                        N021116  001  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.05MG                         N021116  002  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.075MG                        N021116  003  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.088MG                        N021116  010  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.1MG                          N021116  004  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.112MG                        N021116  011  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.125MG                        N021116  005  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.137MG                        N021116  012  Dec 07, 2004   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.15MG                         N021116  006  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.175MG                        N021116  007  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.2MG                          N021116  008  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4
    AB1,  +                       0.3MG                          N021116  009  Oct 24, 2002   Apr CTEC
    AB2,
    AB3,
    AB4

        LIDOCAINE HYDROCHLORIDE
          GEL;OPHTHALMIC
            AKTEN
          +!  THEA PHARMA         3.5%                           N022221  001  Oct 07, 2008   Apr CAHN
          INJECTABLE;INJECTION
            LIDOCAINE HYDROCHLORIDE
    AP        AFAXYS              1%                             A215132  001  Jun 09, 2022   Jun NEWA
>A> AP        SINTETICA SA        1%                             A214267  001  Sep 19, 2022   Sep NEWA
>A> AP                            2%                             A214267  002  Sep 19, 2022   Sep NEWA
    AP                            4%                             A214269  001  May 05, 2022   Apr NEWA
            LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE
    AP    !   HOSPIRA             4%                             A088295  001  May 17, 1984   Apr CTEC
          INJECTABLE;SPINAL
            LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%
          +!  HOSPIRA             5%                             A083914  001                  Jul CRLD
          SOLUTION;TOPICAL
            LIDOCAINE HYDROCHLORIDE
    AT        NOVITIUM PHARMA     4%                             A216250  001  Mar 23, 2022   Mar NEWA
```

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

	+ @	TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Jul DISC

LIDOCAINE AND PRILOCAINE

	@	ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jan DISC
AB	!	AKORN	2.5%;2.5%	A076290	001	Sep 25, 2003	Jul CHRS
AB		ALEOR DERMACEUTICALS	2.5%;2.5%	A213923	001	Apr 08, 2022	Apr NEWA
	@	PADAGIS US	2.5%;2.5%	A212482	001	Jul 27, 2021	Jun CAHN

LIDOCAINE; TETRACAINE

PATCH;TOPICAL

SYNERA

>D>	+!	GALEN SPECIALTY	70MG;70MG	N021623	001	Jun 23, 2005	Sep DISC
>A>	+ @		70MG;70MG	N021623	001	Jun 23, 2005	Sep DISC

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

>A>	@	ATHENEX INC	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep CAHN
>A> AP		GLAND PHARMA LTD	EQ 300MG BASE/ML	A215657	001	Sep 26, 2022	Sep NEWA
>D>	@	PRAXGEN	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Sep CAHN

LINDANE

SHAMPOO;TOPICAL

LINDANE

	@	WOCKHARDT BIO AG	1%	A088191	001	Sep 18, 1984	Jul DISC

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

AP		HIKMA	600MG/300ML (2MG/ML)	A206454	001	Aug 22, 2022	Aug NEWA
	@	HOSPIRA	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	May DISC

TABLET;ORAL

LINEZOLID

	@	AMNEAL PHARMS	600MG	A204536	001	Dec 21, 2015	Jul DISC

LISINOPRIL

TABLET;ORAL

LISINOPRIL

	@	GRAVITI PHARMS	2.5MG	A075999	001	Jul 01, 2002	Apr CAHN
	@		5MG	A075999	002	Jul 01, 2002	Apr CAHN
	@		10MG	A075999	003	Jul 01, 2002	Apr CAHN
	@		20MG	A075999	004	Jul 01, 2002	Apr CAHN
	@		30MG	A075999	005	Jul 01, 2002	Apr CAHN
	@		40MG	A075999	006	Jul 01, 2002	Apr CAHN
	@	STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002	Jan CAHN
	@		5MG	A076071	002	Jul 01, 2002	Jan CAHN
	@		10MG	A076071	003	Jul 01, 2002	Jan CAHN
	@		20MG	A076071	004	Jul 01, 2002	Jan CAHN
	@		30MG	A076071	005	Jul 01, 2002	Jan CAHN
	@		40MG	A076071	006	Jul 01, 2002	Jan CAHN

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

	+ @	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001		Apr DISC
	!	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CAHN
	!	WOCKHARDT BIO AG	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CTEC
AA	!		EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Apr CHRS

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

	@	CHARTWELL RX	2MG	A072993	001	Aug 28, 1992	Mar CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB		LAURUS	100MG;25MG	A213857	001	Mar 21, 2022	Mar NEWA
AB			200MG;50MG	A213857	002	Mar 21, 2022	Mar NEWA

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

	+	ALMATICA	1.5MG	N214826	004	Feb 16, 2022	Feb NEWA

CONCENTRATE;ORAL

LORAZEPAM

	@	LANNETT CO INC	2MG/ML	A079244	001	Apr 28, 2009	Jun DISC

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

	@	HIKMA	25MG	A077459	001	Oct 06, 2010	Jul DISC

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

EYSUVIS

	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020	Aug CAHN

INVELTYS

	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018	Aug CAHN

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		CHARTWELL RX	10MG	A075300	001	Dec 17, 2001	Aug CAHN
AB			20MG	A075300	002	Dec 17, 2001	Aug CAHN
AB			40MG	A075300	003	Dec 17, 2001	Aug CAHN

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

	@	AMNEAL	8MCG	A209450	001	Nov 30, 2021	May DISC
	@		24MCG	A209450	002	Nov 30, 2021	May DISC
AB		ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022	Jun NEWA
AB			24MCG	A201442	002	Jun 27, 2022	Jun NEWA
AB		DR REDDYS	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB			24MCG	A206994	002	Feb 08, 2022	Jan NEWA
	@	TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Aug DISC
AB			8MCG	A209920	001	Jan 18, 2022	Jan NEWA
	@		24MCG	A209920	002	Jan 18, 2022	Aug DISC
AB			24MCG	A209920	002	Jan 18, 2022	Jan NEWA

LUMATEPERONE TOSYLATE

CAPSULE;ORAL

CAPLYTA

	+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022	May NEWA
	+		EQ 21MG BASE	N209500	003	Apr 22, 2022	May NEWA

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Aug CMFD
AB			40MG	A208028	002	Jan 03, 2019	Aug CMFD
AB			60MG	A208028	003	Jan 03, 2019	Aug CMFD
AB			80MG	A208028	004	Jan 03, 2019	Aug CMFD
AB			120MG	A208028	005	Jan 03, 2019	Aug CMFD
>A> AB		MSN	20MG	A208037	001	Sep 09, 2022	Sep NEWA
>A> AB			40MG	A208037	002	Sep 09, 2022	Sep NEWA
>A> AB			60MG	A208037	003	Sep 09, 2022	Sep NEWA
>A> AB			80MG	A208037	004	Sep 09, 2022	Sep NEWA
>A> AB			120MG	A208037	005	Sep 09, 2022	Sep NEWA

LUTETIUM LU 177 DOTATATE

SOLUTION;INTRAVENOUS

LUTATHERA

	+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jun CAIN

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

SOLUTION;INTRAVENOUS

PLUVICTO

	+!	AAA USA NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022	Mar NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	!	PAR FORM	5%	A201511	001	Feb 12, 2013	Feb CHRS

SULFAMYLON

	+ @	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Feb DISC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

AP		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun NFTG

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

AP		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	Jun CTNA
AP			30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	A215371	001	Jun 08, 2022	May NFTG

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	001		Jun CFTG

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982	May CFTG

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

	@	MILLA PHARMS	2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jul DISC
AP			2GM/50ML (40MG/ML)	A209642	001	Nov 08, 2021	Jun CAHN
	@		4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jul DISC
AP			4GM/100ML (40MG/ML)	A209642	002	Nov 08, 2021	Jun CAHN
	@		4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jul DISC
AP			4GM/50ML (80MG/ML)	A209642	003	Nov 08, 2021	Jun CAHN

MARAVIROC

TABLET;ORAL

MARAVIROC

AB		HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan NFTG
AB			300MG	A203347	002	Feb 07, 2022	Jan NFTG

SELZENTRY

AB	+	VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan CFTG
AB	+!		300MG	N022128	002	Aug 06, 2007	Jan CFTG

MAVACAMTEN

CAPSULE;ORAL

CAMZYOS

>A>	+	BRISTOL	2.5MG	N214998	001	Apr 28, 2022	Sep CAHN
>A>	+		5MG	N214998	002	Apr 28, 2022	Sep CAHN
>A>	+		10MG	N214998	003	Apr 28, 2022	Sep CAHN
>A>	+!		15MG	N214998	004	Apr 28, 2022	Sep CAHN
>D>	+	MYOKARDIA	2.5MG	N214998	001	Apr 28, 2022	Sep CAHN
	+		2.5MG	N214998	001	Apr 28, 2022	Apr NEWA
>D>	+		5MG	N214998	002	Apr 28, 2022	Sep CAHN
	+		5MG	N214998	002	Apr 28, 2022	Apr NEWA
>D>	+		10MG	N214998	003	Apr 28, 2022	Sep CAHN
	+		10MG	N214998	003	Apr 28, 2022	Apr NEWA
>D>	+!		15MG	N214998	004	Apr 28, 2022	Sep CAHN
	+!		15MG	N214998	004	Apr 28, 2022	Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

AA	APNAR PHARMA LP	12.5MG	A087128	002		Apr CAHN
AA		25MG	A087128	001		Apr CAHN
AA	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb NEWA
AA		25MG	A200432	002	Feb 17, 2022	Feb NEWA
AA		50MG	A200432	003	Feb 17, 2022	Feb NEWA
AA	LUPIN LTD	12.5MG	A203003	001	Aug 11, 2022	Aug NEWA
AA		25MG	A203003	002	Aug 11, 2022	Aug NEWA
AA		50MG	A203003	003	Aug 11, 2022	Aug NEWA

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

AA	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE;INJECTION

MEDROXYPROGESTERONE ACETATE

AB	EUGIA PHARMA	150MG/ML	A212824	001	Aug 22, 2022	Aug NEWA
AB		150MG/ML	A212844	001	Aug 31, 2022	Aug NEWA
@	SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Jul DISC
@		150MG/ML	A210761	001	Apr 24, 2019	Jul DISC

MELOXICAM

CAPSULE;ORAL

VIVLODEX

+ @	ICEUTICA OPERATIONS	5MG	N207233	001	Oct 22, 2015	Mar CAHN
+ @		10MG	N207233	002	Oct 22, 2015	Mar CAHN

SUSPENSION;ORAL

MELOXICAM

+!	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	May CTNA
+!		7.5MG/5ML	N021530	001	Jun 01, 2004	May CMFD

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

>A> AP	ARTHUR GRP	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN
>D> @	NANJING	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN
@		EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Apr CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

@	ANI PHARMS	14MG	A205365	002	Feb 28, 2020	Apr DISC
>A> AB	XIAMEN LP PHARM CO	7MG	A213985	001	Oct 11, 2022	Sep NEWA
>A> AB		14MG	A213985	002	Oct 11, 2022	Sep NEWA
>A> AB		28MG	A213985	003	Oct 11, 2022	Sep NEWA

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	ALLIED	5MG	A209527	001	May 07, 2018	Feb CAHN
AB		10MG	A209527	002	May 07, 2018	Feb CAHN
AB	ESKAYEF	5MG	A209527	001	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Aug CAHN
>A> AB	HETERO LABS LTD V	5MG	A204389	001	Sep 26, 2022	Sep NEWA
>A> AB		10MG	A204389	002	Sep 26, 2022	Sep NEWA
AB	RENATA	5MG	A209527	001	May 07, 2018	Jul CAHN
AB		10MG	A209527	002	May 07, 2018	Jul CAHN
@	RISING	5MG	A079225	001	Jan 30, 2015	Jan CAHN
@		10MG	A079225	002	Jan 30, 2015	Jan CAHN

MEPERIDINE HYDROCHLORIDE

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>A> @	ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009	Sep CAHN
>A> @		75MG	A040893	002	Jun 24, 2009	Sep CAHN
>A> @		100MG	A040893	003	Jun 24, 2009	Sep CAHN
>A> @		150MG	A040893	004	Jun 24, 2009	Sep CAHN
>D> @	GENUS	50MG	A040893	001	Jun 24, 2009	Sep CAHN
@		50MG	A040893	001	Jun 24, 2009	Apr CAHN
>D> @		75MG	A040893	002	Jun 24, 2009	Sep CAHN
@		75MG	A040893	002	Jun 24, 2009	Apr CAHN

```
          TABLET;ORAL
            MEPERIDINE HYDROCHLORIDE
>D>         @                       100MG                           A040893  003  Jun 24, 2009   Sep CAHN
            @                       100MG                           A040893  003  Jun 24, 2009   Apr CAHN
>D>         @                       150MG                           A040893  004  Jun 24, 2009   Sep CAHN
            @                       150MG                           A040893  004  Jun 24, 2009   Apr CAHN
            @ MIKART                50MG                            A040893  001  Jun 24, 2009   Mar CAHN
            @                       75MG                            A040893  002  Jun 24, 2009   Mar CAHN
            @                       100MG                           A040893  003  Jun 24, 2009   Mar CAHN
            @                       150MG                           A040893  004  Jun 24, 2009   Mar CAHN

        MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
          INJECTABLE;INJECTION
            MEPERGAN
            @ HIKMA                 25MG/ML;25MG/ML                 N011730  001                   Jul CAHN

        MEROPENEM
          INJECTABLE;INJECTION
            MEROPENEM
>A> AP        BROOKS STERISCIENCE   500MG/VIAL                     A216154  001  Aug 18, 2022   Sep CAHN
>A> AP                              1GM/VIAL                       A216154  002  Aug 18, 2022   Sep CAHN
>D> AP        STERISCIENCE          500MG/VIAL                     A216154  001  Aug 18, 2022   Sep CAHN
    AP                              500MG/VIAL                     A216154  001  Aug 18, 2022   Aug NEWA
>D> AP                              1GM/VIAL                       A216154  002  Aug 18, 2022   Sep CAHN
    AP                              1GM/VIAL                       A216154  002  Aug 18, 2022   Aug NEWA

        MESALAMINE
          CAPSULE, EXTENDED RELEASE;ORAL
            MESALAMINE
    AB        SUN PHARM             500MG                          A214585  001  May 11, 2022   Apr NFTG
    AB        TEVA PHARMS USA       375MG                          A209970  001  May 06, 2022   Apr NEWA
            PENTASA
    AB    +!  TAKEDA PHARMS USA     500MG                          N020049  002  Jul 08, 2004   Apr CFTG
          SUPPOSITORY;RECTAL
            MESALAMINE
>D> AB        AMNEAL                1GM                            A210509  001  Jan 02, 2020   Sep DISC
>A>         @                       1GM                            A210509  001  Jan 02, 2020   Sep DISC
          TABLET, DELAYED RELEASE;ORAL
            ASACOL HD
          + @ APIL                  800MG                          N021830  001  May 29, 2008   May DISC
            MESALAMINE
          !   ZYDUS PHARMS          800MG                          A203286  001  Jul 21, 2017   May CTEC
    AB    !                         800MG                          A203286  001  Jul 21, 2017   May CHRS

        METAPROTERENOL SULFATE
          SYRUP;ORAL
            METAPROTERENOL SULFATE
>A>       !   ANDA REPOSITORY       10MG/5ML                       A073632  001  Jul 22, 1992   Sep CAHN
>D>       !   GENUS                 10MG/5ML                       A073632  001  Jul 22, 1992   Sep CAHN

        METFORMIN HYDROCHLORIDE
          SOLUTION;ORAL
            METFORMIN HYDROCHLORIDE
    AB        VISTAPHARM            500MG/5ML                      A212677  001  Aug 19, 2022   Aug NEWA
          TABLET, EXTENDED RELEASE;ORAL
            METFORMIN HYDROCHLORIDE
    AB1       AMNEAL PHARMS NY      500MG                          A078596  001  Jan 03, 2008   Feb CTEC
    AB                              750MG                          A078596  002  Jan 03, 2008   Feb CTEC
            @ AMTA                  500MG                          A213394  001  Aug 03, 2021   Jan DISC
            @                       1GM                            A213394  002  Aug 03, 2021   Jan DISC
    AB3       PRINSTON INC          500MG                          A212681  001  Jun 09, 2022   Jun NEWA
    AB3                             1GM                            A212681  002  Jun 09, 2022   Jun NEWA
    AB2       SCIEGEN PHARMS INC    500MG                          A214629  001  Feb 22, 2022   Feb NEWA
    AB2                             1GM                            A214629  002  Feb 22, 2022   Feb NEWA

        METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE
          TABLET;ORAL
            ACTOPLUS MET
          + @ TAKEDA PHARMS USA     500MG;EQ 15MG BASE             N021842  001  Aug 29, 2005   May DISC
```

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

	@ NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb DISC
	@	10MG	A210484	002	Aug 02, 2018	Feb DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	+! KEY THERAP	5MG	N005378	002		Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

DESOXYN

	@ KEY THERAP	5MG	N005378	004		Aug CAHN
	@	10MG	N005378	003		Aug CAHN
	@	15MG	N005378	005		Aug CAHN

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB	BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018	Apr CAHN
AB		50MG	A207438	002	Oct 05, 2018	Apr CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+ VALIDUS PHARMS	1GM	N017681	001		Apr CMFD

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022	Jul NEWA
AP	HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Aug CAHN

TABLET;ORAL

METHOCARBAMOL

>A> AA	ACME LABS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
>A> AA		750MG	A203550	002	Feb 08, 2017	Sep CAHN
	@ CHARTWELL MOLECULAR	500MG	A084756	002	Mar 31, 2003	Aug CAHN
	@	750MG	A084756	001		Aug CAHN
>D> AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Sep CAHN
>D> AA		750MG	A203550	002	Feb 08, 2017	Sep CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS

REDITREX

>D>	+! CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Sep DISC
>A>	+ @	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019	Sep DISC
>D>	+!	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Sep DISC
>A>	+ @	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019	Sep DISC
>D>	+!	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Sep DISC
>A>	+ @	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019	Sep DISC
>D>	+!	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Sep DISC
>A>	+ @	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019	Sep DISC
>D>	+!	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Sep DISC
>A>	+ @	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019	Sep DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE LPF

	+ @ HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan CRLD

METHOTREXATE PRESERVATIVE FREE

	+ @ HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan CRLD
	+ @	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan CRLD

METHOTREXATE SODIUM

	+ @ HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan CRLD
	+ @	EQ 20MG BASE/VIAL	N011719	001		Jan CRLD
	+ @	EQ 25MG BASE/ML	N011719	005		Jan CRLD
	+ @	EQ 50MG BASE/VIAL	N011719	003		Jan CRLD
	+ @	EQ 100MG BASE/VIAL	N011719	006		Jan CRLD

METHOTREXATE SODIUM PRESERVATIVE FREE

	@ EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar CAHN

		INJECTABLE;INJECTION					
		METHOTREXATE SODIUM PRESERVATIVE FREE					
		@	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar CAHN
		@	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar CAHN
		@	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar CAHN
AP		HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan CHRS
	+ @	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan CRLD
		MEXATE-AQ					
	+ @	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan CRLD
	METHYLDOPA						
		TABLET;ORAL					
		METHYLDOPA					
>D>		ACCORD HLTHCARE	250MG	A070084	001	Oct 15, 1985	Sep DISC
>A>	@		250MG	A070084	001	Oct 15, 1985	Sep DISC
	@		500MG	A070085	001	Oct 15, 1985	Aug DISC
	METHYLPHENIDATE						
		FILM, EXTENDED RELEASE;TRANSDERMAL					
		DAYTRANA					
AB	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006	Mar CFTG
AB	+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006	Mar CFTG
AB	+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006	Mar CFTG
AB	+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006	Mar CFTG
		METHYLPHENIDATE					
AB		MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	A206497	001	Mar 14, 2022	Mar NFTG
AB			15MG/9HR (1.6MG/HR)	A206497	002	Mar 14, 2022	Mar NFTG
AB			20MG/9HR (2.2MG/HR)	A206497	003	Mar 14, 2022	Mar NFTG
AB			30MG/9HR (3.3MG/HR)	A206497	004	Mar 14, 2022	Mar NFTG
	METHYLPHENIDATE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE;ORAL					
		ADHANSIA XR					
	+ @	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Jul DISC
	+ @		35MG	N212038	002	Feb 27, 2019	Jul DISC
	+ @		45MG	N212038	003	Feb 27, 2019	Jul DISC
	+ @		55MG	N212038	004	Feb 27, 2019	Jul DISC
	+ @		70MG	N212038	005	Feb 27, 2019	Jul DISC
	+ @		85MG	N212038	006	Feb 27, 2019	Jul DISC
		METADATE CD					
AB2	+	AYTU BIOPHARMA	10MG	N021259	003	May 27, 2003	May CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	May CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	May CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	May CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	May CAHN
AB2	+!		60MG	N021259	006	Feb 19, 2006	May CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		METHYLPHENIDATE HYDROCHLORIDE					
AB		ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb NEWA
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb CTEC
	@	RHODES PHARMS	18MG	A214111	001	May 31, 2022	Jun DISC
AB			18MG	A214111	001	May 31, 2022	May NEWA
	@		27MG	A214111	002	May 31, 2022	Jun DISC
AB			27MG	A214111	002	May 31, 2022	May NEWA
	@		36MG	A214111	003	May 31, 2022	Jun DISC
AB			36MG	A214111	003	May 31, 2022	May NEWA
	@		54MG	A214111	004	May 31, 2022	Jun DISC
AB			54MG	A214111	004	May 31, 2022	May NEWA
		RELEXXII					
	+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022	Jun NEWA
	+		27MG	N216117	002	Jun 23, 2022	Jun NEWA
	+		36MG	N216117	003	Jun 23, 2022	Jun NEWA
	+		45MG	N216117	004	Jun 23, 2022	Jun NEWA
	+		54MG	N216117	005	Jun 23, 2022	Jun NEWA
	+		63MG	N216117	006	Jun 23, 2022	Jun NEWA
	+!		72MG	N216117	007	Jun 23, 2022	Jun NEWA

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

		@	AMNEAL	4MG	A207481	001	Sep 21, 2021	Mar DISC
		@		8MG	A207481	002	Sep 21, 2021	Mar DISC
		@		16MG	A207481	003	Sep 21, 2021	Mar DISC
		@		32MG	A207481	004	Sep 21, 2021	Mar DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

	AB	+	PFIZER	40MG/ML	N011757	001		Jul CHRS
	AB	+		80MG/ML	N011757	004		Jul CHRS

METHYLPREDNISOLONE ACETATE

	AB	!	AMNEAL	40MG/ML	A210043	001	May 20, 2019	Jul CHRS
	AB	!		80MG/ML	A210043	002	May 20, 2019	Jul CHRS
		@	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jul DISC
	AB			40MG/ML	A214297	001	Jan 21, 2022	Jan NEWA
	AB			80MG/ML	A214297	002	Jan 21, 2022	Jan NEWA
>D>	AB		SAGENT PHARMS INC	80MG/ML	A201835	003	Jun 27, 2018	Sep CHRS
>A>	AB	!		80MG/ML	A201835	003	Jun 27, 2018	Sep CHRS

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

		@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015	Jul DISC
		@		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015	Jul DISC
		@		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015	Jul DISC
		@		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015	Jul DISC
>A>	AP		HIKMA	EQ 40MG BASE/VIAL	A203125	001	Sep 26, 2022	Sep NEWA
>A>	AP			EQ 125MG BASE/VIAL	A203125	002	Sep 26, 2022	Sep NEWA
	AP		TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan CMFD
	AP			EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan CMFD
	AP			EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan CMFD
	AP			EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan CMFD
	AP			EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

	AB	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb CTEC
	AB		NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		@	CHARTWELL RX	EQ 5MG BASE	A074478	001	Oct 05, 1995	Mar CAHN
		@		EQ 10MG BASE	A072215	001	Jan 30, 1990	Mar CAHN
		@		EQ 10MG BASE	A074478	002	Oct 05, 1995	Mar CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

		@	PRINSTON INC	EQ 100MG TARTRATE	A210597	001	Jan 04, 2022	Aug DISC
		@		EQ 200MG TARTRATE	A210597	002	Jan 04, 2022	Aug DISC
>A>	AB		SUNSHINE	EQ 50MG TARTRATE	A214004	001	Sep 26, 2022	Sep NEWA
>A>	AB			EQ 100MG TARTRATE	A214004	002	Sep 26, 2022	Sep NEWA
>A>	AB			EQ 200MG TARTRATE	A214004	003	Sep 26, 2022	Sep NEWA
	AB		YICHANG HUMANWELL	EQ 25MG TARTRATE	A213854	004	Aug 01, 2022	Jul NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

		@	STERISCIENCE	1MG/ML	A090317	001	Apr 19, 2010	Feb CAHN

TABLET;ORAL

METOPROLOL TARTRATE

		@	CHARTWELL RX	50MG	A073288	001	Mar 25, 1994	Mar CAHN
		@		100MG	A073289	001	Mar 25, 1994	Mar CAHN

METRONIDAZOLE

		CREAM;TOPICAL					
		NORITATE					
	+!	BAUSCH	1%	N020743	001	Sep 26, 1997	Jul CAHN
		GEL;VAGINAL					
		METRONIDAZOLE					
AB		GLENMARK PHARMS LTD	0.75%	A215794	001	Jan 27, 2022	Jan NEWA
		INJECTABLE;INJECTION					
		METRONIDAZOLE					
	@	HIKMA	500MG/100ML	N018907	001	Mar 30, 1984	Jul CAHN
		METRONIDAZOLE IN PLASTIC CONTAINER					
	@	RISING	500MG/100ML	A205531	001	May 09, 2017	Jan CAHN

MEXILETINE HYDROCHLORIDE

		CAPSULE;ORAL					
		MEXILETINE HYDROCHLORIDE					
>A> AB		AUCTA	150MG	A215315	001	Aug 26, 2022	Sep CAHN
>A> AB			200MG	A215315	002	Aug 26, 2022	Sep CAHN
>A> AB			250MG	A215315	003	Aug 26, 2022	Sep CAHN
>D> AB		ZENARA	150MG	A215315	001	Aug 26, 2022	Sep CAHN
AB			150MG	A215315	001	Aug 26, 2022	Aug NEWA
>D> AB			200MG	A215315	002	Aug 26, 2022	Sep CAHN
AB			200MG	A215315	002	Aug 26, 2022	Aug NEWA
>D> AB			250MG	A215315	003	Aug 26, 2022	Sep CAHN
AB			250MG	A215315	003	Aug 26, 2022	Aug NEWA

MICAFUNGIN SODIUM

		INJECTABLE;INTRAVENOUS					
		MICAFUNGIN SODIUM					
>A> AP		NANJING KING-FRIEND	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022	Sep NEWA
>A> AP			EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022	Sep NEWA

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

		OINTMENT;TOPICAL					
		VUSION					
	+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jul CAIN

MIDAZOLAM

		SOLUTION;INTRAVENOUS					
		MIDAZOLAM IN 0.8% SODIUM CHLORIDE					
	+!	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	Jul NEWA
	+!		100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022	Jul NEWA

MIDAZOLAM HYDROCHLORIDE

		INJECTABLE;INJECTION					
		MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE					
	@	STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan CAHN
	@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan CAHN
		MIDOZALAM HYDROCHLORIDE					
	@	STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Feb CAHN
	@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Feb CAHN
		SOLUTION;INTRAMUSCULAR					
		MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)					
>D>	+!	RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Sep DISC
>A>	+ @		EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Sep DISC
	+!		EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022	Aug NEWA
		SEIZALAM					
	+!	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	May CAHN
		SYRUP;ORAL					
		MIDAZOLAM HYDROCHLORIDE					
	@	AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Aug DISC

MIGLITOL

		TABLET;ORAL					
		MIGLITOL					
AB		WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015	Aug CAHN
AB			50MG	A203965	002	Feb 24, 2015	Aug CAHN
AB			100MG	A203965	003	Feb 24, 2015	Aug CAHN

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB		BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Jan NEWA

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

	+!	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019	Jan CAHN

ZILXI

	+!	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020	Jan CAHN

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		TORRENT	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB			EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB			EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

INJECTABLE;INJECTION

MINOCIN

AP	+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001		Jul CFTG

MINOCYCLINE HYDROCHLORIDE

AP		NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Jul 22, 2022	Jul NFTG

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		BEXIMCO PHARMS USA	EQ 50MG BASE	A215466	001	May 27, 2022	May NEWA
AB			EQ 75MG BASE	A215466	002	May 27, 2022	May NEWA
AB			EQ 100MG BASE	A215466	003	May 27, 2022	May NEWA
AB		TORRENT	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB			EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB			EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

>A> AB		SIDMAK LABS INDIA	EQ 55MG BASE	A204394	002	Oct 07, 2022	Sep NEWA
>A> AB			EQ 65MG BASE	A204394	003	Oct 07, 2022	Sep NEWA
>A> AB			EQ 115MG BASE	A204394	006	Oct 07, 2022	Sep NEWA

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

>A> AB		LUPIN LTD	25MG	A209485	001	Sep 28, 2022	Sep NEWA
>A> AB			50MG	A209485	002	Sep 28, 2022	Sep NFTG
>A> AB		ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Sep NEWA
>A> AB			50MG	A209488	002	Sep 29, 2022	Sep NEWA

MYRBETRIQ

>D>	+!	APGDI	25MG	N202611	001	Jun 28, 2012	Sep CTEC
>A> AB	+!		25MG	N202611	001	Jun 28, 2012	Sep CTEC
>D>	+!		50MG	N202611	002	Jun 28, 2012	Sep CFTG
>A> AB	+!		50MG	N202611	002	Jun 28, 2012	Sep CFTG

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB			30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB			45MG	A205798	003	Jun 01, 2017	Jan CAHN

MISOPROSTOL

TABLET;ORAL

CYTOTEC

AB	+	PFIZER	0.1MG	N019268	003	Sep 21, 1990	Mar CTEC
AB	+!		0.2MG	N019268	001	Dec 27, 1988	Mar CTEC

MISOPROSTOL

AB		ANI PHARMS	0.1MG	A076095	001	Jul 10, 2002	Mar CMFD
AB			0.2MG	A076095	002	Jul 10, 2002	Mar CMFD

MITAPIVAT SULFATE

TABLET;ORAL

PYRUKYND

	+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022	Feb NEWA
	+		EQ 20MG BASE	N216196	002	Feb 17, 2022	Feb NEWA
	+!		EQ 50MG BASE	N216196	003	Feb 17, 2022	Feb NEWA

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

>A>	AP	HONG KONG	5MG/VIAL	A214505	001	Sep 08, 2022	Sep NEWA
>A>	AP		20MG/VIAL	A214505	002	Sep 08, 2022	Sep NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL

RYALTRIS

	+!	GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022	Jan NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

SINGULAIR

AB	+!	ORGANON	EQ 4MG BASE/PACKET	N021409	001	Jul 26, 2002	Mar CAHN

TABLET;ORAL

MONTELUKAST SODIUM

>D>	AB	ADAPTIS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep CAHN
>A>	AB	GRAVITI PHARMS	EQ 10MG BASE	A209012	001	Apr 24, 2017	Sep CAHN
>D>	AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	Sep DISC
>A>		@	EQ 10MG BASE	A206112	001	Apr 26, 2017	Sep DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

>D>	AB	ADAPTIS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep CAHN
>D>	AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep CAHN
>A>	AB	GRAVITI PHARMS	EQ 4MG BASE	A209011	001	Apr 18, 2017	Sep CAHN
>A>	AB		EQ 5MG BASE	A209011	002	Apr 18, 2017	Sep CAHN

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	@	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Jul DISC
	@		30MG	A200411	002	Apr 12, 2016	Jul DISC
	@		40MG	A200411	007	Jul 25, 2018	Jul DISC
	@		50MG	A200411	003	Apr 12, 2016	Jul DISC
	@		60MG	A200411	004	Apr 12, 2016	Jul DISC
	@		80MG	A200411	005	Apr 12, 2016	Jul DISC
	@		100MG	A200411	006	Apr 12, 2016	Jul DISC
	@	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
	@		30MG	A203158	002	Aug 04, 2021	Jan DISC
	@		50MG	A203158	003	Aug 04, 2021	Jan DISC
	@		60MG	A203158	004	Aug 04, 2021	Jan DISC
	@		80MG	A203158	005	Aug 04, 2021	Jan DISC
	@		100MG	A203158	006	Aug 04, 2021	Jan DISC
		UPSHER SMITH LABS	20MG	A202104	002	Jun 03, 2013	Jul CTEC
			30MG	A202104	003	Jun 03, 2013	Jul CTEC
			50MG	A202104	004	Jun 03, 2013	Jul CTEC
			60MG	A202104	005	Jun 03, 2013	Jul CTEC
			80MG	A202104	006	Jun 03, 2013	Jul CTEC
	!		100MG	A202104	007	Jun 03, 2013	Jul CTEC

INJECTABLE;INJECTION

MORPHINE SULFATE

	+!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	May CMFD
	+ @		50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD

SOLUTION;ORAL

MORPHINE SULFATE

	@	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	Aug DISC

TABLET;ORAL

MORPHINE SULFATE

>A>	@	INGENUS PHARMS NJ	15MG	A215584	001	Feb 07, 2022	Sep CAHN
>A>	@		30MG	A215584	002	Feb 07, 2022	Sep CAHN
>D>	@	NOVAST LABS	15MG	A215584	001	Feb 07, 2022	Sep CAHN
	@		15MG	A215584	001	Feb 07, 2022	Aug CAHN
>D>	@		30MG	A215584	002	Feb 07, 2022	Sep CAHN
	@		30MG	A215584	002	Feb 07, 2022	Aug CAHN
	@	RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
AB			15MG	A215584	001	Feb 07, 2022	Jan NEWA
	@		30MG	A215584	002	Feb 07, 2022	Feb DISC
AB			30MG	A215584	002	Feb 07, 2022	Jan NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+!	IMPRIMIS PHARMS USA	EQ 0.5% BASE	N022428	001	Nov 19, 2010	Jun CAHN

MOXIFLOXACIN HYDROCHLORIDE

AT1		INDOCO	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Apr CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB		PADAGIS ISRAEL	EQ 2% BASE	A212465	001	Aug 03, 2022	Jul NEWA

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

AB		AMNEAL	500MG	A090606	001	Jul 16, 2010	Jun CMFD

NADOLOL

TABLET;ORAL

NADOLOL

AB		AUROBINDO PHARMA	20MG	A201893	003	Jun 07, 2022	Jun NEWA

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

	@	STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN
	@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION

REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

!		PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA

REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR
+	@	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jul CAHN
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jul CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

>A>	@	ANDA REPOSITORY	0.4MG/ML	A207846	001	Dec 17, 2018	Sep CAHN
AP		HIKMA	1MG/ML	A212300	001	Jun 10, 2022	Jun NEWA
AP		MYLAN LABS LTD	1MG/ML	A213843	001	Jun 09, 2022	Jun NEWA
AP		PAR STERILE PRODUCTS	1MG/ML	A215964	001	Jul 29, 2022	Jul NEWA
>D>	@	VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Sep CAHN

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

+	@	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	May DISC
+!			10MG/0.4ML (10MG/0.4ML)	N215457	001	Feb 28, 2022	Feb NEWA

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

AB		PADAGIS ISRAEL	4MG/SPRAY	A211951	001	Jun 21, 2022	Jun NEWA

NANDROLONE DECANOATE

INJECTABLE;INJECTION

DECA-DURABOLIN

	@	WOODWARD SPECL	50MG/ML	N013132	001	Jun 12, 1986	Apr CAHN
	@		100MG/ML	N013132	002	Jun 12, 1986	Apr CAHN
+	@		200MG/ML	N013132	003	Jun 12, 1986	Apr CAHN

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

AB		HETERO LABS LTD III	25MG/ML	A215776	001	Jun 07, 2022	May NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

>D> AB		AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Sep DISC
>A>		@	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Sep DISC
AB			EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Mar NEWA
>D> AB			EQ 5MG BASE	A213349	002	Mar 31, 2022	Sep DISC
>A>		@	EQ 5MG BASE	A213349	002	Mar 31, 2022	Sep DISC
AB			EQ 5MG BASE	A213349	002	Mar 31, 2022	Mar NEWA
>D> AB			EQ 10MG BASE	A213349	003	Mar 31, 2022	Sep DISC
>A>		@	EQ 10MG BASE	A213349	003	Mar 31, 2022	Sep DISC
AB			EQ 10MG BASE	A213349	003	Mar 31, 2022	Mar NEWA
>D> AB			EQ 20MG BASE	A213349	004	Mar 31, 2022	Sep DISC
>A>		@	EQ 20MG BASE	A213349	004	Mar 31, 2022	Sep DISC
AB			EQ 20MG BASE	A213349	004	Mar 31, 2022	Mar NEWA
AB		PRINSTON INC	EQ 2.5MG BASE	A212682	001	Apr 07, 2022	Apr NEWA
AB			EQ 5MG BASE	A212682	002	Apr 07, 2022	Apr NEWA
AB			EQ 10MG BASE	A212682	003	Apr 07, 2022	Apr NEWA
AB			EQ 20MG BASE	A212682	004	Apr 07, 2022	Apr NEWA
AB		REYOUNG	EQ 2.5MG BASE	A212917	001	Dec 17, 2021	May CAHN
AB			EQ 5MG BASE	A212917	002	Dec 17, 2021	May CAHN
AB			EQ 10MG BASE	A212917	003	Dec 17, 2021	May CAHN
AB			EQ 20MG BASE	A212917	004	Dec 17, 2021	May CAHN
AB		UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Mar NEWA
AB			EQ 5MG BASE	A213830	002	Mar 15, 2022	Mar NEWA
AB			EQ 10MG BASE	A213830	003	Mar 15, 2022	Mar NEWA
AB			EQ 20MG BASE	A213830	004	Mar 15, 2022	Mar NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

>A>		VYDUO					
>A>		PRINSTON INC	EQ 5MG BASE;80MG	A210596	001	Sep 19, 2022	Sep NFTG

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIL

	+!	ALLERGAN	2%	N021009	001	Dec 08, 1999	Jul CTEC

NEDOCROMIL SODIUM

	@	AKORN	2%	A090638	001	Aug 22, 2012	Jul DISC

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

	@	CHARTWELL MOLECULAR	500MG	A204435	001	Jun 10, 2016	Aug CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	@	AM REGENT	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr DISC
	@		10MG/10ML (1MG/ML)	A209182	002	May 04, 2018	Apr DISC
AP		DR REDDYS	3MG/3ML (1MG/ML)	A216291	001	Jul 06, 2022	Jul CPOT
AP			3MG/ML (1MG/ML)	A216291	001	Jul 06, 2022	Jun NFTG
AP	+!	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018	Jun CFTG
AP		HIKMA	3MG/3ML (1MG/ML)	A216206	001	Jul 13, 2022	Jul NEWA

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

>D> AB		PRINSTON INC	200MG	A078644	001	May 22, 2012	Sep DISC
>A>		@	200MG	A078644	001	May 22, 2012	Sep DISC

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

>D> AB		ALVOGEN	100MG	A204621	002	Nov 09, 2015	Sep DISC
>A>		@	100MG	A204621	002	Nov 09, 2015	Sep DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

	@ BEIJING	500MG	A214428	001	Nov 22, 2021	May DISC
	@	1GM	A214428	002	Nov 22, 2021	May DISC
AB	MACLEODS PHARMS LTD	500MG	A204934	001	Mar 03, 2022	Feb NEWA
AB		1GM	A204934	002	Mar 03, 2022	Feb NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

+!	HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008	Apr CAHN

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016	Apr CAHN
+!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016	Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2	ALKEM LABS LTD	30MG	A216067	001	Mar 29, 2022	Mar NEWA
AB2		60MG	A216067	002	Mar 29, 2022	Mar NEWA
AB2		90MG	A216067	003	Mar 29, 2022	Mar NEWA
	@ RISING	30MG	A201071	001	Dec 03, 2010	Aug CAHN
	@	60MG	A201071	002	Dec 03, 2010	Aug CAHN
	@	90MG	A201071	003	Dec 03, 2010	Aug CAHN

NIMODIPINE

SOLUTION;ORAL

NYMALIZE

+ @	AZURITY	3MG/ML	N203340	001	May 10, 2013	Mar CAHN
+!		6MG/ML	N203340	002	Apr 08, 2020	Mar CAHN

NITISINONE

CAPSULE;ORAL

NITISINONE

AB	DIPHARMA	2MG	A212390	001	May 26, 2022	May NEWA
AB		5MG	A212390	002	May 26, 2022	May NEWA
AB		10MG	A212390	003	May 26, 2022	May NEWA
AB	MEDUNIK	2MG	A212390	001	May 26, 2022	Jun CAHN
AB		5MG	A212390	002	May 26, 2022	Jun CAHN
AB		10MG	A212390	003	May 26, 2022	Jun CAHN

NITRIC OXIDE

GAS;INHALATION

NOXIVENT

	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr CAHN
AA		800PPM	A207141	002	Oct 02, 2018	Apr CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

	@ AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Jul DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

>A>	@ ATHEM	25MG	A074336	001	Jan 25, 1995	Sep CAHN
>A>	@	50MG	A074336	002	Jan 25, 1995	Sep CAHN
>A>	@	100MG	A074336	003	Jan 25, 1995	Sep CAHN
	@ AUROBINDO PHARMA USA	100MG	A077025	001	Aug 18, 2004	Apr CAHN
>D>	@ PHARMGEN	25MG	A074336	001	Jan 25, 1995	Sep CAHN
>D>	@	50MG	A074336	002	Jan 25, 1995	Sep CAHN
>D>	@	100MG	A074336	003	Jan 25, 1995	Sep CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	ALVOGEN	75MG;25MG	A215002	001	Jul 20, 2022	Jul NEWA
AB	INVENTIA	75MG;25MG	A211013	001	Feb 18, 2022	Feb NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

	AB2	ZYDUS PHARMS	0.1MG/HR	A089885	002	Oct 30, 2017	Aug CAHN
	AB2		0.2MG/HR	A089884	001	Oct 30, 1998	Aug CAHN
	AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Aug CAHN
	AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Aug CAHN

TABLET;SUBLINGUAL

NITROGLYCERIN

>D>	AB	ALVOGEN	0.3MG	A211604	001	Apr 30, 2019	Sep CAHN
>D>	AB		0.4MG	A211604	002	Apr 30, 2019	Sep CAHN
>D>	AB		0.6MG	A211604	003	Apr 30, 2019	Sep CAHN
>A>	AB	NATCO	0.3MG	A211604	001	Apr 30, 2019	Sep CAHN
>A>	AB		0.4MG	A211604	002	Apr 30, 2019	Sep CAHN
>A>	AB		0.6MG	A211604	003	Apr 30, 2019	Sep CAHN
		@ ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022	Aug DISC
	AB		0.3MG	A210153	001	Mar 08, 2022	Feb NEWA
		@	0.4MG	A210153	002	Mar 08, 2022	Aug DISC
	AB		0.4MG	A210153	002	Mar 08, 2022	Feb NEWA
		@	0.6MG	A210153	003	Mar 08, 2022	Aug DISC
	AB		0.6MG	A210153	003	Mar 08, 2022	Feb NEWA

NITROSTAT

	AB	+ VIATRIS	0.3MG	N021134	001	May 01, 2000	Jan CAHN
	AB	+	0.4MG	N021134	002	May 01, 2000	Jan CAHN
	AB	+!	0.6MG	N021134	003	May 01, 2000	Jan CAHN

NIZATIDINE

SOLUTION;ORAL

NIZATIDINE

		@ AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009	Jun DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

	AP	ZYDUS PHARMS	EQ 1MG BASE/ML	A216341	001	Jul 19, 2022	Jul NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A>		+! INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022	Sep NEWA
>A>		+!	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N215700	002	Sep 15, 2022	Sep NEWA
>A>		+!	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N215700	003	Sep 15, 2022	Sep NEWA

NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE

>D>	AB1	AMNEAL PHARMS	0.35MG	A202260	001	Aug 01, 2013	Sep DISC
>A>		@	0.35MG	A202260	001	Aug 01, 2013	Sep DISC

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

		@ AUROBINDO PHARMA LTD	EQ 10MG BASE	A074835	001	Jun 30, 1997	Feb CAHN
		@	EQ 25MG BASE	A074835	002	Jun 30, 1997	Feb CAHN
		@	EQ 50MG BASE	A074835	003	Jun 30, 1997	Feb CAHN
		@	EQ 75MG BASE	A074835	004	Jun 30, 1997	Feb CAHN

NYSTATIN

SUSPENSION;ORAL

NILSTAT

		+ @ GLENMARK PHARMS LTD	100,000 UNITS/ML	N050299	001		Apr CAHN

NYSTATIN

>D>	AA	AKORN	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Sep DISC
>A>		@	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Sep DISC
	AA	LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Aug CAHN
	AA	MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Feb NEWA
	AA	VISTAPHARM	100,000 UNITS/ML	A064142	002	Mar 07, 2011	May CMS1

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214181	001	Jul 13, 2022	Jul NEWA

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214186	001	Mar 04, 2022	Feb NEWA
>A>	@ CHARTWELL RX	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	Sep CAHN
>D>	@ VITRUVIAS THERAP	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019	Sep CAHN

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

+!	AMRYT	EQ 20MG BASE	N208232	001	Jun 26, 2020	Jan CAHN

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP	HERITAGE PHARMS	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CMFD
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CMFD
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Apr CMFD
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CMFD
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Apr CMFD

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

>D> AT	AKORN	0.3%	A076615	001	May 14, 2004	Sep DISC
>A>	@	0.3%	A076615	001	May 14, 2004	Sep DISC

SOLUTION/DROPS;OTIC

OFLOXACIN

	@ FDC LTD	0.3%	A215038	001	Jan 19, 2022	Jun DISC
AT		0.3%	A215038	001	Jan 19, 2022	Jan NEWA
AT	MANKIND PHARMA	0.3%	A216130	001	Jul 14, 2022	Jul NEWA

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	CHARTWELL MOLECULAR	2.5MG	A203333	001	Mar 15, 2016	Mar CAHN
AB		5MG	A203333	002	Mar 15, 2016	Mar CAHN
AB		7.5MG	A203333	003	Mar 15, 2016	Mar CAHN
AB		10MG	A203333	004	Mar 15, 2016	Mar CAHN
AB		15MG	A203333	005	Mar 15, 2016	Mar CAHN
AB		20MG	A203333	006	Mar 15, 2016	Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	CHARTWELL MOLECULAR	5MG	A203456	001	Mar 16, 2016	Mar CAHN
AB		10MG	A203456	002	Mar 16, 2016	Mar CAHN
AB		15MG	A203456	003	Mar 16, 2016	Mar CAHN
AB		20MG	A203456	004	Mar 16, 2016	Mar CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	GLW	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Jun CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

	@ STRIDES PHARMA	10MG	A075876	001	May 29, 2003	Jan CAHN
	@	20MG	A075876	002	May 29, 2003	Jan CAHN
	@	40MG	A075876	003	Jan 21, 2009	Jan CAHN

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

KONVOMEP

+!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022	Aug NEWA

```
>A>     OMIDENEPAG ISOPROPYL
>A>       SOLUTION;OPHTHALMIC
>A>         OMLONTI
>A>       +!  SANTEN                0.002%                          N215092  001  Sep 22, 2022   Sep NEWA

        ONDANSETRON
          TABLET, ORALLY DISINTEGRATING;ORAL
            ONDANSETRON
    AB        CHARTWELL MOLECULES   4MG                             A077406  003  Dec 26, 2006   Apr CMFD
    AB                              8MG                             A077406  004  Dec 26, 2006   Apr CMFD
                                    16MG                            A077406  001  Dec 26, 2006   Apr CMFD
                                    24MG                            A077406  002  Dec 26, 2006   Apr CMFD

        ONDANSETRON HYDROCHLORIDE
          INJECTABLE;INJECTION
            ONDANSETRON HYDROCHLORIDE
    AP        ATLANTIDE             EQ 2MG BASE/ML                  A077577  001  Dec 26, 2006   Mar CAHN
            @ EUGIA PHARMA          EQ 2MG BASE/ML                  A202599  001  Dec 21, 2012   Jun DISC
            @ STERISCIENCE          EQ 2MG BASE/ML                  A078257  001  Apr 23, 2008   Feb CAHN
            ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
    AP        ATLANTIDE             EQ 2MG BASE/ML                  A077716  001  Dec 26, 2006   Mar CAHN
            @ EUGIA PHARMA          EQ 2MG BASE/ML                  A202600  001  Dec 21, 2012   Jul DISC
            @ STERISCIENCE          EQ 2MG BASE/ML                  A078244  001  Apr 23, 2008   Feb CAHN
          TABLET;ORAL
            ONDANSETRON HYDROCHLORIDE
            @ AUROBINDO PHARMA      EQ 24MG BASE                    A078539  003  Jul 31, 2007   Feb DISC
            @ CASI PHARMS INC       EQ 24MG BASE                    A077517  003  Jun 25, 2007   Feb DISC
    AB        CHARTWELL MOLECULES   EQ 4MG BASE                     A077303  001  Jun 25, 2007   May CMFD
    AB                              EQ 8MG BASE                     A077303  002  Jun 25, 2007   May CMFD
    AB  !                           EQ 24MG BASE                    A077303  004  Jun 25, 2007   May CMFD
            @ DR REDDYS LABS LTD    EQ 16MG BASE                    A076183  004  Dec 26, 2006   Mar DISC
            @                       EQ 24MG BASE                    A076183  001  Dec 26, 2006   Feb DISC
    AB        GLENMARK GENERICS     EQ 8MG BASE                     A077535  002  Jun 25, 2007   May CHRS
    AB  !                           EQ 8MG BASE                     A077535  002  Jun 25, 2007   Feb CHRS
            @                       EQ 24MG BASE                    A077535  003  Jun 25, 2007   Feb DISC
            @ TEVA                  EQ 4MG BASE                     A076252  001  Jun 25, 2007   Feb DISC
            @                       EQ 8MG BASE                     A076252  002  Jun 25, 2007   Feb DISC
            @                       EQ 24MG BASE                    A076252  003  Jun 25, 2007   Feb DISC
            ZOFRAN
          + @ NOVARTIS              EQ 4MG BASE                     N020103  001  Dec 31, 1992   Feb DISC
          + @                       EQ 8MG BASE                     N020103  002  Dec 31, 1992   Feb DISC
          + @                       EQ 24MG BASE                    N020103  003  Aug 27, 1999   Feb DISC

        ORPHENADRINE CITRATE
          TABLET, EXTENDED RELEASE;ORAL
            ORPHENADRINE CITRATE
    AB        BAYSHORE PHARMS LLC   100MG                           A091158  001  Jul 27, 2012   Aug CAHN

        OSELTAMIVIR PHOSPHATE
          CAPSULE;ORAL
            OSELTAMIVIR PHOSPHATE
    AB        ACCORD HLTHCARE       EQ 30MG BASE                    A214726  001  Jul 25, 2022   Jul NEWA
    AB                              EQ 45MG BASE                    A214726  002  Jul 25, 2022   Jul NEWA
    AB                              EQ 75MG BASE                    A214726  003  Jul 25, 2022   Jul NEWA
          FOR SUSPENSION;ORAL
            OSELTAMIVIR PHOSPHATE
    AB        ALVOGEN               EQ 6MG BASE/ML                  A208823  001  Oct 31, 2017   May CAHN
            @ APTAPHARMA INC        EQ 6MG BASE/ML                  A212858  001  Aug 30, 2021   Mar DISC
    AB        HETERO LABS LTD V     EQ 6MG BASE/ML                  A209590  001  Mar 28, 2022   Mar NEWA
>D> AB        LEADING               EQ 6MG BASE/ML                  A214949  001  Feb 28, 2022   Sep DISC
>A>         @                       EQ 6MG BASE/ML                  A214949  001  Feb 28, 2022   Sep DISC
    AB                              EQ 6MG BASE/ML                  A214949  001  Feb 28, 2022   Feb NEWA
    AB        MSN                   EQ 6MG BASE/ML                  A215313  001  May 02, 2022   Apr NEWA
            @ STRIDES PHARMA        EQ 6MG BASE/ML                  A211894  001  Jan 13, 2022   Jul DISC
    AB                              EQ 6MG BASE/ML                  A211894  001  Jan 13, 2022   Jan NEWA
```

OTESECONAZOLE

CAPSULE;ORAL

VIVJOA

+!	MYCOVIA PHARMS	150MG	N215888	001	Apr 26, 2022	Apr NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

@	PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Aug DISC
@		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Aug DISC
@	STERISCIENCE	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Feb CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

@	CHARTWELL MOLECULAR	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Mar CAHN
@		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Mar CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB	UNITED RES LABS	10MG	A071026	002	Aug 10, 1987	Apr CAHN
AB		15MG	A071026	003	Aug 10, 1987	Apr CAHN
AB		30MG	A071026	001	Aug 10, 1987	Apr CAHN

SERAX

+ @	ALPHARMA US PHARMS	10MG	N015539	002		Jan CRLD
+ @		15MG	N015539	004		Jan CRLD
+ @		30MG	N015539	006		Jan CRLD

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB	RUBICON	300MG/5ML	A215726	001	Aug 30, 2022	Aug NEWA

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@	CHARTWELL RX	5MG/5ML	A075039	001	Jan 29, 1999	Mar CAHN
AA !	LANNETT CO INC	5MG/5ML	A074520	001	Mar 29, 1996	Mar CHRS
@	WOCKHARDT BIO AG	5MG/5ML	A074868	001	Feb 12, 1997	Mar DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB	BEXIMCO PHARMS USA	5MG	A213550	001	Jul 14, 2022	Jul NEWA
AB	STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020	Jul CMFD

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@	NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Feb DISC
@	WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Apr DISC

TABLET;ORAL

ROXYBOND

	PROTEGA PHARMS	5MG	N209777	001	Apr 20, 2017	Mar CMFD
@		5MG	N209777	001	Apr 20, 2017	Feb CAHN
		15MG	N209777	002	Apr 20, 2017	Mar CMFD
@		15MG	N209777	002	Apr 20, 2017	Feb CAHN
		30MG	N209777	003	Apr 20, 2017	Mar CMFD
@		30MG	N209777	003	Apr 20, 2017	Feb CAHN

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL

AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Feb CTNA

POWDER;INTRAVENOUS

PACLITAXEL

+!	HBT LABS INC	100MG/VIAL	N211875	001	Jul 27, 2022	Jul NEWA

PACRITINIB CITRATE

CAPSULE;ORAL

VONJO

		+!	CTI BIOPHARMA CORP	EQ 100MG BASE	N208712	001	Feb 28, 2022	Feb NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

>D>	BX		AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep CTEC
>A>	AB			1.5MG	A204707	001	Sep 23, 2019	Sep CTEC
>D>	BX			3MG	A204707	002	Sep 23, 2019	Sep CTEC
>A>	AB			3MG	A204707	002	Sep 23, 2019	Sep CTEC
>D>	BX			6MG	A204707	003	Sep 23, 2019	Sep CTEC
>A>	AB			6MG	A204707	003	Sep 23, 2019	Sep CTEC
>D>	BX			9MG	A204707	004	Sep 23, 2019	Sep CTEC
>A>	AB			9MG	A204707	004	Sep 23, 2019	Sep CTEC
	AB		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Jun NEWA
	AB			3MG	A208643	002	Jun 29, 2022	Jun NEWA
	AB			6MG	A208643	003	Jun 29, 2022	Jun NEWA
	AB			9MG	A208643	004	Jun 29, 2022	Jun NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

		!	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jul CMFD
		@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan DISC
	AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jul CMFD
		@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan DISC

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

	AP		ASPIRO	EQ 40MG BASE/VIAL	A213778	001	May 18, 2022	May NEWA
	AP		BE PHARMS	EQ 40MG BASE/VIAL	A216171	001	May 18, 2022	May NEWA
	AP		GLAND PHARMA LTD	EQ 40MG BASE/VIAL	A204400	001	May 18, 2022	May NEWA
	AP		KNACK	EQ 40MG BASE/VIAL	A214680	001	May 19, 2022	May NEWA
	AP		NANJING KING-FRIEND	EQ 40MG BASE/VIAL	A215860	001	Aug 29, 2022	Aug NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

>D>	AB		L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	Sep DISC
>A>		@		EQ 20MG BASE	A203024	001	May 07, 2014	Sep DISC
	AB		MANKIND PHARMA	EQ 40MG BASE	A215880	001	Jul 26, 2022	Jul NEWA

PARICALCITOL

SOLUTION;INTRAVENOUS

PARICALCITOL

		@	AKORN	0.005MG/ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug DISC
		@		0.01MG/2ML (0.005MG/ML)	A207692	001	Oct 16, 2017	Aug CPOT
		@	RISING	0.002MG/ML (0.002MG/ML)	A203897	001	Nov 02, 2017	Mar DISC

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

		+ @	APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
		+ @		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
		+ @		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
		+ @		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

	AB	+!	APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

	AB		CHARTWELL RX	EQ 10MG BASE	A076618	001	Aug 15, 2005	Mar CAHN
	AB			EQ 20MG BASE	A076618	002	Aug 15, 2005	Mar CAHN
	AB			EQ 30MG BASE	A076618	003	Aug 15, 2005	Mar CAHN
	AB			EQ 40MG BASE	A076618	004	Aug 15, 2005	Mar CAHN

PAXIL

	AB	+	APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb CAHN

TABLET;ORAL
PAXIL

AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb CAHN
AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb CAHN
AB	+!		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

	@	SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan DISC
	@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan DISC
AB			EQ 37.5MG BASE	A213612	003	May 26, 2022	May NEWA

PAXIL CR

AB	+	APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+!		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PAROXETINE MESYLATE

TABLET;ORAL
PEXEVA

	+ @	SEBELA IRELAND LTD	EQ 40MG BASE	N021299	004	Jul 03, 2003	Jun DISC

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL
MACUGEN

	+ @	BAUSCH AND LOMB INC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	Jun CAHN

PEMETREXED

SOLUTION;INTRAVENOUS
PEMETREXED

	+!	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	May CMFD
	+!		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	May CMFD
	+!		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	May CMFD

PEMETREXED DISODIUM

POWDER;INTRAVENOUS
ALIMTA

AP	+!	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007	May CFTG
AP	+!		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004	May CFTG

PEMETREXED DISODIUM

AP		ACCORD HLTHCARE	EQ 100MG BASE/VIAL	A203485	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A203485	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A203485	003	May 25, 2022	May NEWA
AP		AMNEAL	EQ 500MG BASE/VIAL	A210047	001	Aug 04, 2022	Jul NEWA
AP		APOTEX	EQ 100MG BASE/VIAL	A203774	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A203774	002	May 25, 2022	May NFTG
AP			EQ 750MG BASE/VIAL	A209851	001	May 25, 2022	May NEWA
AP			EQ 1GM BASE/VIAL	A209085	001	May 25, 2022	May NEWA
AP		BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	Aug NEWA
AP			EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	Aug NEWA
AP		BIOCON PHARMA	EQ 1GM BASE/VIAL	A211090	001	May 25, 2022	May NEWA
AP		DR REDDYS	EQ 100MG BASE/VIAL	A202596	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A202596	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A202596	003	May 25, 2022	May NEWA
AP		EUGIA PHARMA	EQ 100MG BASE/VIAL	A214632	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A214632	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A214632	003	May 25, 2022	May NEWA
AP		FRESENIUS KABI USA	EQ 100MG BASE/VIAL	A090384	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A090384	002	May 25, 2022	May NFTG
AP	!		EQ 750MG BASE/VIAL	A090384	003	May 25, 2022	May NEWA
AP	!		EQ 1GM BASE/VIAL	A090384	004	May 25, 2022	May NEWA
AP		HOSPIRA	EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	Aug CAHN
AP			EQ 100MG BASE/VIAL	A202111	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	Aug CAHN
AP			EQ 500MG BASE/VIAL	A202111	002	May 25, 2022	May NFTG
AP			EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	Aug CAHN
AP			EQ 1GM BASE/VIAL	A202111	003	May 25, 2022	May NEWA
AP		JIANGSU HANSOH PHARM	EQ 100MG BASE/VIAL	A208696	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A208696	002	May 25, 2022	May NFTG
AP		NANG KUANG PHARM CO	EQ 100MG BASE/VIAL	A207352	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A207352	002	May 25, 2022	May NFTG
AP		QILU PHARM HAINAN	EQ 100MG BASE/VIAL	A204890	001	May 25, 2022	May NFTG
AP			EQ 500MG BASE/VIAL	A204890	002	May 25, 2022	May NFTG
AP		WAVERLEY PHARMA INC	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	May NFTG

POWDER;INTRAVENOUS
PEMETREXED DISODIUM

	AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	May NFTG
	AP	ZYDUS PHARMS	EQ 100MG BASE/VIAL	A214073	001	May 25, 2022	May NFTG
	AP		EQ 500MG BASE/VIAL	A214073	002	May 25, 2022	May NFTG
	AP		EQ 1GM BASE/VIAL	A214073	003	May 25, 2022	May NEWA

SOLUTION;INTRAVENOUS
PEMETREXED DISODIUM

	+!	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jul NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jul NEWA
	+!		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jul NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jul NEWA
	+!	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Aug CTNA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Aug CTNA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Aug CTNA
	+!	HOSPIRA INC	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218	001	Jun 22, 2022	Jun NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218	002	Jun 22, 2022	Jun NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218	003	Jun 22, 2022	Jun NEWA
	+!	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	Aug CTNA
	+!		EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657	001	May 26, 2022	May NEWA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	Aug CTNA
	+!		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657	002	May 26, 2022	May NEWA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	Aug CTNA
	+!		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657	003	May 26, 2022	May NEWA

PEMETREXED DITROMETHAMINE

POWDER;INTRAVENOUS
PEMETREXED DITROMETHAMINE

	+!	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CAHN
	+!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Aug CTNA
	+!		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Jun NEWA
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CAHN
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Aug CTNA
	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Jun NEWA
>D>	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Sep DISC
>A>	+ @		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Sep DISC
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CAHN
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Aug CTNA
	+!		EQ 1GM BASE/VIAL	N208746	003	Jun 10, 2022	Jun NEWA

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION
PENTAMIDINE ISETHIONATE

	AP	XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022	Mar NEWA

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION
PENTOBARBITAL SODIUM

	AP	HIKMA	50MG/ML	A203619	001	Nov 13, 2017	Aug CAHN

PERINDOPRIL ERBUMINE

TABLET;ORAL
PERINDOPRIL ERBUMINE

>D>	AB	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	Sep CTEC
>A>			2MG	A079070	001	Nov 10, 2009	Sep CTEC
>D>	AB		4MG	A079070	002	Nov 10, 2009	Sep CTEC
>A>			4MG	A079070	002	Nov 10, 2009	Sep CTEC
>D>	AB	HIKMA	2MG	A090072	001	Nov 10, 2009	Sep DISC
>A>		@	2MG	A090072	001	Nov 10, 2009	Sep DISC
>D>	AB		4MG	A090072	002	Nov 10, 2009	Sep DISC
>A>		@	4MG	A090072	002	Nov 10, 2009	Sep DISC

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB	APPCO	2MG	A210163	001	May 18, 2022	May	NEWA
AB		4MG	A210163	002	May 18, 2022	May	NEWA
AB		8MG	A210163	003	May 18, 2022	May	NEWA
AB		16MG	A210163	004	May 18, 2022	May	NEWA
	@ MYLAN	2MG	A206691	001	Apr 14, 2017	Mar	DISC
	@	4MG	A206691	002	Apr 14, 2017	Mar	DISC
	@	8MG	A206691	003	Apr 14, 2017	Mar	DISC
	@	16MG	A206691	004	Apr 14, 2017	Mar	DISC

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

AA	CHARTWELL	35MG	A089452	001	Oct 30, 1991	Apr	CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	NOVITIUM PHARMA	10MG	A215042	001	Jul 19, 2022	Jul	NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	+! SANDOZ	30MG	A087190	001		Feb	CRLD

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

	@ LANNETT	37.5MG	A040555	001	Apr 15, 2005	Jul	DISC

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

	+! DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Jun	CAHN
	+ @	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Jun	CAHN

PHENYLEPHRINE HYDROCHLORIDE

AP1	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb	CMFD
AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb	CMFD
AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb	CMFD
AP1	MANKIND PHARMA	10MG/ML (10MG/ML)	A217069	001	Aug 30, 2022	Aug	NEWA
AP1		50MG/5ML (10MG/ML)	A217069	002	Aug 30, 2022	Aug	NEWA
AP1		100MG/10ML (10MG/ML)	A217069	003	Aug 30, 2022	Aug	NEWA
	@ PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Jan	DISC

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

>A> AT	MANKIND PHARMA	2.5%	A216859	001	Sep 29, 2022	Sep	NEWA

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	+! VIATRIS	125MG/5ML	N008762	001		Feb	CAHN

DILANTIN-30

	@ VIATRIS	30MG/5ML	N008762	002		Feb	CAHN

PHENYTOIN

AB	PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Apr	CAHN
AB	VISTAPHARM	125MG/5ML	A040342	002	Aug 18, 2005	May	CMS1

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

	+! VIATRIS	30MG EXTENDED	A084349	001		Feb	CAHN
AB	+!	100MG EXTENDED	A084349	002		Feb	CAHN

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

	@ CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022	Jul	DISC
AB2	!	1MG/0.5ML	A212424	001	Apr 22, 2022	Apr	NFTG
	!	1MG/0.5ML	A214596	001	Apr 22, 2022	Jul	CTEC
AB2	!	1MG/0.5ML	A214596	001	Apr 22, 2022	Jul	CHRS
AB2		1MG/0.5ML	A214596	001	Apr 22, 2022	Apr	NFTG

INJECTABLE;INJECTION
PHYTONADIONE

		@	10MG/ML	A212424	002	Apr 22, 2022	Jul DISC
AB2	!		10MG/ML	A212424	002	Apr 22, 2022	Apr NFTG
	!		10MG/ML	A214596	002	Apr 22, 2022	Jul CTEC
AB2	!		10MG/ML	A214596	002	Apr 22, 2022	Jul CHRS
AB2			10MG/ML	A214596	002	Apr 22, 2022	Apr NFTG
AB1		DR REDDYS	10MG/ML	A207719	001	May 22, 2019	Apr CTEC

VITAMIN K1

AB1	+!	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Apr CTEC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
ISOPTO CARPINE

AT	+!	NOVARTIS	1%	N200890	001	Jun 22, 2010	May CHRS
AT	+!		2%	N200890	002	Jun 22, 2010	May CHRS

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAM

AP		STERISCIENCE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	May CMFD
		@	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	May CMFD
		@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	May CMFD
		@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb CAHN

PIRFENIDONE

CAPSULE;ORAL
PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan NEWA
AB		AMNEAL	267MG	A212569	001	Jan 03, 2022	May CMFD
		@	267MG	A212569	001	Jan 03, 2022	Jan DISC
AB		LAURUS	267MG	A212724	001	Jul 19, 2022	Jul NEWA
AB		SANDOZ INC	267MG	A212600	001	Jun 13, 2022	Jun NEWA
AB		SCIEGEN PHARMS INC	267MG	A212077	001	Aug 01, 2022	Jul NEWA

TABLET;ORAL
ESBRIET

AB	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan CFTG
AB	+!		801MG	N208780	003	Jan 11, 2017	Jan CFTG

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan NFTG
AB			801MG	A212730	002	Jan 25, 2022	Jan NFTG
AB		AIZANT	267MG	A212747	001	Jul 21, 2022	Jul NEWA
AB			534MG	A212747	002	Jul 21, 2022	Jul NEWA
AB			801MG	A212747	003	Jul 21, 2022	Jul NEWA
AB		ALEMBIC PHARMS LTD	267MG	A212708	001	May 20, 2022	May NEWA
AB			801MG	A212708	002	May 20, 2022	May NEWA
AB		AMNEAL	267MG	A212570	001	Mar 25, 2022	Mar NEWA
AB			801MG	A212570	002	Mar 25, 2022	Mar NEWA
>A> AB		HETERO LABS LTD V	267MG	A212674	001	Sep 21, 2022	Sep NEWA
>A> AB			801MG	A212674	002	Sep 21, 2022	Sep NEWA
AB		LAURUS	267MG	A212722	001	Jul 19, 2022	Jul NEWA
AB			534MG	A212722	002	Jul 19, 2022	Jul CTEC
			534MG	A212722	002	Jul 19, 2022	Jul NEWA
AB			801MG	A212722	003	Jul 19, 2022	Jul NEWA
AB		MICRO LABS	267MG	A212680	001	May 18, 2022	May NEWA
AB			801MG	A212680	002	May 18, 2022	May NEWA
AB		MSN	267MG	A212772	001	May 24, 2022	May NEWA
AB			801MG	A212772	002	May 24, 2022	May NEWA
AB		SANDOZ INC	267MG	A212560	001	Apr 28, 2022	Apr NEWA
AB			801MG	A212560	002	Apr 28, 2022	Apr NEWA
AB		SCIEGEN PHARMS INC	267MG	A212078	001	Aug 01, 2022	Jul NEWA
AB			801MG	A212078	002	Aug 01, 2022	Jul NEWA
AB		TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan NFTG
AB			801MG	A212759	002	Jan 25, 2022	Jan NFTG

POLIDOCANOL

SOLUTION;INTRAVENOUS

VARITHENA

>D>	+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Sep DISC
>A>	+ @		77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Sep DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@	NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Feb DISC

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

	@	MYLAN	1MG	A210275	001	Jan 26, 2022	Feb CAHN
	@		1MG	A210275	001	Jan 26, 2022	Feb DISC
AB			1MG	A210275	001	Jan 26, 2022	Jan NEWA
	@		2MG	A210275	002	Jan 26, 2022	Feb CAHN
	@		2MG	A210275	002	Jan 26, 2022	Feb DISC
AB			2MG	A210275	002	Jan 26, 2022	Jan NEWA
	@		3MG	A210275	003	Jan 26, 2022	Feb CAHN
	@		3MG	A210275	003	Jan 26, 2022	Feb DISC
AB			3MG	A210275	003	Jan 26, 2022	Jan NEWA
	@		4MG	A210275	004	Jan 26, 2022	Feb CAHN
	@		4MG	A210275	004	Jan 26, 2022	Feb DISC
AB			4MG	A210275	004	Jan 26, 2022	Jan NEWA
AB		TEVA PHARMS USA	1MG	A209956	001	May 04, 2022	Apr NEWA
AB			2MG	A209956	002	May 04, 2022	Apr NEWA
AB			3MG	A209956	003	May 04, 2022	Apr NEWA
AB			4MG	A209956	004	May 04, 2022	Apr NEWA

POMALYST

AB	+	CELGENE	1MG	N204026	001	Feb 08, 2013	Apr CTEC
	+		1MG	N204026	001	Feb 08, 2013	Feb CTEC
AB	+		1MG	N204026	001	Feb 08, 2013	Jan CTEC
AB	+		2MG	N204026	002	Feb 08, 2013	Apr CTEC
	+		2MG	N204026	002	Feb 08, 2013	Feb CTEC
AB	+		2MG	N204026	002	Feb 08, 2013	Jan CTEC
AB	+		3MG	N204026	003	Feb 08, 2013	Apr CTEC
	+		3MG	N204026	003	Feb 08, 2013	Feb CTEC
AB	+		3MG	N204026	003	Feb 08, 2013	Jan CTEC
AB	+!		4MG	N204026	004	Feb 08, 2013	Apr CTEC
	+!		4MG	N204026	004	Feb 08, 2013	Feb CTEC
AB	+!		4MG	N204026	004	Feb 08, 2013	Jan CTEC

PONESIMOD

TABLET;ORAL

PONVORY

	+!	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Aug CHRS
	+		20MG	N213498	010	Mar 18, 2021	Aug CHRS

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

NOXAFIL POWDERMIX KIT

	+ @	MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan DISC

SOLUTION;INTRAVENOUS

NOXAFIL

AP	+!	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	May CFTG

POSACONAZOLE

AP		PAR STERILE PRODUCTS	300MG/16.7ML (18MG/ML)	A208768	001	May 25, 2022	May NFTG

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB		BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan NEWA
AB		DR REDDYS	100MG	A212500	001	Apr 07, 2022	Apr NEWA
AB		SPECGX LLC	100MG	A212226	001	May 10, 2022	Apr NEWA

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

		@ EXELA PHARMA	2MEQ/ML	A212692	001	Oct 20, 2021	Mar DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

		@ LANNETT CO INC	8MEQ	A204210	001	Mar 28, 2016	Mar DISC
		@	10MEQ	A204210	002	Mar 28, 2016	Mar DISC

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

		@ GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jul DISC
	AA		20MEQ	A213467	001	Jan 27, 2022	Jan NEWA
	AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022	Mar NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

>D>	AP	! HOSPIRA	2MEQ/ML	A080205	001		Sep CRLD
>A>	AP	+!	2MEQ/ML	A080205	001		Sep CRLD

POTASSIUM CHLORIDE 10MEQ

	AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar CMFD
	AP		746MG/100ML	A211087	002	Sep 09, 2020	Mar CMFD

POTASSIUM CHLORIDE 20MEQ

	AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar CMFD
	AP		1.49GM/100ML	A211087	005	May 07, 2021	Mar CMFD

POTASSIUM CHLORIDE 40MEQ

	AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar CMFD

SOLUTION;ORAL

POTASSIUM CHLORIDE

	AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan NEWA
	AA		40MEQ/15ML	A214656	002	Jan 13, 2022	Jan NEWA
		@ TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Apr DISC
	AA		20MEQ/15ML	A214076	001	Jan 26, 2022	Jan NEWA
		@	40MEQ/15ML	A214076	002	Jan 26, 2022	Apr DISC
	AA		40MEQ/15ML	A214076	002	Jan 26, 2022	Jan NEWA
	AA	WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022	May NEWA
	AA		40MEQ/15ML	A213062	002	Jun 06, 2022	May NEWA

TABLET, EXTENDED RELEASE;ORAL

K-TAB

	+ @	ABBVIE	8MEQ	N018279	002	Aug 01, 1988	Mar DISC

POTASSIUM CHLORIDE

	AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul CMFD
	AB1		20MEQ	A214395	002	Jan 28, 2021	Jul CMFD
	AB3	RUBICON	10MEQ	A215725	001	Jul 25, 2022	Jul NEWA
	AB3		20MEQ	A215725	002	Jul 25, 2022	Jul NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

	AP	+! BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002	Aug CTEC
	AP	FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020	Aug CMFD

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

	AP	FRESENIUS KABI USA	150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021	Aug CMFD

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

	AP	+! BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002		Aug CTEC
	AP	FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020	Aug CMFD

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

MIRAPEX

	+ @	BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997	Mar DISC
	+ @		0.25MG	N020667	002	Jul 01, 1997	Mar DISC
	+ @		0.5MG	N020667	006	Feb 12, 1998	Mar DISC
	+ @		0.75MG	N020667	007	Jul 30, 2007	Mar DISC
	+ @		1MG	N020667	003	Jul 01, 1997	Mar DISC
	+ @		1.5MG	N020667	005	Jul 01, 1997	Mar DISC

PRAMIPEXOLE DIHYDROCHLORIDE

	AB	! GLENMARK GENERICS	0.25MG	A090781	002	Oct 08, 2010	Mar CHRS
>D>	AB	GRAVITI PHARMS	0.25MG	A211088	001	Oct 03, 2018	Sep CAHN
>D>	AB		0.5MG	A211088	002	Oct 03, 2018	Sep CAHN
>D>	AB		0.75MG	A211088	003	Oct 03, 2018	Sep CAHN

```
          TABLET;ORAL
            PRAMIPEXOLE DIHYDROCHLORIDE
>D> AB                            1MG                              A211088  004  Oct 03, 2018   Sep CAHN
>D> AB                            1.5MG                            A211088  005  Oct 03, 2018   Sep CAHN
>A> AB        RISING              0.25MG                           A211088  001  Oct 03, 2018   Sep CAHN
>A> AB                            0.5MG                            A211088  002  Oct 03, 2018   Sep CAHN
>A> AB                            0.75MG                           A211088  003  Oct 03, 2018   Sep CAHN
>A> AB                            1MG                              A211088  004  Oct 03, 2018   Sep CAHN
>A> AB                            1.5MG                            A211088  005  Oct 03, 2018   Sep CAHN
          TABLET, EXTENDED RELEASE;ORAL
            PRAMIPEXOLE DIHYDROCHLORIDE
    AB        ALEMBIC PHARMS LTD  0.375MG                          A204518  001  Jan 02, 2019   Apr CMFD
    AB                            0.75MG                           A204518  002  Jan 02, 2019   Apr CMFD
    AB                            1.5MG                            A204518  003  Jan 02, 2019   Apr CMFD
    AB                            2.25MG                           A204518  004  Jan 02, 2019   Apr CMFD
    AB                            3MG                              A204518  005  Jan 02, 2019   Apr CMFD
    AB                            3.75MG                           A204518  006  Jan 02, 2019   Apr CMFD
    AB                            4.5MG                            A204518  007  Jan 02, 2019   Apr CMFD
    AB        NOVAST LABS         0.375MG                          A213444  001  Feb 03, 2022   Jan NEWA
    AB                            0.75MG                           A213444  002  Feb 03, 2022   Jan NEWA
    AB                            1.5MG                            A213444  003  Feb 03, 2022   Jan NEWA
    AB                            2.25MG                           A213444  004  Feb 03, 2022   Jan NEWA
    AB                            3MG                              A213444  005  Feb 03, 2022   Jan NEWA
    AB                            3.75MG                           A213444  006  Feb 03, 2022   Jan NEWA
    AB                            4.5MG                            A213444  007  Feb 03, 2022   Jan NEWA

        PRASUGREL HYDROCHLORIDE
          TABLET;ORAL
            PRASUGREL
            @ CHARTWELL RX        EQ 5MG BASE                      A205790  001  Oct 16, 2017   Aug CAHN
            @                     EQ 10MG BASE                     A205790  002  Oct 16, 2017   Aug CAHN
            @ USPHARMA WINDLAS    EQ 5MG BASE                      A205790  001  Oct 16, 2017   Apr DISC
            @                     EQ 10MG BASE                     A205790  002  Oct 16, 2017   Apr DISC

        PRAZOSIN HYDROCHLORIDE
          CAPSULE;ORAL
            PRAZOSIN HYDROCHLORIDE
            @ ANI PHARMS          EQ 1MG BASE                      A072577  002  May 16, 1989   Aug DISC
            @                     EQ 2MG BASE                      A072577  001  May 16, 1989   Aug DISC
            @                     EQ 5MG BASE                      A072577  003  May 16, 1989   Feb DISC

        PREDNISOLONE
          TABLET;ORAL
            PREDNISOLONE
          +!  WATSON LABS         5MG                              A080354  001                  Mar CRLD

>D>     PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
>D>       OINTMENT;OPHTHALMIC
>D>         BLEPHAMIDE S.O.P.
>D>       !   ALLERGAN            0.2%;10%                         A087748  001  Dec 03, 1986   Sep DISC
>A>         @                     0.2%;10%                         A087748  001  Dec 03, 1986   Sep DISC
          SUSPENSION;OPHTHALMIC
            BLEPHAMIDE
          + @ ALLERGAN            0.2%;10%                         N012813  002                  Aug DISC

        PREDNISOLONE SODIUM PHOSPHATE
          TABLET, ORALLY DISINTEGRATING;ORAL
            PREDNISOLONE SODIUM PHOSPHATE
            @ RISING              EQ 10MG BASE                     A202179  001  Apr 10, 2013   Jul CAHN
            @                     EQ 15MG BASE                     A202179  002  Apr 10, 2013   Jul CAHN
            @                     EQ 30MG BASE                     A202179  003  Apr 10, 2013   Jul CAHN

        PREDNISONE
          SOLUTION;ORAL
            PREDNISONE
          +!  HIKMA               5MG/5ML                          A088703  001  Nov 08, 1984   May CRLD
          TABLET;ORAL
            PREDNISONE
    AB        AUROBINDO PHARMA LTD  2.5MG                          A215672  001  Mar 28, 2022   Mar NEWA
    AB                            5MG                              A215672  002  Mar 28, 2022   Mar NEWA
    AB                            10MG                             A215672  003  Mar 28, 2022   Mar NEWA
    AB                            20MG                             A215672  004  Mar 28, 2022   Mar NEWA
```

TABLET;ORAL
PREDNISONE

AB		50MG	A215672	005	Mar 28, 2022	Mar NEWA

PREGABALIN

CAPSULE;ORAL
PREGABALIN

AB	ALLIED	50MG	A210585	001	Dec 26, 2019	Feb CAHN
AB		75MG	A210585	002	Dec 26, 2019	Feb CAHN
AB		100MG	A210585	003	Dec 26, 2019	Feb CAHN
AB		150MG	A210585	004	Dec 26, 2019	Feb CAHN
AB		200MG	A210585	005	Dec 26, 2019	Feb CAHN
AB		300MG	A210585	006	Dec 26, 2019	Feb CAHN
AB	ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb NEWA
AB		50MG	A212988	002	Mar 08, 2022	Feb NEWA
AB		75MG	A212988	003	Mar 08, 2022	Feb NEWA
AB		100MG	A212988	004	Mar 08, 2022	Feb NEWA
AB		150MG	A212988	005	Mar 08, 2022	Feb NEWA
AB		200MG	A212988	006	Mar 08, 2022	Feb NEWA
AB		225MG	A212988	007	Mar 08, 2022	Feb NEWA
AB		300MG	A212988	008	Mar 08, 2022	Feb NEWA
	@ LUPIN LTD	25MG	A091040	001	May 03, 2022	Jul DISC
AB		25MG	A091040	001	May 03, 2022	Apr NEWA
	@	50MG	A091040	002	May 03, 2022	Jul DISC
AB		50MG	A091040	002	May 03, 2022	Apr NEWA
	@	75MG	A091040	003	May 03, 2022	Jul DISC
AB		75MG	A091040	003	May 03, 2022	Apr NEWA
	@	100MG	A091040	004	May 03, 2022	Jul DISC
AB		100MG	A091040	004	May 03, 2022	Apr NEWA
	@	150MG	A091040	005	May 03, 2022	Jul DISC
AB		150MG	A091040	005	May 03, 2022	Apr NEWA
	@	200MG	A091040	006	May 03, 2022	Jul DISC
AB		200MG	A091040	006	May 03, 2022	Apr NEWA
	@	225MG	A091040	007	May 03, 2022	Jul DISC
AB		225MG	A091040	007	May 03, 2022	Apr NEWA
	@	300MG	A091040	008	May 03, 2022	Jul DISC
AB		300MG	A091040	008	May 03, 2022	Apr NEWA
AB	MARKSANS PHARMA	25MG	A216197	001	Jul 18, 2022	Jul NEWA
AB		50MG	A216197	002	Jul 18, 2022	Jul NEWA
AB		75MG	A216197	003	Jul 18, 2022	Jul NEWA
AB		100MG	A216197	004	Jul 18, 2022	Jul NEWA
AB		150MG	A216197	005	Jul 18, 2022	Jul NEWA
AB		200MG	A216197	006	Jul 18, 2022	Jul NEWA
AB		225MG	A216197	007	Jul 18, 2022	Jul NEWA
AB		300MG	A216197	008	Jul 18, 2022	Jul NEWA
AB	PRINSTON INC	25MG	A207883	001	Sep 01, 2022	Aug NEWA
AB		50MG	A207883	002	Sep 01, 2022	Aug NEWA
AB		75MG	A207883	003	Sep 01, 2022	Aug NEWA
AB		100MG	A207883	004	Sep 01, 2022	Aug NEWA
AB		150MG	A207883	005	Sep 01, 2022	Aug NEWA
AB		200MG	A207883	006	Sep 01, 2022	Aug NEWA
AB		225MG	A207883	007	Sep 01, 2022	Aug NEWA
AB		300MG	A207883	008	Sep 01, 2022	Aug NEWA
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Jul CAHN
AB		75MG	A210585	002	Dec 26, 2019	Jul CAHN
AB		100MG	A210585	003	Dec 26, 2019	Jul CAHN
AB		150MG	A210585	004	Dec 26, 2019	Jul CAHN
AB		200MG	A210585	005	Dec 26, 2019	Jul CAHN
AB		300MG	A210585	006	Dec 26, 2019	Jul CAHN

SOLUTION;ORAL
PREGABALIN

AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

	@ MYLAN	82.5MG	A211948	001	Apr 13, 2021	Mar DISC
AB		82.5MG	A211948	001	Apr 13, 2021	Mar CAHN
	@	165MG	A211967	001	Nov 04, 2021	Mar DISC
AB	RUBICON	82.5MG	A215249	001	Mar 22, 2022	Mar NEWA
AB		165MG	A215249	002	Mar 22, 2022	Mar NEWA
AB		330MG	A215249	003	Mar 22, 2022	Mar NEWA
>A> AB	SCIEGEN PHARMS INC	82.5MG	A215675	001	Sep 14, 2022	Sep NEWA
>A> AB		165MG	A215675	002	Sep 14, 2022	Sep NEWA
>A> AB		330MG	A215675	003	Sep 14, 2022	Sep NEWA

```
        TABLET, EXTENDED RELEASE;ORAL
          PREGABALIN
    AB      ZYDUS PHARMS          82.5MG                          A215577  001  Aug 26, 2022   Aug NEWA
    AB                            165MG                           A215577  002  Aug 26, 2022   Aug NEWA
    AB                            330MG                           A215577  003  Aug 26, 2022   Aug NEWA

      PRIMIDONE
        TABLET;ORAL
          PRIMIDONE
    AB      RUBICON               50MG                            A214896  001  Jun 28, 2022   Jun NEWA
    AB                            250MG                           A214896  002  Jun 28, 2022   Jun NEWA

      PROBENECID
        TABLET;ORAL
          PROBENECID
          @ AUROBINDO PHARMA USA  500MG                           A084211  002                  Jul CAHN

      PROCHLORPERAZINE EDISYLATE
        INJECTABLE;INJECTION
          PROCHLORPERAZINE EDISYLATE
    AP      EUGIA PHARMA          EQ 5MG BASE/ML                  A213873  001  Jul 14, 2022   Jul NEWA

      PROCHLORPERAZINE MALEATE
        TABLET;ORAL
          PROCHLORPERAZINE MALEATE
>D> AB      MYLAN                 EQ 5MG BASE                     A040185  002  Oct 28, 1996   Sep DISC
>A>       @                       EQ 5MG BASE                     A040185  002  Oct 28, 1996   Sep DISC
>D> AB                            EQ 10MG BASE                    A040185  001  Oct 28, 1996   Sep DISC
>A>       @                       EQ 10MG BASE                    A040185  001  Oct 28, 1996   Sep DISC
    AB      NOVITIUM PHARMA       EQ 5MG BASE                     A216202  001  Jun 13, 2022   Jul CAHN
    AB                            EQ 10MG BASE                    A216202  002  Jun 13, 2022   Jul CAHN
    AB      ZENARA                EQ 5MG BASE                     A216202  001  Jun 13, 2022   Jun NEWA
    AB                            EQ 10MG BASE                    A216202  002  Jun 13, 2022   Jun NEWA
    AB      ZYDUS                 EQ 5MG BASE                     A216495  001  Aug 08, 2022   Jul NEWA
    AB                            EQ 10MG BASE                    A216495  002  Aug 08, 2022   Jul NEWA

      PROMAZINE HYDROCHLORIDE
        INJECTABLE;INJECTION
          SPARINE
          @ HIKMA                 25MG/ML                         N010349  008                  Jul CAHN
          @                       50MG/ML                         N010349  006                  Jul CAHN

      PROMETHAZINE HYDROCHLORIDE
        INJECTABLE;INJECTION
          PROMETHAZINE HYDROCHLORIDE
          @ ATLANTIDE             25MG/ML                         A040785  001  Sep 26, 2008   Mar CAHN
          @                       50MG/ML                         A040785  002  Sep 26, 2008   Mar CAHN
    AP  +!  WEST-WARD PHARMS INT  25MG/ML                         A083312  001                  Apr CRLD
    AP  +!                        50MG/ML                         A083312  002                  Apr CRLD

      PROPIOMAZINE HYDROCHLORIDE
        INJECTABLE;INJECTION
          LARGON
          @ HIKMA                 20MG/ML                         N012382  002                  Jul CAHN

      PROPRANOLOL HYDROCHLORIDE
        INJECTABLE;INJECTION
          PROPRANOLOL HYDROCHLORIDE
          @ ATHENEX INC           1MG/ML                          A075792  001  Aug 29, 2000   Feb DISC
          @ CHARTWELL INJECTABLE  1MG/ML                          A075792  001  Aug 29, 2000   Mar CAHN
    AP  !   HIKMA FARMACEUTICA    1MG/ML                          A077760  001  Jan 31, 2008   Feb CTEC
        SOLUTION;ORAL
          PROPRANOLOL HYDROCHLORIDE
          @ PAI HOLDINGS PHARM    20MG/5ML                        A071984  001  Mar 03, 1989   Apr CAHN
          @                       40MG/5ML                        A071985  001  Mar 03, 1989   Apr CAHN
        TABLET;ORAL
          PROPRANOLOL HYDROCHLORIDE
          @ CHARTWELL RX          10MG                            A070663  001  Jun 13, 1986   Mar CAHN
          @                       20MG                            A070664  001  Jun 13, 1986   Mar CAHN
          @                       40MG                            A070665  001  Jun 13, 1986   Mar CAHN
          @                       60MG                            A070666  001  Oct 10, 1986   Mar CAHN
          @                       80MG                            A070667  001  Jun 13, 1986   Mar CAHN
```

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

	@ CHARTWELL MOLECULAR	50MG	A080016	001		Aug CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

PYRIDOSTIGMINE BROMIDE

AA	MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022	Apr NEWA

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB	EYWA	30MG	A211181	002	May 14, 2019	Jun CTEC
AB	IMPAX LABS	30MG	A040502	002	Jun 28, 2022	Jun NEWA

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB	HETERO LABS LTD V	EQ 25MG BASE	A204316	001	Jun 16, 2022	Jun NEWA
AB		EQ 50MG BASE	A204316	002	Jun 16, 2022	Jun NEWA
AB		EQ 100MG BASE	A204316	003	Jun 16, 2022	Jun NEWA
AB		EQ 200MG BASE	A204316	004	Jun 16, 2022	Jun NEWA
AB		EQ 300MG BASE	A204316	005	Jun 16, 2022	Jun NEWA
AB		EQ 400MG BASE	A204316	006	Jun 16, 2022	Jun NEWA
AB	PRINSTON INC	EQ 25MG BASE	A206954	001	Aug 24, 2022	Aug NEWA
AB		EQ 50MG BASE	A206954	002	Aug 24, 2022	Aug NEWA
AB		EQ 100MG BASE	A206954	003	Aug 24, 2022	Aug NEWA
AB		EQ 200MG BASE	A206954	004	Aug 24, 2022	Aug NEWA
AB		EQ 300MG BASE	A206954	005	Aug 24, 2022	Aug NEWA
AB		EQ 400MG BASE	A206954	006	Aug 24, 2022	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	PRINSTON INC	EQ 50MG BASE	A208781	001	Apr 26, 2022	Apr NEWA
AB		EQ 150MG BASE	A208781	002	Apr 26, 2022	Apr NEWA
AB		EQ 200MG BASE	A208781	003	Apr 26, 2022	Apr NEWA
AB		EQ 300MG BASE	A208781	004	Apr 26, 2022	Apr NEWA
AB	UNICHEM	EQ 50MG BASE	A215478	001	Aug 15, 2022	Aug NEWA
AB		EQ 150MG BASE	A215478	002	Aug 15, 2022	Aug NEWA
AB		EQ 200MG BASE	A215478	003	Aug 15, 2022	Aug NEWA
AB		EQ 300MG BASE	A215478	004	Aug 15, 2022	Aug NEWA
AB		EQ 400MG BASE	A215478	005	Aug 15, 2022	Aug NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	@ CHARTWELL RX	EQ 5MG BASE	A076803	001	Mar 02, 2005	Mar CAHN
	@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Mar CAHN
	@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Mar CAHN
	@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Mar CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB	EYWA	324MG	A212589	001	Sep 17, 2021	Aug CMFD
	@	324MG	A212589	001	Sep 17, 2021	Mar DISC
AB	! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Aug CTEC
	!	324MG	A089338	001	Feb 11, 1987	Mar CTEC

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

	+! MSD SUB MERCK	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013	Jun CAHN

TABLET;ORAL

ISENTRESS

	+! MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jun CAHN

ISENTRESS HD

	+! MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Jun CAHN

TABLET, CHEWABLE;ORAL

ISENTRESS

	+ MSD SUB MERCK	EQ 25MG BASE	N203045	001	Dec 21, 2011	Jun CAHN
	+!	EQ 100MG BASE	N203045	002	Dec 21, 2011	Jun CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

>D>	AB	APPCO	8MG	A213815	001	Oct 26, 2020	Sep CAHN
	AB	ENALTEC	8MG	A215435	001	Aug 24, 2022	Aug NEWA
>A>	AB	UPSHER SMITH LABS	8MG	A213815	001	Oct 26, 2020	Sep CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@	CHARTWELL RX	1.25MG	A077514	001	Jun 18, 2008	Mar CAHN
@		2.5MG	A077514	002	Jun 18, 2008	Mar CAHN
@		5MG	A077514	003	Jun 18, 2008	Mar CAHN
@		10MG	A077514	004	Jun 18, 2008	Mar CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

@	MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	Jul DISC

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@	LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010	Jul DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

+	SPIL	500MG	N216018	001	Feb 28, 2022	Mar CAHN
+!		1GM	N216018	002	Feb 28, 2022	Mar CAHN
+	SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Feb NEWA
+!		1GM	N216018	002	Feb 28, 2022	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

AB	HETERO LABS LTD III	500MG	A212788	001	May 05, 2022	Apr NEWA
AB		1GM	A212788	002	May 05, 2022	Apr NEWA
AB	I3 PHARMS	500MG	A213517	001	Apr 27, 2022	Apr NEWA
AB		1GM	A213517	002	Apr 27, 2022	Apr NEWA
AB	VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan NEWA
AB		1GM	A214035	002	Jan 19, 2022	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

@	DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan DISC
@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan DISC

REGADENOSON

SOLUTION;INTRAVENOUS

LEXISCAN

AP	+!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008	Apr CFTG

RAGADENOSON

AP		IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May NEWA

REGADENOSON

AP		ACCORD HLTHCARE	0.4MG/5ML (0.08MG/ML)	A213236	001	Apr 11, 2022	Apr NFTG
AP		APOTEX	0.4MG/5ML (0.08MG/ML)	A207604	001	Apr 11, 2022	Apr NFTG
AP		DR REDDYS	0.4MG/5ML (0.08MG/ML)	A213210	001	Apr 11, 2022	Apr NFTG
AP		GLAND PHARMA LTD	0.4MG/5ML (0.08MG/ML)	A207320	001	Jul 12, 2022	Jul NEWA
AP		HONG KONG	0.4MG/5ML (0.08MG/ML)	A212806	001	Apr 11, 2022	Apr NFTG
AP		HOSPIRA	0.4MG/5ML (0.08MG/ML)	A214349	001	Aug 31, 2022	Aug NEWA
AP		IMS LTD	0.4MG/5ML (0.08MG/ML)	A214252	001	May 23, 2022	May CMS1

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

REMIFENTANIL HYDROCHLORIDE

AP	HIKMA	EQ 1MG BASE/VIAL	A210594	001	Oct 13, 2020	Jul CAHN
AP		EQ 2MG BASE/VIAL	A210594	002	Oct 13, 2020	Jul CAHN
AP		EQ 5MG BASE/VIAL	A210594	003	Oct 13, 2020	Jul CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

	@	BOSCOGEN	0.5MG	A091517	001	Apr 24, 2015	Aug DISC
	@		1MG	A091517	002	Apr 24, 2015	Aug DISC
	@		2MG	A091517	003	Apr 24, 2015	Aug DISC

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

AB		CHARTWELL MOLECULAR	150MG	A065390	001	Mar 28, 2008	Jun CAHN
AB			300MG	A065390	002	Mar 28, 2008	Jun CAHN

RILUZOLE

FILM;ORAL

EXSERVAN

	+!	AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Aug CAHN

SUSPENSION;ORAL

TIGLUTIK KIT

	+!	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Jun CAHN

RIOCIGUAT

TABLET;ORAL

ADEMPAS

AB	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013	Aug CFTG
AB	+		1MG	N204819	002	Oct 08, 2013	Aug CFTG
AB	+		1.5MG	N204819	003	Oct 08, 2013	Aug CFTG
AB	+		2MG	N204819	004	Oct 08, 2013	Aug CFTG
AB	+!		2.5MG	N204819	005	Oct 08, 2013	Aug CFTG

RIOCIGUAT

AB		MSN	0.5MG	A211135	001	Sep 01, 2022	Aug NFTG
AB			1MG	A211135	002	Sep 01, 2022	Aug NFTG
AB			1.5MG	A211135	003	Sep 01, 2022	Aug NFTG
AB			2MG	A211135	004	Sep 01, 2022	Aug NFTG
AB			2.5MG	A211135	005	Sep 01, 2022	Aug NFTG

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

	+ @	APIL	5MG	N020835	002	Apr 14, 2000	Aug DISC
	+ @		30MG	N020835	001	Mar 27, 1998	Aug DISC

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

	@	ATLANTIDE	1MG/ML	A078744	001	Oct 08, 2009	Apr CAHN
AA		CHARTWELL MOLECULAR	1MG/ML	A202386	001	Jan 12, 2015	Aug CMFD
	@		1MG/ML	A202386	001	Jan 12, 2015	May CAHN
AA		LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	May CAHN

RITONAVIR

TABLET;ORAL

RITONAVIR

AB		CIPLA	100MG	A202573	001	Jan 15, 2015	Mar CAHN
AB			100MG	A203759	001	May 10, 2022	Apr NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB		ZYDUS PHARMS	4.6MG/24HR	A206318	001	Mar 04, 2019	Aug CAHN
AB			9.5MG/24HR	A206318	002	Mar 04, 2019	Aug CAHN
AB			13.3MG/24HR	A206318	003	Mar 04, 2019	Aug CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

	+ @	ORGANON LLC	EQ 5MG BASE	N020864	001	Jun 29, 1998	Jul CAHN
AB	+!		EQ 10MG BASE	N020864	002	Jun 29, 1998	Jul CAHN

RIZATRIPTAN BENZOATE

>D> AB		CREEKWOOD PHARMS	EQ 5MG BASE	A202047	001	Dec 31, 2012	Sep CAHN
AB			EQ 5MG BASE	A202047	001	Dec 31, 2012	May CAHN

TABLET;ORAL
RIZATRIPTAN BENZOATE

>D>	AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Sep CAHN
	AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	May CAHN
		@ JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	May DISC
		@	EQ 10MG BASE	A203252	002	Dec 31, 2014	May DISC
>A>	AB	PHARMGEN	EQ 5MG BASE	A202047	001	Dec 31, 2012	Sep CAHN
>A>	AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Sep CAHN
>D>	AB	SANDOZ	EQ 5MG BASE	A079230	001	Dec 31, 2012	Sep DISC
>A>		@	EQ 5MG BASE	A079230	001	Dec 31, 2012	Sep DISC
>D>	AB		EQ 10MG BASE	A079230	002	Dec 31, 2012	Sep DISC
>A>		@	EQ 10MG BASE	A079230	002	Dec 31, 2012	Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

>D>	AB	SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Sep DISC
>A>		@	EQ 5MG BASE	A078739	001	Jul 01, 2013	Sep DISC
>D>	AB		EQ 10MG BASE	A078739	002	Jul 01, 2013	Sep DISC
>A>		@	EQ 10MG BASE	A078739	002	Jul 01, 2013	Sep DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

	AP	PRINSTON INC	50MG/5ML (10MG/ML)	A212668	001	May 26, 2022	May NEWA
	AP		100MG/10ML (10MG/ML)	A212668	002	May 26, 2022	May NEWA

ROFLUMILAST

CREAM;TOPICAL
ZORYVE

	+!	ARCUTIS	0.3%	N215985	001	Jul 29, 2022	Jul NEWA

TABLET;ORAL
DALIRESP

	AB	+ ASTRAZENECA	250MCG	N022522	002	Jan 23, 2018	Aug CFTG

ROFLUMILAST

	AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Aug CMFD
	AB	MSN	250MCG	A208256	001	Sep 07, 2022	Aug NFTG
	AB		500MCG	A208256	002	Sep 07, 2022	Aug NEWA
	AB	MYLAN	500MCG	A208257	001	Jul 13, 2018	Aug CMFD
	AB	PRINSTON INC	500MCG	A208299	001	May 10, 2022	Apr NEWA
>D>		@ ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Sep CMFD
>A>	AB		500MCG	A208303	001	Feb 10, 2022	Sep CMFD
		@	500MCG	A208303	001	Feb 10, 2022	Jul DISC
	AB		500MCG	A208303	001	Feb 10, 2022	Feb NEWA

ROMIDEPSIN

SOLUTION;INTRAVENOUS
ROMIDEPSIN

	+ @	TEVA PHARMS USA INC	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020	Jul DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ROPINIROLE HYDROCHLORIDE

	AB	PRINSTON INC	EQ 2MG BASE	A204413	001	May 11, 2022	Apr NEWA
	AB		EQ 4MG BASE	A204413	002	May 11, 2022	Apr NEWA
	AB		EQ 6MG BASE	A204413	003	May 11, 2022	Apr NEWA
	AB		EQ 8MG BASE	A204413	004	May 11, 2022	Apr NEWA
	AB		EQ 12MG BASE	A204413	005	May 11, 2022	Apr NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
ROPIVACAINE HYDROCHLORIDE

	AP	GLAND PHARMA LTD	200MG/100ML (2MG/ML)	A210102	001	Aug 18, 2022	Aug NEWA
	AP		400MG/200ML (2MG/ML)	A210102	002	Aug 18, 2022	Aug NEWA

ROSUVASTATIN CALCIUM

TABLET;ORAL
ROSUVASTATIN CALCIUM

		@ STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan CAHN
		@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan CAHN
		@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan CAHN
		@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan CAHN
		@ ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	Mar CAHN
		@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Mar CAHN

```
        TABLET;ORAL
          ROSUVASTATIN CALCIUM
          @                       EQ 20MG BASE                    A206513  003  Mar 01, 2019   Mar CAHN
          @                       EQ 40MG BASE                    A206513  004  Mar 01, 2019   Mar CAHN

      RUFINAMIDE
        SUSPENSION;ORAL
          RUFINAMIDE
          @ LUPIN LTD             40MG/ML                         A213457  001  Dec 18, 2020   Apr DISC
        TABLET;ORAL
          RUFINAMIDE
            LUPIN LTD             100MG                           A204964  001  Aug 17, 2022   Aug NFTG
    AB                            200MG                           A204964  002  Aug 17, 2022   Aug NEWA
    AB                            400MG                           A204964  003  Aug 17, 2022   Aug NEWA

      SAPROPTERIN DIHYDROCHLORIDE
        POWDER;ORAL
          SAPROPTERIN DIHYDROCHLORIDE
    AB      ANNORA PHARMA         100MG/PACKET                    A215420  001  Aug 18, 2022   Aug NEWA
    AB                            500MG/PACKET                    A215420  002  Aug 18, 2022   Aug NEWA
    AB      DR REDDYS             500MG/PACKET                    A215798  001  May 13, 2022   May NEWA
        TABLET;ORAL
          SAPROPTERIN DIHYDROCHLORIDE
    AB      ANNORA PHARMA         100MG                           A215534  001  Aug 23, 2022   Aug NEWA

      SELEGILINE HYDROCHLORIDE
        TABLET;ORAL
          SELEGILINE HYDROCHLORIDE
          @ BOSCOGEN              5MG                             A074912  001  Apr 30, 1998   Apr DISC

      SELENIUM SULFIDE
        LOTION/SHAMPOO;TOPICAL
          SELENIUM SULFIDE
        !   PADAGIS US            2.5%                            A089996  001  Jan 10, 1991   Jun CTEC
          @ WOCKHARDT BIO AG      2.5%                            A088228  001  Sep 01, 1983   Jun DISC

      SELINEXOR
        TABLET;ORAL
          XPOVIO
        +   KARYOPHARM THERAPS    20MG                            N212306  001  Jul 03, 2019   Mar CHRS
        +!                        60MG                            N212306  004  Apr 15, 2021   Mar CHRS

      SELPERCATINIB
        CAPSULE;ORAL
          RETEVMO
>A>     +   LOXO ONCOL ELI LILLY  40MG                            N213246  001  May 08, 2020   Sep CAHN
>A>     +!                        80MG                            N213246  002  May 08, 2020   Sep CAHN
>D>     +   LOXO ONCOLOGY INC     40MG                            N213246  001  May 08, 2020   Sep CAHN
>D>     +!                        80MG                            N213246  002  May 08, 2020   Sep CAHN

      SEMAGLUTIDE
        SOLUTION;SUBCUTANEOUS
          OZEMPIC
        +!  NOVO                  8MG/3ML (2.68MG/ML)             N209637  003  Mar 28, 2022   Apr NEWA

      SERTRALINE HYDROCHLORIDE
        CONCENTRATE;ORAL
          ZOLOFT
    AA  +!  VIATRIS               EQ 20MG BASE/ML                 N020990  001  Dec 07, 1999   Jan CAHN
        TABLET;ORAL
          ZOLOFT
    AB  +   VIATRIS               EQ 25MG BASE                    N019839  005  Mar 06, 1996   Jan CAHN
    AB  +                         EQ 50MG BASE                    N019839  001  Dec 30, 1991   Jan CAHN
    AB  +!                        EQ 100MG BASE                   N019839  002  Dec 30, 1991   Jan CAHN
        + @                       EQ 150MG BASE                   N019839  003  Dec 30, 1991   Jan CAHN
        + @                       EQ 200MG BASE                   N019839  004  Dec 30, 1991   Jan CAHN
```

SEVELAMER CARBONATE

		FOR SUSPENSION;ORAL					
		SEVELAMER CARBONATE					
		@ LUPIN LTD	800MG/PACKET	A201513	001	Dec 23, 2021	Jul DISC
		@	2.4GM/PACKET	A201513	002	Dec 23, 2021	Jul DISC
		TABLET;ORAL					
		SEVELAMER CARBONATE					
>A>	AB	ARTHUR GRP	800MG	A200959	001	Mar 20, 2018	Sep CAHN
		@ LUPIN LTD	800MG	A204600	001	Jan 14, 2021	May DISC
	AB	MICRO LABS	800MG	A215537	001	Feb 07, 2022	Jan NEWA
		@ STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020	Jan CAHN
>D>	AB	TWI PHARMS	800MG	A200959	001	Mar 20, 2018	Sep CAHN

SILDENAFIL CITRATE

		FOR SUSPENSION;ORAL					
		REVATIO					
	AB	+! VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb CAHN
		SILDENAFIL CITRATE					
	AB	LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022	Mar NEWA
	AB	MSN	EQ 10MG BASE/ML	A214641	001	Feb 08, 2022	Jan NEWA
		@ TRIS PHARMA INC	EQ 10MG BASE/ML	A212312	001	Nov 17, 2021	Apr DISC
>A>	AB	ZYDUS	EQ 10MG BASE/ML	A215708	001	Sep 29, 2022	Sep NEWA
		SOLUTION;INTRAVENOUS					
		REVATIO					
	AP	+! VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb CAHN
		TABLET;ORAL					
		REVATIO					
	AB	+! VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb CAHN
		VIAGRA					
	AB	+ VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb CAHN
	AB	+	EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb CAHN
	AB	+!	EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb CAHN

SILODOSIN

		CAPSULE;ORAL					
		SILODOSIN					
		@ UPSHER SMITH LABS	4MG	A213230	001	Jan 03, 2022	Feb DISC
		@	8MG	A213230	002	Jan 03, 2022	Feb DISC

SIMVASTATIN

		TABLET;ORAL					
		SIMVASTATIN					
		@ CHARTWELL RX	5MG	A077766	001	Dec 20, 2006	Mar CAHN
		@	10MG	A077766	002	Dec 20, 2006	Mar CAHN
		@	20MG	A077766	003	Dec 20, 2006	Mar CAHN
		@	40MG	A077766	004	Dec 20, 2006	Mar CAHN
		@	80MG	A077766	005	Dec 20, 2006	Mar CAHN

SIROLIMUS

		GEL;TOPICAL					
		HYFTOR					
		+! NOBELPHARMA	0.2%	N213478	001	Mar 22, 2022	Mar NEWA
		SOLUTION;ORAL					
		SIROLIMUS					
		@ TORRENT	1MG/ML	A215016	001	Dec 27, 2021	Jun DISC

SODIUM BICARBONATE

		INJECTABLE;INJECTION					
		SODIUM BICARBONATE					
	AP	! HOSPIRA	0.5MEQ/ML	A202981	001	Mar 04, 2016	Apr CHRS

SODIUM CHLORIDE

		SOLUTION;INTRAVENOUS					
		SODIUM CHLORIDE 23.4%					
	AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
	AP	+! HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F 18

	+ @	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Mar CRLD

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

	@	GE HEALTHCARE	200uCi	N017630	003	Jan 08, 1993	Aug NEWA

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

	@	AKORN	25MG/ML	A208635	001	May 04, 2017	Jun DISC
>A>	@	ANDA REPOSITORY	25MG/ML	A209834	001	Jun 26, 2018	Sep CAHN
AP		BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Apr CMFD
	@		25MG/ML	A214971	001	Jul 12, 2021	Jan DISC
AP		CAPLIN	25MG/ML	A211016	001	Nov 29, 2019	Mar CAHN
>D>	@	VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018	Sep CAHN

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

AP	+!	EXELA PHARMA	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018	Aug CFTG
AP	+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017	Aug CFTG

SODIUM NITROPRUSSIDE

		HAINAN POLY	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Aug NFTG
AP			20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Aug NFTG
AP			50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Aug NFTG

SODIUM PHENYLBUTYRATE

PELLETS;ORAL

PHEBURANE

	+!	MEDUNIK	84GM/BOT	N216513	001	Jun 17, 2022	Jun NEWA

>A> SODIUM PHENYLBUTYRATE; TAURURSODIOL

>A> FOR SUSPENSION;ORAL

>A> RELYVRIO

>A>	+!	AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022	Sep NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

VISICOL

	@	SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000	Aug CAIN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES

AP		FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Mar NFTG

SODIUM PHOSPHATES IN PLASTIC CONTAINER

AP	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Mar CFTG

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

	+ @	PAI HOLDINGS PHARM	453.6GM/BOT	A088786	001	Sep 11, 1984	Apr CAHN

SUSPENSION;ORAL, RECTAL

KIONEX

AA		ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar CMFD

SPS

AA	+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Mar CTEC

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		HIKMA	60MG/2ML (30MG/ML)	A209937	001	Dec 09, 2019	Aug CAHN

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

>A>		PEDMARK						
>A>	+!	FENNEC PHARMS INC	12.5GM/100ML (125MG/ML)	N212937	001	Sep 20, 2022	Sep NEWA

SOFOSBUVIR

TABLET;ORAL

		SOFOSBUVIR					
	@	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jul DISC
AB			400MG	A211353	001	Jan 27, 2022	Jan NFTG
		SOVALDI					
	+!	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jul CTEC
AB	+!		400MG	N204671	001	Dec 06, 2013	Jan CFTG

SOLIFENACIN SUCCINATE

TABLET;ORAL

		SOLIFENACIN SUCCINATE					
	@	ACCORD HLTHCARE	5MG	A207477	001	Jan 04, 2022	Jul DISC
	@		10MG	A207477	002	Jan 04, 2022	Jul DISC
	@	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	Jan DISC
	@		10MG	A209719	002	May 20, 2019	Jan DISC
AB		ANNORA PHARMA	5MG	A215761	001	Jun 15, 2022	Jun NEWA
AB			10MG	A215761	002	Jun 15, 2022	Jun NEWA

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

		SUNOSI					
	+	AXSOME MALTA	EQ 75MG BASE	N211230	001	Jun 17, 2019	May CAHN
	+!		EQ 150MG BASE	N211230	002	Jun 17, 2019	May CAHN

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

		ODOMZO					
	+!	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb CAHN

SORAFENIB TOSYLATE

TABLET;ORAL

		NEXAVAR					
AB	+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	Apr CTEC
		SORAFENIB TOSYLATE					
AB		DR REDDYS	EQ 200MG BASE	A216073	001	Jun 07, 2022	May NEWA
AB		MYLAN	EQ 200MG BASE	A207012	001	Sep 10, 2020	Apr CMFD

SOTALOL HYDROCHLORIDE

SOLUTION;ORAL

		SOTYLIZE					
	+!	AZURITY	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014	Mar CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

		STERILE WATER FOR INJECTION					
AP	!	MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019	Feb CTEC
AP		NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

		SUCCINYLCHOLINE CHLORIDE					
	@	BE PHARMS	20MG/ML	A216003	001	Feb 07, 2022	Aug DISC
AP			20MG/ML	A216003	001	Feb 07, 2022	Jan NEWA
AP		MEITHEAL	20MG/ML	A214514	001	Oct 19, 2021	Mar CAHN

SUCRALFATE

SUSPENSION;ORAL

		SUCRALFATE					
>A> AB		MYLAN	1GM/10ML	A212913	001	Sep 12, 2022	Sep NEWA
AB		VISTAPHARM	1GM/10ML	A211884	001	Mar 15, 2022	Mar NEWA

TABLET;ORAL

		SUCRALFATE					
AB		AMNEAL PHARMS	1GM	A215576	001	Apr 15, 2022	Apr NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@ LUPIN LTD	200MG/5ML;40MG/5ML	A212699	001	Jan 05, 2021	May DISC
AB	NOVITIUM PHARMA	200MG/5ML;40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA

SULINDAC

TABLET;ORAL

SULINDAC

	@ RISING	150MG	A073039	002	Jun 22, 1993	Jul CAHN
	@	200MG	A073039	001	Jun 22, 1993	Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

	@ STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB	DR REDDYS	EQ 12.5MG BASE	A215843	001	Apr 11, 2022	Apr NEWA
AB		EQ 25MG BASE	A215843	002	Apr 11, 2022	Apr NEWA
AB		EQ 37.5MG BASE	A215843	003	Apr 11, 2022	Apr NEWA
AB		EQ 50MG BASE	A215843	004	Apr 11, 2022	Apr NEWA

TADALAFIL

SUSPENSION;ORAL

TADLIQ

+!	CMP DEV LLC	20MG/5ML	N214522	001	Jun 17, 2022	Jun NEWA

TABLET;ORAL

ALYQ

>A>						
>A> AB2	TEVA PHARMS INC	20MG	A216932	001	Oct 12, 2022	Sep NEWA

TADALAFIL

AB1	AUSTARPHARMA	2.5MG	A208824	001	Oct 27, 2020	Mar CAHN
AB1		5MG	A208824	002	Oct 27, 2020	Mar CAHN
AB1		10MG	A208824	003	Oct 27, 2020	Mar CAHN
AB1		20MG	A208824	004	Oct 27, 2020	Mar CAHN
	@ CHARTWELL RX	2.5MG	A210716	001	Dec 29, 2020	May CAHN
	@	5MG	A210716	002	Dec 29, 2020	May CAHN
	@	10MG	A210716	003	Dec 29, 2020	May CAHN
	@	20MG	A210716	004	Dec 29, 2020	May CAHN
AB1	PRINSTON INC	2.5MG	A210609	001	Aug 11, 2022	Aug NEWA
AB1		5MG	A210609	002	Aug 11, 2022	Aug NEWA
AB1		10MG	A210609	003	Aug 11, 2022	Aug NEWA
AB2		20MG	A210608	001	Aug 11, 2022	Aug NEWA
AB1		20MG	A210609	004	Aug 11, 2022	Aug NEWA

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018	Jul CAHN

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT	SANDOZ INC	0.0015%	A209040	001	Jan 28, 2022	Jan NEWA

ZIOPTAN

AT +!	THEA PHARMA	0.0015%	N202514	001	Feb 10, 2012	Apr CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

AB	ACME LABS	0.4MG	A214730	001	May 04, 2022	Apr NEWA

TAPINAROF
CREAM;TOPICAL
VTAMA

	+!	DERMAVANT SCI	1%	N215272	001	May 23, 2022	May NEWA

TAVABOROLE
SOLUTION;TOPICAL
TAVABOROLE

AB		CHARTWELL RX	5%	A211963	001	Feb 03, 2021	Mar CAHN
AB		IDENTIRX	5%	A211963	001	Feb 03, 2021	Mar CMFD

TAZAROTENE
GEL;TOPICAL
TAZAROTENE

>A> AB		COSETTE	0.05%	A215433	001	Sep 13, 2022	Sep NFTG
>A> AB			0.1%	A214136	001	Sep 13, 2022	Sep NFTG

TAZORAC

>D>	+!	ALLERGAN	0.05%	N020600	001	Jun 13, 1997	Sep CFTG
>A> AB	+!		0.05%	N020600	001	Jun 13, 1997	Sep CFTG
>D>	+!		0.1%	N020600	002	Jun 13, 1997	Sep CFTG
>A> AB	+!		0.1%	N020600	002	Jun 13, 1997	Sep CFTG

LOTION;TOPICAL
ARAZLO

	+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019	May CAHN

TECHNETIUM TC-99M SUCCIMER
POWDER;INTRAVENOUS
NEPHROSCAN

	+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Mar CAIN

TECHNETIUM TC-99M SUCCIMER KIT
POWDER;INTRAVENOUS
NEPHROSCAN

	+!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT
INJECTABLE;INJECTION
MYOVIEW

	+!	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Feb CMFD

TECOVIRIMAT
SOLUTION;INTRAVENOUS
TPOXX

	+!	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)	N214518	001	May 18, 2022	May NEWA

TEDUGLUTIDE RECOMBINANT
POWDER;SUBCUTANEOUS
GATTEX KIT

	+!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Apr CAHN

TEGASEROD MALEATE
TABLET;ORAL
ZELNORM

	+ @	ALFASIGMA	EQ 6MG BASE	N021200	002	Jul 24, 2002	Jun DISC

TEMOZOLOMIDE
CAPSULE;ORAL
TEMOZOLOMIDE

	@	ANI PHARMS	5MG	A203490	001	Jul 13, 2016	Jun DISC
	@		20MG	A203490	002	Jul 13, 2016	Jun DISC
	@		100MG	A203490	003	Jul 13, 2016	Jun DISC
	@		140MG	A203490	004	Jul 13, 2016	Jun DISC
	@		180MG	A203490	005	Jul 13, 2016	Jun DISC
	@		250MG	A203490	006	Jul 13, 2016	Mar DISC
AB		HERITAGE	5MG	A078879	001	Mar 01, 2010	Jan CMFD
AB			20MG	A078879	002	Mar 01, 2010	Jan CMFD
AB			100MG	A078879	003	Mar 01, 2010	Jan CMFD
AB			140MG	A078879	005	Mar 01, 2010	Jan CMFD
AB			180MG	A078879	006	Mar 01, 2010	Jan CMFD
AB			250MG	A078879	004	Mar 01, 2010	Jan CMFD

TENAPANOR HYDROCHLORIDE

TABLET;ORAL

IBSRELA

	+!	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Feb CMFD

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		CHARTWELL	300MG	A206481	001	Jul 26, 2018	Jul CMFD

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB		CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007	Mar CMFD
	@	HERITAGE PHARMA AVET	EQ 250MG BASE	A076377	001	Jul 02, 2007	Jul DISC

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

	@	AKORN	1MG/ML	A078151	001	Jan 07, 2008	Aug DISC
AP	!	CHARTWELL INJECTABLE	1MG/ML	A076770	001	Apr 23, 2004	Mar CAHN

>A> TERLIPRESSIN ACETATE

>A> POWDER;INTRAVENOUS

>A> TERLIVAZ

>A>	+!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022	Sep NEWA

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

	+ @	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan DISC
	+ @		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan DISC
	+ @		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan DISC
	+ @		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan DISC

TESTOSTERONE

AB1	!	ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan CHRS
AB2	!	PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan CHRS

TESTOSTERONE CYPIONATE

SOLUTION;INTRAMUSCULAR

TESTOSTERONE CYPIONATE

>D>	+!	SLAYBACK PHARMA LLC	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep DISC
>A>	+ @		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep DISC
	+!		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jun NEWA

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

KYZATREX

	+	MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022	Jul NEWA
	+		150MG	N213953	002	Jul 27, 2022	Jul NEWA
	+!		200MG	N213953	003	Jul 27, 2022	Jul NEWA

TLANDO

	+!	ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022	Mar NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

	@	HIKMA	12.5MG	A209739	001	Apr 08, 2019	Feb DISC
	@		25MG	A209739	002	Apr 08, 2019	Feb DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

>A> AB		TEVA PHARMS INC	300MG	A216961	001	Oct 12, 2022	Sep NEWA
>A> AB			450MG	A216961	002	Oct 12, 2022	Sep NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP		EUGIA PHARMA	100MG/ML	A208703	001	Apr 20, 2022	Apr NEWA

THIOGUANINE

TABLET;ORAL

THIOGUANINE

	+!	WOODWARD SPECL	40MG	N012429	001		Apr CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB		AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb NEWA
AB			2MG	A215456	002	Feb 28, 2022	Feb NEWA
AB			5MG	A215456	003	Feb 28, 2022	Feb NEWA
AB			10MG	A215456	004	Feb 28, 2022	Feb NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	2MG	A208181	001	Dec 08, 2017	Jul DISC
	@		4MG	A208181	002	Dec 08, 2017	Jul DISC
	@		12MG	A208181	003	Dec 08, 2017	Jul DISC
	@		16MG	A208181	004	Dec 08, 2017	Jul DISC

TICAGRELOR

TABLET;ORAL

BRILINTA

	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Feb CTEC

TICAGRELOR

	@	MYLAN	60MG	A208597	001	Jul 09, 2021	Feb DISC
	@		90MG	A208597	002	Jul 09, 2021	Feb DISC

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

	@	XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Jun DISC

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	+!	THEA PHARMA	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr CAHN
AT	+!		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

>A> AB		DR REDDYS	EQ 0.25% BASE	A215733	001	Sep 22, 2022	Sep NEWA
>A> AB			EQ 0.5% BASE	A215733	002	Sep 22, 2022	Sep NEWA
AB		GLAND PHARMA LTD	EQ 0.25% BASE	A214645	001	Jun 24, 2022	Jun NEWA

TIMOPTIC-XE

AB	+	BAUSCH	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CAHN
AB	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Jul CAHN
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Jul CAHN

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

	@	AKORN	EQ 0.5% BASE	A074516	001	Mar 25, 1997	Jul DISC
>D> AT1			EQ 0.5% BASE	A075163	001	Sep 10, 2002	Sep DISC
>A>	@		EQ 0.5% BASE	A075163	001	Sep 10, 2002	Sep DISC
>A> AT3		INGENUS PHARMS LLC	EQ 0.25% BASE	A216533	001	Sep 13, 2022	Sep NEWA
>A> AT3			EQ 0.5% BASE	A216533	002	Sep 13, 2022	Sep NEWA
AT3		MICRO LABS	EQ 0.5% BASE	A216596	001	Sep 07, 2022	Aug NEWA

TIMOPTIC

AT1	+	BAUSCH	EQ 0.25% BASE	N018086	001		Apr CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Apr CAHN
AT1	+	BAUSCH AND LOMB INC	EQ 0.25% BASE	N018086	001		Jul CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jul CAHN

```
          SOLUTION/DROPS;OPHTHALMIC
            TIMOPTIC IN OCUDOSE
    AT3   +!  BAUSCH AND LOMB INC    EQ 0.25% BASE                    N019463  001  Nov 05, 1986   Feb CAHN
    AT3   +!                         EQ 0.5% BASE                     N019463  002  Nov 05, 1986   Feb CAHN

        TINIDAZOLE
          TABLET;ORAL
            TINIDAZOLE
>D> AB        HIKMA                  250MG                            A201172  001  Apr 30, 2012   Sep DISC
>A>         @                        250MG                            A201172  001  Apr 30, 2012   Sep DISC
>D> AB                               500MG                            A201172  002  Apr 30, 2012   Sep DISC
>A>         @                        500MG                            A201172  002  Apr 30, 2012   Sep DISC

        TIOPRONIN
          TABLET;ORAL
            TIOPRONIN
    AB        PAR PHARM INC          100MG                            A216198  001  Jun 02, 2022   May NEWA

        TIRZEPATIDE
          SOLUTION;SUBCUTANEOUS
            MOUNJARO
          +!  ELI LILLY AND CO       2.5MG/0.5ML (2.5MG/0.5ML)        N215866  001  May 13, 2022   May NEWA
          +!                         5MG/0.5ML (5MG/0.5ML)            N215866  002  May 13, 2022   May NEWA
          +!                         7.5MG/0.5ML (7.5MG/0.5ML)        N215866  003  May 13, 2022   May NEWA
          +!                         10MG/0.5ML (10MG/0.5ML)          N215866  004  May 13, 2022   May NEWA
          +!                         12.5MG/0.5ML (12.5MG/0.5ML)      N215866  005  May 13, 2022   May NEWA
          +!                         15MG/0.5ML (15MG/0.5ML)          N215866  006  May 13, 2022   May NEWA

        TOBRAMYCIN
          SOLUTION;INHALATION
            TOBRAMYCIN
>A> AN        MANKIND PHARMA         300MG/4ML                        A216725  001  Sep 22, 2022   Sep NEWA

        TOBRAMYCIN SULFATE
          INJECTABLE;INJECTION
            TOBRAMYCIN SULFATE
            @ AKORN                  EQ 40MG BASE/ML                  A205179  001  Sep 16, 2014   Aug DISC

        TOFACITINIB CITRATE
          TABLET, EXTENDED RELEASE;ORAL
            TOFACITINIB
            @ ZYDUS PHARMS           EQ 11MG BASE                     A214264  001  Aug 19, 2021   Jan DISC
            @                        EQ 22MG BASE                     A214264  002  Aug 19, 2021   Jan DISC
            XELJANZ XR
          +   PFIZER                 EQ 11MG BASE                     N208246  001  Feb 23, 2016   Jan CTEC
          +!                         EQ 22MG BASE                     N208246  002  Dec 12, 2019   Jan CTEC

        TOLVAPTAN
          TABLET;ORAL
            SAMSCA
    AB    +   OTSUKA                 15MG                             N022275  001  May 19, 2009   Feb CFTG
            TOLVAPTAN
    AB        ALKEM LABS LTD         15MG                             A211891  003  Sep 06, 2022   Aug NEWA
    AB        APOTEX                 15MG                             A207605  002  Sep 06, 2022   Aug NEWA
    AB        HETERO LABS LTD V      15MG                             A205646  002  Sep 06, 2022   Aug NEWA
    AB        PAR PHARM INC          15MG                             A206119  001  Feb 15, 2022   Feb NFTG
    AB                               30MG                             A206119  002  Feb 15, 2022   Feb NEWA

        TOPIRAMATE
          TABLET;ORAL
            TOPIRAMATE
            @ ATLANTIDE              25MG                             A090353  001  Sep 01, 2010   Apr CAHN
            @                        50MG                             A090353  002  Sep 01, 2010   Apr CAHN
            @                        100MG                            A090353  003  Sep 01, 2010   Apr CAHN
            @                        200MG                            A090353  004  Sep 01, 2010   Apr CAHN
            @ UPSHER SMITH LABS      25MG                             A078499  001  Jan 07, 2010   Mar DISC
            @                        50MG                             A078499  002  Jan 07, 2010   Mar DISC
            @                        100MG                            A078499  003  Jan 07, 2010   Mar DISC
            @                        200MG                            A078499  004  Jan 07, 2010   Mar DISC
```

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP	TEYRO LABS	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Apr CAHN

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

@	MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074	001	Nov 24, 2017	Mar DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>D> AB	MYLAN	50MG	A075986	001	Jun 21, 2002	Sep DISC
>A> @		50MG	A075986	001	Jun 21, 2002	Sep DISC
>D> AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Sep CHRS
>A> AB !		50MG	A075964	001	Jun 19, 2002	Sep CHRS
>D>	ULTRAM					
>D> AB +!	JANSSEN PHARMS	50MG	N020281	002	Mar 03, 1995	Sep DISC
>A> + @		50MG	N020281	002	Mar 03, 1995	Sep DISC
+ @		100MG	N020281	001	Mar 03, 1995	Aug CRLD

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

>D> AB1	MYLAN	100MG	A205257	001	Dec 22, 2015	Sep DISC
>A> @		100MG	A205257	001	Dec 22, 2015	Sep DISC
@		200MG	A205257	002	Dec 22, 2015	Jun DISC
@		300MG	A205257	003	Dec 22, 2015	Jun DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

@	AKORN	100MG/ML	A206594	001	Sep 28, 2017	Jun DISC
@		100MG/ML	A206634	001	Jun 09, 2016	Jun DISC
>A> @	ANDA REPOSITORY	100MG/ML	A202755	001	Feb 25, 2016	Sep CAHN
>D> @	VIRTUS PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Sep CAHN

TRANYLCYPROMINE SULFATE

TABLET;ORAL

TRANYLCYPROMINE SULFATE

AB	CROSSMEDIKA SA	EQ 10MG BASE	A213503	001	Jun 27, 2022	Jun NEWA

TREPROSTINIL

POWDER;INHALATION

TYVASO DPI

+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022	May NEWA
+		0.032MG/INH	N214324	002	May 23, 2022	May NEWA
+		0.048MG/INH	N214324	003	May 23, 2022	May NEWA
+!		0.064MG/INH	N214324	004	May 23, 2022	May NEWA

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED;NASAL

NASACORT

@	CHATTEM SANOFI	0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN
@		0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	ENCUBE	0.1%	A208848	001	Sep 18, 2017	Jul CAHN

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

+!	PACIRA PHARMS INC	32MG/VIAL	N208845	001	Oct 06, 2017	Feb CAHN

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

AB	CUSTOPHARM INC	40MG/ML	A213543	001	Jan 19, 2022	Jan NEWA
AB	EUGIA PHARMA	40MG/ML	A212400	001	Jul 05, 2022	Jun NEWA
AB	LONG GROVE PHARMS	40MG/ML	A213543	001	Jan 19, 2022	Jan CAHN

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT	ENCUBE	0.1%	A205373	001	May 13, 2016	Jul CAHN

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

@	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE;INJECTION

ARISTOSPAN

	+ @	SANDOZ INC	5MG/ML	N016466	001		Jul DISC
	+ @		20MG/ML	N016466	002		Jul DISC

TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE

AB		EYWA	50MG	A214768	001	Jul 06, 2022	Jun NEWA
AB			100MG	A214768	002	Jul 06, 2022	Jun NEWA

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

TRIENTINE HYDROCHLORIDE

>A> AB		ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021	Sep CAHN
AB		HETERO LABS LTD III	250MG	A216356	001	Jun 23, 2022	Jun NEWA
	@	LUPIN LTD	250MG	A211637	001	May 21, 2020	Apr DISC
>D> AB		PHARMA LIFE	250MG	A209945	001	Aug 13, 2021	Sep CAHN

TRIENTINE TETRAHYDROCHLORIDE

TABLET;ORAL

CUVRIOR

	+!	ORPHALAN	300MG	N215760	001	Apr 28, 2022	Apr NEWA

TRIFLURIDINE

SOLUTION/DROPS;OPHTHALMIC

TRIFLURIDINE

	@	AKORN	1%	A205438	001	Jul 28, 2017	Aug DISC

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	AZURITY	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017	Jun CAHN

TROSPIUM CHLORIDE

TABLET;ORAL

TROSPIUM CHLORIDE

AB		AMICI	20MG	A215781	001	Feb 16, 2022	Feb NEWA
AB		ENALTEC	20MG	A215781	001	Feb 16, 2022	May CAHN
AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Jul CAHN

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

	+ @	DORC	0.15%	N022278	001	Feb 20, 2009	Jul DISC

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL

RINVOQ

	+	ABBVIE INC	15MG	N211675	001	Aug 16, 2019	Jan CHRS
	+		30MG	N211675	002	Jan 14, 2022	Apr CHRS
	+!		30MG	N211675	002	Jan 14, 2022	Jan NEWA
	+!		45MG	N211675	003	Mar 16, 2022	Mar NEWA

URSODIOL

CAPSULE;ORAL

ACTIGALL

	@	TEVA BRANDED PHARM	150MG	N019594	001	Dec 31, 1987	Apr CAHN
AB	+!		300MG	N019594	002	Dec 31, 1987	Apr CAHN

URSODIOL

	@	VGYAAN	300MG	A214329	001	Jul 28, 2021	Feb DISC

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB		AIRIS PHARMA PVT LTD	50MG/ML	A210169	001	Feb 17, 2022	Feb NEWA
>A> AB		HETERO LABS LTD V	50MG/ML	A211475	001	Oct 04, 2022	Sep NEWA
AB		MSN	50MG/ML	A210169	001	Feb 17, 2022	Aug CAHN

```
          TABLET;ORAL
            VALGANCICLOVIR HYDROCHLORIDE
            @ MYLAN                 EQ 450MG BASE                    A205151  001  Mar 03, 2021   Mar DISC
    AB                              EQ 450MG BASE                    A205151  001  Mar 03, 2021   Mar CAHN

        VALPROATE SODIUM
          INJECTABLE;INJECTION
            VALPROATE SODIUM
            @ MYLAN                 EQ 100MG BASE/ML                 A208120  001  Dec 22, 2021   May DISC

        VALPROIC ACID
          SYRUP;ORAL
            VALPROIC ACID
>D> AA        BIOPHARM              250MG/5ML                        A090517  001  May 28, 2010   Sep CAHN
>A> AA        ECI PHARMS LLC        250MG/5ML                        A090517  001  May 28, 2010   Sep CAHN
            @ WOCKHARDT BIO AG      250MG/5ML                        A070868  001  Jul 01, 1986   Mar DISC

        VALRUBICIN
          SOLUTION;INTRAVESICAL
            VALRUBICIN
    AO        HIKMA                 40MG/ML                          A206430  001  Apr 19, 2019   Aug CAHN

        VANCOMYCIN HYDROCHLORIDE
          INJECTABLE;INJECTION
            VANCOCIN HYDROCHLORIDE
            @ STERISCIENCE          EQ 500MG BASE/VIAL               A060180  001                   Jan CAHN
            @                       EQ 500MG BASE/VIAL               A062476  001  Mar 15, 1984   Jan CAHN
            @                       EQ 500MG BASE/VIAL               A062716  001  Mar 13, 1987   Jan CAHN
            @                       EQ 500MG BASE/VIAL               A062812  001  Nov 17, 1987   Jan CAHN
            @                       EQ 1GM BASE/VIAL                 A060180  002  Mar 21, 1986   Jan CAHN
            @                       EQ 1GM BASE/VIAL                 A062476  002  Mar 21, 1986   Jan CAHN
            @                       EQ 1GM BASE/VIAL                 A062716  002  Mar 13, 1987   Jan CAHN
            @                       EQ 1GM BASE/VIAL                 A062812  002  Nov 17, 1987   Jan CAHN
            @                       EQ 10GM BASE/VIAL                A062812  003  Nov 17, 1987   Jan CAHN
            VANCOMYCIN HYDROCHLORIDE
    AP        ASPIRO                EQ 500MG BASE/VIAL               A216591  001  Jul 06, 2022   Jun NEWA
    AP                              EQ 1GM BASE/VIAL                 A216591  002  Jul 06, 2022   Jun NEWA
>D> AP    !   HOSPIRA               EQ 750MG BASE/VIAL               A062912  002  Jan 07, 2009   Sep CHRS
>A> AP                              EQ 750MG BASE/VIAL               A062912  002  Jan 07, 2009   Sep CHRS
>D> AP    !                         EQ 750MG BASE/VIAL               A062933  002  May 27, 2009   Sep CHRS
>A> AP                              EQ 750MG BASE/VIAL               A062933  002  May 27, 2009   Sep CHRS
            @ KNACK                 EQ 500MG BASE/VIAL               A213059  001  Feb 15, 2022   Aug DISC
    AP                              EQ 500MG BASE/VIAL               A213059  001  Feb 15, 2022   Feb NEWA
            @                       EQ 750MG BASE/VIAL               A213059  002  Feb 15, 2022   Aug DISC
    AP                              EQ 750MG BASE/VIAL               A213059  002  Feb 15, 2022   Feb NEWA
            @                       EQ 1GM BASE/VIAL                 A213059  003  Feb 15, 2022   Aug DISC
    AP                              EQ 1GM BASE/VIAL                 A213059  003  Feb 15, 2022   Feb NEWA
    AP        NANJING KING-FRIEND   EQ 500MG BASE/VIAL               A215197  001  Jul 28, 2022   Jul NEWA
>A> AP                              EQ 750MG BASE/VIAL               A215195  001  Sep 15, 2022   Sep NEWA
    AP                              EQ 1GM BASE/VIAL                 A215197  002  Jul 28, 2022   Jul NEWA
    AP                              EQ 5GM BASE/VIAL                 A215196  001  Jul 27, 2022   Jul NEWA
    AP                              EQ 10GM BASE/VIAL                A215196  002  Jul 27, 2022   Jul NEWA
          POWDER;INTRAVENOUS
            VANCOMYCIN HYDROCHLORIDE
          + @ MYLAN LABS LTD        EQ 250MG BASE/VIAL               N209481  001  Jul 10, 2018   Feb DISC

        VARDENAFIL HYDROCHLORIDE
          TABLET;ORAL
            LEVITRA
          + @ BAYER HLTHCARE        EQ 20MG BASE                     N021400  004  Aug 19, 2003   Feb DISC
            VARDENAFIL HYDROCHLORIDE
    AB    !   ZYDUS PHARMS          EQ 20MG BASE                     A208960  004  Oct 31, 2018   Feb CHRS
          TABLET, ORALLY DISINTEGRATING;ORAL
            STAXYN
          + @ BAYER HLTHCARE        10MG                             N200179  001  Jun 17, 2010   May DISC
            VARDENAFIL HYDROCHLORIDE
    AB    !   ALEMBIC PHARMS LTD    10MG                             A208324  001  Nov 16, 2018   May CHRS
```

VARENICLINE TARTRATE

SPRAY;NASAL

TYRVAYA

	+!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021	Aug CDFR

TABLET;ORAL

CHANTIX

	+ @	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Apr DISC
	+ @		EQ 1MG BASE	N021928	002	May 10, 2006	Apr DISC
AB	+		EQ 1MG BASE	N021928	002	May 10, 2006	Feb CHRS

VARENICLINE TARTRATE

		PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Apr CTEC
	!		EQ 1MG BASE	A201785	002	Aug 11, 2021	Apr CTEC
AB	!		EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb CHRS

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN

>D>	AP	AMNEAL	20UNTS/ML (20UNITS/ML)	A212944	001	Aug 05, 2022	Sep CPOT
>A>	AP		20UNITS/ML (20UNITS/ML)	A212944	001	Aug 05, 2022	Sep CPOT
	AP		20UNTS/ML (20UNITS/ML)	A212944	001	Aug 05, 2022	Jul NEWA
	AP	AMPHASTAR PHARMS INC	20UNITS/ML (20UNITS/ML)	A211857	001	Jul 18, 2022	Jul NEWA
	AP	EUGIA PHARMA	20UNITS/ML (20UNITS/ML)	A214314	001	Aug 15, 2022	Aug NEWA

VENLAFAXINE BESYLATE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE BESYLATE

	+!	ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022	Jun NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	AB	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Aug CMFD
	@		EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jan DISC
	AB		EQ 75MG BASE	A214654	002	Aug 06, 2021	Aug CMFD
	@		EQ 75MG BASE	A214654	002	Aug 06, 2021	Jan DISC
	AB		EQ 150MG BASE	A214654	003	Aug 06, 2021	Aug CMFD
	@		EQ 150MG BASE	A214654	003	Aug 06, 2021	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	@	PHARMADAX INC	EQ 75MG BASE	A214423	001	Jan 04, 2022	Sep CAHN
	@		EQ 75MG BASE	A214423	001	Jan 04, 2022	Jul DISC
>D>	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Sep CAHN
	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Jul DISC
>A>	@	SUNNY	EQ 75MG BASE	A214423	001	Jan 04, 2022	Sep CAHN
>A>	@		EQ 150MG BASE	A214423	002	Jan 04, 2022	Sep CAHN
	AB	ZYDUS PHARMS	EQ 37.5MG BASE	A215622	001	Aug 30, 2022	Aug NEWA
	AB		EQ 75MG BASE	A215622	002	Aug 30, 2022	Aug NEWA
	AB		EQ 150MG BASE	A215622	003	Aug 30, 2022	Aug NEWA
	AB		EQ 225MG BASE	A215622	004	Aug 30, 2022	Aug NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	+	SOCIETAL CDMO	120MG	N019614	001	May 29, 1990	Jun CAHN
AB	+		180MG	N019614	003	Jan 09, 1992	Jun CAHN
AB	+		240MG	N019614	002	May 29, 1990	Jun CAHN
	+!		360MG	N019614	004	May 10, 1996	Jun CAHN

VERELAN PM

	+	SOCIETAL CDMO	100MG	N020943	001	Nov 25, 1998	Jun CAHN
	+		200MG	N020943	002	Nov 25, 1998	Jun CAHN
	+!		300MG	N020943	003	Nov 25, 1998	Jun CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP	ACIC PHARMS	2.5MG/ML	A215829	001	Mar 17, 2022	Mar NEWA
AP	MANKIND PHARMA	2.5MG/ML	A214653	001	Jun 15, 2022	Jun NEWA

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

	@	CHARTWELL RX	40MG	A073168	001	Jul 31, 1992	Mar CAHN
	@		80MG	A071423	001	May 24, 1988	Mar CAHN
	@		120MG	A071424	001	May 25, 1988	Mar CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

	AA	ELITE LABS INC	500MG/PACKET	A214961	001	Jun 24, 2022	Jun NEWA
>D>	AA	GRANULES	500MG/PACKET	A213469	001	Apr 24, 2020	Sep DISC
>A>		@	500MG/PACKET	A213469	001	Apr 24, 2020	Sep DISC
		@ LUPIN LTD	500MG/PACKET	A211790	001	Mar 10, 2022	Jul DISC
	AA		500MG/PACKET	A211790	001	Mar 10, 2022	Mar NEWA
	AA	MSN	500MG/PACKET	A215363	001	Sep 07, 2022	Aug NEWA

TABLET;ORAL

VIGABATRIN

	AB	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Jun NEWA
	AB	AUROBINDO PHARMA LTD	500MG	A215601	001	May 10, 2022	Apr NEWA
	AB	HIKMA	500MG	A213104	001	Aug 29, 2022	Aug NEWA
	AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

	AB	TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019	May CMFD
	AB		20MG	A208212	002	Sep 30, 2019	May CMFD
	AB		40MG	A208212	003	Sep 30, 2019	May CMFD

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

	AP	! JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Apr CHRS

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

		@ RISING	200MG/5ML	A202361	001	May 28, 2013	Aug CAHN

INJECTABLE;INTRAVENOUS

VORICONAZOLE

	AP	HONG KONG	200MG/VIAL	A214516	001	May 09, 2022	Apr NEWA
	AP	MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Jun CAHN
>A>	AP	MYLAN LABS LTD	200MG/VIAL	A210849	001	Oct 11, 2022	Sep NEWA

VORINOSTAT

CAPSULE;ORAL

ZOLINZA

	+!	MSD SUB MERCK	100MG	N021991	001	Oct 06, 2006	Jun CAHN

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Mar CTEC
	+		EQ 10MG BASE	N204447	002	Sep 30, 2013	Mar CTEC
	+!		EQ 20MG BASE	N204447	004	Sep 30, 2013	Mar CTEC

VORTIOXETINE HYDROBROMIDE

		@ ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Mar DISC
		@	EQ 10MG BASE	A211146	002	Sep 17, 2021	Mar DISC
		@	EQ 20MG BASE	A211146	003	Sep 17, 2021	Mar DISC

VUTRISIRAN

SOLUTION;SUBCUTANEOUS

AMVUTTRA

	+!	ALNYLAM PHARMS INC	25MG/0.5ML (25MG/0.5ML)	N215515	001	Jun 13, 2022	Jun NEWA

ZAFIRLUKAST

TABLET;ORAL

ZAFIRLUKAST

	AB	RISING PHARMS	10MG	A204928	001	Aug 25, 2022	Aug NEWA
	AB		20MG	A204928	002	Aug 25, 2022	Aug NEWA

ZALEPLON

CAPSULE;ORAL

ZALEPLON

AB		CHARTWELL MOLECULAR	5MG	A077505	001	Jun 20, 2008	Mar CAHN
AB			10MG	A077505	002	Jun 20, 2008	Mar CAHN

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

>A> AB		ANNORA PHARMA	600MG	A215742	001	Oct 11, 2022	Sep NEWA

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

	@	EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC

ZINC CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

AP	+!	AM REGENT	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Apr CFTG
AP	+!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Apr CFTG
AP		GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022	Apr NFTG
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022	Apr NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	+!	VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan CAHN
AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan CAHN
AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan CAHN
AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan CAHN

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

AP	+!	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CPOT
AP	+!		EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN

ZIPRASIDONE MESYLATE

AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CPOT

POWDER;INTRAMUSCULAR

GEODON

AP	+!	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR

ZIPRASIDONE MESYLATE

AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR
>A> AP		MSN	EQ 20MG BASE/VIAL	A216091	001	Sep 15, 2022	Sep NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

AP		AMNEAL	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	May CAHN
	@	EUGIA PHARMA	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Jul DISC
	@		EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Jul DISC

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

AB		CHARTWELL MOLECULAR	5MG	A077388	001	Jul 30, 2012	Mar CAHN
AB			10MG	A077388	002	Jul 30, 2012	Mar CAHN

ZONISAMIDE

SUSPENSION;ORAL

ZONISADE

	+!	AZURITY	100MG/5ML	N214273	001	Jul 15, 2022	Jul NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL
ACETAMINOPHEN, ASPIRIN AND CAFFEINE

	AUROBINDO PHARMA LTD	250MG;250MG;65MG	A211695	001	Feb 02, 2022	Jan NEWA

ADAPALENE

GEL;TOPICAL
ADAPALENE

	TARO PHARMS	0.1%	A215940	001	Jan 14, 2022	Jan NEWA

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL
GAVISCON

+ @	CHATTEM SANOFI	80MG;20MG	N018685	001	Dec 09, 1983	May DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Jun CAHN
@	CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Jun CAHN
@	CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Mar CAHN

TABLET;ORAL
CETIRIZINE HYDROCHLORIDE ALLERGY

	GLENMARK PHARMS INC	5MG	A078427	003	Dec 28, 2007	May CAHN
		10MG	A078427	004	Dec 28, 2007	May CAHN

TABLET, CHEWABLE;ORAL
CHILDREN'S ZYRTEC ALLERGY

+	J AND J CONSUMER INC	2.5MG	N021621	007	Nov 30, 2020	Jun CMFD
+		10MG	N021621	004	Nov 16, 2007	Jun CMFD

CLEMASTINE FUMARATE

TABLET;ORAL
CLEMASTINE FUMARATE

@	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995	Jul DISC

CROMOLYN SODIUM

SPRAY, METERED;NASAL
CROMOLYN SODIUM

>D>	PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001	Sep DISC
>A> @		5.2MG/SPRAY	A075427	001	Dec 12, 2001	Sep DISC

DICLOFENAC SODIUM

GEL;TOPICAL
DICLOFENAC SODIUM

	AKORN	1%	A209484	001	Nov 21, 2018	Mar CMKT

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL
IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	AUROBINDO PHARMA	38MG;200MG	A216204	001	May 31, 2022	May NEWA

DOCOSANOL

CREAM;TOPICAL
DOCOSANOL

	ALEOR DERMACEUTICALS	10%	A215839	001	May 03, 2022	Apr NEWA
>A>	ENCUBE	10%	A212385	001	Oct 07, 2022	Sep NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

	GRAVITI PHARMS	EQ 20MG BASE	A216349	001	Jun 24, 2022	Jun NEWA

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

+ @	DEXCEL PHARMA	EQ 20MG BASE	N214278	001	Oct 20, 2020	Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

	GLENMARK PHARMS INC	10MG	A077146	001	Mar 07, 2005	Jun CAHN
		20MG	A090837	001	Aug 04, 2010	May CAHN
	VKT PHARMA	10MG	A215822	001	Jan 28, 2022	Jan NEWA
		20MG	A215822	002	Jan 28, 2022	Jan NEWA

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	ATLANTIDE	30MG	A079112	002	Feb 08, 2012	Apr CAHN
@	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jun DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	ATLANTIDE	30MG	A079112	001	Feb 08, 2012	Apr CAHN
@	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE ALLERGY

	ATLANTIDE	60MG	A079112	004	Feb 08, 2012	Apr CAHN
		180MG	A079112	006	Feb 08, 2012	Apr CAHN
@	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE HIVES

	ATLANTIDE	60MG	A079112	003	Feb 08, 2012	Apr CAHN
		180MG	A079112	005	Feb 08, 2012	Apr CAHN
@	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jun DISC

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN
+!		60MG;120MG	N020786	002	Jan 24, 2011	Jan CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN
+!		180MG;240MG	N021704	002	Jan 24, 2011	Jan CAHN

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS	60MG;120MG	A215434	001	May 31, 2022	May NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

	DR REDDYS	600MG	A215932	001	Mar 15, 2022	Mar NEWA
		1.2GM	A215932	002	Mar 15, 2022	Mar NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	GRANULES	600MG;60MG	A216082	001	Aug 22, 2022	Aug NEWA
		1.2GM;120MG	A216082	002	Aug 22, 2022	Aug NEWA
	L PERRIGO CO	600MG;60MG	A214407	001	Feb 01, 2022	Jan NEWA
		1.2GM;120MG	A214407	002	Feb 01, 2022	Jan NEWA

IBUPROFEN

SUSPENSION/DROPS;ORAL

IBUPROFEN

	STRIDES PHARMA	50MG/1.25ML	A214071	001	Jun 09, 2022	Jun NEWA

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+!	ZUREX PHARMA	70%	N210872	001	Apr 26, 2019	Jul CMFD

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

>D>	TEVA PHARMS USA	0.5%	A212485	001	Mar 21, 2022	Sep DISC
>A>	@	0.5%	A212485	001	Mar 21, 2022	Sep DISC
		0.5%	A212485	001	Mar 21, 2022	Mar NEWA

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC						
ALAWAY						
BAUSCH	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CPOT
BAUSCH AND LOMB INC	EQ 0.025% BASE	A208158	001	Sep 24, 2020	Mar CAHN
CHILDREN'S ALAWAY					
+ BAUSCH AND LOMB	EQ 0.025% BASE	N021996	002	Feb 11, 2015	Mar CPOT
+	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Mar CTNA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL					
LANSOPRAZOLE					
GLENMARK PHARMS INC	15MG	A202727	001	May 18, 2012	May CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL					
XYZAL ALLERGY 24HR					
+! CHATTEM SANOFI	2.5MG/5ML	N209090	001	Jan 31, 2017	Jan CAHN
TABLET;ORAL					
XYZAL ALLERGY 24HR					
+! CHATTEM SANOFI	5MG	N209089	001	Jan 31, 2017	Jan CAHN

LEVONORGESTREL

TABLET;ORAL					
LEVONORGESTREL					
@ L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL					
LOPERAMIDE HYDROCHLORIDE					
@ AKORN	1MG/5ML	A074352	001	Nov 17, 1995	Jun DISC

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL					
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
GRANULES	2MG;125MG	A215981	001	Aug 29, 2022	Aug NEWA

LORATADINE

TABLET, CHEWABLE;ORAL					
CHILDREN'S CLARITIN					
+ BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Apr CHRS
CLARITIN					
+! BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018	Apr CHRS

MINOXIDIL

AEROSOL, FOAM;TOPICAL					
MINOXIDIL					
PERRIGO PHARMA INTL	5%	A091344	001	Apr 28, 2011	Jan CAHN
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
@ AKORN	2%	A074731	001	Dec 24, 1996	Aug DISC
MINOXIDIL (FOR WOMEN)					
@ AKORN	2%	A074731	002	May 11, 2005	Aug DISC
THEROXIDIL					
PURE SOURCE	2%	A078176	001	Nov 09, 2007	Jun CAHN
	5%	A076239	001	Aug 24, 2004	Jun CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL					
NASONEX 24HR ALLERGY					
+! PERRIGO PHARMA INTL	0.05MG/SPRAY	N215712	001	Mar 17, 2022	Mar NEWA

NAPROXEN SODIUM

CAPSULE;ORAL					
NAPROXEN SODIUM					
STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022	Aug NEWA
TABLET;ORAL					
NAPROXEN SODIUM					
YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019	Jul CMFD

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ @	BAYER	220MG;120MG	N021076	001	Nov 29, 1999	Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA	220MG;120MG	A211360	001	Jun 01, 2022	May NEWA
!	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004	Jan CHRS

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

	AUROBINDO PHARMA LTD	EQ 2MG BASE	A215357	001	May 13, 2022	May NEWA
		EQ 4MG BASE	A215357	002	May 13, 2022	May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

@	BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	Jun CAHN
@	GLENMARK PHARMS INC	EQ 0.1% BASE	A200810	001	Jun 28, 2017	May CAHN
@	MYLAN	EQ 0.2% BASE	A204620	001	Jun 16, 2020	May DISC
@	RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Jul CAHN
@		EQ 0.2% BASE	A204620	001	Jun 16, 2020	Jul CAHN

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+!	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017	Feb CHRS

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	L PERRIGO CO	EQ 20MG BASE	A216096	001	May 24, 2022	May NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@	CHARTWELL RX	20MG;1.1GM	A204137	001	Jul 15, 2016	Jul CAHN

ZEGERID OTC

+!	RILEY CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar CAHN

FOR SUSPENSION;ORAL

ZEGERID OTC

+!	RILEY CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

+ @	ROXANE	1GM/ML	N018551	001	Feb 19, 1982	Jan CRLD

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

!	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999	Jun CHRS

SUDAFED 12 HOUR

@	MCNEIL CONS	120MG	A073585	001	Oct 31, 1991	Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>D>		PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002	Sep DISC
>A>	@		EQ 75MG BASE	A076195	001	Aug 30, 2002	Sep DISC
>D>		PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011	Sep DISC
>A>	@		EQ 150MG BASE	A091429	001	May 11, 2011	Sep DISC
>D>			EQ 150MG BASE	A091429	002	May 11, 2011	Sep DISC
>A>	@		EQ 150MG BASE	A091429	002	May 11, 2011	Sep DISC
		THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019	Jul CAHN
			EQ 150MG BASE	A210228	001	Aug 30, 2019	Jul CAHN

ZANTAC 150

+ @	CHATTEM SANOFI	EQ 150MG BASE	N021698	001	Aug 31, 2004	Jan CAHN
+ @		EQ 150MG BASE	N021698	002	Mar 13, 2007	Jan CAHN

TABLET;ORAL						
ZANTAC 75						
+ @	CHATTEM SANOFI	EQ 75MG BASE	N020520	001	Dec 19, 1995	Jan CAHN
TABLET, EFFERVESCENT;ORAL						
ZANTAC 75						
+ @	CHATTEM SANOFI	EQ 75MG BASE	N020745	001	Feb 26, 1998	Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL						
NASACORT ALLERGY 24 HOUR						
+!	CHATTEM SANOFI	0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jan CAHN
+!		0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jan CAHN
TRIAMCINOLONE ACETONIDE						
	PERRIGO PHARMA INTL	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jan CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2022

NO SEPTEMBER 2022 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2022 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ PD						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
ABALOPARATIDE - TYMLOS						
N 208743 001	11255842	Jan 10, 2040	U-3322			
ABROCITINIB - CIBINQO						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ABROCITINIB - CIBINQO						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	10239883	Jul 11, 2032	U-2666	>A>	NCE	Oct 31, 2022
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	RE43431*PED	Jul 13, 2026				
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
ALBUTEROL SULFATE - PROAIR HFA						
N 021457 001	11395889	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR DIGIHALER						
N 205636 002	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			
ALECTINIB HYDROCHLORIDE - ALECENSA						
N 208434 001	>A> 11433076	Apr 24, 2035	DP			
ALLOPURINOL; LESINURAD - DUZALLO						
N 209203 001	8357713	Dec 22, 2029	DP U-2104			
ALLOPURINOL; LESINURAD - DUZALLO						
N 209203 002	8357713	Dec 22, 2029	DP U-2104			
ALPELISIB - VIJOICE						
N 215039 001	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE						
N 215039 002	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
ALPELISIB - VIJOICE						
N 215039 003	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 001	11197835	Dec 02, 2030	U-2106			
AMANTADINE HYDROCHLORIDE - GOCOVRI						
N 208944 002	11197835	Dec 02, 2030	U-2106			
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE						
N 208078 001	10626088	Feb 25, 2037	DP		>A> ODE-223	Nov 28, 2025
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ						
N 208081 001	11235169	Oct 15, 2040	U-3303			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMISULPRIDE - BARHEMSYS						
N 209510 001	11357753	Feb 09, 2038	U-2754			
AMISULPRIDE - BARHEMSYS						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
AMLODIPINE BENZOATE - KATERZIA						
N 211340 001	11364230	Oct 06, 2037	DP			
AMLODIPINE BESYLATE - NORLIQVA						
N 214439 001	11253474	Feb 24, 2041	DP U-3309			
	11253474	Feb 24, 2041	DP U-3310			
	11253474	Feb 24, 2041	DP U-3311			
>A>	11458095	Feb 24, 2041	DP U-3309			
>A>	11458095	Feb 24, 2041	DP U-3310			
>A>	11458095	Feb 24, 2041	DP U-3311			
AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK						
N 215152 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK						
N 215153 001	7977488	Aug 11, 2028	DS		NCE	May 03, 2027
	9186411	Aug 11, 2030	DP		GAIN	May 03, 2032
AMPHOTERICIN B - AMPHOTERICIN B						
A 212514 001					CGT	Aug 14, 2022
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE						
A 212025 001					CGT	Aug 24, 2022
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 001	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 002	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 003	11419769	Dec 16, 2031	DP U-2825			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 004	11419769	Dec 16, 2031	DP U-2825			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 005	11419769	Dec 16, 2031	DP U-2825			
APREMILAST - OTEZLA						
N 205437 001	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
APREMILAST - OTEZLA						
N 205437 002	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
APREMILAST - OTEZLA						
N 205437 003	6962940	Mar 19, 2023	U-1504		I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA							
N 205437 003		9018243	Mar 19, 2023	U-1595			
		9018243	Mar 19, 2023	U-2656			
		9018243	Mar 19, 2023	U-2658			
		9018243	Mar 19, 2023	U-3276			
		9724330	Mar 19, 2023	U-1561			
		9724330	Mar 19, 2023	U-1595			
		9724330	Mar 19, 2023	U-2656			
		9724330	Mar 19, 2023	U-2658			
		9724330	Mar 19, 2023	U-3276			
APREPITANT - APONVIE							
N 216457 001	>A>	10500208	Sep 18, 2035	DP			
	>A>	10624850	Sep 18, 2035	U-3440			
	>A>	10953018	Sep 18, 2035	U-3440			
	>A>	11173118	Sep 18, 2035	DP			
	>A>	9561229	Sep 18, 2035	DP U-3440			
	>A>	9808465	Sep 18, 2035	U-3440			
	>A>	9974742	Sep 18, 2035	DP			
	>A>	9974793	Sep 18, 2035	DP			
	>A>	9974794	Sep 18, 2035	DP U-3440			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 001		11344547	Sep 24, 2033	U-1632			
		11344547	Sep 24, 2033	U-3245			
		11344547	Sep 24, 2033	U-814			
		11400087	Sep 24, 2033	U-1632			
		11400087	Sep 24, 2033	U-3245			
		11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 002		11344547	Sep 24, 2033	U-1632			
		11344547	Sep 24, 2033	U-3245			
		11344547	Sep 24, 2033	U-814			
		11400087	Sep 24, 2033	U-1632			
		11400087	Sep 24, 2033	U-3245			
		11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 003		11344547	Sep 24, 2033	U-1632			
		11344547	Sep 24, 2033	U-3245			
		11344547	Sep 24, 2033	U-814			
		11400087	Sep 24, 2033	U-1632			
		11400087	Sep 24, 2033	U-3245			
		11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 004		11344547	Sep 24, 2033	U-1632			
		11344547	Sep 24, 2033	U-3245			
		11344547	Sep 24, 2033	U-814			
		11400087	Sep 24, 2033	U-1632			
		11400087	Sep 24, 2033	U-3245			
		11400087	Sep 24, 2033	U-814			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202 001		11229378	Jul 11, 2031	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202 002		11229378	Jul 11, 2031	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT							
N 207202 003		11229378	Jul 11, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	11229378	Jul 11, 2031	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	11229378	Jul 11, 2031	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	11229378	Jul 11, 2031	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	11273158	Apr 06, 2039	U-543			
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 001	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS U-1374		ODE-382	Oct 29, 2028
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 002	11407735	May 14, 2040	DS		ODE-381	Oct 29, 2028
	8829195	May 13, 2033	DS U-1374		ODE-382	Oct 29, 2028
ATROPINE SULFATE - ATROPINE SULFATE						
A 216120 001					CGT	Jan 29, 2023
ATROPINE SULFATE - ATROPINE SULFATE						
A 216120 002					CGT	Jan 29, 2023
AVACOPAN - TAVNEOS						
N 214487 001					ODE-377	Oct 07, 2028
AXITINIB - INLYTA						
N 202324 001	10869924	Jan 12, 2037	U-3044			
AXITINIB - INLYTA						
N 202324 002	10869924	Jan 12, 2037	U-3044			
AZACITIDINE - VIDAZA						
N 050794 001					I-889	May 20, 2025
BACLOFEN - FLEQSUVY						
N 215602 001	11324696	Sep 29, 2037	DP			
>A>	11446246	Sep 08, 2037	U-3433			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 002	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 210854 003	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BALOXAVIR MARBOXIL - XOFLUZA						
N 214410 001	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
BARICITINIB - OLUMIANT						
N 207924 001	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
BARICITINIB - OLUMIANT						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	9089574	Nov 30, 2032	U-3372		I-891	May 10, 2025
BARICITINIB - OLUMIANT						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
BECLOMETHASONE DIPROPIONATE - QVAR 80						
N 020911 001	11395889	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 40						
N 020911 002	11395889	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 001	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER						
N 207921 002	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
BELUMOSUDIL MESYLATE - REZUROCK						
N 214783 001	11311541	Apr 09, 2035	U-3369			
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 001					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 002					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 003					ODE*	Dec 07, 2022
BENDAMUSTINE HYDROCHLORIDE - TREANDA						
N 022249 004					ODE*	Dec 07, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO						
N 205580 001					ODE*	Dec 07, 2022
BENZOYL PEROXIDE - EPSOLAY						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	>A> 11426378	Aug 18, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE						
A 212433 001				>A>	CGT	Mar 13, 2023
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 001	11230530	Mar 09, 2035	U-3300			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	11230530	Mar 09, 2035	U-3300			
BETAINE - BETAINE						
A 214864 001					CGT	Aug 02, 2022
BEXAROTENE - BEXAROTENE						
A 215398 001					CGT	Nov 13, 2022
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY						
N 210251 002					NCE	Feb 07, 2023
					ODE-378	Oct 07, 2028
BREXANOLONE - ZULRESSO						
N 211371 001					NPP	Jun 16, 2025
BREXPIPRAZOLE - REXULTI						
N 205422 001	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 002	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 003	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 004	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 005	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 005	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 006	8618109	Apr 12, 2026	U-3281		NPP	Dec 27, 2024
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
BRIGATINIB - ALUNBRIG						
N 208772 001	9012462	Apr 28, 2031	DS			
BRIGATINIB - ALUNBRIG						
N 208772 002	9012462	Apr 28, 2031	DS			
BRIGATINIB - ALUNBRIG						
N 208772 003	9012462	Apr 28, 2031	DS			
BUDESONIDE - TARPEYO						
N 215935 001					NP	Dec 15, 2024
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 001	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
N 021929 002	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE						
N 212122 001	11331442	May 10, 2038	DP			
BUPIVACAINE - EXPAREL						
N 022496 001	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
BUPIVACAINE - EXPAREL						
N 022496 002	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
>A>	11452691	Jan 22, 2041	DP U-3439			
BUPIVACAINE - POSIMIR						
N 204803 001	11400019	Jan 12, 2041	DP			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 001	11253504	Mar 13, 2034	U-3118			
>A>	11413350	Apr 20, 2035	U-3417			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	11253504	Mar 13, 2034	U-3118			
>A>	11413350	Apr 20, 2035	U-3417			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	11253504	Mar 13, 2034	U-3118			
>A>	11413350	Apr 20, 2035	U-3417			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	11253504	Mar 13, 2034	U-3118			
	>A> 11413350	Apr 20, 2035	U-3417			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	>A> 11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	>A> 11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	>A> 11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	>A> 11433066	Sep 18, 2032	U-3131			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	>A> 11433066	Sep 18, 2032	U-3131			
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	>A> 10058518	Nov 05, 2034	U-3419		>A> NP	Aug 18, 2025
	>A> 10064857	Nov 05, 2034	U-3419			
	>A> 10080727	Nov 05, 2034	U-3419			
	>A> 10092560	Nov 05, 2034	U-3419			
	>A> 10092561	Nov 05, 2034	U-3419			
	>A> 10105327	Nov 05, 2034	U-3419			
	>A> 10105361	Nov 05, 2034	U-3419			
	>A> 10251879	Nov 05, 2034	U-3419			
	>A> 10463634	Nov 05, 2034	U-3419			
	>A> 10512643	Nov 05, 2034	U-3419			
	>A> 10548857	Nov 05, 2034	U-3419			
	>A> 10596167	Nov 05, 2034	U-3419			
	>A> 10772850	Nov 05, 2034	U-3419			
	>A> 10780064	Jan 07, 2040	U-3419			
	>A> 10780066	Nov 09, 2034	U-3419			
	>A> 10786469	Nov 05, 2034	U-3419			
	>A> 10786496	Nov 05, 2034	U-3419			
	>A> 10799497	Nov 05, 2034	U-3419			
	>A> 10806710	Nov 05, 2034	U-3419			
	>A> 10864209	Nov 05, 2034	U-3419			
	>A> 10874663	Nov 05, 2034	U-3419			
	>A> 10874664	Nov 05, 2034	U-3419			
	>A> 10874665	Nov 05, 2034	U-3419			
	>A> 10881624	Nov 05, 2034	U-3419			
	>A> 10881657	Nov 05, 2034	U-3419			
	>A> 10894046	Nov 05, 2034	U-3419			
	>A> 10894047	Nov 05, 2034	U-3419			
	>A> 10898453	Nov 05, 2034	U-3419			
	>A> 10925842	Jan 07, 2040	U-3419			
	>A> 10933034	Nov 05, 2034	U-3419			
	>A> 10940124	Jan 07, 2040	U-3419			
	>A> 10945973	Nov 05, 2034	U-3419			
	>A> 10966941	Nov 05, 2034	U-3419			
	>A> 10966942	Jan 07, 2040	U-3419			
	>A> 10966974	Nov 05, 2034	U-3419			
	>A> 11020389	Nov 05, 2034	U-3419			
	>A> 11058648	Nov 05, 2034	U-3419			
	>A> 11090300	Nov 05, 2034	U-3419			
	>A> 11096937	Nov 05, 2034	U-3419			
	>A> 11123343	Nov 05, 2034	U-3419			
	>A> 11129826	Nov 05, 2034	U-3419			
	>A> 11141388	Nov 05, 2034	U-3419			
	>A> 11141416	Nov 05, 2034	U-3419			
	>A> 11147808	Nov 05, 2034	U-3419			
	>A> 11185515	Nov 05, 2034	U-3419			
	>A> 11191739	Nov 05, 2034	DP U-3419			
	>A> 11197839	Nov 05, 2034	DP U-3419			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY							
N 215430	001	>A> 11207281	Nov 05, 2034	U-3419			
		>A> 11213521	Nov 05, 2034	U-3419			
		>A> 11229640	Nov 05, 2034	U-3419			
		>A> 11234946	Nov 05, 2034	U-3419			
		>A> 11253491	Nov 05, 2034	U-3419			
		>A> 11253492	Nov 05, 2034	U-3419			
		>A> 11273133	Nov 05, 2034	U-3419			
		>A> 11273134	Nov 05, 2034	U-3419			
		>A> 11285118	Nov 05, 2034	U-3419			
		>A> 11285146	Nov 05, 2034	U-3419			
		>A> 11291638	Nov 05, 2034	U-3419			
		>A> 11291665	Nov 05, 2034	U-3419			
		>A> 11298351	Nov 05, 2034	U-3419			
		>A> 11298352	Nov 05, 2034	U-3419			
		>A> 11311534	Nov 05, 2034	U-3419			
		>A> 11344544	Nov 05, 2034	U-3419			
		>A> 11357744	Nov 05, 2034	U-3419			
		>A> 11364233	Nov 05, 2034	U-3419			
		>A> 11382874	Nov 05, 2034	U-3419			
		>A> 11419867	Nov 05, 2034	U-3419			
		>A> 11426370	Nov 05, 2034	U-3419			
		>A> 11426401	Nov 05, 2034	U-3419			
		>A> 11433067	Nov 05, 2034	DP U-3419			
		>A> 11439636	Nov 05, 2034	U-3419			
		>A> 8569328	Oct 29, 2033	DP U-3419			
		>A> 9168234	Nov 05, 2034	U-3419			
		>A> 9198905	Nov 05, 2034	U-3419			
		>A> 9205083	Nov 05, 2034	U-3419			
		>A> 9238032	Nov 05, 2034	U-3419			
		>A> 9278095	Nov 05, 2034	U-3419			
		>A> 9314462	Nov 05, 2034	U-3419			
		>A> 9370513	Nov 05, 2034	U-3419			
		>A> 9375429	Nov 05, 2034	U-3419			
		>A> 9408815	Nov 05, 2034	U-3419			
		>A> 9421176	Nov 05, 2034	U-3419			
		>A> 9457023	Nov 05, 2034	U-3419			
		>A> 9457025	Nov 05, 2034	U-3419			
		>A> 9474731	Nov 05, 2034	U-3419			
		>A> 9486450	Nov 05, 2034	U-3419			
		>A> 9700528	Nov 05, 2034	U-3419			
		>A> 9700553	Nov 05, 2034	U-3419			
		>A> 9707191	Nov 05, 2034	U-3419			
		>A> 9763932	Nov 05, 2034	U-3419			
		>A> 9861595	Nov 05, 2034	U-3419			
		>A> 9867819	Nov 05, 2034	U-3419			
		>A> 9968568	Nov 05, 2034	U-3419			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063	001	11278544	Apr 21, 2024	U-1583			
		11324741	May 29, 2029	U-1583			
CABOTEGRAVIR - APRETUDE							
N 215499	001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
		11224597	Sep 15, 2031	DP			
		8410103	Apr 28, 2026	DS DP			
CABOTEGRAVIR SODIUM - VOCABRIA							
N 212887	001	8410103	Apr 28, 2026	DS DP U-3061		M-273	Jan 31, 2025
		8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT							
N 212888	001	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
		11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
		7125879	Apr 21, 2025	DS DP U-3348			
		8410103	Apr 28, 2026	DS DP U-3348			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	11224597	Sep 15, 2031	DP U-3348		D-184	Jan 31, 2025
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8410103	Apr 28, 2026	DS DP U-3348			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	11298349	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	11298349	Feb 10, 2032	DP			
CALCIFEDIOL - RAYALDEE						
N 208010 001	11253528	Mar 14, 2034	DP			
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	>A> 11426373	Sep 19, 2037	U-3432			
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	>A> 11446258	Jun 17, 2035	U-2780			
	>A> 11446258	Jun 17, 2035	U-2781			
	>A> 11446258	Jun 17, 2035	U-3071			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - DHIVY						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
CASIMERSEN - AMONDYS 45						
N 213026 001	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 001					NPP	Nov 23, 2023
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 002					NPP	Nov 23, 2023
CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE						
N 050779 003					NPP	Nov 23, 2023
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	10420841	Mar 14, 2034	U-1672		NPP	Apr 21, 2025
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			
	7129232	May 15, 2028	DS DP U-36			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
CIPROFLOXACIN - OTIPRIO						
N 207986 001	11246863	Nov 27, 2038	DP			
	11369566	Apr 21, 2029	DP			
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	11337989	Mar 15, 2033	U-1			
>A>	11439610	Mar 15, 2033	DS DP			
	6706276	Mar 06, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLADRIBINE - MAVENCLAD						
N 022561 001 >A>	10849919	Nov 23, 2038	U-3411			
CLASCOTERONE - WINLEVI						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
	8865690	Jul 24, 2023	U-2942			
	9211295	Jul 24, 2023	DP			
	9433628	Feb 28, 2029	DP			
CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE						
A 214668 001					CGT	Feb 01, 2023
CLINDAMYCIN PHOSPHATE - XACIATO						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP	Dec 07, 2024
					GAIN	Dec 07, 2029
CLINDAMYCIN PHOSPHATE; TRETINOIN - CLINDAMYCIN PHOSPHATE AND TRETINOIN						
A 212845 001					CGT	Oct 09, 2022
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
COBIMETINIB FUMARATE - COTELLIC						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		>A> M-278	Jul 28, 2025
	10478400*PED	Dec 29, 2036			>A> PED	Jan 28, 2026
	10590102	Jun 30, 2036	DS DP U-1776			
	10590102*PED	Dec 30, 2036				
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				
	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
CRIZOTINIB - XALKORI						
N 202570 001	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
CRIZOTINIB - XALKORI						
N 202570 002	7825137	May 12, 2027	U-3057		I-897	Jul 14, 2025
	7825137	May 12, 2027	U-3058			
	7825137	May 12, 2027	U-3403			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE						
N 212501 003	10993952	Feb 15, 2036	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001					I-894	Jun 22, 2025
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002					I-894	Jun 22, 2025
DACOMITINIB - VIZIMPRO						
N 211288 001	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACOMITINIB - VIZIMPRO						
N 211288 002	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
DACOMITINIB - VIZIMPRO						
N 211288 003	10596162	Feb 02, 2026	U-3338			
	10603314	Feb 02, 2026	U-3337			
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jun 30, 2025	DP			
	8604072	Jul 20, 2022	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 002					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 003					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 004					M-238	Feb 22, 2022
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005					M-238	Feb 22, 2022
DAPSONE - ACZONE						
N 207154 001	11273132	Nov 18, 2033	DP			
DAPTOMYCIN - DAPZURA RT						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 001	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ						
N 214985 002	10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
DAROLUTAMIDE - NUBEQA						
N 212099 001	11168058	Feb 27, 2038	DS DP		>A> I-900	Aug 05, 2025
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	8501238	Dec 19, 2028	DS DP U-1636			
DEFERIPRONE - FERRIPROX						
N 212269 001	11357731	Oct 25, 2038	U-3083			
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	11236328	Jun 22, 2032	U-3301			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	7728143	Jun 19, 2031	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	7728143	Jun 19, 2031	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 001	>A> 11419914	Jun 15, 2030	U-3431			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 002	>A> 11419914	Jun 15, 2030	U-3431			
DEUCRAVACITINIB - SOTYKTU						
N 214958 001	>A> 10000480	Nov 07, 2033	DS DP		>A> NCE	Sep 09, 2027
	>A> 11021475	Nov 07, 2033	U-3434			
	>A> RE47929	Nov 07, 2033	DS DP U-3434			
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
DEXAMETHASONE - DEXAMETHASONE						
A 216295 001					>A> CGT	Mar 08, 2023
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	>A> 11097061	Jun 23, 2039	DP U-3418			
DEXAMETHASONE - HEMADY						
N 211379 001	11304961	Dec 18, 2037	DP U-3344			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DEXTROAMPHETAMINE - XELSTRYM						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
DIAZEPAM - VALTOCO						
N 211635 001	11241414	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO						
N 211635 002	11241414	Mar 27, 2029	DP			
DIAZEPAM - VALTOCO						
N 211635 003	11241414	Mar 27, 2029	DP			
DICLOFENAC EPOLAMINE - LICART						
N 206976 001	11344520	Feb 20, 2035	U-3393			
	11351133	Feb 20, 2035	U-3393			
DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM						
A 216845 001					>A> CGT	Mar 29, 2023
DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM						
A 216845 002					>A> CGT	Mar 29, 2023
DIGOXIN - DIGOXIN						
A 214982 001					CGT	Aug 16, 2022
DIHYDROERGOTAMINE MESYLATE - TRUDHESA						
N 213436 001	11266799	Nov 05, 2036	DP			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	11246850	Nov 16, 2035	U-1384			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	11246850	Nov 16, 2035	U-1384			
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO						
N 211994 001	11234985	Jan 24, 2031	DP U-257			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	10016372	Jul 26, 2037	U-3334			
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	9993466	Jul 26, 2037	DP			
DORAVIRINE - PIFELTRO						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2630			
	8486975	Oct 07, 2031	DS DP U-3308			
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2629			
	8486975	Oct 07, 2031	DS DP U-3307			
DOXEPIN HYDROCHLORIDE - DOXEPIN HYDROCHLORIDE						
A 213796 001					CGT	Oct 29, 2022
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	11234954	Jan 18, 2028	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	11234954	Jan 18, 2028	U-620			
DRONABINOL - SYNDROS						
N 205525 001	11253472	Aug 06, 2028	DS DP			
DROSPIRENONE - SLYND						
N 211367 001	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	>A> 11439598	Jun 28, 2031	DP			
DROSPIRENONE - DROSPIRENONE						
N 216285 001	10179140	Jun 28, 2031	U-2553		>A> NP	Jun 29, 2025
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	>A> 11439598	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 001	11202772	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 002	11202772	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 003	11202772	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE						
N 212516 004	11202772	Apr 13, 2037	DP			
DUVELISIB - COPIKTRA						
N 211155 001	11312718	Jan 10, 2032	DP			
DUVELISIB - COPIKTRA						
N 211155 002	11312718	Jan 10, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EDARAVONE - RADICAVA ORS						
N 215446 001	10987341	Nov 01, 2039	DP		NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
EFINACONAZOLE - JUBLIA						
N 203567 001	11213519	Jan 03, 2028	U-2720			
ELAGOLIX SODIUM - ORILISSA						
N 210450 002	11344551	Mar 14, 2034	U-3388			
	11344551	Mar 14, 2034	U-3389			
ELBASVIR; GRAZOPREVIR - ZEPATIER						
N 208261 001					NPP	Dec 09, 2024
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001 >A>	11426407	Oct 06, 2035	DS DP U-3425			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002 >A>	11426407	Oct 06, 2035	DS DP U-3425			
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
ELUXADOLINE - VIBERZI						
N 206940 001	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
ELUXADOLINE - VIBERZI						
N 206940 002	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	9949997	May 17, 2034	U-2292		M-82	Feb 24, 2025
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				
ENALAPRIL MALEATE - EPANED						
N 208686 001	11173141	Mar 25, 2036	DP			
ENCORAFENIB - BRAFTOVI						
N 210496 002	9474754	Aug 05, 2033	U-2802			
ENTRECTINIB - ROZLYTREK						
N 212725 001	11253515	Jul 18, 2038	DP			
ENTRECTINIB - ROZLYTREK						
N 212725 002	11253515	Jul 18, 2038	DP			
EPHEDRINE SULFATE - EMERPHED						
N 213407 001	11241400	May 16, 2040	U-3183			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
N 213994 002	10869845	Jan 22, 2040	DP			
EPINEPHRINE - SYMJEPI						
N 207534 001	11141540	Oct 20, 2036	DP U-3379			
EPINEPHRINE - SYMJEPI						
N 207534 002	11141540	Oct 20, 2036	DP U-3379			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 001	10961190	Oct 19, 2037	DS			
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA						
N 211109 002	10961190	Oct 19, 2037	DS			
ERIBULIN MESYLATE - HALAVEN						
N 201532 001	6214865	Jul 20, 2023	DS			
	6214865*PED	Jan 20, 2024				
	RE46965	Jan 08, 2027	DP			
	RE46965*PED	Jul 08, 2027				
ERTUGLIFLOZIN - STEGLATRO						
N 209803 001					M-275	Sep 17, 2024
ERTUGLIFLOZIN - STEGLATRO						
N 209803 002					M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 001					M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 002					M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 003					M-275	Sep 17, 2024
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 004					M-275	Sep 17, 2024
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 001					M-275	Sep 17, 2024
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 002					M-275	Sep 17, 2024
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	8785500	Mar 05, 2033	U-2502			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 002	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 003	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 004	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
ESTRADIOL - IMVEXXY						
N 208564 001	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
ESTRADIOL - IMVEXXY						
N 208564 002	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	8058280	Jan 28, 2024	DS		>A> I-898	Aug 05, 2025
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
FEDRATINIB HYDROCHLORIDE - INREBIC						
N 212327 001	11400092	Sep 24, 2039	U-3409			
FENFLURAMINE HYDROCHLORIDE - FINTEPLA						
N 212102 001	10452815	Jun 29, 2038	U-2859		I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	10950331	Sep 28, 2035	U-3098			
	10950331*PED	Mar 28, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENFLURAMINE HYDROCHLORIDE - FINTEPLA							
N 212102	001	11040018	Aug 02, 2037	U-2861			
		11040018	Aug 02, 2037	U-3347			
		11040018*PED	Feb 02, 2038				
		11406606	Aug 02, 2037	U-3406			
		11406606	Aug 02, 2037	U-3407			
		11406606*PED	Feb 02, 2038				
		9549909	May 03, 2033	U-2858			
		9549909*PED	Nov 03, 2033				
		9603814	May 03, 2033	U-2858			
		9603814*PED	Nov 03, 2033				
		9603815	May 03, 2033	U-2858			
		9603815*PED	Nov 03, 2033				
		9610260	May 03, 2033	U-2858			
		9610260*PED	Nov 03, 2033				
FENOPROFEN CALCIUM - FENOPROFEN CALCIUM							
A 214475	001					CGT	Feb 11, 2023
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565	001	11123321	Oct 20, 2023	DS DP U-2555			
		11123321	Oct 20, 2023	DS DP U-2557			
		11123321	Oct 20, 2023	DS DP U-3312			
		11123321	Oct 20, 2023	DS DP U-3313			
		11291645	Oct 20, 2023	DS DP U-3351			
		11291645	Oct 20, 2023	DS DP U-3352			
	>A>	11433091	Jan 08, 2027	U-3435			
	>A>	11433091	Jan 08, 2027	U-3436			
	>A>	11433091	Jan 08, 2027	U-3437			
	>A>	11433091	Jan 08, 2027	U-3438			
		7754702	Feb 15, 2028	U-1432			
		7754702	Feb 15, 2028	U-2555			
		7754702	Feb 15, 2028	U-2556			
		7754702	Feb 15, 2028	U-2557			
		7754702	Feb 15, 2028	U-3312			
		7754702	Feb 15, 2028	U-3313			
		7754702	Feb 15, 2028	U-3314			
		8895612	Jan 08, 2027	U-1620			
		8895612	Jan 08, 2027	U-3050			
		8895612	Jan 08, 2027	U-3051			
		8895612	Jan 08, 2027	U-3115			
		8895612	Jan 08, 2027	U-3116			
		8895612	Jan 08, 2027	U-3315			
		8895612	Jan 08, 2027	U-3316			
FERRIC CARBOXYMALTOSE - INJECTAFER							
N 203565	002	11123321	Oct 20, 2023	DS DP U-2555			
		11123321	Oct 20, 2023	DS DP U-2557			
		11123321	Oct 20, 2023	DS DP U-3312			
		11123321	Oct 20, 2023	DS DP U-3313			
		11291645	Oct 20, 2023	DS DP U-3351			
		11291645	Oct 20, 2023	DS DP U-3352			
	>A>	11433091	Jan 08, 2027	U-3435			
	>A>	11433091	Jan 08, 2027	U-3436			
	>A>	11433091	Jan 08, 2027	U-3437			
	>A>	11433091	Jan 08, 2027	U-3438			
		7754702	Feb 15, 2028	U-2555			
		7754702	Feb 15, 2028	U-2556			
		7754702	Feb 15, 2028	U-2557			
		7754702	Feb 15, 2028	U-3312			
		7754702	Feb 15, 2028	U-3313			
		7754702	Feb 15, 2028	U-3314			
		8895612	Jan 08, 2027	U-1620			
		8895612	Jan 08, 2027	U-3050			
		8895612	Jan 08, 2027	U-3051			
		8895612	Jan 08, 2027	U-3115			
		8895612	Jan 08, 2027	U-3116			
		8895612	Jan 08, 2027	U-3315			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	8895612	Jan 08, 2027	U-3316			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555			
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	>A> 11433091	Jan 08, 2027	U-3435			
	>A> 11433091	Jan 08, 2027	U-3436			
	>A> 11433091	Jan 08, 2027	U-3437			
	>A> 11433091	Jan 08, 2027	U-3438			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	>A> 11234938	Nov 26, 2034	DP			
	>A> 11446252	Nov 26, 2034	DP			
FINAFLOXACIN - XTORO						
N 206307 001	9993483	Jul 02, 2030	DP			
FINERENONE - KERENDIA						
N 215341 001					>A> M-279	Sep 01, 2025
FINERENONE - KERENDIA						
N 215341 002					>A> M-279	Sep 01, 2025
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207971 001					>A> PC	Mar 20, 2023
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207985 001					>A> PC	Mar 20, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 207991 001					>A> PC	Mar 20, 2023
FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE						
A 208008 001					>A> PC	Mar 20, 2023
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 001					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 002					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 003					NPP	Mar 22, 2025
FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%						
N 207648 004					NPP	Mar 22, 2025
FLIBANSERIN - ADDYI						
N 022526 001	>A> 7151103	May 09, 2028	U-1734			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 003	>A> 8932557	May 19, 2029	DS			
FLORTAUCIPIR F-18 - TAUVID						
N 212123 004	>A> 8932557	May 19, 2029	DS			
FLUOCINOLONE ACETONIDE - YUTIQ						
N 210331 001	>A> 7998108	Jan 12, 2028	DP U-3410			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	>A> 11439777	May 24, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	11357935	Sep 24, 2038	DP			
>A>	11439777	May 24, 2040	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
>A>	11439777	May 24, 2040	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
>A>	11439777	May 24, 2040	DP			
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 001					D-186	May 02, 2025
FOSAPREPITANT DIMEGLUMINE - EMEND						
N 022023 002					D-186	May 02, 2025
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 001	11312698	May 23, 2032	DS DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 210493 002	11312698	May 23, 2032	DS DP			
FOSTAMATINIB DISODIUM - TAVALISSE						
N 209299 001	RE48898	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE						
N 209299 002	RE48898	Jan 19, 2026	DP			
GALLIUM GA-68 DOTATOC - GALLIUM GA 68 DOTATOC						
N 210828 001					ODE-383	Aug 21, 2026
					W	Aug 21, 2026
GALLIUM GA-68 GOZETOTIDE - ILLUCCIX						
N 214032 001	11027031	Jul 28, 2035	U-3317			
GALLIUM GA-68 GOZETOTIDE - LOCAMETZ						
N 215841 001	11369590	Aug 15, 2028	DS DP U-3400		NP	Mar 23, 2025
GANAXOLONE - ZTALMY						
N 215904 001	10603308	Aug 10, 2037	U-3374		NCE	Jun 01, 2027
	7858609	Nov 28, 2026	DP			
	8022054	Nov 28, 2026	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026	U-3374			
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026	U-3374			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT DELIST REQUESTED	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GANAXOLONE - ZTALMY						
N 215904 001	10603308	Aug 10, 2037		U-3374	NCE	Jun 01, 2027
	7858609	Nov 28, 2026		DP		
	8022054	Nov 28, 2026		DP		
	8318714	Nov 28, 2026		DP		
	8367651	Nov 28, 2026		DP		
	8618087	Nov 28, 2026		U-3374		
	9029355	Nov 28, 2026		DP		
	9056116	Nov 28, 2026		U-3374		
GIVOSIRAN SODIUM - GIVLAARI						
N 212194 001	11028392	Oct 03, 2034	DS	DP U-2672		
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 209394 001	11246866	Jun 24, 2036		DP		
	11246866*PED	Dec 24, 2036				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 215110 001	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
GLYCOPYRROLATE - LONHALA MAGNAIR KIT						
N 208437 001	11278683	Aug 16, 2026		DP		
HALOBETASOL PROPIONATE - LEXETTE						
N 210566 001					NPP	Aug 18, 2024
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT						
N 022555 001	11235168	Jan 04, 2038		U-2250		
	11311620	Dec 19, 2036		U-2250		
HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
A 215586 001					CGT	Oct 09, 2022
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 001	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 002	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 003	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 004	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 005	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 006	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	11304908	Aug 24, 2027		DP		
	11304909	Aug 24, 2027		U-1556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)						
N 021945 004	11304962	May 02, 2036	U-2236			
IBRUTINIB - IMBRUVICA						
N 205552 001	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	>A> 10478439	Jun 03, 2031	U-1456			
	>A> 10478439	Jun 03, 2031	U-1650			
	>A> 10478439	Jun 03, 2031	U-1684			
	>A> 10478439	Jun 03, 2031	U-1946			
	>A> 10478439	Jun 03, 2031	U-1947			
	>A> 10478439	Jun 03, 2031	U-2241			
	>A> 10478439	Jun 03, 2031	U-2242			
	>A> 10478439	Jun 03, 2031	U-2665			
	>A> 10478439	Jun 03, 2031	U-3422			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002 >A>	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
>A>	10478439	Jun 03, 2031	U-1456			
>A>	10478439	Jun 03, 2031	U-1650			
>A>	10478439	Jun 03, 2031	U-1684			
>A>	10478439	Jun 03, 2031	U-1946			
>A>	10478439	Jun 03, 2031	U-1947			
>A>	10478439	Jun 03, 2031	U-2241			
>A>	10478439	Jun 03, 2031	U-2242			
>A>	10478439	Jun 03, 2031	U-2665			
>A>	10478439	Jun 03, 2031	U-3422			
>A>	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563 002		10106548	Jun 03, 2033	DS DP			
		10106548*PED	Dec 03, 2033				
		10125140	Jun 03, 2033	DS DP			
		10125140*PED	Dec 03, 2033				
		10213386	Mar 03, 2036	DP			
		10213386*PED	Sep 03, 2036				
		10463668	Oct 24, 2034			U-2654	
		10463668*PED	Apr 24, 2035				
	>A>	10478439	Jun 03, 2031			U-1456	
	>A>	10478439	Jun 03, 2031			U-1650	
	>A>	10478439	Jun 03, 2031			U-1684	
	>A>	10478439	Jun 03, 2031			U-1946	
	>A>	10478439	Jun 03, 2031			U-1947	
	>A>	10478439	Jun 03, 2031			U-2241	
	>A>	10478439	Jun 03, 2031			U-2242	
	>A>	10478439	Jun 03, 2031			U-2665	
	>A>	10478439	Jun 03, 2031			U-3422	
	>A>	10478439*PED	Dec 03, 2031				
		10653696	Jun 03, 2031			U-1456	
		10653696*PED	Dec 03, 2031				
		10695350	Oct 24, 2034			U-2846	
		10695350*PED	Apr 24, 2035				
		10751342	Jun 03, 2031			U-1491	
		10751342	Jun 03, 2031			U-1946	
		10751342	Jun 03, 2031			U-2943	
		10751342	Jun 03, 2031			U-2944	
		10751342*PED	Dec 03, 2031				
		10828259	Mar 03, 2036	DP			
		10828259*PED	Sep 03, 2036				
		10961251	Jun 03, 2033	DP			
		10961251*PED	Dec 03, 2033				
		7514444	Dec 28, 2026	DS DP			
		7514444*PED	Jun 28, 2027				
		8008309	Nov 13, 2027	DS DP			
		8008309*PED	May 13, 2028				
		8476284	Dec 28, 2026			U-1456	
		8476284	Dec 28, 2026			U-1650	
		8476284	Dec 28, 2026			U-1946	
		8476284	Dec 28, 2026			U-1947	
		8476284	Dec 28, 2026			U-2241	
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026			U-1456	
		8497277	Dec 28, 2026			U-1491	
		8497277	Dec 28, 2026			U-1650	
		8497277	Dec 28, 2026			U-1946	
		8497277	Dec 28, 2026			U-1947	
		8497277	Dec 28, 2026			U-2241	
		8497277	Dec 28, 2026			U-2242	
		8497277*PED	Jun 28, 2027				
		8563563	Apr 26, 2027			U-1491	
		8563563	Apr 26, 2027			U-1650	
		8563563	Apr 26, 2027			U-1946	
		8563563	Apr 26, 2027			U-2241	
		8563563	Apr 26, 2027			U-2242	
		8563563*PED	Oct 26, 2027				
		8697711	Dec 28, 2026	DS DP			
		8697711*PED	Jun 28, 2027				
		8703780	Dec 28, 2026			U-1491	
		8703780	Dec 28, 2026			U-2242	
		8703780*PED	Jun 28, 2027				
		8735403	Dec 28, 2026	DS DP			
		8735403*PED	Jun 28, 2027				
		8754090	Jun 03, 2031			U-1456	
		8754090*PED	Dec 03, 2031				
		8754091	Dec 28, 2026	DP			
		8754091*PED	Jun 28, 2027				
		8952015	Dec 28, 2026			U-1456	
		8952015	Dec 28, 2026			U-1491	
		8952015	Dec 28, 2026			U-1650	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	002	8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-1947			
		8952015	Dec 28, 2026	U-2241			
		8952015	Dec 28, 2026	U-2242			
		8952015*PED	Jun 28, 2027				
		8957079	Dec 28, 2026	DS DP			
		8957079*PED	Jun 28, 2027				
		8999999	Jun 03, 2031	U-1491			
		8999999	Jun 03, 2031	U-1946			
		8999999	Jun 03, 2031	U-2241			
		8999999	Jun 03, 2031	U-2242			
		8999999*PED	Dec 03, 2031				
		9125889	Jun 03, 2031	U-1650			
		9125889*PED	Dec 03, 2031				
		9181257	Dec 28, 2026	DS			
		9181257*PED	Jun 28, 2027				
		9296753	Oct 30, 2033	DS			
		9296753*PED	Apr 30, 2034				
		9655857	Mar 03, 2036	DP			
		9655857*PED	Sep 03, 2036				
		9725455	Jun 03, 2033	DS			
		9725455*PED	Dec 03, 2033				
		9795604	Oct 24, 2034	U-2969			
		9795604	Oct 24, 2034	U-2970			
		9795604*PED	Apr 24, 2035				
		9801881	Jun 03, 2031	U-1491			
		9801881	Jun 03, 2031	U-2242			
		9801881*PED	Dec 03, 2031				
		9801883	Jun 03, 2031	U-2159			
		9801883	Jun 03, 2031	U-2243			
		9801883*PED	Dec 03, 2031				
		9814721	Jun 03, 2031	U-1947			
		9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA							
N 210563	003	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
		10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
		10004746	Jun 03, 2031	U-2241			
		10004746	Jun 03, 2031	U-2242			
		10004746*PED	Dec 03, 2031				
		10010507	Mar 03, 2036	DP			
		10010507*PED	Sep 03, 2036				
		10016435	Jun 03, 2031	U-1650			
		10016435*PED	Dec 03, 2031				
		10106548	Jun 03, 2033	DS DP			
		10106548*PED	Dec 03, 2033				
		10125140	Jun 03, 2033	DS DP			
		10125140*PED	Dec 03, 2033				
		10213386	Mar 03, 2036	DP			
		10213386*PED	Sep 03, 2036				
		10463668	Oct 24, 2034	U-2654			
		10463668*PED	Apr 24, 2035				
	>A>	10478439	Jun 03, 2031	U-1456			
	>A>	10478439	Jun 03, 2031	U-1650			
	>A>	10478439	Jun 03, 2031	U-1684			
	>A>	10478439	Jun 03, 2031	U-1946			
	>A>	10478439	Jun 03, 2031	U-1947			
	>A>	10478439	Jun 03, 2031	U-2241			
	>A>	10478439	Jun 03, 2031	U-2242			
	>A>	10478439	Jun 03, 2031	U-2665			
	>A>	10478439	Jun 03, 2031	U-3422			
	>A>	10478439*PED	Dec 03, 2031				
		10653696	Jun 03, 2031	U-1456			
		10653696*PED	Dec 03, 2031				
		10695350	Oct 24, 2034	U-2846			
		10695350*PED	Apr 24, 2035				
		10751342	Jun 03, 2031	U-1491			
		10751342	Jun 03, 2031	U-1946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		>A> NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		>A> PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 004	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
IBRUTINIB - IMBRUVICA						
N 217003 001	>A> 10106548	Jun 03, 2033	DS DP		>A> NP	Aug 24, 2025
	>A> 10125140	Jun 03, 2033	DS DP		>A> PED	Feb 24, 2026
	>A> 10478439	Jun 03, 2031	U-3422			
	>A> 10961251	Jun 03, 2033	DP			
	>A> 7514444	Dec 28, 2026	DS DP			
	>A> 8008309	Nov 13, 2027	DS DP			
	>A> 8497277	Dec 28, 2026	U-3422			
	>A> 8697711	Dec 28, 2026	DS DP			
	>A> 8735403	Dec 28, 2026	DS DP			
	>A> 8754091	Dec 28, 2026	DP			
	>A> 8957079	Dec 28, 2026	DS DP			
	>A> 9181257	Dec 28, 2026	DS			
	>A> 9296753	Oct 30, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 217003 001	>A> 9725455	Jun 03, 2033	DS			
	>A> 9795604	Oct 24, 2034	U-3422			
ICOSAPENT ETHYL - ICOSAPENT ETHYL						
A 209525 001					>A> PC	Mar 08, 2023
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
IMIQUIMOD - ZYCLARA						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
IMIQUIMOD - ZYCLARA						
N 022483 002	11318130	Dec 11, 2029	U-68			
INCLISIRAN SODIUM - LEQVIO						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
INDIGOTINDISULFONATE SODIUM - BLUDIGO						
N 216264 001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
IODIXANOL - IODIXANOL						
A 214271 001					CGT	Jan 09, 2023
IODIXANOL - IODIXANOL						
A 214271 002					CGT	Jan 09, 2023
IRINOTECAN HYDROCHLORIDE - ONIVYDE						
N 207793 001	11369597	Jun 12, 2033	U-1848			
ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE						
A 211290 001					CGT	Jun 20, 2022
IVACAFTOR - KALYDECO						
N 207925 001	11147770	Feb 27, 2033	DP U-3339			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 002	11147770	Feb 27, 2033	DP U-3339			
IVACAFTOR - KALYDECO						
N 207925 003	11147770	Feb 27, 2033	DP U-3339			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	8846718	Jul 02, 2029	U-1908			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	8846718	Jul 02, 2029	U-2375			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	8846718	Jul 02, 2029	U-2375			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	>A> 10597384	Dec 04, 2028	DS DP U-3430			
	>A> 10646481	Aug 13, 2029	DP			
	>A> 7495103	May 20, 2027	DS DP			
	>A> 7973038	Nov 08, 2026	U-3424			
	>A> 8324242	Aug 05, 2027	U-3424			
	>A> 8410274	Dec 28, 2026	DP			
	>A> 8507534	Sep 20, 2030	DS DP			
	>A> 8653103	Dec 04, 2028	DP			
	>A> 8716338	Sep 20, 2030	DP U-3426			
	>A> 8741933	Nov 08, 2026	U-3424			
	>A> 8754224	Dec 28, 2026	DS DP			
	>A> 8846718	Jul 02, 2029	U-3427			
	>A> 8993600	Dec 11, 2030	DP			
	>A> 9150552	Dec 04, 2028	U-3427			
	>A> 9192606	Sep 29, 2029	DP U-3428			
	>A> 9216969	Nov 08, 2026	DP			
	>A> 9670163	Dec 28, 2026	DP U-3429			
	>A> 9931334	Dec 28, 2026	DP U-3429			
IVOSIDENIB - TIBSOVO						
N 211192 001	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785			
	10610125	Jun 21, 2030	U-3385			
	10653710	Oct 18, 2036	U-3387			
	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
LACOSAMIDE - VIMPAT						
N 022253 001					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 002					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 003					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022253 004					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022254 001					NPP	Oct 14, 2024
LACOSAMIDE - VIMPAT						
N 022255 001					NPP	Oct 14, 2024
LENALIDOMIDE - LENALIDOMIDE						
A 201452 001					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 002					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 003					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 201452 004					PC	Aug 30, 2022
LENALIDOMIDE - LENALIDOMIDE						
A 209348 001					>A> PC	Mar 06, 2023
LENALIDOMIDE - LENALIDOMIDE						
A 209348 002					>A> PC	Mar 06, 2023
LENVATINIB MESYLATE - LENVIMA						
N 206947 001					M-272	Dec 19, 2024
LENVATINIB MESYLATE - LENVIMA						
N 206947 002					M-272	Dec 19, 2024
LESINURAD - ZURAMPIC						
N 207988 001	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
LEVOKETOCONAZOLE - RECORLEV						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	9918984	Jan 10, 2026	U-3283			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	10537538	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - ERMEZA						
N 215809 001	9345772	Feb 27, 2035	DP			
LIDOCAINE - ZTLIDO						
N 207962 001	11278623	May 10, 2031	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	11311679	Jan 20, 2026	DP			
>A>	11446443	Oct 20, 2025	DP			
LORAZEPAM - LOREEV XR						
N 214826 004	8999393	Jan 08, 2034	DP U-3210			
LORLATINIB - LORBRENA						
N 210868 001	11299500	Oct 04, 2038	DS			
LORLATINIB - LORBRENA						
N 210868 002	11299500	Oct 04, 2038	DS			
LOTEPREDNOL ETABONATE - INVELTYS						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	11219596	May 03, 2033	U-2985			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	11261447	Nov 20, 2038	DS DP U-2995			
>A>	11401517	Aug 14, 2035	DS DP U-2995			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500	003	11026951	Dec 03, 2034	U-3364			
		11052084	Aug 30, 2039	DP U-3362			
		11052084	Aug 30, 2039	DP U-3363			
		8648077	Dec 01, 2029	DS DP			
		9199995	Mar 12, 2029	U-2713			
		9616061	May 27, 2029	DP			
		9956227	Dec 03, 2034	U-2714			
		RE48825	Feb 12, 2029	DS			
		RE48839	Dec 28, 2029	U-3271			
		RE48839	Dec 28, 2029	U-814			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO							
N 215833	001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
		10406240	Aug 15, 2028	DS DP U-3345			
		11318121	Aug 15, 2028	DS DP U-3345			
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB							
N 213135	001	11382864	Aug 04, 2037	U-3164			
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE							
A 202511	001				>A>	PC	Mar 06, 2023
MARALIXIBAT CHLORIDE - LIVMARLI							
N 214662	001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
		11260053	May 26, 2031	U-3290			
		11376251	Oct 26, 2032	U-3290			
MARAVIROC - MARAVIROC							
A 203347	001					PC	Aug 06, 2022
MARAVIROC - MARAVIROC							
A 203347	002					PC	Aug 06, 2022
MARIBAVIR - LIVTENCITY							
N 215596	001					NCE	Nov 23, 2026
MAVACAMTEN - CAMZYOS							
N 214998	001	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
		9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS							
N 214998	002	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
		9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS							
N 214998	003	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
		9585883	Jun 19, 2034	U-3373			
MAVACAMTEN - CAMZYOS							
N 214998	004	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
		9585883	Jun 19, 2034	U-3373			
MELOXICAM - ANJESO							
N 210583	001	11253478	May 26, 2030	DP U-3318			
MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO							
N 214383	001	11344622	Apr 25, 2032	U-3093			
		6992207	Jun 25, 2023	DS DP U-3093			
MEROPENEM; VABORBACTAM - VABOMERE							
N 209776	001 >A>	11376237	Apr 06, 2039	U-3421			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MESALAMINE - MESALAMINE						
A 214585 001					CGT	Nov 14, 2022
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 001	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 002	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 003	11166947	Jan 25, 2038	U-3299			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 001	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 002	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 003	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 004	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 005	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001					NP	Jun 19, 2023
MIDOSTAURIN - RYDAPT						
N 207997 001	7973031	Oct 09, 2028	U-2007			
MIGALASTAT HYDROCHLORIDE - GALAFOLD						
N 208623 001	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
>A>	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	8592362	Feb 12, 2029	U-2371	Y		
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MITAPIVAT SULFATE - PYRUKYND						
N 216196 001	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MITAPIVAT SULFATE - PYRUKYND						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	11400101	Sep 04, 2034	U-3297			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO						
N 212045 001	11135155	Aug 26, 2034	DP			
NALOXONE HYDROCHLORIDE - ZIMHI						
N 212854 001	11027072	May 24, 2039	DP			
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NAPROXEN SODIUM - NAPROXEN SODIUM							
N 021920 001		11090280	Mar 03, 2026	DP U-1731			
		11090280	Mar 03, 2026	DP U-1732			
NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE							
A 216291 001						CGT	Jan 21, 2023
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068 001						ODE-380	Sep 23, 2028
						PED	Mar 23, 2029
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068 002						ODE-380	Sep 23, 2028
						PED	Mar 23, 2029
NILOTINIB HYDROCHLORIDE - TASIGNA							
N 022068 003						ODE-380	Sep 23, 2028
						PED	Mar 23, 2029
NIMODIPINE - NYMALIZE							
N 203340 002		11207306	Apr 16, 2038	U-2804			
		11413277	Apr 16, 2038	DP U-2804			
NITRIC OXIDE - GENOSYL							
N 202860 001		11291793	Aug 18, 2025	DP			
		11383059	Aug 18, 2025	U-3037			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700 001	>A>	10888534	Apr 26, 2039	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700 002	>A>	10888534	Apr 26, 2039	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700 003	>A>	10888534	Apr 26, 2039	DP			
OBETICHOLIC ACID - OCALIVA							
N 207999 001		RE48286	Feb 21, 2027	DS DP			
OBETICHOLIC ACID - OCALIVA							
N 207999 002		RE48286	Feb 21, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA							
N 208232 001		11338011	Feb 03, 2036	U-2857			
ODEVIXIBAT - BYLVAY							
N 215498 001		11365182	Jun 20, 2039	U-3186			
		11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY							
N 215498 002		11365182	Jun 20, 2039	U-3186			
		11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY							
N 215498 003		11365182	Jun 20, 2039	U-3186			
		11365182	Jun 20, 2039	U-3187			
ODEVIXIBAT - BYLVAY							
N 215498 004		11365182	Jun 20, 2039	U-3186			
		11365182	Jun 20, 2039	U-3187			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI							
N 213378	001	11241425	Aug 23, 2031	U-3137			
		11351166	Aug 23, 2031	U-3140			
		11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI							
N 213378	002	11241425	Aug 23, 2031	U-3137			
		11351166	Aug 23, 2031	U-3140			
		11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI							
N 213378	003	11241425	Aug 23, 2031	U-3137			
		11351166	Aug 23, 2031	U-3140			
		11351166	Aug 23, 2031	U-3141			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI							
N 213378	004	11241425	Aug 23, 2031	U-3137			
		11351166	Aug 23, 2031	U-3140			
		11351166	Aug 23, 2031	U-3141			
OLAPARIB - LYNPARZA							
N 208558	001	>A> 8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
		>A> 8071579	Aug 12, 2027	U-2103			
		>A> 8071579	Aug 12, 2027	U-2480			
		>A> 8071579	Aug 12, 2027	U-2482			
		>A> 8071579	Aug 12, 2027	U-2483			
		>A> 8071579	Aug 12, 2027	U-2716			
		>A> 8071579	Aug 12, 2027	U-2819			
		>A> 8071579	Aug 12, 2027	U-2820			
		>A> 8071579	Aug 12, 2027	U-2821			
		>A> 8071579	Aug 12, 2027	U-2822			
		>A> 8071579	Aug 12, 2027	U-2823			
		>A> 8071579	Aug 12, 2027	U-2824			
		>A> 8071579	Aug 12, 2027	U-2832			
		>A> 8071579	Aug 12, 2027	U-2833			
		>A> 8071579	Aug 12, 2027	U-3333			
		>A> 8143241	Aug 12, 2027	U-2101			
		>A> 8143241	Aug 12, 2027	U-2103			
		>A> 8143241	Aug 12, 2027	U-2480			
		>A> 8143241	Aug 12, 2027	U-2482			
		>A> 8143241	Aug 12, 2027	U-2483			
		>A> 8143241	Aug 12, 2027	U-2716			
		>A> 8143241	Aug 12, 2027	U-2819			
		>A> 8143241	Aug 12, 2027	U-2820			
		>A> 8143241	Aug 12, 2027	U-2821			
		>A> 8143241	Aug 12, 2027	U-2822			
		>A> 8143241	Aug 12, 2027	U-2823			
		>A> 8143241	Aug 12, 2027	U-2824			
		>A> 8143241	Aug 12, 2027	U-2832			
		>A> 8143241	Aug 12, 2027	U-2833			
		>A> 8143241	Aug 12, 2027	U-3333			
		>A> 8859562	Aug 04, 2031	U-2101			
		>A> 8859562	Aug 04, 2031	U-2103			
		>A> 8859562	Aug 04, 2031	U-2480			
		>A> 8859562	Aug 04, 2031	U-2482			
		>A> 8859562	Aug 04, 2031	U-2483			
		>A> 8859562	Aug 04, 2031	U-2716			
		>A> 8859562	Aug 04, 2031	U-2819			
		>A> 8859562	Aug 04, 2031	U-2820			
		>A> 8859562	Aug 04, 2031	U-2821			
		>A> 8859562	Aug 04, 2031	U-2822			
		>A> 8859562	Aug 04, 2031	U-2823			
		>A> 8859562	Aug 04, 2031	U-2824			
		>A> 8859562	Aug 04, 2031	U-2832			
		>A> 8859562	Aug 04, 2031	U-2833			
		>A> 8859562	Aug 04, 2031	U-3333			
		>A> 8912187	Mar 12, 2024	U-2101			
		>A> 8912187	Mar 12, 2024	U-2480			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA							
N 208558	001	>A> 8912187	Mar 12, 2024	U-2482			
		>A> 8912187	Mar 12, 2024	U-2483			
		>A> 8912187	Mar 12, 2024	U-2819			
		>A> 8912187	Mar 12, 2024	U-2820			
		>A> 8912187	Mar 12, 2024	U-2821			
		>A> 8912187	Mar 12, 2024	U-2822			
		>A> 8912187	Mar 12, 2024	U-2823			
		>A> 8912187	Mar 12, 2024	U-2824			
		>A> 8912187	Mar 12, 2024	U-3333			
OLAPARIB - LYNPARZA							
N 208558	002	>A> 8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
		>A> 8071579	Aug 12, 2027	U-2103			
		>A> 8071579	Aug 12, 2027	U-2480			
		>A> 8071579	Aug 12, 2027	U-2482			
		>A> 8071579	Aug 12, 2027	U-2483			
		>A> 8071579	Aug 12, 2027	U-2716			
		>A> 8071579	Aug 12, 2027	U-2819			
		>A> 8071579	Aug 12, 2027	U-2820			
		>A> 8071579	Aug 12, 2027	U-2821			
		>A> 8071579	Aug 12, 2027	U-2822			
		>A> 8071579	Aug 12, 2027	U-2823			
		>A> 8071579	Aug 12, 2027	U-2824			
		>A> 8071579	Aug 12, 2027	U-2832			
		>A> 8071579	Aug 12, 2027	U-2833			
		>A> 8071579	Aug 12, 2027	U-3333			
		>A> 8143241	Aug 12, 2027	U-2101			
		>A> 8143241	Aug 12, 2027	U-2103			
		>A> 8143241	Aug 12, 2027	U-2480			
		>A> 8143241	Aug 12, 2027	U-2482			
		>A> 8143241	Aug 12, 2027	U-2483			
		>A> 8143241	Aug 12, 2027	U-2716			
		>A> 8143241	Aug 12, 2027	U-2819			
		>A> 8143241	Aug 12, 2027	U-2820			
		>A> 8143241	Aug 12, 2027	U-2821			
		>A> 8143241	Aug 12, 2027	U-2822			
		>A> 8143241	Aug 12, 2027	U-2823			
		>A> 8143241	Aug 12, 2027	U-2824			
		>A> 8143241	Aug 12, 2027	U-2832			
		>A> 8143241	Aug 12, 2027	U-2833			
		>A> 8143241	Aug 12, 2027	U-3333			
		>A> 8859562	Aug 04, 2031	U-2101			
		>A> 8859562	Aug 04, 2031	U-2103			
		>A> 8859562	Aug 04, 2031	U-2480			
		>A> 8859562	Aug 04, 2031	U-2482			
		>A> 8859562	Aug 04, 2031	U-2483			
		>A> 8859562	Aug 04, 2031	U-2716			
		>A> 8859562	Aug 04, 2031	U-2819			
		>A> 8859562	Aug 04, 2031	U-2820			
		>A> 8859562	Aug 04, 2031	U-2821			
		>A> 8859562	Aug 04, 2031	U-2822			
		>A> 8859562	Aug 04, 2031	U-2823			
		>A> 8859562	Aug 04, 2031	U-2824			
		>A> 8859562	Aug 04, 2031	U-2832			
		>A> 8859562	Aug 04, 2031	U-2833			
		>A> 8859562	Aug 04, 2031	U-3333			
		>A> 8912187	Mar 12, 2024	U-2101			
		>A> 8912187	Mar 12, 2024	U-2480			
		>A> 8912187	Mar 12, 2024	U-2482			
		>A> 8912187	Mar 12, 2024	U-2483			
		>A> 8912187	Mar 12, 2024	U-2819			
		>A> 8912187	Mar 12, 2024	U-2820			
		>A> 8912187	Mar 12, 2024	U-2821			
		>A> 8912187	Mar 12, 2024	U-2822			
		>A> 8912187	Mar 12, 2024	U-2823			
		>A> 8912187	Mar 12, 2024	U-2824			
		>A> 8912187	Mar 12, 2024	U-3333			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OTESECONAZOLE - VIVJOA						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			
	8754227	Apr 22, 2031	U-3366			
	9840492	Mar 17, 2036	DS DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ						
N 212520 001	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039	U-2849			
PACRITINIB CITRATE - VONJO						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332			
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 005	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			
PALIPERIDONE PALMITATE - INVEGA HAFYERA						
N 207946 006	11304951	May 07, 2041	U-3349			
	11324751	May 07, 2041	U-3359			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - EMPAVELI						
N 215014 001	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
PEMIGATINIB - PEMAZYRE						
N 213736 001					>A> I-899	Aug 26, 2025
PEMIGATINIB - PEMAZYRE						
N 213736 002					>A> I-899	Aug 26, 2025
PEMIGATINIB - PEMAZYRE						
N 213736 003					>A> I-899	Aug 26, 2025
PERAMPANEL - FYCOMPA						
N 202834 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 002	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 003	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 004	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERAMPANEL - FYCOMPA						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
PERFLUTREN - DEFINITY						
N 021064 001	11266750	Mar 16, 2037	U-665			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERFLUTREN - DEFINITY RT						
N 021064 002	11266750	Mar 16, 2037	U-665			
	11395856	Dec 28, 2035	DS DP U-665			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	8580299	Jun 14, 2029	U-3399		NPP	Jun 24, 2025
	8895057	Jun 09, 2028	U-3398			
	9011906	Jun 09, 2028	U-3398			
PHYTONADIONE - PHYTONADIONE						
A 214596 001					CGT	Oct 30, 2022
PHYTONADIONE - PHYTONADIONE						
A 214596 002					CGT	Oct 30, 2022
PILOCARPINE HYDROCHLORIDE - VUITY						
N 214028 001	11285134	Apr 24, 2039	U-3252			
PIMAVANSERIN TARTRATE - NUPLAZID						
N 210793 001 >A>	11452721	Aug 27, 2038	DP			
PIRFENIDONE - ESBRIET						
N 022535 001	8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET						
N 208780 001	8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET						
N 208780 002	8383150	May 10, 2028	DP U-2361			
PIRFENIDONE - ESBRIET						
N 208780 003	8383150	May 10, 2028	DP U-2361			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 001	8207197	Mar 07, 2030	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX						
N 211150 002	8207197	Mar 07, 2030	DS DP			
PLECANATIDE - TRULANCE						
N 208745 001	11319346	Mar 01, 2032	DP			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 004	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
POSACONAZOLE - NOXAFIL						
N 205053 001					I-881	Jun 17, 2024
POSACONAZOLE - NOXAFIL						
N 205596 001					I-881	Jun 17, 2024
PRALSETINIB - GAVRETO						
N 213721 001	11273160	Apr 03, 2039	U-2952			
PRASTERONE - INTRAROSA						
N 208470 001	8957054	Jan 08, 2030	U-1922			
RANOLAZINE - ASPRUZYO SPRINKLE						
N 216018 002	10898444	Jan 24, 2038	DP			
REMDESIVIR - VEKLURY						
N 214787 001	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
REMDESIVIR - VEKLURY						
N 214787 002	10695361	Sep 16, 2036	U-2984		D-183	Jan 21, 2025
	10695361	Sep 16, 2036	U-3249		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMDESIVIR - VEKLURY						
N 214787 002	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
REMIMAZOLAM BESYLATE - BYFAVO						
N 212295 001	10961250	Jul 10, 2027	DP U-2968			
REVEFENACIN - YUPELRI						
N 210598 001	11247969	Mar 10, 2025	DP			
RIBOCICLIB SUCCINATE - KISQALI						
N 209092 001	8415355	Mar 13, 2031	DS DP		NPP	Dec 10, 2024
RILPIVIRINE HYDROCHLORIDE - EDURANT						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
RIOCIGUAT - ADEMPAS						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIOCIGUAT - ADEMPAS						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
RIPRETINIB - QINLOCK						
N 213973 001	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	>A> 11426390	Aug 12, 2040	U-3416			
	>A> 11433056	Aug 12, 2040	U-3423			
RISDIPLAM - EVRYSDI						
N 213535 001					NPP	May 27, 2025
RIVAROXABAN - XARELTO						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVAROXABAN - XARELTO						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP	Dec 20, 2024
					PED	Jun 20, 2025
ROFLUMILAST - ZORYVE						
N 215985 001	10940142	Jun 07, 2037	DP		NP	Jul 29, 2025
	11129818	Aug 25, 2037	DP U-3408			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	DP U-3408			
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10610530	Jun 12, 2028	U-3229		I-896	Jul 18, 2025
	10610530	Jun 12, 2028	U-3404			
	10869870	May 20, 2031	U-3229			
	10869870	May 20, 2031	U-3404			
	11219624	May 20, 2031	DP U-3229			
	8822481	Jun 12, 2028	U-3229			
	8822481	Jun 12, 2028	U-3404			
	9079912	Dec 12, 2026	U-3229			
	9079912	Dec 12, 2026	U-3404			
	9974790	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3404			
SECNIDAZOLE - SOLOSEC						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10335390	Sep 04, 2035	DP U-3270			
	10682338	Sep 04, 2035	DP U-2583			
	10682338	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			
	10857133	Sep 04, 2035	DP U-2583			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SECNIDAZOLE - SOLOSEC						
N 209363 001	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	11311679	Jan 20, 2026	DP			
	>A> 11446443	Oct 20, 2025	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 002	11311679	Jan 20, 2026	DP			
	>A> 11446443	Oct 20, 2025	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP		NCE	Dec 05, 2022
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	>A> 11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	11382957	Dec 16, 2031	DP			
SEMAGLUTIDE - WEGOVY						
N 215256 001	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 002	11318191	Feb 17, 2041	DP U-3162			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - WEGOVY						
N 215256 003	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 004	11318191	Feb 17, 2041	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 005	11318191	Feb 17, 2041	DP U-3162			
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001					I-892	Jun 16, 2025
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 001	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 002	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 003	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
SIROLIMUS - HYFTOR						
N 213478 001					NP	Mar 22, 2025
SODIUM NITRITE - SODIUM NITRITE						
N 203922 001	>A> 9687506	Feb 10, 2030	DP U-3394			
	>A> 9687506	Feb 10, 2030	DP U-3395			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N 201444 001	>A> 10479686	Jul 07, 2030	DP U-3390			
	>A> 9345724	Jul 07, 2030	DS DP U-2015			
	>A> 9585912	Jul 07, 2030	DS DP			
	>A> 9687506	Feb 10, 2030	DP U-3394			
	>A> 9687506	Feb 10, 2030	DP U-3395			
SODIUM OXYBATE - XYREM						
N 021196 001	10213400	Mar 15, 2033	U-2499			
	10213400*PED	Sep 15, 2033				
	10864181	Mar 15, 2033	U-1532			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	>A> 10479686	Jul 07, 2030	DP U-3390			
	>A> 9345724	Jul 07, 2030	DS DP U-2015			
	>A> 9585912	Jul 07, 2030	DS DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	11406662	Feb 10, 2032	DS			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	11406662	Feb 10, 2032	DS			
SOFOSBUVIR - SOVALDI						
N 212480 001					ODE*	Apr 07, 2024
					PED	Oct 07, 2024
SOFOSBUVIR - SOVALDI						
N 212480 002					ODE*	Apr 07, 2024
					PED	Oct 07, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 001					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 208341 002					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002					M-277	Apr 27, 2025
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	10266523	Mar 30, 2036	DS DP			
SOTORASIB - LUMAKRAS						
N 214665 001	10519146	May 21, 2038	DS DP			
	11236091	May 20, 2040	DS DP U-3306			
>A>	11426404	Aug 11, 2040	U-3306			
SPINOSAD - NATROBA						
N 022408 001	9895388	Nov 25, 2033	U-3365			
SPIRONOLACTONE - CAROSPIR						
N 209478 001	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
SUCRALFATE - SUCRALFATE						
A 211884 001					CGT	Sep 11, 2022
SUMATRIPTAN - TOSYMRA						
N 210884 001	11337962	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH						
N 208223 001	11364224	Jan 29, 2036	U-72			
TACROLIMUS - ENVARSUS XR						
N 206406 001	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	11077096	Aug 30, 2024	DP			
	11419823	May 30, 2028	DP			
TADALAFIL - TADLIQ						
N 214522 001	11382917	Dec 24, 2038	DP U-3397			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
TAPINAROF - VTAMA						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
>A>	11458108	May 19, 2036	DP			
TASIMELTEON - HETLIOZ						
N 205677 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
TAZAROTENE - TAZAROTENE						
A 214136 001					>A> CGT	Mar 13, 2023
TAZAROTENE - ARAZLO						
N 211882 001	11311482	May 11, 2038	U-2368			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	9439985	Jan 30, 2029	DP			
TECOVIRIMAT - TPOXX						
N 208627 001	7737168	Sep 04, 2031	U-2346			
TECOVIRIMAT - TPOXX						
N 214518 001	10576165	Aug 02, 2031	DP		NCE	Jul 13, 2023
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-3377			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	7847061	Nov 01, 2025	U-1320	Y		
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320	Y		
	9060992*PED	May 01, 2026				
TELOTRISTAT ETIPRATE - XERMELO						
N 208794 001	7709493	Feb 28, 2031	DS U-1979			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE							
N 216318 001		11311554	Mar 25, 2039	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863 001	>A>	11446440	Aug 21, 2031	DP			
	>A>	11446441	Jan 24, 2026	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863 002	>A>	11446440	Aug 21, 2031	DP			
	>A>	11446441	Jan 24, 2026	DP			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863 003	>A>	11446440	Aug 21, 2031	DP			
	>A>	11446441	Jan 24, 2026	DP			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089 001		11331325	Jan 06, 2027	U-2506			
	>A>	11426416	Apr 12, 2030	U-3420			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089 002		11331325	Jan 06, 2027	U-2506			
	>A>	11426416	Apr 12, 2030	U-3420			
TESTOSTERONE UNDECANOATE - JATENZO							
N 206089 003		11331325	Jan 06, 2027	U-2506			
	>A>	11426416	Apr 12, 2030	U-3420			
TESTOSTERONE UNDECANOATE - TLANDO							
N 208088 001		10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
		10716794	Nov 30, 2030	U-1500			
		11304960	Jan 08, 2029	DP U-1500			
		11311555	Nov 30, 2030	U-1500			
		11364249	Nov 30, 2030	U-1500			
	>A>	11433083	Nov 30, 2030	U-1500			
		8778922	Jan 08, 2029	DP U-1500			
		8865695	Jan 08, 2029	U-1500			
		9943527	Nov 30, 2030	U-1500			
		9949985	Nov 30, 2030	U-1500			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 001		10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
		10576090	Dec 31, 2030	DP			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 002		10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
		10576090	Dec 31, 2030	DP			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 003		10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
		10576090	Dec 31, 2030	DP			
TICAGRELOR - BRILINTA							
N 022433 001		10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
		10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
		10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
		8425934	Apr 17, 2030	DP		PED	May 05, 2024
		8425934*PED	Oct 17, 2030				
		RE46276	Oct 30, 2024	DS DP U-1935			
		RE46276	Oct 30, 2024	DS DP U-1936			
		RE46276	Oct 30, 2024	DS DP U-1937			
		RE46276	Oct 30, 2024	DS DP U-1938			
		RE46276	Oct 30, 2024	DS DP U-2838			
		RE46276	Oct 30, 2024	DS DP U-2839			
		RE46276	Oct 30, 2024	DS DP U-2988			
		RE46276*PED	Apr 30, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TICAGRELOR - BRILINTA						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
TICAGRELOR - BRILINTA						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			PED	Nov 28, 2023
	8425934	Apr 17, 2030	DP		PED	May 05, 2024
	8425934*PED	Oct 17, 2030				
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 001					CGT	Aug 25, 2022
TIMOLOL MALEATE - TIMOLOL MALEATE						
A 212592 002					CGT	Aug 25, 2022
TIOPRONIN - THIOLA EC						
N 211843 001	>A> 11458104	Nov 14, 2038	U-3441	>A>	ODE*	Jun 28, 2026
TIOPRONIN - THIOLA EC						
N 211843 002	>A> 11458104	Nov 14, 2038	U-3441	>A>	ODE*	Jun 28, 2026
TIRZEPATIDE - MOUNJARO						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIRZEPATIDE - MOUNJARO						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	6821987	Apr 26, 2023	DS DP U-3100			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	6821987	Apr 26, 2023	DS DP U-3100			
TOFACITINIB CITRATE - XELJANZ						
N 203214 001					I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ						
N 203214 002					I-879	Dec 14, 2024
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 002	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
TOLVAPTAN - TOLVAPTAN						
A 206119 001					PC	Sep 06, 2022
TOPIRAMATE - EPRONTIA						
N 214679 001	>A> 11433046	Aug 21, 2040	U-3413			
	>A> 11433046	Aug 21, 2040	U-3414			
	>A> 11433046	Aug 21, 2040	U-3415			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001					I-895	Jun 22, 2025
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002					I-895	Jun 22, 2025
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003					I-895	Jun 22, 2025
TREPROSTINIL - TYVASO DPI						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - TYVASO DPI						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - TYVASO DPI						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TRETINOIN - ALTRENO						
N 209353 001	11324710	Aug 22, 2038	U-2368			
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370			
ULIPRISTAL ACETATE - ELLA						
N 022474 001					M-271	Jun 24, 2024
UMBRALISIB TOSYLATE - UKONIQ						
N 213176 001	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			
UPADACITINIB - RINVOQ						
N 211675 001	10995095	Oct 17, 2036	U-3298		I-880	Dec 14, 2024
	11365198	Oct 17, 2036	U-3275		I-883	Jan 14, 2025
	8962629	Jan 15, 2031	DS U-3255		I-886	Mar 16, 2025
	8962629	Jan 15, 2031	DS U-3275		I-888	Apr 29, 2025
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
UPADACITINIB - RINVOQ						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
UPADACITINIB - RINVOQ						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
VARENICLINE TARTRATE - TYRVAYA						
N 213978 001	11224598	Oct 19, 2035	U-1900			
VASOPRESSIN - VASOPRESSIN						
A 211538 001					PC	Jul 17, 2022
VASOPRESSIN - VASOSTRICT						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
VENETOCLAX - VENCLEXTA						
N 208573 001	11369599	May 23, 2032	DP			
>A>	11413282	Sep 06, 2033	U-3412			
VENETOCLAX - VENCLEXTA						
N 208573 002	11369599	May 23, 2032	DP			
>A>	11413282	Sep 06, 2033	U-3412			
VENETOCLAX - VENCLEXTA						
N 208573 003	11369599	May 23, 2032	DP			
>A>	11413282	Sep 06, 2033	U-3412			
VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE						
N 215429 001	6717015	Mar 27, 2023	DS DP U-451			
	7776358	May 16, 2028	DP			
VERICIGUAT - VERQUVO						
N 214377 001 >A>	11439642	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 002 >A>	11439642	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 003 >A>	11439642	May 19, 2031	U-3062			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 001	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
>A>	11458143	Sep 04, 2029	U-3442			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 002	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
>A>	11458143	Sep 04, 2029	U-3442			
VILOXAZINE HYDROCHLORIDE - QELBREE						
N 211964 003	11324753	Sep 04, 2029	U-727		NPP	Apr 29, 2025
>A>	11458143	Sep 04, 2029	U-3442			
VOCLOSPORIN - LUPKYNIS						
N 213716 001	7332472	Oct 17, 2023	DS DP U-3056			
VORAPAXAR SULFATE - ZONTIVITY						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
VOXELOTOR - OXBRYTA						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VUTRISIRAN - AMVUTTRA						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396			
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			
	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
ZINC SULFATE - ZINC SULFATE						
A 216249 001					CGT	Dec 24, 2022
ZINC SULFATE - ZINC SULFATE						
A 216249 002					CGT	Dec 24, 2022
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 001					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 002					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 003					M-232	Jan 28, 2025
ZIPRASIDONE HYDROCHLORIDE - GEODON						
N 020825 004					M-232	Jan 28, 2025

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42ND Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm